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 SUMMARY	In	 all	 organisms	 the	 functional	 and	 structural	 plasticity	 of	 proteins	 is	 defined	 by	post-translational	 modifications	 (PTM).	 ADP-ribosylation	 is	 an	 ancient	 PTM	 that	comes	 in	 a	 monomeric	 and	 polymeric	 form	 in	 mammalian	 cells	 and	 has	 been	identified	 to	 be	 involved	 in	 important	 cellular	 processes	 and	 misregulated	 in	disease.	 Inhibitors	 of	 ADP-ribosylation	 are	 now	 used	 in	 the	 clinic	 to	 treat	 cancer,	however	many	aspects	of	the	PTM	remain	enigmatic;	especially	which	proteins	are	modified	during	which	conditions,	what	are	the	amino	acid	acceptor	sites	and	which	sites	are	modified	by	which	ADP-ribosyltransferase.			 The	 aim	 of	 this	 thesis	was	 to	 develop	 and	 apply	mass	 spectrometry	 based	methods	 to	 systematically	 and	 accurately	map	 ADP-ribosylation	 sites	 in	 cells	 and	tissues	 during	 physiological	 and	 pathological	 conditions	 and	 characterize	 their	biological	function.	First,	 we	 established	 a	 new	 enrichment	 protocol	 and	 optimized	 the	 mass	spectrometry	method,	which	let	to	the	identification	of	the	oxidative	stress-induced	ADP-ribosylome	in	HeLa	cells	and	the	finding	that	serine	serves	as	the	major	nuclear	ADP-ribose	 acceptor	 site.	 The	 modified	 proteins	 were	 mostly	 associated	 with	functions	 in	 regulation	of	 transcription,	 chromosome	organization	 as	well	 as	DNA	and	RNA	metabolic	processes.	We	also	 found	that	a	small	number	of	 tyrosines	are	ADP-ribosylated.	Furthermore	we	identified	high	levels	of	arginine	ADP-ribosylated	proteins	in	mouse	liver	extracts	on	proteins	having	a	role	in	metabolism.		Second,	 we	 found	 that	 ARTD1	 is	 the	 main	 mediator	 of	 nuclear	 ADP-ribosylation	 during	 oxidative	 stress	 in	 cultured	 cells,	 having	 selectivity	 for	 serine	and	tyrosine	modification.	ARTD2	only	modified	a	small	number	of	detected	targets.	This	 suggested	 that	 ARTD1	 catalyzes	 poly-ADP-ribosylation	 as	 well	 as	 de	 novo	protein	ADP-ribosylation.			Third	 we	mapped	 the	 ADP-ribosylome	 of	 heart	 and	 skeletal	 muscle	 tissue	and	revealed	a	widespread	role	of	ARTC1	arginine	ADP-ribosylation	of	extracellular	and	plasma	membrane	proteins,	as	well	as	ARTC1	independent	ADP-ribosylation	in	mitochondria.		Together,	 we	 could	 identify	 enzyme-substrate	 relationships	 for	 several	hundred	ADP-ribosylation	 sites	 catalyzed	by	ARTD1,	ARTD2,	ARTC1	and	ARTC2.2	and	we	got	mechanistic	insight	into	the	function	of	a	few	selected	ADP-ribosylation	sites.	 We	 are	 now	 able	 to	 accurately	 localize	 ADP-ribosylation	 sites	 and	 to	 map	tissue	and	treatment	specific	ADP-ribosylation	sites.	
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 ZUSAMMENFASSUNG	Funktionelle	 und	 strukturelle	 Proteineigenschaften	 können	 in	 allen	 Organismen	durch	 post-translationale	 Modifikationen	 (PTM)	 beeinflusst	 werden.	 ADP-Ribosylierung	 ist	 eine	 PTM,	 welche	 sowohl	 als	 Mono-	 als	 auch	 als	 Polymer	vorkommt,	 in	 wichtige	 zelluläre	 Prozesse	 involviert	 ist	 und	 unter	 pathologischen	Konditionen	fehlreguliert	sein	kann.	Obwohl	Inhibitoren	von	ADP-Ribosylierung	in	der	 Krebsbehandlung	 eigesetzt	 werden,	 bleiben	 viele	 Aspekte	 unklar.	 Es	 ist	ungenügend	geklärt,	welche	Proteine	unter	welchen	Bedingungen	modifiziert	sind,	welche	 Aminosäuren	 als	 Akzeptoren	 fungieren	 und	 inwieweit	 die	 verschiedenen	ADP-Ribosyltransferasen	in	die	Etablierung	der	Modifikation	involviert	sind.	Das	Ziel	dieser	Doktorarbeit	war	es,	massenspektrometrische	Methoden	zu	entwickeln,	 um	 systematisch	 und	 präzise	 ADP-Ribosylierungsstellen	 im	 Proteom	von	 	 Zellen	 und	 Geweben	 zu	 kartieren	 und	 deren	 biologische	 Funktion	 zu	analysieren.			 In	einem	ersten	Schritt	haben	wir	ein	neues	Anreicherungsprotokoll	für	ADP-ribosylierte	 Peptide	 etabliert	 und	 die	 massenspektrometrische	 Methode	 dafür	optimiert.	 Mithilfe	 dieses	 Protokolls,	 war	 es	 uns	 gelungen,	 das	 durch	 oxidativen	Stress	induzierte	ADP-Ribosylom	in	HeLa	Zellen	zu	identifizieren.	Die	modifizierten	Proteine	 spielen	 eine	 Rolle	 in	 der	 transkriptionellen	 	 Regulation,	 Chromosomen	Organisation	sowie	in	DNA	und	RNA	metabolischen	Prozessen.			 In	einem	zweiten	Schritt	konnten	wir	zeigen,	dass	ARTD1	der	Hauptregulator	der	 von	 oxidativem	 Stress	 induzierten,	 nukleären	 ADP-Ribosylierung	 war	 und	Proteine	 selektiv	 an	 Serin	 oder	Tyrosin	modifizierte.	 ARTD2	war	 dagegen	nur	 für	die	 Modifikation	 einer	 kleinen	 Anzahl	 von	 unterschiedlichen	 identifizierten	Proteinen	verantwortlich.			 In	 einem	 dritten	 Schritt	 haben	 wir	 das	 ADP-Ribosylom	 von	 Herz-	 und	Skelettmuskeln	 der	 Maus	 charakterisiert.	 Wir	 konnten	 zeigen,	 dass	 ARTC1	 eine	weitreichende	 Rolle	 in	 der	 Arginin-spezifischen	 ADP-Ribosylierung	 von	Membranproteinen,	 sowie	 extrazellulären	 Proteinen	 spielte.	 Im	 Gegensatz	 dazu,	haben	 wir	 auch	 eine	 ARTC1	 unabhängige,	 mitochondriale	 ADP-Ribosylierung	beobachtet.			 Diese	Daten	ermöglichten	es	uns,	Substrat-Enzym-Beziehungen	für	mehrere	hundert	 ARTD1-,	 ARTD2-,	 ARTC1-	 und	 ARTC2.2-abhängige	 ADP-Ribosylierungsstellen	 zu	 erstellen	 und	 die	 funktionelle	 Relevanz	 der	Modifikation	für	einige	Proteine	zu	studieren.	Wir	sind	nun	in	der	Lage	ADP-ribosylierte	Proteine	und	 deren	 Modifikationsstellen	 präzise	 zu	 identifizieren	 und	 gewebe-	 und	behandlungsspezifische	ADP-Ribosylierungsstellen	zu	charakterisieren.		
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INTRODUCTION	
 INTRODUCTION	The	successful	sequencing	of	the	human	genome	in	the	last	decade	revealed	that	it	consists	 of	 20’000	 to	 25’000	 genes,	 which	 is	 significantly	 lower	 than	 previously	anticipated	 [1].	 It	 is	 now	 clear	 that	 post-transcriptional	 and	 post-translational	events	 are	 leading	 to	 a	 high	 number	 of	 functionally	 distinct	 proteins.	Most	 of	 the	proteome	 complexity	 is	 mediated	 by	 post-translational	 modification	 of	 proteins,	such	as	phosphorylation,	glycosylation	or	ADP-ribosylation	[2].	In	this	introduction	I	will	first	provide	an	overview	of	the	biological	significance	and	diversity	of	PTMs	in	general	and	describe	 their	mode	of	action	on	 the	example	of	phosphorylation,	 the	most	 extensively	 studied	 PTM	 up	 to	 date.	 I	 will	 then	 focus	 on	 protein	 ADP-ribosylation,	 introduce	 transferases,	 hydrolases	 and	 interactors	 of	 protein	 ADP-ribosylation	and	discuss	the	diverse	biological	roles	that	have	been	assigned	to	this	PTM.	I	will	summarize	the	state	of	research	of	mass	spectrometry	based	large-scale	PTM	analysis	and	then	describe	in	detail	existing	mass	spectrometric	workflows	for	the	study	of	ADP-ribosylated	proteins.	
1 Proteoforms	and	proteome	complexity	Genes	 encode	 the	 information	 for	 the	 amino	 acid	 sequences	 of	 proteins,	 the	foundation	 of	 the	 basic	 functional	 properties	 of	 a	 protein.	 Alternative	 mRNA	splicing,	 allelic	 variations	 but	 mainly	 differential	 PTMs	 of	 proteins	 give	 rise	 to	multiple	 different	 gene	 products,	 thereby	 vastly	 increasing	 the	 complexity	 of	 the	proteome	 compared	 to	 the	 genome	 [2].	 Specific	 molecular	 forms	 of	 proteins	produced	from	a	single	gene	are	called	proteoforms	and	can	have	functionally	very	different	 roles	 [3].	 Proteoforms	 tremendously	 increase	 the	 functional	 and	regulatory	possibility	of	a	cell	far	beyond	the	genetically	encoded	protein	function.	Hence,	 much	 of	 the	 complexity	 of	 the	 biological	 machinery	 is	 contributed	 by	different	proteoforms	rather	than	by	a	high	number	of	different	genes.			 In	 all	 kingdoms	 of	 life	 the	 dynamic	 functional	 and	 structural	 properties	 of	proteins	are	defined	and	controlled	by	a	variety	of	post-translational	modifications	[4].	 PTMs	 are	 protein	 modifications	 that	 consist	 in	 the	 attachment	 of	 diverse	chemical	 groups,	 the	 addition	 of	 peptides	 or	 polypeptides	 or	 the	 proteolytic	
6
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processing.	 Large-scale	 analysis	 revealed	 that	 at	 least	 50%	 of	 the	 proteins	 in	humans	can	carry	site	specific	PTMs	[2].	PTMs	can	also	occur	on	multiple	sites	of	the	same	protein,	as	for	example	in	the	histone	code,	however	the	combinatorial	nature	of	multi-site	PTMs	is	very	complex	and	remains	largely	elusive	up	to	date.			 More	 than	300	 chemically	different	PTMs	are	known	 [5].	 	Among	 the	best-studied	 PTMs	 are	 covalent	 modification	 of	 amino	 acid	 side	 chains	 by	phosphorylation,	acetylation,	ubiquitination	and	glycosylation.	It	is	thought	that	the	enzymes	carrying	out	post-translational	modification	of	proteins	account	for	around	5%	 of	 the	 protein	 coding	 human	 genome	 [6].	 Importantly,	 many	 PTMs	 are	reversible;	making	PTM-controlled	processes	highly	dynamic.		In	 the	 case	 of	 protein	 phosphorylation,	 518	 putative	 kinases	 and	 189	 protein	phosphatases	 are	 expected	 to	 catalyze,	 respectively	 revert	 the	 modification	 in	human	[7,	8].	The	complete	phosphoproteome	is	not	yet	known	for	any	species,	but	current	 estimates	 are	 that	 40-45%	 of	 the	 eukaryotic	 proteome	 is	 a	 target	 for	phosphorylation	 [9].	 Phosphorylation	 is	 involved	 in	 many	 different	 biological	processes	 ranging	 from	 signal	 transduction	 to	 regulation	 of	 enzyme	 activity,	protein-protein	 as	 well	 as	 protein-ligand	 interaction,	 cellular	 localization	 and	protein	turnover,	as	shown	in	the	overview	in	Figure	1	[4,	10].		It	has	become	clear	that	 inhibiting	 PTM-regulated	 processes	 has	 a	 high	 potential	 as	 a	 pharmaceutical	intervention.	 That	 is	 exemplified	 by	 the	 46	 drugs	 targeting	 kinases,	 which	 were	approved	by	the	US	Food	and	Drug	Administration	by	2016	[11].				
Figure	 1	 Diverse	 roles	 of	 reversible	 post-
translational	 modification	 exemplified	 with	
protein	 phosphorylation.	 Protein	 kinases	 add	 a	phosphate	 donated	 by	 ATP	 to	 a	 target	 protein;	phosphatases	 are	 able	 to	 remove	 it	 again	 (center	circle).	 Phosphorylation	 of	 an	 enzyme	 can	 act	 as	 a	switch	 between	 different	 functional	 states	 of	 the	protein,	 allowing	 cells	 to	 rapidly	 respond	 to	 certain	stimuli.	 Examples	 how	 phosphorylation	 and	 other	PTMs	 affect	 protein	 function	 are	 shown	 in	 the	 outer	circle.	Adapted	from	[10].	
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2 Protein	ADP-ribosylation	Protein	 ADP-ribosylation	 is	 a	 covalent,	 post-translational	 modification	 that	 is	catalyzed	by	ADP-ribosyltransferases	(ARTs).	These	enzymes	require	nicotinamide	adenine	 dinucleotide	 (NAD+)	 as	 a	 substrate	 to	 transfer	 one	 ADP-ribose	 (ADPr)	moiety	onto	specific	amino	acid	residues	(mono	ADP-ribosylation	or	MARylation)	or	onto	already	protein	bound	ADP-ribose	(poly-ADP-ribosylation	or	PARylation)	[12].	In	 several	 bacterial	 pathogens	 toxins	 have	 been	 identified	 that	 have	 ADP-ribosylating	activity	toward	host	proteins	in	order	to	affect	cell	physiology	[13].	22	human	ARTs	are	known,	which	are	subdivided	in	ARTC	(C	for	C2/C3	cholera	toxin-like)	and	ARTD	(D	for	diphtheria	toxin	like)	according	to	the	structural	homology	of	their	 catalytic	 domain	 to	 bacterial	 toxins	 [14].	 Additionally,	 two	 members	 of	 the	Sirtuin	 family	 are	 considered	 to	 have	ADP-ribosylating	 activity.	 Endogenous	ADP-ribosylation	is	thought	to	be	fully	reversible	and	a	set	of	ADP-ribosylhydrolases	with	different	specificities	has	been	identified.	Furthermore,	many	proteins	contain	ADP-ribose	 interaction	 domain.	 A	 scheme	 of	 the	 ADP-ribosylation	 circle	 is	 shown	 in	Figure	2.	
	
Figure	2	The	ADP-ribosylation	circle.	ARTs	and	certain	sirtuins	can	MARylate	proteins	on	specific	amino	acid	acceptor	 sites	 by	 consuming	 NAD+.	 MARylation	 is	 reversible	 by	 ARH1,	 and	MDO1/2.	 ARTD1,	 2,	 5	 and	 6	 can	extend	 MARylation	 to	 PARylation.	 PARylation	 can	 be	 reduced	 to	 MARylation	 by	 PARG,	 TARG	 and	 ARH3.	Modified	from	[15].	
3 ADP-ribosyltransferases	
3.1 Prokaryotic	ADP-ribosylating	toxins	ADP-ribosyltransferases	show	a	widespread	distribution	in	biological	systems.	They	are	 found	 in	 various	 prokaryotes.	 Bacterial	 ADP-ribosyltransferases	 often	 act	 as	toxins	 by	 mono-ADP-ribosylating	 eukaryotic	 proteins	 to	 promote	 bacterial	
O
OH
*
OH
O
OH OH
O
O
O -
P
O
O -
PO O N
N N
N
NH 2
O
OH OH
O
OH OH
O
O
O -
P
O
O -
PO O N
N N
N
NH 2O
OH OH
O
OH O
O
O
O -
P
O
O -
PO O N
N N
N
NH 2O
OH OH
O
OH O
O
O
O -
P
O
O -
PO O N
N N
N
NH 2O
OH O
N
N N
N
NH 2
MARylation
Protein
Protein
Protein
NAD +
ARTDs, ARTCs, 
Sirtuins
ARH1, MDO1/2,
TARG1
nicotinamide
n ADP-ribose of poly-ADP-ribose (PAR)
WWE domain
PBZ
PBZ
macrodomain type II
terminal ADP-ribose
Possible 
bran h ng point
(ARTD1)
mono-ADP-ribose
macrodomain type I
PARylation
ARTD1, 2, 5, 6
PARG, TARG,
ARH3
NAD +
nicotinamide
MARylation
Protein
Protein
PARylation
O
OH
*
OH
O
OH OH
O
O
O -
P
O
O -
O O N
N N
N
NH 2
P
O
Protein
n ADP-ribose of poly-ADP-ribose (PAR)
Possible 
branching point
O
OH OH
O
OH
O
O
O -
P
O
O -
O O N
N N
N
NH 2
P
O O
OH OH
O
OH
O
O
O -
P
O
O -
O O N
N N
N
NH 2
P
O O
OH OH
O
OH
O
O
O -
P
O
O -
O O N
N N
N
NH 2
P
OH
O
OH
N
N N
N
NH 2
MARylation
Protein Protein
Protein
NAD+
ARTDs, ARTCs, 
Sirtuins
nicotinamide
PARylation
ARTDs
1, 2, 5, 6
NAD+
nicotinamide
O
OH
*
OH
O
OH OH
O
O
O -
P
O
O -
O O N
N N
N
NH 2
P tein
P
O
P tein
terminal ADP-ribose
Possible 
branching point
O
OH OH
O
OH
O
O
O -
P
O
O -
O O N
N N
N
NH 2
P
O O
OH OH
O
OH
O
O
O -
P
O
O -
O O N
N N
N
NH 2
P
O O
OH OH
O
OH
O
O
O -
P
O
O -
O O N
N N
N
NH 2
P
OH
O
OH
N
N N
N
NH 2 n ADP-ribose 
MARylation
Protein Protein
Protein
ARH1, MDO1/2, 
TARG1
PARylation
PARG
ARH3
O
OH
*
OH
O
OH OH
O
O
O -
P
O
O -
O O N
N N
N
NH 2
P tein
P
O
P tein
terminal ADP-riboseO
OH OH
O
OH
O
O
O -
P
O
O -
O O N
N N
N
NH 2
P
O O
OH OH
O
OH
O
O
O -
P
O
O -
O O N
N N
N
NH 2
P
O O
OH OH
O
O
O -
P
O
O -
O OP
O
OH
N
N N
N
NH 2 n ADP-ribose 
MARylation
Protein Protein
Protein
PARylation
O
OH
*
OH
O
OH OH
O
O
O -
P
O
O -
O O N
N N
N
NH 2
P tein
P
O
P tein
terminal ADP-riboseO
OH OH
O
OH
O
O
O -
P
O
O -
O O N
N N
N
NH 2
P
O O
OH OH
O
OH
O
O
O -
P
O
O -
O O N
N N
N
NH 2
P
O O
OH OH
O
OH
O
O
O -
P
O
O -
O O N
N N
N
NH 2
P
OH
O
OH
N
N N
N
NH 2 n ADP-ribose 
ARH1, MDO1/2, 
TARG1
PARG
ARH3
O
OH OH
O
OH OH
O
O
O -
P
O
O -
PO O N
N N
N
NH 2O
OH OH
O
OH O
O
O
O -
P
O
O -
PO O N
N N
N
NH 2O
OH O
O
O -
P
O
O -
PO O N
N N
N
NH 2 PBZ
PBZ
macrodomain type II
terminal ADP-ribose
Possible 
branching point
(ARTD1)
WWE domain
PBZ
PBZ
macrodomain type II
MARylation
Protein Protein
Protein
PARylation
O
OH
*
OH
O
OH OH
O
O
O -
P
O
O -
O O N
N
N
NH 2
P tein
P
N
O
P tein
terminal ADP-riboseO
OH OH
O
OH
O
O
O -
P
O
O -
O O N
N N
N
NH 2
P
O O
OH OH
O
OH
O
O
O -
P
O
O -
O N
N N
N
NH 2
P
O O
OH OH
O
OH
O
O
O -
P
O
O -
O O N
N N
N
NH 2
P
OH
O
OH
N
N N
N
NH 2
macrodomain type I
O
NAD +
nicotinamide
NAD +
ARTD1,2,5,6
PARG, TARG, ARH3
nicotinamide
8
INTRODUCTION	
pathogenesis	 in	 humans,	 insects	 or	 plants	 [16].	 	 Toxin	mediated	ADP-ribosylation	disrupts	 host	 cell	 activity	 by	 modulating	 the	 activity	 of	 host	 proteins	 [16]	 (as	summarized	in			Figure	3).	
		
Figure	 3	 Overview	 of	 known	 ADP-ribosylating	 toxins,	 their	 bacterial	 origin	 and	 their	 eukaryotic	
substrate	proteins.	Adapted	from	[16].	Prominent	 examples	 are	 the	 ADP-ribosylation	 of	 the	 diphtamide	 in	elongation	factor	2,	thereby	inhibiting	protein	synthesis,	and	both	ADP-ribosylation	of	the	RHO	GTPases,	which	are	known	to	modulate	the	state	of	actin	polymerization,	and	 the	 direct	 ADP-ribosylation	 of	 actin	 lead	 to	 the	 destruction	 of	 the	 host	 actin	cytoskeleton	[16].	The	 catalytic	 domain	 of	 the	 ADP-ribosyltransferases	 from	 prokaryotes	 to	eukaryotes	 show	 a	 high	 structural	 conservation,	 indeed	 it	 is	 suggested	 that	diversification	of	the	ARTs	happened	during	the	development	of	different	bacterial	
Toxin Bacterium Eukaryotic substrate
DT-like toxins
DT Corynebacterium diphtheriae eEF2
PE Pseudomonas aeruginosa eEF2
ChxA Vibrio cholerae eEF2
CT-like toxins
CT V. cholerae G s
Heat-labile enterotoxin Escherichia coli (ETEC) G s
PT Bordetella pertussis G i
C2-like binary toxins
C2 toxin Clostridium botulinum G-actin
Iota toxin Clostridium perfringens G-actin
CDT Clostridium difficile G-actin
CST Clostridium spiroforme G-actin
VIP Bacillus cereus G-actin
SpvB Salmonella spp. G-actin
AexT Aeromonas hydrophila G-actin
Photox Photorhabdus luminescens G-actin
C3-like toxins
C3bot C. botulinum RHOA, RHOB and RHOC
C3Stau/EDIN Staphylococcus aureus RHOA, RHOB, RHOC and RHOE
C3cer B. cereus RHOA, RHOB and RHOC
ExoS P. aeruginosa RAS, ERM proteins and vimentin
ExoT P. aeruginosa CrkI and CrkII
HopU1 Pseudomonas syringae GRP7
SpyA Streptococcus pyogenes Vimentin and actin
Novel toxins
TT Salmonella enterica Unknown
PTC3 P. luminescens G-actin
PTC5 P. luminescens RHOA, RHOB and RHOC
α
α
α
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conflict	 system	 and	 that	 eukaryotes	 acquired	 the	 ART	 genes	 through	 subsequent	horizontal	gene	transfer	[17].	
3.2 ARTD	family	of	eukaryotic	ADP-ribosyltransferases	The	eukaryotic	ARTD	family,	also	known	as	poly(ADP-ribose)polymerases	(PARP),	consists	 of	 17	 proteins,	 all	 of	 which	 are	 intracellular	 and	 localized	 to	 various	compartments	(summarized	in	Figure	4)	[12].	Four	of	them	are	known	to	catalyze	PARylation	(ARTD1,	2,	5	and	6),	twelve	catalyze	MARylation	(ARTD3,	4,	7,	8,	9,	10,	11,	12,	14,	15,	16	and	17)	and	at	least	one	seems	to	be	catalytically	inactive	(ARTD	13).		
	
Figure	4	Overview	of	the	ARTD	family,	enzymatic	activity	and	domain	architecture.	Adapted	from	[14].		The	 ARTD	 nomenclature	 follows	 the	 structural	 homology	 and	 the	 implicated	enzymatic	features.	ARTD1-6	are	characterized	by	the	conserved	amino	acid	triade	H-Y-E	that	has	been	identified	in	their	active	center	[18].	These	three	residues	have	a	 key	 role	 in	 the	 catalytic	 transfer	 of	 ADP-ribose.	 The	 H	 and	 Y	 are	 important	 for	binding	NAD+	and	 the	E	 functions	 in	catalysis	and	elongation	of	PAR	[14].	All	 four	ARTDs	capable	of	PARylation	(ARTD1,	2,	5	and	6)	do	contain	this	motif.	ARTD3	and	4	 also	 contain	 the	 H-Y-E	 motif,	 they	 are	 able	 to	 MARylate,	 however	 no	 direct	evidence	exists	that	they	are	also	able	to	PARylate	[19].	
//
domain architecture
//
//
Name Alternative names Enzymatic activity
ARTD1 PARP1 PAR - branched
ARTD2 PARP2 PAR - branched
ARTD3 PARP3 MAR
ARTD4 PARP4, vPARP MAR
ARTD5 PARP5a, TNKS1 PAR - oligo
ARTD6 PARP5b, TNKS2 PAR - oligo
ARTD7 PARP15, BAL3 MAR
ARTD8 PARP14, BAL2 MAR
ARTD9 PARP9, BAL1 MAR
ARTD10 PARP10 MAR
ARTD11 PARP11 MAR
ARTD12 PARP12 MAR
ARTD13 PARP13, ZC3HAV1 Inactive
ARTD14 PARP7, tiPARP MAR
ARTD15 PARP16 MAR
ARTD16 PARP8 MAR
ARTD17 PARP6 MAR
Domain architecture
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ARTD7,	8,	10-12,	14-17	contain	a	H-Y-I	motif	and	they	have	been	shown	to	be	able	to	catalyze	only	MARylation	[14].	Absence	of	the	E	in	the	motif	is	suspected	to	be	 the	 reason	 for	 their	 inability	 to	 catalyze	 PARylation.	 In	 order	 to	 still	 catalyze	MARylation,	 it	 is	 proposed	 that	 these	 enzymes	 are	 using	 acidic	 residues	 of	 the	substrate	protein,	in	a	substrate	assisted	catalysis	process,	to	replace	the	missing	E	[20].	 Indeed,	 mutating	 the	 catalytic	 E	 residue	 in	 ARTD1	 leads	 to	 a	 shift	 from	PARylation	to	MARylation	[21].	ARTD9	and	13	are	missing	the	H	for	NAD+	binding	and	therefore	have	been	considered	to	be	catalytically	inactive,	however	ARTD9	has	recently	 been	 shown	 to	 have	 MARylation	 activity	 when	 in	 complex	 with	 the	 E3-ubiquitin	ligase	Dtx3L	against	the	C-terminal	carboxylate	of	ubiquitin	[22].	
3.3 ARTC	family	of	eukaryotic	ADP-ribosyltransferases	The	 ARTC	 family,	 also	 known	 as	 ecto-ARTs	 or	 GPI-linked	 NAD(P)+-arginine	 ADP-ribosyltransferases,	consists	of	four	members	in	human	(as	summarized	in	Figure	5)	and	six	members	in	mouse.		
	
Figure	5	Overview	of	the	human	ARTC	family	enzymatic	activity	and	domain	architecture.	ARTC2.1	and	2.2	are	not	shown,	since	they	are	pseudo	genes	in	human.	As	indicated	in	the	key:	glycosylphosphatidylinositol-anchor	(GPI),	signal	peptide	(SP),	ADP-ribosyl	transferase	domain	(ART).		Adapted	from	[23]	and	Uniprot.		ARTC1,	2	and	5	contain	the	characteristic	cholera	toxin	R-S-E	catalytic	motif	in	their	active	center.	R	and	S	are	important	for	the	NAD+	binding	and	E	functions	again	in	the	catalysis	[14].	ARTC1-4	are	facing	the	extracellular	site	of	the	cell	and	are	bound	with	a	glycosylphosphatidylinositol	 (GPI)	anchor	 to	 the	plasma	membrane.	Mainly	based	on	mRNA	expression	data,	human	and	mouse	ARTC1	have	been	identified	to	be	 expressed	 in	 skeletal	muscle,	 heart,	 epithelial	 cells	 and	 activated	 granulocytes	[23].	 ARTC2.1	 and	 ARTC2.2	 (also	 known	 as	 Art2a	 and	 Art2b	 respectively)	 are	expressed	in	the	mouse,	but	in	human	they	contain	a	premature	stop-codon	and	are	
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therefore	not	expressed	 [24].	 In	mouse	ARTC2.2	seems	 to	be	constitutively	active,	however	 ARTC2.1	 is	 only	 active	 in	 the	 presence	 of	 reducing	 agents,	 due	 to	 an	inactivating	disulfide	bond,	which	is	absent	in	all	other	ARTCs	[23].		Mouse	ARTC2.1	and	ARTC2.2	are	expressed	on	T	cells	[25].	ARTC3	and	4	lack	the	R-S-E	motif,	which	prevents	them	from	binding	NAD+	and	renders	them	catalytically	inactive.	ARTC3	is	expressed	broadly	and	ARTC4	on	erythrocytes.	ARTC5	lacks	the	GPI-anchor	and	is	therefore	a	secreted	protein	and	is	expressed	in	testis	[25].		
3.4 	Sirtuins	The	mammalian	sirtuin	family	consists	of	7	members	(SIRT1-7)	and	is	well	known	for	their	NAD+	dependent	deacetylation	activity	in	the	case	of	SIRT1-3,	5	and	6	[26].		Sirtuins	deacetylate	a	variety	of	proteins,	with	histones	being	 the	most	prominent	targets.	 During	 protein	 deacetylation	 by	 sirtuins	 an	 NAD+	molecule	 is	 cleaved	 to	nicotinamide	 and	 ADP-ribose,	 whereas	 the	 acetyl	 group	 is	 transferred	 from	 an	acetylated	lysine	to	the	ADP-ribose.	This	reaction	generates	nicotinamide,	O-acetyl-ADP-ribose	 and	 a	 deacetylated	 lysine	 residue.	 The	 o-acetyl-ADP-ribose	 can	 be	further	 processed	 by	 certain	 macrodomains	 and	 ARH	 (macroD2,	 C6orf130	 and	ARH3)	enzymes,	which	also	have	a	role	in	protein	de-ADP-ribosylation	as	discussed	below	[27-29].			 Protein	 MARylation	 has	 been	 proposed	 as	 an	 alternative	 reaction	mechanism	for	some	of	the	Sirtuins,	however	the	reaction	has	been	described	as	less	efficient	 compared	 to	 the	 deacetylation	 activity.	 	 Still	 it	 is	 believed	 that	 the	mitochondrial	 SIRT4	 MARylates	 glutamate	 dehydrogenase	 (GDH),	 which	 has	functional	implications	on	the	glutamine/glutamate	turnover	and	on	mitochondrial	ATP-synthesis	[30].	 	There	are	also	some	indications	that	SIRT6,	which	is	localized	to	the	nucleus,	ADP-ribosylates	certain	targets	including	ARTD1	[31].	
3.5 NAD+	metabolism	and	ADP-ribosyltransferases	Intracellular	NAD+	stems	from	two	different	sources;	it	is	produced	either	by	de	novo	synthesis	 or	 via	 a	 salvage	 pathway	 from	 precursor	 molecules.	De	 novo	 synthesis	starts	from	the	amino	acid	tryptophan	and	the	salvage	pathway	from	the	naturally	occurring	 vitamins:	 nicotinamide	 (NA),	 nicotinic	 acid	 (NAM)	 and	 nicotinamide	
12
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riboside	 (NR)	 [32].	 	 It	 is	 thought	 that	 distinct	 NAD+	 pools	 exist	 in	 the	cytosolic/nuclear	 and	 mitochondrial	 compartment,	 however	 the	 pools	 are	interconnected	 by	 a	 set	 of	 cellular	 processes.	 These	 pools	 individually	 regulate	compartment	 specific	metabolic	 pathways	 [33].	 	 Three	 enzyme	 classes,	 the	 ARTs,	the	Sirtuins	and	the	cADPr	synthases	require	NAD+	as	a	cofactor	and	compete	for	it.	Activation	 of	 ARTD1,	 for	 example	 during	 excessive	 DNA	 damage,	 reduces	 NAD+	levels	 to	 20-30%	 of	 their	 normal	 levels,	 which	 dramatically	 reduces	 NAD+	availability	 for	 nuclear	 Sirtuins,	 impairing	 their	 deacetylation	 function	 [33].	 Also	under	 steady-state	 conditions	 ARTD1	 seems	 to	 consume	 high	 amounts	 of	 NAD+,	since	NAD+	is	increased	up	to	2	fold	in	ARTD1-KO	mouse	tissue	[34].		Apart	 from	 genetic	 interventions	 several	 strategies	 exist,	 which	 have	 the	potential	to	boost	NAD+	levels,	also	in	a	compartment-specific	manner.	Among	these	are	 PARPi	 treatment	 or	 supplementation	 with	 NA,	 NAM,	 NR	 or	 NAM	mononucleotide	 [32].	 There	 are	 by	 now	 many	 examples	 of	 physiological	 and	pathophysiological	 conditions	 where	 modulation	 of	 NAD+	 levels	 or	 NAD+	metabolism	 has	 shown	 beneficial	 effects	 including	 aging,	 insulin	 resistance,	 fatty	liver,	 dyslipidemia,	 hypertension,	 neurodegeneration,	 muscle	 function	 and	 heart	function	[32,	33].	The	origin	 and	 role	of	 extracellular	NAD+,	 the	 substrate	of	ARTCs,	 is	 still	 not	 very	well	 understood.	 The	 NAD+	 concentration	 in	 plasma	 under	 normal	 conditions	 is	estimated	 to	 be	 around	 0.1	 μM,	 however	 high	 amounts	 of	 NAD+	 can	 be	 released	during	lytic	processes,	such	as	tissue	damage	and	necrosis	[35,	36].	Furthermore,	it	is	 thought	 that	 NAD+	 as	 well	 as	 other	 nucleotides	 are	 released	 by	 controlled	mechanisms	 during	 hypoxia	 and	 inflammation	 [35,	 36].	 Extracellular	 NAD+	 is	rapidly	degraded	by	ectoenzymes	such	as	the	NADase	CD38	[23].	
4 ADP-ribosylhydrolases	Several	 enzymes	 that	 remove	 ADP-ribose	 from	 mono-	 and	 poly-ADP-ribosylated	substrates	have	been	 identified,	most	probably	 rendering	ADP-ribosylation	 a	 fully	reversible	 PTM	 [37].	 Mammalian	 ADP-ribosylhydrolases	 characterized	 so	 far,	include	 poly-ADP-ribose	 glycohydrolase	 (PARG)	 and	 ADP-ribosylhydrolase	 3	
13
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(ARH3),	 both	of	which	are	 able	 to	hydrolyze	poly-ADP-ribose	 and	 the	mono-ADP-ribosyl	 arginine	 hydrolase	 1	 (ARH1)	 [38-40].	 ARH2	 is	 thought	 to	 be	 catalytically	inactive	[29].	In	addition,	the	macrodomain-containing	proteins	MacroD1,	MacroD2,	and	C6orf130	have	also	been	shown	to	exhibit	mono-ADP-ribosylhydrolase	activity	against	ADP-ribosylated	acidic	amino	acids	[41-43].		
5 ADP-ribosylation	interactors		There	are	several	protein	domains	known,	which	have	binding	affinity	 for	specific	parts	of	MAR	or	PAR	(as	indicated	in	Figure	6)	[37].		
	
Figure	6	Overview	of	four	distinct	MAR	and	PAR	binding	domains	and	their	specificity.	Adapted	from	[37].	These	 domains	 include	 structurally	 well-characterized	 binding	 modules	 such	 as	macrodomain,	PAR-binding	zinc	 finger	 (PBZ),	WWE	and	PAR-binding	motif	 (PBM)	[37].	 Forkhead-associated	 (FHA)	 and	 BRCA1	 C-terminal	 (BRCT)	 domains,	 both	previously	associated	with	phospho-site	binding,	have	also	certain	affinity	towards	ADP-ribosylation	 sites	 [44].	 Furthermore,	 newly	 emerging	 PAR	 binders	 belong	 to	previously	 described	 DNA	 or	 RNA	 binding	 domains	 such	 as	 the	 RNA	 recognition	motif	 (RRM),	 oligonucleotide/oligosaccharide-binding	 fold	 (OB-fold),	 PIN	 domains	as	well	as	low	complexity	domains	such	as	SR	repeats,	KR-rich	motifs	and	RG/RGG	repeats	[44].	Proteins	containing	MAR	or	PAR	binding	domains	include	DNA	repair	factors,	 chromatin	 remodelers,	 cell	 cycle	 regulators,	 RNA-binding	 proteins,	
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transcription	 factors	and	 E3-ubiquitin	 ligases.	 They	 are	 regulating	 multi-protein	assemblies	 at	 sites	 of	 DNA	 damage,	 chromatin	 remodeling,	 phase	 separation	 of	proteins	through	aggregation	and	PAR-dependent	ubiquitination	[44-46].		Interestingly,	 multiple	 ADP-ribose	 binding	 domains	 have	 been	 identified	 in	bacteria,	 archea	 and	 viruses	 [29,	 47-49].	 Af1521	 is	 a	 protein	 found	 in	 the	thermophilic	 organism	Archaeoglobus	 fulgidus which	 binds	 to	 MARylation	 and	PARylation,	with	a	relatively	 low	dissociation	constant	of	KD=126± 21	nM	for	 free	ADP-ribose	[47,	50].	Due	to	these	properties	Af1521	was	broadly	used	as	a	tool	to	study	ADP-ribosylation	as	discussed	later	[50].				
6 Biological	roles	of	intracellular	ADP-ribosylation	
6.1 Biological	functions	of	PARylation	ARTD1,	2,	5	and	6	have	been	published	to	catalyze	PARylation	and	several	biological	functions	 of	 these	 enzymes	 are	 discussed	 below.	 The	 first	 PARylation	 targets	identified	 included	 the	core	histones	and	ARTD1	 itself	 [51].	Based	on	 the	 stability	towards	 chemical	 treatments,	 it	 was	 initially	 proposed,	 that	 protein	 PARylation	consists	 of	 ester	 and	 ketamine	 bonds	 formed	 by	 ADP-ribosylation	 of	glutamic/aspartic	 acid	 residues	 and	 lysine/arginine	 residues	 respectively	 [52].	Specific	 glutamic	 acid	 residues	 in	 histones	H1	 and	H2B,	 as	well	 as	 the	 C-terminal	lysine	residue	of	H1,	were	reported	as	ADP-ribose	acceptors	[53,	54].	More	recent	studies	 however	 proposed,	 based	 on	 in	 vitro	 reactions	 in	 combination	 with	 site	directed	mutagenesis	 and	MS	measurement,	 that	 lysine	 residues	 are	modified	 on	ARTD1	and	histones	[55,	56].	However,	the	exact	in	vivo	modification	sites	are	still	under	debate	[57-59].	 	ARTD1	 activity	 has	 been	 shown	 to	 be	 regulated	 by	 post-translational	modifications,	 such	 as	 phosphorylation,	 acetylation,	 SUMOylation	 and	 ADP-ribosylation,	 by	 direct	 protein-protein	 interactions	 or	 DNA	 damage-dependent	activation	[60].	Recently	the	protein	C4orf27/HPF1	was	found	to	act	as	a	factor	for	ARTD1	 PARylation,	 shifting	 ARTD1	 activity	 from	 auto	 modification	 to	 histone	PARylation	and	driving	the	specificity	for	serine	ADP-ribosylation	[61,	62].	
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ARTD1	is	recruited	to	DNA	double	strand	breaks	and	nicks	through	its	DNA	binding	domain	in	response	to	DNA	damage	and	was	identified	to	play	a	role	in	DNA	repair,	re-initiation	of	stalled	replication	forks	and	regulation	of	telomere	length	[63,	64].	PARylation	of	ARTD1	itself	and	other	proteins	at	the	site	of	DNA	damage	serves	as	a	scaffold	 for	 the	recruitment	of	various	DNA	repair	proteins	and	remodels	 the	chromatin	 [65].	More	 specifically	 it	was	proposed	 that	ARTD1	 is	 involved	 in	 base	excision	repair	and	repair	of	single	strand	breaks,	involving	the	binding	of	the	single	strand	 break	 intermediates	 [66].	 These	 findings	 have	 been	 extended	 and	 it	 was	appreciated	more	recently	 that	ARTD1	also	seems	 to	have	a	 role	 in	double	strand	break	repair	[67].	Although	ARTD1	is	not	required	for	viability	in	mice,	these	mice	or	 isolated	 mouse	 embryonic	 fibroblasts	 exhibit	 some	 DNA	 repair	 defects	 and	elevated	chromosomal	abnormalities	[68,	69].		 ARTD1	 enzymatic	 activity	 is	 additionally	 involved	 in	 development,	 cell	differentiation	 and	 pluripotency	 by	 means	 of	 chromatin	 ADP-ribosylation	 [70].	ARTD1	 activity	 was	 also	 associated	 with	 regulation	 of	 metabolic	 functions,	 for	example	in	the	mouse	liver,	where	the	circadian	entrainment	of	feeding	behavior	is	regulated	 trough	 ADP-ribosylation	 of	 the	 CLOCK	 protein	 complex	[71].	Furthermore,	 there	 is	 clear	 evidence	 that	ADP-ribosylation	by	ARTD1,	but	 also	by	other	ARTD	members,	plays	 an	 important	 role	 in	different	 aspects	of	 the	 immune	response	 and	 inflammation	 [72].	 	 The	 high	 consumption	 of	 NAD+	 by	 ARTD1	 to	generate	PAR	has	secondary	effects	on	the	energy	metabolism,	apoptotic	pathways	and	 on	 a	 number	 of	 NAD+	 dependent	 enzymes,	 such	 as	 the	 Sirtuins	 as	 discussed	above	(introduction	chapter	3.5)	[73].		ARTD2	is	the	closest	paralog	to	ARTD1	and	is	able	to	bind	DNA	through	its	WGR	domain,	which	can	also	interact	with	RNA	[74,	75].	ARTD2	has	been	associated	with	DNA	repair	pathways,	such	as	base	excision	repair,	and	chromosome	stability,	however	 ARTD1	 contributes	 to	 more	 than	 90%	 of	 PAR	 produced	 during	 DNA	damage	 conditions	 [60,	 75,	 76].	 ARTD2	 KO	 mice	 are	 viable	 like	 ARTD1	 KO,	 but	interestingly	 ARTD1	 and	 ARTD2	 double	 KO	mice	 die	 at	 the	 onset	 of	 gastrulation	[77].	ARTD1	and	2	have	been	 identified	 to	work	 in	 concert	 for	 example	 at	 stalled	replication	 forks	 [78].	 ARTD2	 is	 also	 associated	 with	 metabolic	 regulation	 and	
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ARTD2	KO	mice	show	increased	energy	expenditure	and	mitochondrial	biogenesis	[34].		 	ARTD	 5	 and	 6	 (also	 known	 as	 Tankyrase	 1	 and	 2)	 poly-ADP-ribosylate	cellular	 targets,	 however	 their	 biological	 functions	 are	 very	different	 from	ARTD1	and	 ARTD2	 and	 involve	 telomere	 homeostasis,	 Wnt/β-catenin	 signaling,	 glucose	metabolism	and	 cell	 cycle	 progression	 [79].	 Interestingly,	 some	of	 these	 functions	are	 executed	 through	 a	 process	 that	 involves	 PARylation	 of	 a	 target	 proteins	 by	ARTD5	 or	 6,	 which	 acts	 as	 a	 signal	 for	 ubiquitination	 of	 the	 same	 target	 by	 the	ubiquitin	E3-ligase	RNF146	and	subsequent	proteasomal	degradation	[46].		
6.2 PARP	inhibitors	as	therapeutics	PARP	inhibitors	(PARPi)	are	small	molecules	that	are	designed	to	 inhibit	 the	ADP-ribosylation	activity	of	different	ARTDs.	Most	PARPi	are	thought	to	interact	with	the	NAD+	 binding	 sites	 in	 the	 catalytic	 domains	 of	 ARTDs,	 but	 show	 very	 different	selectivity,	potency	and	cytotoxicity	[80].		Initially,	 PARPi	 were	 evaluated	 for	 their	 ability	 to	 sensitize	 tumor	 cells	 to	conventional	 DNA	 damage	 inducing	 treatments,	 due	 to	 the	 central	 role	 of	 ARTD1	and	 2	 in	 the	 DNA	 damage	 response	 [81].	 Cells	 deficient	 for	 the	 homologous	recombination	DNA	repair	pathway,	such	as	BRCA1/2	mutated	cells,	were	found	to	be	sensitive	to	PARPi.	This	finding	laid	the	foundation	for	the	broad	use	of	PARPi	in	cancer	 research	 [82,	 83].	 It	 is	 thought	 that	 this	 sensitivity	 to	PARPi	 is	 following	 a	classical	 synthetic	 lethality	 set	 up,	 a	 genetic	 concept,	 which	 proposes	 that	 the	simultaneous	 perturbation	 of	 two	 genes	 (or	 proteins)	 results	 in	 cellular	 death,	whereas	the	single	perturbation	would	not	have	an	effect	[81].	However,	the	exact	mechanism	how	PARPi	exhibit	their	cytotoxic	effect	is	still	not	very	well	understood.	Inhibition	of	ARTD1	is	thought	to	lead	to	an	accumulation	of	DNA	damage	through	obstructed	single-strand	break	repair	and/or	 trapping	of	ARTD1	at	damaged	sites	on	 the	 DNA,	 thereby	 impairing	 DNA	 replication	 [81].	 Furthermore	 other	 ARTD	associated	 roles	 might	 be	 involved	 in	 the	 response	 to	 PARPi,	 such	 as	 chromatin	remodeling,	 transcription,	 normal	 DNA	 replication	 as	 well	 as	 inflammatory	responses	[84,	85].		 	
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The	 PARPi	 olaparib	 (KuDOS/AstraZeneca),	 rucaparib	 (Pfizer/Clovis)	 and	niraparib	 (Merck/Tesaro),	 are	 now	 approved	 as	 a	 monotherapy	 of	 advanced	ovarian	 cancer	 for	 patients	with	 germ	 line	mutated	BRCA1/2,	who	 relapsed	 from	previous	chemotherapeutic	treatments	[81].	More	than	70	clinical	trials	are	ongoing	for	testing	PARPi	in	various	cancers	[84].	The	anti-inflammatory	effect	of	PARPi	has	been	 shown	 in	a	variety	of	 local	inflammation	 models,	 where	 PARPi	 have	 been	 used	 to	 prevent	 innate	 immune	responses	 and	 the	 onset	 of	 inflammatory	 diseases.	 More	 specifically,	 PARPi	 have	shown	to	ameliorate	acute	organ	damage	upon	LPS	treatment	in	animal	models	and	they	 reduce	 ischemia	 reperfusion	 injury	 or	 attenuate	 inflammation	 in	 models	 of	colitis	[86-90].	
7 Functional	roles	of	extracellular	ADP-ribosylation	Members	 of	 the	 ARTC	 family	 ADP-ribosylate	 membrane	 proteins	 and	 proteins	present	 in	 extracellular	 body	 fluids	 [25].	 It	 is	 thought	 that	 ARTC	 mediated	 ADP-ribosylation	 is	 highly	 arginine	 specific	 and	 it	was	 shown	 that	 a	N-glycosidic	 bond	between	arginine	and	ADP-ribose	is	generated	[91].	Arginine	is	positively	charged	at	a	 neutral	 pH	 and	 its	 ADP-ribosylation	 brings	 in	 two	 negative	 charges,	 which	will	affect	 the	 electrostatic	 surface	potential	 of	 the	protein	 and	may	 thereby	modulate	protein-protein	interactions	[91].		ARTC1	 ADP-ribosylates	 members	 of	 the	 integrin	 family	 of	 adhesion	molecules	on	skeletal	muscle	cells	and	leukocytes.	Integrins	function	as	mechanical	linker	between	the	intracellular	cytoskeleton	and	the	extracellular	matrix	and	as	an	out-side-in	transmitter	of	information	on	location,	local	environment,	adhesive	state	and	 surrounding	 matrix.	 The	 integrin	 family	 of	 proteins	 consists	 of	 alpha	 (e.g.	ITGA7)	and	beta	subtypes	 (e.g.	 ITGB1),	which	 form	transmembrane	heterodimers.	These	 complexes	 exist	 in	 several	 conformational	 states,	 which	 dictate	 their	extracellular	 ligand	 binding	 affinity	 and	 their	 intracellular	 interaction	 with	cytoplasmic	proteins.	 	 In	an	 inactive	state	 the	 integrins	are	usually	 in	a	bent	 form,	while	when	activated	they	show	an	extended	form.	However,	several	 intermediate	states	exist.	[92].	ADP-ribosylation	of	integrin	α7	(ITGA7)	by	ARTC1	modulates	the	
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binding	 of	 integrin	 α7β1	 to	 laminin	 [93].	 It	 is	 proposed	 that	 an	 arginine	 residue	located	in	the	central	region	of	ITGA7	is	involved	in	the	interaction	with	a	negative	region	of	 ITGB1	and	at	 low	NAD+	 concentration	 (10	μM),	 the	arginine	 in	 ITGA7	 is	ADP-ribosylated,	 subsequently	 repels	 ITGB1	 and	 induces	 the	 formation	 of	 a	 high	affinity	 conformer.	 In	 contrast,	 increasing	 NAD+	 concentration	 (100	 μM)	 lead	 to	ADP-ribosylation	of	additional	site(s)	located	in	the	headpiece	of	ITGA7,	where	the	ligand-binding	site	 is	 located,	 resulting	 in	 steric	hindrance	and	direct	 inhibition	of	ligand	binding	[94].		Another	 identified	 ARTC1	 ADP-ribosylation	 target	 is	 the	 defensin,	 human	neutrophil	peptide	1	(HNP1).	HNPs	are	host	defense	peptides,	which	contribute	to	innate	 immunity	 by	 microbial	 killing	 and	 regulating	 the	 inflammatory	 response.	ARTC1,	 found	 on	 airway	 epithelial	 cells,	 ADP-ribosylates	 HNP1	 on	 R14	 and	 R24,	altering	 its	 biological	 activity.	 ADP-ribosylated	 HNP1	 has	 decreased	 antimicrobial	and	cytotoxic	activities	but	still	stimulated	T	cell	chemotaxis.	ADP-ribosylated	HNP1	was	found	in	bronchoalveolar	lavage	fluid	from	smokers	but	not	from	nonsmokers	[95,	96].			 ARTC1,	 2.1	 and	 2.2	 are	 GPI-anchored	membrane	 proteins	 and	 seem	 to	 be	concentrated	 in	 lipid	 rafts	 on	 the	 cell	 surface.	 This	 could	 give	 them	 specificity	 to	other	membrane	proteins	associated	with	lipid	rafts	[25].	ARTC2.2	is	expressed	on	T	cells,	and	one	of	its	major	targets	is	the	P2X7	ion	channel.	MARylation	of	P2X7	on	R125	leads	to	its	activation	and	thereby	induces	the	influx	of	Ca2+	and	Na+	as	well	as	the	efflux	of	K+	[97].	Downstream	effects	of	P2X7	activation	include	inflammasome	activation,	 processing	 and	 release	 of	 cytokines	 (IL-1β,	IL-18,	 IL-1	 receptor	antagonist	and	IL-36α),	and	the	release	and	activation	of	meatlloproteases	(mainly	ADAM10	and	17)	resulting	in	the	shedding	of	cell-surface	molecules	[98].	Prolonged	activation	 of	 P2X7	 stimulates	 apoptosis	 [98].	 This	 is	 observed	 in	 a	 process	 called	NAD+-induced	 cell	 death,	 where	 ARTC2.2	 mediated	 ADP-ribosylation	 keeps	 the	P2X7	 channel	 open,	 leading	 to	 T	 cell	 death,	 already	 at	 extracellular	 NAD+	concentration	as	low	as	1	μM	[35].	Interestingly,	a	recent	study	has	shown	that	the	activation	 of	 T	 cells	 or	 the	 ADP-ribosylation	 of	 P2X7	 by	 ARTC2.2	 leads	 to	membrane-proximal	proteolysis	of	ARTC2.2	itself	by	ADAM17	[99].	The	proteolytic	
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shedding	 of	 ARTC2.2	 shifts	 its	 substrate	 specificity	 from	 membrane	 proteins	 to	secretory	proteins	[99].	So	far	it	is	not	clear	what	the	targets	of	soluble	ARTC2.2	are.	Soluble	 ARTC2.2	 may	 provide	 an	 unknown	 mode	 of	 regulation	 by	 the	 ADP-ribosylation	of	cytokines	or	other	secretory	proteins	and	might	be	directly	involved	in	 modulating	 inflammatory	 reactions.	 Interestingly,	 the	 presumed	 ADAM17	cleavage	 site	 within	 ARTC2.2	 close	 to	 the	 GPI-anchor	 is	 conserved	 in	 the	 GPI-anchored	ARTC1	as	well	as	ARTC3,	indicating	that	they	might	also	be	shed	[99].		
8 Large-scale	 analysis	 of	 post-translational	 modifications	 by	 mass	
spectrometry	
8.1 Identification	of	PTMs	by	mass	spectrometry	Mass	spectrometry	(MS)	has	emerged	as	a	powerful	 tool	 to	systematically	 identify	and	 quantify	 the	 cellular	 proteome	 and	 is	 also	 very	 well	 suited	 for	 the	 study	 of	PTMs.	Mass	spectrometry	allows	the	measurement	of	whole	protein	entities,	called	top-down	proteomics,	or	the	study	of	peptides	generated	by	proteolytic	cleavage	of	proteins,	called	bottom	up	proteomics.		The	big	advantage	of	top	down	proteomic	is	that	 it	 allows	 the	 measurement	 of	 multiple	 PTM	 on	 the	 same	 protein,	 thereby	identifying	 the	 exact	 proteoform.	 Top-down	 proteomics	 is	 technically	 and	computationally	 very	 demanding	 and	 up	 to	 date	 it	 is	 not	 possible	 to	 analyze	complex	 mixture,	 therefore	 the	 preferred	 and	 most	 widely	 used	 approach	 for	proteome	 and	 PTM	 discovery	 consists	 in	 a	 combination	 of	 bottom-up	 proteomics	and	 data	 dependent	 acquisition	 (DDA)	 [100]	 (Figure	 7).	 In	 bottom-up	proteomics	proteins	are	extracted	from	a	specific	sample	and	are	enzymatically	digested	(most	commonly	by	trypsin)	into	peptides.	Based	on	their	hydrophobicity	the	peptides	are	subsequently	 separated	 on	 a	 reverse-phase	 liquid	 chromatography	 column	 (LC),	which	is	coupled	online	to	an	electrospray.	Peptides	are	ionized	and	transferred	to	the	mass	spectrometer,	where	their	mass	is	determined	before	they	are	selected	for	fragmentation	 in	 the	 gas	 phase	 to	 generate	MS/MS	 spectra.	 In	 conventional	 DDA	approaches	the	data	is	collected	by	selecting	a	fixed	number	of	peptide	precursors	for	fragmentation	based	on	their	relative	intensity	[101].	
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Figure	 7	 Proteomic	 workflow	 for	 the	 large	 scale	 identification	 of	 PTMs.	 Proteins	 are	 isolated	 from	biological	samples	and	are	enzymatically	digested	into	peptides.	For	large	scale	PTM	analysis	it	is	then	necessary	to	 reduce	 the	 complexity	 of	 the	 sample	 by	 enrichment	 of	 the	modified	 peptides,	 using	 antibodies	 or	 affinity	resins	against	the	specific	PTM	(depicted	here	are	phosphorylation,	methylation	and	acetylation).	Alternatively	deep	 fractionation	 alone	 or	 in	 combination	 with	 enrichment	 also	 helps	 to	 reduce	 complexity.	 Samples	 are	further	 resolved	 on	 a	 LC,	 eluted,	 ionized	 and	 introduced	 into	 the	 MS	 system.	 The	 MS	 records	 the	 peptide	precursor	 ion	 mass-to-charge	 ratio	 (m/z)	 with	 high	 accuracy.	 In	 the	 common	 DAA	 mode	 single	 peptide	precursors	are	then	queried	based	on	their	intensity	for	fragmentation	and	a	MS/MS	measurement	is	performed	to	identify	the	peptide	sequence	and	location	of	modifications.	Adapted	from	[102].	Alternatively,	 other	 data	 collection	methods,	 such	 as	 targeted	 proteomics	 or	 data	independent	 acquisition	 (DIA)	 can	 be	 used	 and	 have	 been	 shown	 to	 increase	 the	sensitivity	and	reproducibility	of	the	measurement,	also	for	peptides	carrying	PTMs.	However,	 these	 latter	approaches	 require	advanced	bioinformatics	workflows	and	previous	knowledge	of	the	peptides	one	wants	to	look	for	[103].			To	 record	 peptide	 fragments	 in	 the	 MS/MS	 scan	 the	 selected	 peptide	precursor	 needs	 to	 be	 fragmented.	Usually	 collision-induced	 dissociation	 (CID)	 or	higher-energy	collisional	dissociation	 (HCD)	 fragmentation	 is	used,	however	other	methods	with	different	properties	such	as	electron	transfer	dissociation	(ETD)	are	available	 and	 are	 beneficial	 for	 the	 analysis	 of	 specific	 types	 of	 PTMs	 [100,	 104,	105].		
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Figure 2 | Generalized mass-spectrometry-based proteomics workflow. In the vast majority of proteomics experiments, 
the extracted proteins are first digested into peptides, usually by trypsin, to create molecular species that are much more 
manageable in both sample handling and mass spectrometry (MS) analysis. Enzymatic digestion of a full proteome generates 
hundreds of thousands of peptides: this sample complexity is not directly compatible with the MS analysis. Therefore, the first 
step in the proteomics workflow is most often directed at reducing the sample complexity either by sample prefractionation 
or enrichment. In sample prefractionation, the peptide population is fractionated according to its physicochemical 
properties, such as charge, isoelectric point, hydrophobicity or combinations of these. It is essential here that the chosen 
fractionation technique is orthogonal to the liquid chromatography (LC) separation just before MS analysis. Alternatively, 
specific subsets of the sample can be targeted through enrichment of peptides containing modifications (for example, 
phosphorylation (P), dimethylation (M 2) or acetylation (Ac)) using affinity-based resins or tibody-based immunoprecipita-
tion (IP). These prefractionated or enriched samples are then introduced to the LC system for an additional separation step to 
educe complexity further; this can be achieved by using, for example, u tra-high-performanc  liquid chromatography (UHPLC). 
Ideally, all peptides eluted from the LC are queried by the mass spectrometer, but in everyday practice, many peptides elute 
simultaneously and compete f r efficient ionization: highly abundant species can suppress the ionization of co- luting less 
abundant species, thus preventing their MS analysis. After ionization, peptide precursor ions are introduced into the  
mass spectrometer, which records their mass-to-charge (m/z) ratio with high accuracy. For identification, single precursors 
are selected (on the basis of observed intensity) and subjected to a tandem MS (MS/MS) event — most commonly, 
collision-induced dissociation (CID) — to generate characteristic fragment ions for the selected precursor. Peaks labelled 
‘b’ are amino-terminal fragment ions, and peaks labelled ‘y’ are carboxy-terminal fragment ions. The combination of 
precursor m/z and its fragment ions is then matched to known peptide sequences from large protein databases using search 
algorithms such as Mascot or SEQUEST. Finally, data are quantified (either relatively or absolutely); for example the three  
data analysis panels in the figure might represent three experimental conditions in which the different proteins (represented 
by different coloured lines) may or may not change in abundance. These protein abundances are then interpreted  
and visualized in the context of the biological system under study. HILIC, hypdrophilic interaction liquid chromatography.
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If	 the	 genome	 sequence	 of	 the	 analyzed	 organism	 is	 known,	 the	 MS/MS	spectra	can	easily	be	analyzed	by	suitable	software	in	order	to	identify	the	peptide	sequence,	 map	 it	 to	 the	 respective	 protein,	 and	 relatively	 quantify	 the	 individual	peptide	 types.	 PTMs	on	 the	peptides	 lead	 to	 characteristic	mass	 shifts	 and	 can	be	computationally	localized	at	single	amino	acid	resolution	on	to	the	peptide	sequence	if	the	corresponding	MS/MS	spectrum	has	a	high	enough	quality.		
8.2 Enrichment	of	PTM	carrying	peptides	In	 order	 to	 reliably	 identify	 peptides	 carrying	 a	 specific	 type	 of	 PTM	 by	 MS	 in	biological	 samples,	 it	 is	 often	 required	 to	 perform	 enrichments	 on	 the	 peptide	 or	protein	 level,	 due	 to	 the	 low	 stoichiometry	 of	 PTM	 sites	 and	 the	 high	 sample	complexity	 (Figure	 7).	 In	 the	 case	 of	 serine/threonine	 phosphorylation	 the	 most	efficient	 enrichment	 strategies	 consist	 of	 Immobilized	 Metal	 Affinity	Chromatography	(IMAC)	or	TiO2	resins,	which	are	however	suboptimal	for	the	less	abundant	 tyrosine	 phosphorylation	 [106].	 Tyrosine	 phosphorylation	 is	 more	reliably	 identified	 using	 antibodies	 or	 engineered	 high	 affinity	 binding	 reagents	[107].	 Also	 for	 acetylation,	 ubiquitination	 and	 ubiquitination-like	 modifications	antibody-based	 peptide	 enrichment	 techniques	 proved	 to	 be	 the	 most	 efficient	methods	for	reliable	identifications	of	many	sites	[106].	O-	and	N-glycosylation	are	successfully	enriched	using	lectins	which	are	carbohydrate	binding	proteins	[106].		For	 individual	PTM	types,	several	 factors	need	to	be	considered	to	perform	proteomic	experiments.	This	includes	the	absence	of	efficient	enrichment	reagents,	the	 large	 amounts	 of	 starting	 material	 that	 is	 needed,	 the	 unfavorable	 physico-chemical	 properties	 of	 modified	 peptides	 and	 the	 PTM	 structure	 and	 stability.	Certain	 modifications,	 such	 as	 glycosylation,	 with	 complex	 glycan	 structure,	 and	nucleotide	 based	 PTMs	 may	 prove	 very	 difficult	 to	 be	 detected	 by	 MS	 due	 to	ionization	and	fragmentation	 issues	and	might	require	enzymatic	or	chemical	pre-treatment.	 Other	 modifications	 are	 very	 labile	 to	 sample	 preparation	 conditions	such	 as	 pH,	 as	 for	 example	 histidine	 phosphorylation,	 undergo	 insource	fragmentation	upon	 ionization	or	are	 too	extensively	 fragmented	 in	 the	MS/MS	 to	accurately	localize	them	onto	the	peptide	sequence	[108,	109].		
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Stream-lined	protocols	 for	 bottom-up	proteomics	 are	 now	widely	 available	for	 a	 subset	 of	 PTMs	 such	 as	 phosphorylation,	 ubiquitination,	 ubiquitin-like	modification,	 glycosylation,	 methylation,	 acetylation	 and	 other	 types	 of	 acylation	[100].	 Furthermore,	 many	 unique	 and	 innovative	 mass	 spectrometry	 based	workflows	have	allowed	the	identification	of	exotic	and	previously	unknown	PTMs,	such	as	different	forms	of	lipidations	[5].		
8.3 Interpreting	PTMs	by	proteomics	exemplified	by	phosphoproteomics	At	 present,	 more	 than	 260’000	 PTM	 sites	 have	 been	 identified	 in	 the	 human	proteome	 [110].	 PTM	 proteomics	 studies	 have	 reached	 a	 remarkable	 depth	 and	sophistication,	 with	 the	 main	 surprises	 being	 the	 high	 numbers	 of	 PTMs,	 their	diversity	 and	 their	 involvement	 in	 all	 sorts	 of	 regulatory	 cellular	 processes,	exemplified	 by	 several	 recent	 phospho-proteomic	 studies	 [100].	 The	 deepest	phospho-proteome	ever	measured	for	a	single	cell	 line	 identified	50’000	phospho-sites	 targeting	 75%	 of	 the	 proteome	 [111].	 Great	 improvements	 have	 also	 been	made	 in	 the	 temporal	 resolution	 of	 PTM	 analysis.	 A	 recent	 study	 looking	 at	 the	kinetics	of	phosphorylation	based	insulin	signaling	in	mouse	liver	revealed	that	this	is	unexpectedly	fast.	 	In	vivo	 insulin	stimulation	affected	10%	of	the	liver	phospho-proteome	 and	maximal	 phosphorylation	was	 already	 reached	 after	 30s	 of	 insulin	stimulation	 for	 many	 sites,	 such	 as	 functionally	 characterized	 phospho-sites	 on	transcription	factors	[112].	To	 understand	 the	 principles	 of	 PTM	 signaling	 and	 function	 it	 is	 also	important	 to	 study	 how	 PTMs	 and	 PTM	 sites	 evolved.	 The	 evolution	 of	 phospho-sites	 in	 the	 proteome	was	 analyzed	 in	 closely	 related	 Saccharomyces	 fungi	 [113].	These	 species	 span	 a	 divergence	 time	 of	 around	 18	 million	 years,	 which	 is	comparable	with	the	time	separating	humans	from	their	last	common	ancestor	with	the	apes.	3000	 to	5000	phospho-sites	per	species	were	detected	and	 it	was	 found	that	 around	69%	of	phospho-sites	were	not	present	 in	 the	 last	 common	ancestor.	Extending	 the	 analysis	 and	 comparing	18	different	 fungal	 species	with	 a	 common	ancestor	 700	 million	 years	 ago,	 the	 authors	 of	 that	 study	 found	 that	 only	 2%	 of	phosphorylation	sites	are	conserved.	This	is	in	stark	contrast	to	the	conservation	of	
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overall	 protein	 domains,	 where	 more	 than	 73%	 are	 conserved	 since	 the	 last	common	 ancestor.	 	 Lack	 of	 conservation	 appears	 to	 contradict	 the	 view	 that	phosphorylation	is	a	strictly	controlled	and	regulated	event.	Indeed,	it	is	likely	that	there	 exists	 a	 certain	 level	 of	 phosphorylation	 “noise”,	 due	 to	 kinase	 promiscuity,	however	 noise	 opens	 up	 the	 possibility	 for	 evolutionary	 adaptation	 and	 can	 be	 a	phenotypic	 attribute	 [114].	 It	 is	 proposed	 that	 the	 rapid	 evolution	 of	phosphorylation	 or	 other	 PTMs	 can	 contribute	 to	 phenotypic	 diversity	 in	 various	systems,	 for	 example	 in	 yeast	 adapting	 to	 a	 new	 environment,	 but	 also	 in	 cancer	cells	circumventing	growth	control	[114].		
9 Proteome-wide	Identification	of	ADP-ribosylation	by	Mass	Spectrometry	
9.1 Challenges	in	identifying	the	ADP-ribosylome	To	elucidate	the	functional	role	of	protein	ADP-ribosylation,	systematical	analysis	of	all	ADP-ribosylated	proteins	and	identification	of	their	ADP-ribose	acceptor	sites	are	necessary.	Mass	spectrometry-based	proteomics	is	probably	the	most	powerful	tool	for	the	analysis	of	PTMs.	However,	the	analysis	of	ADP-ribosylation	has	proven	to	be	very	challenging	 for	several	 reasons,	 including	 the	highly	 transient	nature	and	 the	low	abundance	of	ADP-ribosylated	proteins,	the	special	physicochemical	properties	of	the	PTM	(bulky,	highly	charged,	heterogeneous	structure,	labile),	and	the	number	of	different	amino	acids	that	were	reported	to	be	modified	(glutamic	acid,	aspartic	acid,	lysine,	arginine,	serine	and	cysteine)	[14,	109].	Characterization	of	ADP-ribose	acceptor	sites	by	MS	has	significantly	improved	following	the	development	of	high-resolution	mass	spectrometers	and	novel	fragmentation	techniques.	As	discussed	in	the	 following	 sections,	 ADP-ribosylation	 sites	 can	 now	 be	 identified	 at	 a	 single	amino	 acid	 resolution	 in	 many	 cases,	 since	 several	 enzymatic	 and	 chemical	treatments	have	been	established	to	reduce	the	complexity	of	ADP-ribosylation	and	since	 specialized	 MS	 methods	 combining	 multiple	 fragmentation	 types	 were	integrated	[109].			 Comparable	 to	 many	 other	 PTMs,	 the	 fraction	 of	 ADP-ribosylated	 cellular	proteins	is	very	low.	Thus,	studying	this	group	of	modified	proteins	requires	specific	
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ADP-ribosylated	protein/peptide	 enrichment	methodologies.	Great	 successes	have	been	 made	 by	 applying	 affinity	 purifications,	 phosphoproteomic	 enrichment	techniques	or	chemical	proteomic	approaches	as	discussed	below.	However,	there	is	still	no	approach	or	reagent	available	that	has	a	high	efficiency	for	binding	to	ADP-ribose	independent	of	the	amino	acid	acceptor	sites.		Sample	 preparation	 methods	 are	 critical	 since	 PARylation	 as	 well	 as	MARylation	 are	 highly	 transient	 PTMs,	 which	 are	 reversed	 within	 minutes	 by	hydrolases.	 Additionally,	 introduction	 of	 stress,	 DNA	 damage	 or	 release	 of	 NAD+	during	cell	lysis	may	lead	to	sample	preparation-induced	ADP-ribosylation	[50].		PARylation	 as	 a	 huge,	 heterogeneous	 and	 highly	 charged	 peptide	modification	 is	 so	 far	 incompatible	 with	 current	 peptide	 MS	 methods	 and	 no	established	workflows	are	able	to	differentiate	between	MARylation	and	PARylation	sites.		
9.2 Affinity	purification	of	ADP-ribosylated	proteins		Several	 large	scale	proteomic	studies	have	been	performed	in	which	specific	ADPr	affinity	enrichment	techniques	were	applied	on	the	protein	level	in	order	to	identify	proteins	 that	 are	 associated	with	MAR	or	PAR	 [50,	 115-117].	 These	 studies	 could	not	 identify	 which	 proteins	 are	 ADP-ribosylated,	 nor	 is	 the	 enrichment	 specific	enough	to	determine	ADP-ribosylation	sites,	however	they	represent	an	important	early	 contribution	 to	 the	 identification	 of	 the	 ADP-ribosylome	 and	 several	conclusions	could	be	made.	The	experimental	set	up	 for	 these	studies	consisted	of	human	 cells	 that	 were	 exposed	 to	 genotoxic	 stress	 treatments	 to	 stimulate	 the	PARylation	 activity	 of	 ARTD1	 and	 2.	 Cells	 were	 lysed	 and,	 subsequently,	 ADP-ribosylated	 proteins	 were	 enriched	 with	 the	 10H	 anti-PAR	 antibody,	 or	 ADPr	binding	 proteins,	 such	 as	 PARG-dead	 or	 Af1521.	 Proteins	 were	 digested	 into	peptides	and	identified	by	MS.	The	enrichment	is	performed	under	non-denaturing	conditions	in	these	approaches,	therefore	the	identified	proteins	consist	not	only	of	ADP-ribosylated	proteins	but	also	of	ADP-ribose	 interactors	and	more	importantly	of	 the	 large	non-covalent	 interaction	network,	summarized	as	the	ADP-ribosylated	interactome	[50,	115-118].	These	studies	identified	around	830	proteins,	and	could	
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link	them	to	the	canonical	role	of	PARylation,	the	DNA	damage	response,	but	also	to	novel	 interesting	biological	 functions,	such	as	RNA	processing,	stress	granules,	 the	mitotic	 spindle	 and	 nucleoli	 [109].	 The	 overlap	 of	 the	 identified	 proteins	 in	 the	individual	 studies	 is	 very	 limited,	 less	 than	 50%,	 most	 probably	 due	 to	 the	 very	different	 enrichment	 approaches	 and	 different	 cell	 lysis	 procedures.	 To	 fully	understand	the	 functional	contribution	of	ADP-ribosylation	 to	biological	processes	and	to	make	mechanistic	predictions,	it	is	important	to	resolve	ADP-ribosylation	at	the	level	of	the	amino	acid	attachment	site.		
9.3 Phosphoproteomic	enrichment	approaches	Phosphopeptide	 enrichments	 were	 also	 found	 to	 co-enrich	 ADP-ribosylated	peptides,	 and	 protocols	 have	 been	 optimized	 for	 the	 specific	 enrichment	 of	 ADP-ribosylated	 or	 phospho-ribosylated	 peptides	 [119-122].	 Phosphodiesterases	 (such	as	 snake	 venom	 phosphodiesterase)	 and	 NUDIX	 hydrolases	 were	 used	 to	 reduce	MAR	or	PAR	to	a	protein-bound	phospho-ribose	[122,	123].	The	resulting	phospho-ribosylated	 peptides	 are	 subsequently	 enriched	 using	 either	 Fe(III)-IMAC	 or	TiO2 microspheres,	which	have	a	high	affinity	for	phospho	groups.	The	conversion	of	protein-bound	MAR	or	PAR	to	phospho-ribose	leads	to	a	detectable	mass	signature	of	212.01	Da.	Phosphoproteomic	approaches	have	proven	useful	in	the	analysis	of	in	
vitro	ADP-ribosylated	proteins	or	purified	protein	fractions.	In	contrast,	for	cellular	proteomic	approaches	these	techniques	lack	sensitivity	due	to	the	co-enrichment	of	the	 much	 more	 abundant	 phosphorylated	 peptides	 and,	 thus,	 only	 few	 in	 vivo	targets	could	be	detected	so	far	[124,	125].	
9.4 Chemical-proteomic	approaches	based	on	boronate	affinity	chromatography	An	 enrichment	 protocol	 based	 on	 the	 isolation	 of	 ADP-ribosylated	 peptides	 by	boronate	 affinity	 chromatography	 and	 subsequent	modified	 peptide	 elution	 using	hydroxylamine	 (NH2OH)	 highlighted	 for	 the	 first	 time	 the	 widespread	 ADP-ribosylation	 of	 substrate	 proteins	 [58].	 Boron	 covalently	 binds	 ADP-ribosylated	proteins	through	esterification	with	the	1,2-cis-diol	moieties	within	ADP-ribose.	The	ester	 bond	 between	 the	 first	 ADP-ribose	 unit	 of	 PAR	 and	 the	 side	 chain	 of	 the	
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carboxyl	 group	 of	 an	 ADP-ribosylated	 aspartic	 or	 glutamic	 acid	 is	 susceptible	 to	NH2OH	attack.	This	reaction	converts	 the	ADP-ribosylated	acidic	amino	acid	 into	a	hydroxamic	acid	derivative,	adding	15.01	Da	to	the	initial	amino	acid	weight,	which	is	detectable	by	MS	and	provides	ADP-ribose	acceptor	site	localization	information	(Figure	8A).	
	
Figure	 8	 Overview	 of	 chemical	 proteomic	 strategies	 to	 identify	 ADP-ribosylation	 sites	 or	 ADP-
ribosylated	proteins.	A)	Principle	of	hydroxylamine	elution,	to	identify	ADP-ribosylation	sites	on	acidic	amino	acids,	 as	 applied	 after	 boronate	 affinity	 chromatography.	Adapted	 from	 [58].	 B)	 Chemical-genetic	 enrichment	approach	using	 labeled	NAD+	 and	 engineered	ARTDs.	Adapted	 from	 [126]	C)	 Labeling	of	Adenosine,	which	 is	metabolically	 incorporated	 into	 cells,	 converted	 to	 labeled	 NAD+	 and	 used	 for	 ADP-ribosylation,	 can	 be	employed	to	enrich	modified	proteins.	Adapted	from	[127].	The	major	drawback	of	 this	protocol	 is	 that	 the	 chemical	 reaction	employed	here,	limits	 the	 detection	 of	 ADP-ribosylated	 amino	 acids	 to	 glutamates	 and	 aspartates.	Furthermore	 it	 is	 difficult	 to	 prove	 that	 the	 observed	 sites	 really	 stem	 from	previously	 ADP-ribosylated	 residues.	 The	 study	 identified	 1048	 potential	 ADP-ribosylation	sites	on	E	and	D	on	340	proteins,	 involved	 in	a	wide	array	of	nuclear	functions.	Most	 of	 the	 observed	 sites	were	 sensitive	 to	 PARP	 inhibitor	 treatment.	Additionally,	 hydroxylamine	 treatment	 has	 also	 been	 used	 as	 a	 stand-alone	procedure	without	any	enrichment,	but	this	method	only	seems	useful	for	strongly	ADP-ribosylated	targets	[128].	
9.5 Chemical	proteomic	enrichment	based	on	NAD+	or	precursor	labeling	Several	chemical	proteomic	approaches	exist	in	which	NAD+	or	NAD+	precursors	are	labeled	 with	 a	 functional	 chemical	 group,	 which	 can	 later	 be	 employed	 for	 ADP-ribosylated	protein	or	peptide	enrichment	[59,	127,	129-131].		
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An	 in	vitro	 chemical	 genetic	methodology	 that	 allowed	 the	 identification	 of	protein	targets	specific	for	ARTD1,	ARTD2	and	ARTD3	was	recently	published	[59].	This	approach	 is	based	on	 the	combined	use	of	a	newly	developed	NAD+	analog,	8-Bu(3-yne)T-NAD+,	 and	 engineered	 analog-sensitive	 ARTD1,	 ARTD2,	 and	ARTD3	mutant	protein	(asPARPs).	Analog	sensitivity	was	achieved	by	modifying	the	ART	 active	 site	 to	 accommodate	 the	 bulky	 8-Bu(3-yne)T-NAD+.	 Importantly,	 the	modification	of	proteins	using	 this	NAD+	analog	allowed	downstream	azide-alkyne	cycloaddition	 (“click”	 chemistry),	 which	 enabled	 ARTD	 target	 labeling	 and	purification	(Figure	8	B).	 In	contrast	 to	previous	attempts	[129,	130],	screening	of	an	 NAD+	analog	 library	 with	 systematically	 mutated	 ARTD1	 isoforms	 identified	functional	 combinations	 that	 are	 still	 able	 to	 promote	 PARylation	 [59].	 Using	 this	approach,	HeLa	cell	nuclear	extracts	were	co-incubated	with	purified	salmon	sperm	DNA-activated	 asPARP1-3	 and	 8-Bu(3-yne)T-NAD+.	 The	 asPARP-modified	 protein	targets	were	purified	by	“click”	chemistry-based	azide-agarose	crosslinking,	trypsin	digested,	and	 identified	by	MS.	Asp	and	Glu	ADP-ribosylated	peptides	were	eluted	with	 hydroxylamine	 and	 the	 peptides	 as	 well	 as	 the	 hydroxamic	 acid	 signature	measured	 by	 MS.	 The	 same	 workflow	 was	 also	 applied	 to	 nuclei	 isolated	from	Parp1−/−	mouse	 embryonic	 fibroblasts	 (MEFs)	 overexpressing	 asPARP-1.	 A	total	 of	 467	 in	vitro	 ADP-ribosylated	 proteins	were	 identified	 [59].	 A	 handicap	 of	this	methodology	 is	 that	8-Bu(3-yne)T-NAD+,	 like	NAD+,	 is	not	cell	permeable,	and	can	only	be	used	in	in	vitro	or	in	isolated	nuclei-based	ADP-ribosylation	reactions.	It	is	also	unclear	whether	8-Bu(3-yne)T-NAD+-derived	modifications	are	as	reversible	as	 authentic	 ADP-ribosyl	 modifications.	 Furthermore,	 exogenous	 addition	 of	asPARPs	 and	 the	 NAD+ analog	 may	 cause	 off-target	 modifications	 due	 to	 non-physiological	concentrations.	Potential	modifications	of	other	amino	acids,	e.g.,	Ser,	Lys	or	Arg	cannot	be	identified	[126].		A	 Similar	 approach	 by	 another	 group	was	 performed	with	 the	MARylating	ARTD10	and	11,	where	several	hundred	targets	were	 identified	 in	vitro	using	HEK	or	HeLa	 cell	 lysates.	The	 study	 showed	 that	ARTD11	might	have	a	 role	 in	nuclear	pore	biology	[131].	
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In	a	novel	innovative	approach	NAD+	was	not	tagged	itself,	but	an	alkyne-adenosine	analog,	 N6-propargyl	 adenosine	 [127].	 	 This	 analog	 is	 metabolically	 incorporated	into	mammalian	 cells,	 where	 it	 is	 converted	 to	 N6-propargyl	 NAD+	and	 eventually	used	by	ARTDs	for	ADP-ribosylation.	N6-propargyl	labeled	ADP-ribosylated	proteins	were	 conjugated	 with	 azide–biotin,	 affinity	 purified	 with	 streptavidin	 beads	 and	subjected	to	on-bead	protease	digestion	that	was	followed	by	protein	identification	using	MS	(Figure	8	C).	This	approach	has	not	been	combined	with	ADPr	site-specific	mapping	 approaches	 yet,	 however	 the	 method	 is	 very	 promising,	 since	 it	 can	 be	applied	 in	vivo,	unlike	approaches	where	NAD+	 is	 labeled	and	engineered	proteins	need	to	be	used.		
10 Mass	spectrometric	identification	of	ADP-ribose	acceptor	sites	Great	advances	have	been	made	in	establishing	techniques	for	the	identification	of	the	ADP-ribosylome.	However,	 the	most	 challenging	part	 of	 this	 undertaking	 is	 to	identify	 endogenous	 ADP-ribosylation	 sites	 on	 the	 protein	 sequences	with	 a	 high	probability.	The	functional	role	of	ADP-ribosylation	of	a	specific	protein	can	only	be	addressed	 if	 the	 exact	 modification	 site	 is	 known.	 This	 knowledge	 is	 equally	important	 for	 systems	 biology	 studies	 of	 the	 ADP-ribosylome	 as	 well	 as	 for	mechanistic	 studies	 in	 which	 the	 modification	 site	 is	 mutated	 in	 recombinant	proteins	 or	 directly	 in	 cells	 by	 targeted	 genome	 editing.	 For	 a	 long	 time,	 the	identification	 of	 ADP-ribosylation	 sites	 has	 been	 hampered	 by	 low	 efficient	 and	biased	 ADPr-peptide	 enrichment	 strategies	 (as	 discussed	 above),	 technical	limitations	 of	 mass	 spectrometers	 or	 by	 insufficient	 bioinformatic	 solutions	 [58,	109,	132].		Major	 advancements	 have	 been	 made	 in	 the	 core	 technology	 of	 mass	spectrometry	 over	 the	 last	 decade,	 thereby	 dramatically	 increasing	 the	 sensitivity	and	 resolution,	 and	 it	 is	 expected	 that	 this	 fast	 development	 will	 continue	 [100].	Novel	and	customizable	peptide	fragmentation	techniques	are	now	widely	available	and	 facilitate	 PTM	 analysis.	 Early	 studies	 noticed	 that	 MS	 identification	 of	 ADP-ribosylation	 sites	 is	 highly	 dependent	 on	 the	 applied	 fragmentation	 technique.	Initial	 studies	 of	 ADP-ribosylated	 peptides	 were	 dependent	 on	 collision-induced	
29
INTRODUCTION	
dissociation	 (CID),	 the	 main	 fragmentation	 technique	 available	 at	 that	 time.	 The	problem	 with	 CID	 was,	 that	 it	 either	 led	 to	 complete	 fragmentation	 of	 the	 ADP-ribose	moiety	or	to	 incomplete	 fragmentation	of	 the	peptide	backbone,	preventing	identification	 of	 ADP-ribosylation	 sites	 in	 most	 cases.	 It	 was	 noticed	 that	fragmentation	of	the	ADP-ribose	moiety	led	to	a	set	of	indicative	ADP-ribose	marker	ions	(Figure	9)	[133,	134].	
	
Figure	9	Marker	ions	produced	by	the	fragmentation	of	the	ADP-ribose	moiety.		The	 introduction	 and	wide	 availability	 of	 electron	 transfer	 dissociation	 (ETD)	 has	been	beneficial	for	the	analysis	of	several	PTMs	since	it	leads	to	the	stabilization	of	labile	PTMs	on	the	peptide	and	to	a	better fragment ion	series,	which	allows	better	sequence	 and	modification	 site	 assignments	 [135].	 Indeed	 ETD	 has	 proven	 to	 be	advantageous	 for	 the	 localization	 of	 ADP-ribosylation	 sites,	 since	 it	 usually	 leaves	the	ADP-ribose	unit	on	the	peptide	fragment	ions	and	leads	to	proper	fragmentation	of	the	peptide	backbone	[136,	137].	Systematic	analysis	of	in	vitro	ADP-ribosylated	ARTDs	 and	 histones	 revealed	 that	 also	 the	 now	 broadly	 available	 higher	 energy	collisional	 dissociation	 (HCD)	 fragmentation	 led	 to	 the	 efficient	 identification	 of	ADP-ribosylation	sites	[137].		HCD	was	a	shown	to	be	somewhat	less	accurate	than	ETD	 in	 localizing	 the	 ADP-ribosylation	 sites,	 however	 led	 to	 the	 identification	 of	many	more	ADP-ribosylated	peptides	[134,	137].	Furthermore	the	 indicative	ADP-ribose	 fragmentation	 ions	 produced	 during	 HCD	 fragmentation	 were	 used	 in	 a	product	dependent	manner	to	selectively	fragment	only	potentially	ADP-ribosylated	peptides,	increasing	the	number	of	identifications	as	well	as	the	accuracy	of	the	site	assignments	[137].	Still	it	is	not	clear	if	specific	fragmentation	methods	have	biases	towards	specific	amino	acid	acceptor	ADP-ribose	linkages.		
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AIMS	OF	THE	THESIS	
 AIMS	OF	THE	THESIS	ADP-ribosylation	 occurrence,	 dynamics	 and	 function	 on	 a	 system	 level	 remain	elusive	 or	 only	 vaguely	 described.	 The	 aim	 of	 this	 PhD	 project	 was	 to	map	 ADP-ribosylation	 sites	 across	 the	 proteome	 (i.e.	 the	 ADP-ribosylome),	 to	 identify	 their	writers	under	basal	and	stressed	conditions	in	cultured	cells	and	in	mouse	tissues.	Furthermore,	 we	 aimed	 to	 elucidate	 the	 functional	 consequences	 of	 particular	identified	sites.	The	thesis	addressed	the	following	specific	aims:		
(i)	 To	 develop	 proteomic	 methods	 for	 enrichment	 of	 endogenous	 ADP-ribosylated	
proteins	 or	 peptides	 and	 to	 analyze	 ADP-ribosylation	 sites	 by	 optimized	 mass	
spectrometric	methods.		
	
(ii)	To	define	the	contribution	and	site	specificity	of	ARTD1	and	ARTD2	to	the	cellular	
ADP-ribosylome	under	oxidative	stress	conditions	in	cultured	cells.		
	
(iii)	To	elucidate	the	mouse	heart	and	skeletal	muscle	ADP-ribosylome	under	basal	and	
inflammatory	conditions	with	a	focus	on	the	role	of	ARTC1.			 	
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 RESULTS	
1 Overview	of	published	manuscripts		
1.1 Proteome-wide	 identification	 of	 the	 endogenous	 ADP-ribosylome	 of	
mammalian	cells	and	tissue	Authors:	 Martello	 R.*,	 Leutert	 M.*,	 Jungmichel	 S.*,	 Bilan	 V.,	 Larsen	 S.C.,	Young	C.,	Hottiger	M.O.,	and	Nielsen	M.L.	*equal	contribution	Journal:	 Nature	Communications	(2016),	10.1038/ncomms12917	Link:	 https://www.nature.com/articles/ncomms12917	Contribution:	 Prepared	 samples,	 performed	 MS	 measurement	 and	 analysis	 of	mouse	liver,	HeLa	and	recombinant	protein	samples.	Assisted	in	the	development	 of	 certain	 aspects	 of	 the	method.	 Performed	 in	vitro	ADP-ribosylation	assays,	 (Figure	3c-e,	 Figure	4,	 	 Figure	 S3,	 Figure	S4	c,f,	Figure	S5	c,d).	Assisted	in	writing	the	paper.		
1.2 Combining	 Higher-Energy	 Collision	Dissociation	 and	 Electron-Transfer/Higher-
Energy	 Collision	 Dissociation	 Fragmentation	 in	 a	 Product-Dependent	Manner	
Confidently	Assigns	Proteomewide	ADP-Ribose	Acceptor	Sites.	Authors:	 Bilan	V.*,	Leutert	M.*,	Nanni	P.*,	Panse	C.,	and	Hottiger	M.	O.		 *equal	contribution	Journal:	 Analytical	chemistry	(2016),	10.1021/acs.analchem.6b03365	Link:	 http://pubs.acs.org/doi/abs/10.1021/acs.analchem.6b03365	Contributions:	 Planned	 the	 experiments,	 prepared	 samples,	 optimized	 MS	parameter	 and	 measurements,	 performed	 data	 analysis	 together	with	B.V	and	P.N.	Assisted	in	writing	the	manuscript.	
1.3 Analysis	 of	 Chromatin	 ADP-Ribosylation	 at	 the	 Genome-wide	 Level	 and	 at	
Specific	Loci	by	ADPr-ChAP	Authors:		 Bartolomei	G.,	Leutert	M.,	Manzo	M.,	Baubec	T.,	Hottiger	M.O.	Journal:		 Molecular	Cell	(2016),	10.1016/j.molcel.2015.12.025	
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Link:	 http://dx.doi.org/10.1016/j.molcel.2015.12.025 Contributions:		 Performed	 chromatin	 immuno	 purification	 and	 chromatin	 affinity	purification	experiments	and	biochemical	assay		(Figure	3	E,	Figure	S1	C,D,	Figure	S2	C,D,	Figure	S5	A-F).	
1.4 Identification	 of	 ADP-Ribose	 Acceptor	 Sites	 on	 In	 Vitro	Modified	 Proteins	 by	
Liquid	Chromatography-Tandem	Mass	Spectrometry.	Authors:		 Leutert	M.*,	Bilan	V.	*,	Gehrig	P.,	Hottiger	M.O.	*equal	contribution	Journal:		 Methods	Molecular	Biology	(2017),	1608,	137-148.	Link:	 https://link.springer.com/protocol/10.1007%2F978-1-4939-6993-7_10	Contributions:		 Performed	 enrichment,	 MS	 measurement	 and	 data	 analysis	together	with	P.G,	wrote	the	chapter	together	with	V.B	and	M.O.H.		
1.5 Proteome-Wide	 Identification	of	 In	Vivo	ADP-Ribose	Acceptor	 Sites	 by	 Liquid	
Chromatography-Tandem	Mass	Spectrometry.	Authors:		 Larsen	 S.C.*,	 Leutert	 M.*,	 Bilan,	 V.,	 Martello,	 R.,	 Jungmichel,	 S.,	Young,	C.,	Hottiger,	M.O.,	and	Nielsen,	M.L.	*equal	contribution	Journal:		 Methods	Molecular	Biology	(2017),	1608,	149-162.	Link:	 https://link.springer.com/protocol/10.1007%2F978-1-4939-6993-7_11	Contributions:		 Created	figures	and	assisted	in	writing	the	chapter.		
1.6 Identification	of	PARP-Specific	ADP-Ribosylation	Targets	Reveals	a	Regulatory	
Function	for	ADP-Ribosylation	in	Transcription	Elongation	Authors:		 Leutert	M.,	Pedrioli,	D.M.,	and	Hottiger,	M.O.	Journal:		 Molecular	Cell	(2016),	10.1016/j.molcel.2016.07.006	Link:	 http://dx.doi.org/10.1016/j.molcel.2016.07.006	Contributions:		 Created	 figures	 and	 wrote	 the	 preview	 together	 with	 D.M.P.	 and	M.O.H.		
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2 Overview	of	submitted	manuscripts		
2.1 Comprehensive	 in	 vivo	 ADP-ribosylome	 analysis	 identifies	 tyrosine	 ADP-
ribosylation	 of	 HPF1	 and	 reveals	 that	 this	 modification	 modulates	 ARTD1	
activity	Authors:		 Leslie	Pedrioli,	D.M*,	Leutert	M.*,	Bilan	V.,	Nowak	K.,	Gunasekera	K.,	Ferrari	E.,	Imhof	R.,	Malmstöm	L.,	Hottiger	M.O.	*equal	contribution	Contribution:		 Generated	 shARTD1	 and	 shARTD2	 HeLa	 cell	 lines,	 performed	sample	 preparation,	 MS	 measurement	 and	 data	 analysis.	Established	label	free	quantification	workflow	and	analysis	of	ADP-ribosylated	 peptides.	 Contributed	 in	 conceiving	 the	 project,	participated	 in	 manual	 spectra	 validation	 and	 assisted	 in	 writing	the	paper.			
2.2 Proteomic	analyses	identify	ARH3	as	a	serine	mono	ADP-ribosylhydrolase	Authors:		 Abplanalp	 J.,	 Leutert	 M.,	 Frugier	 E.,	 Nowak	 K.,	 Feurer	 R.,	 Kato	 J.,	Kistemaker	 	H.	,	Filippov	D.V.,	Moss	J.,	Caflisch	J.,	Hottiger	M.O.			Contribution:	 Performed	 sample	 preparation,	 MS	 measurements,	 label	 free	quantification	 and	 data	 analysis.	 Established	 ADP-ribosylated	peptide	 demodification	 and	 MS	 quantification	 assay.	 Assisted	 in	writing	the	paper.		
2.3 Ecto-ADP-ribosyltransferase	ARTC2.1	functionally	modulates	FcγR1	and	FcγR2B	
on	microglia	Authors:		 Rissiek	B.,	Menzel	S.,	Leutert	M.,	Cordes	M.,	Behr	M.,	 	Ludewig	P.,		Gelderblom	M.,	Rissiek	A.,	Adriouch	S.,	Hottiger	M.O.,	Koch-Nolte	F.,	Magnus	T.	Contribution:		 Performed	 sample	 preparation,	 MS	 measurements	 and	 data	analysis	and	interpretation.	Assisted	in	writing	the	paper.	
34
RESULTS	
3 Prepared	but	not	yet	submitted	manuscript		
3.1 Proteomic	 characterization	 of	 the	 heart	 and	 skeletal	 muscle	 reveals	
widespread	 Arginine	 ADP-ribosylation	 by	 the	 ectopic	 ADP-ribosyltransferase	
ARTC1	Authors:	 Leutert	M.,	Menzel	S.,	Braren	R.,	Rissiek	B.,	Gehrig	P.,	Zolkiewska	A.,	Koch-Nolte	F.,	Hottiger	M.O.	Contribution:	 Conceived	 and	planned	 the	project,	 performed	 sample	preparation,	MS	 measurments,	 label	 free	 quantification	 and	 data	 analysis.	Assisted	in	writing	the	paper.			 	
35
ARTICLE
Received 7 Apr 2016 | Accepted 15 Aug 2016 | Published 30 Sep 2016
Proteome-wide identification of the endogenous
ADP-ribosylome of mammalian cells and tissue
Rita Martello1,*, Mario Leutert2,3,*, Stephanie Jungmichel1,*, Vera Bilan2,3, Sara C. Larsen1, Clifford Young1,
Michael O. Hottiger2 & Michael L. Nielsen1
Although protein ADP-ribosylation is involved in diverse biological processes, it has remained
a challenge to identify ADP-ribose acceptor sites. Here, we present an experimental workflow
for sensitive and unbiased analysis of endogenous ADP-ribosylation sites, capable of
detecting more than 900 modification sites in mammalian cells and mouse liver. In cells,
we demonstrate that Lys residues, besides Glu, Asp and Arg residues, are the dominant
in vivo targets of ADP-ribosylation during oxidative stress. In normal liver tissue, we find Arg
residues to be the predominant modification site. The cellular distribution and biological
processes that involve ADP-ribosylated proteins are different in cultured cells and liver tissue,
in the latter of which the majority of sites were found to be in cytosolic and mitochondrial
protein networks primarily associated with metabolism. Collectively, we describe a robust
methodology for the assessment of the role of ADP-ribosylation and ADP-ribosyltransferases
in physiological and pathological states.
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Protein ADP-ribosylation refers to the process where anADP-ribose moiety is transferred from NADþ to theamino acid side-chains of target proteins (as mono-ADP-
ribose, MAR) or to an already protein bound ADP-ribose to
form poly-ADP-ribose (PAR). These modifications are primarily
catalysed by a class of enzymes known as ADP-ribosyltransferases
(ARTs), with certain Sirtuin deacetylases also being able to
catalyse ADP-ribosylation1. The ARTs can be divided further
into two major subclasses: ARTCs (cholera toxin-like) and
ARTDs (diphtheria toxin-like, formerly called poly(ADP-ribose)
polymerases (PARPs)), depending on their conserved structural
features2.
While MARylation has been reported to modulate GSK3b
kinase activity and NF-kB signalling3, little is known about the
biological functions of this type of modification. In contrast,
PARylation has emerged as a crucial post-translational
modification (PTM) in cancer development4. PARylation is a
transient PTM5, whose rapid cellular degradation is
predominantly carried out by PAR glycohydrolase (PARG)6.
While PARylation is a key component of the DNA damage
response (DDR) via its central role in the base excision repair
pathway, many of the molecular details and processes affected by
ARTs remain poorly understood. As a result, a detailed
understanding of the molecular mechanisms and functions
affected by ADP-ribosylation remains elusive.
In particular, the inventory of the amino acid residues
modified by ADP-ribosylation remains incomplete. Current
experimental evidence suggests that ADP-ribosylation primarily
occurs on four different amino acids; Lys7, Arg8, Asp and
Glu residues9. In addition, Cys residues were reported to
be MARylated by certain ARTDs or bacterial toxins10.
High-resolution mass spectrometry (MS) has become a valuable
tool for comprehensive identification of PTMs11. However,
current MS-based approaches for mapping ADP-ribosylation
sites are biased towards modifications of only Glu and Asp9,
or they lack sensitivity due to co-enrichment of other PTMs
(that is, phosphorylated peptides)12.
Moreover, protein ADP-ribosylation is a low-abundant
PTM that is rapidly degraded. To overcome this challenge
cellular PARG knockdowns (siPARG) or knockouts have been
developed9,12. Unfortunately, cellular absence of PARG leads
to physiological alterations in cells, hepatocellular carcinoma
in mice13, progressive neurodegeneration14 and excessive
accumulation of PAR chains that are not rapidly degraded and
promote cell death via parthanatos15. Consequently, strategies
requiring knockdown of PARG constitute an improper setting for
analysing physiological ADP-ribosylation and its associated
mechanisms, thus rendering these methods inapplicable for
in vivo analysis of tissues without genetic interventions16.
Moreover, while ADP-ribosylation has been known for more
than 50 years, the cellular stoichiometry of the modification has
remained elusive, primarily due to the lack of methodologies that
can elucidate such information17.
Recently a chemical genetic discovery method for
ARTD targets was reported18, where the NADþ analogue
8-Bu(3-yne)T-NADþ was incubated with cell lysates from cells
overexpressing mutated ARTDs sensitive to the analogue or cell
lysates spiked with recombinant mutated ARTDs. However, as
NADþ is impermeable to the cell membrane, this method
requires either the lysis of cells or the isolation of organelles
(that is, nuclei) followed by the complementation of exogenous
8-Bu(3-yne)T-NADþ , which renders the identification of
ARTD-specific substrates under different cellular conditions,
and at physiological NADþ levels unattainable. Moreover, the
ADP-ribose acceptor sites identified using this methodology were
limited to Glu and Asp modifications9.
To address these limitations, we have developed a protocol for
the unbiased mapping of endogenous ADP-ribosylation sites in
proteins. Our method led to the identification of more than 500
endogenous ADP-ribosylation sites in a single analysis and, as a
result, provides an unprecedented in-depth analysis of protein
ADP-ribosylation. Importantly, as the described workflow is
applied under genetically unperturbed physiological conditions,
we have used our methodology to analyse ADP-ribosylation sites
in both cultured mammalian cells and mouse liver. Collectively,
the workflow presented here represents a major advance in the
detection of ADP-ribose acceptor sites and the identification
of cellular processes regulated by ADP-ribosylation. Thus,
facilitating a better understanding of the complex physiological
and pathological processes that involve ADP-ribosylation,
and the treatment of such conditions with PARP (that is,
ADP-ribosylation) inhibitors.
Results
Identification of endogenous ADP-ribosylation sites. We have
developed a technology for sensitive analysis of endogenous
ADP-ribosylation sites in both cells and tissues that overcomes
several of the above-mentioned limitations of current approaches.
Briefly, proteins are isolated from cells, digested into peptides
first using LysC and then trypsin. We then treat the cellular
peptide digest with PARG, thereby converting all PARylated
amino acids to their MARylated counterparts19. While this
prevents discriminating whether the modification was originally
PARylation or MARylation, the conversion is crucial for feasible
MS analysis. Furthermore, this has the advantage that MARylated
peptides can be unbiasedly enriched with an ADP-ribose-specific
domain20. In contrast to previously described methodologies21,
enrichment at the peptide level with Af1521 in combination with
prior PARG treatment has not been performed before.
Subsequently, the enriched ADP-ribosylated peptides and their
acceptor sites are identified using a high-resolution Orbitrap mass
spectrometer (Q Exactive HF). As no pre-fractionation steps are
employed, the described workflow analyses ADP-ribosylated
peptides from a single sample requiring only a few hours
of sensitive LC-MS operation22. All peptides are fragmented
using higher-energy collisional dissociation (HCD) ensuring high
p.p.m. accuracy on both the precursor and fragment ions23.
Furthermore, ADP-ribosylated peptide identification is aided
by diagnostic ions originating from the fragmentation of the
ADP-ribose group linked to the peptide24,25 (Supplementary
Fig. 1a). Superior advancements over current methodologies are
as follows: First, sample preparation without ARTD, NADþ or
PARG level perturbation9,18 allows analysis of both cells and
tissues under physiological conditions. This will allow us to
broaden our understanding of the mammalian ADP-ribosylation
complexity, and facilitating comparisons across any cellular
condition, cell type and, even, species. To substantiate this, we
have applied our established method to HeLa cells exposed to
hydrogen peroxide (H2O2)-induced oxidative stress (Fig. 1a), and
to normal mouse liver samples. Second, using the Af1521 macro
domain to enrich ADP-ribosylated peptides, which has favourable
binding preferences and relatively high ADP-ribose affinity with a
Kd ofB0.13 mM (ref. 26), allowed unbiased modified amino acid
analysis. Third, we have ensured prevention of lysis-induced
ADP-ribosylation artefacts, as previously reported20, thus
facilitating assessment of the ADP-ribosylome during actual
physiological conditions.
Identification of the H2O2-induced ADP-ribosylome. To
benchmark our methodology, we treated HeLa cells with 500mM
H2O2, which induces PAR formation through oxidative stress
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Figure 1 | Proteome-wide identification of endogenous ADP-ribosylation sites in human cell culture. (a) Schematic representation of the peptide-based
enrichment strategy. HeLa cells were treated with genotoxic stress and digested into peptides. Tryptic digested peptides were treated with PARG enzyme to
convert multimeric ADP-ribosylation into monomeric counterparts, and subsequently ADP-ribosylated peptides were enriched using GST-Af1521
macrodomain. Enriched peptides were analysed by high-resolution LC-MS/MS on an Orbitrap Q-Exactive HF instrument and the data was further
processed by bioinformatic software tools. (b) Comparison of HeLa cells exposed with 500mM H2O2. During cellular knock-down of PARG enzyme
(siPARG) an abundant PAR signal is observed, while under physiological conditions the PAR signal is significantly weaker (compare second lane with fourth
lane on gel). Previous methods for characterizing ADP-ribosylation solely worked under siPARG conditions while the methodology described here
is applicable to physiological conditions. (c) Optimization of the incubation time and amount of PARG enzyme required for converting multimeric
ADP-ribosylated peptides into monomeric counterparts. (d) Validation experiment that confirms PARG treatment does not remove MAR from investigated
peptides. (e) Venn diagram of identified ADP-ribosylation sites identified in two biological replicate analyses. A strong overlap in identified sites
signifies high reproducibility in the developed method. (f) GO functional annotation of significantly regulated proteins in the combined data set
reveal strong enrichment of proteins involved in DNA repair processes compared with annotated GO genes across the entire human genome (indicated
P-valueso0.005). (g) GO term annotation enrichment for cellular distribution of proteins harbouring ADP-ribosylation sites.
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signalling. Under physiological conditions (non-siPARG
conditions), H2O2 treatment induces PAR levels only faintly
detectable by immunoblot (Fig. 1b), while cellular knock-down
of PARG via small interfering RNA (siPARG) causes strong
PAR formation (Fig. 1b). This demonstrates the requirement
for improved sensitivity in studying ADP-ribosylation under
unperturbed physiological conditions.
To ensure complete catalysis of PARylated into MARylated
peptides we next assessed the amount of PARG required to
catalyse a fixed amount of PAR. Previously, PAR levels in HeLa
cells have been reported to range up to 0.1 amol per cell during
H2O2 treatment27. Thus, we incubated 10 mM of purified PAR
with increasing concentrations of PARG and assessed the
temporal efficiency of the catalysis by immune-slot blot
(Fig. 1c). Since the most efficient catalysis was observed when
PAR was treated with PARG for 3 h, we concluded that this
enzyme ratio allowed enzymatic catalysis of PARylated peptides
into MARylated peptides during our enrichment procedure.
As some macrodomains can exhibit hydrolase activity on MAR
moieties28,29, we performed the Af1521 enrichment procedure at
4 !C and incubated samples for only two hours. Moreover, all
subsequent sample handling steps were performed at 4 !C, which
collectively prevents hydrolase activity of the Af1521 macro
domain20. To confirm that PARG exerted no enzymatic hydrolase
activity on MAR (ref. 19) in our workflow, we assessed whether
PARG removes ADP-ribosylation from automodified ARTD1
(also PARP1) or ARTD10 (formerly PARP10; Fig. 1d), which are
known PARylated and MARylated substrates30, respectively.
Using autoradiography assays, hydrolysis of the attached
radioactive [32P]-PAR of the protein substrates was monitored
(Fig. 1d), revealing that PARG was indeed able to convert PAR
chains on ARTD1 into MAR, while no reaction was observed
regarding the auto-MARylation of ARTD10 (Fig. 1d). These
results confirmed that PARG hydrolase activity would not affect
enrichment of MAR residues.
To evaluate the reproducibility of the methodology, we
performed replicate enrichment experiments in HeLa cells.
Following MS analysis, there was a 75% overlap of the high-
confident ADP-ribose acceptor sites identified (localization scores
40.60) between replicates (Fig. 1e). Thus, this indicates high
reproducibility in the established approach, which compares
well with the reproducibility obtained in other proteomic
experiments (Supplementary Note 1)31. From three replicates,
we have identified 739 ADP-ribosylation sites (Localization score
40.60) on 480 proteins after H2O2 treatment (Supplementary
Data 1), with the majority of identified proteins containing a
single modification site (Supplementary Fig. 1b). To corroborate
our identification analysis, we performed a separate MS analysis
employing the complementary fragmentation technique electron
transfer dissociation (ETD)32, which confirmed the localization of
several identified sites (Supplementary Fig. 1c,d; Supplementary
Data 2).
Functional analysis using gene ontology (GO) confirmed that
the identified proteins participate in biological processes known
to involve ADP-ribosylation activity, including transcription,
chromosome organization and response to DNA damage
stimulus33,34 (Fig. 1f). Reassuringly, we find that 76% of the
ADP-ribosylated proteins localize to the nucleus (Fig. 1g), in line
with the cellular localization of ARTD1 and ARTD2 (also
PARP2). Moreover, the cellular abundance profile of identified
ADP-ribosylation protein targets supports the notion that
our methodology is not biased towards abundant proteins
(Supplementary Fig. 1e). Collectively, these results confirm the
feasibility and reproducibility of this novel proteomics approach
for identifying the endogenous ADP-ribosylation sites in cultured
HeLa cells.
Identification of Lys residues as endogenous acceptor sites. As
the Af1521 macro domain binds to the ADP-ribose moiety26 our
methodology allows for unbiased detection of any ADP-ribose
acceptor site. In support of this, no discernable difference was
observed when the amino acid distribution of ADP-ribosylation
sites was compared with the amino acid distribution of the
same residues across the proteome (Fig. 2a). Among the
identified ADP-ribosylation sites, we observed a significant
portion of modifications residing on Lys residues, including the
previously confirmed ARTD1 modification site K498 (ref. 7).
ADP-ribosylation of Lys residues has been suggested as an
artefact related to the release of ADP-ribose moieties during
PARG cleavage of PAR chains17. This suggestion was made based
on observations that ADP-ribose was found to non-enzymatically
attach to Lys, Arg and Cys residues in a glycation process35.
However, the incorporation rate (stoichiometry) achieved in this
study, which utilized large amounts of histone proteins for
in vitro reactions, were estimated to be below 2%, suggesting that
this is an inefficient reaction35. To investigate whether PARG
treatment of PAR chains causes glycation in our experimental
setup, we performed a quantitative experiment using Stable
Isotope Labelling by Amino acids in Cell culture (SILAC)36.
Herein ‘Heavy’ SILAC cell lysates were treated with free PAR
chains before PARG degradation, while ‘Light’ SILAC cell lysates
were left untreated (Supplementary Fig. 2a). Since no
PAR-inducing stress was exerted on these cells, identification of
ADP-ribosylation sites exhibiting increased SILAC ratios would
be indicative of chemical reactions caused by free ADP-ribose
released by PARG. Here we identified 39 ADP-ribosylation sites
equally distributed across Lys, Arg, Glu and Asp residues, and no
increased SILAC ratios were observed for identified modification
sites. These findings strongly suggest that PARG treatment does
not lead to random glycation of Lys or Arg residues (Fig. 2b
and Supplementary Data 3). To substantiate our findings, we
performed a ‘reverse’ SILAC experiment where only light SILAC
cells were treated with free PAR chains, which resulted in a
similar outcome (Fig. 2b). These results confirm that ADP-ribose
moieties released on PARG treatment are unlikely to cause
relevant in vitro artefacts and, combined with the overall
reproducibility of ADP-ribosylation site identification (Fig. 1e),
suggest that the identified ADP-ribosylation sites were not
derived from non-enzymatic glycation.
In addition, an in vitro experiment utilizing a synthesized
histone H2B-like peptide (NH2-PQPAKSAPAPKKG-OH) incu-
bated with free ADP-ribose was performed analogous to
previously reported experiments35. Briefly, the non-modified
H2B peptide was incubated with 1mM ADP-ribose at 37 !C at
pH 9 or 7.5 for two time points (1 h or overnight incubation).
Glycation levels were then determined using time-of-flight (TOF)
MS (Supplementary Fig. 2b). On incubation with free
ADP-ribose, only small levels of glycation were observed,
dependent on pH and incubation time (Supplementary Fig. 2b).
Tandem mass spectrometry (MS/MS) confirmed that glycation
took place at Lys residues (Supplementary Fig. 2c), corroborating
earlier observations that free ADP-ribose is able to modify Lys
residues by non-enzymatic glycation. However, our data reveal
that glycation occurs primarily at high pH and requires
non-physiological concentrations of free ADP-ribose. In
contrast, PARG-released ADP-ribose was not able to induce
similar artefacts at detectable levels. Moreover, the non-enzymatic
glycation of ADP-ribose occurred primarly on several Lys
residues within the short H2B-peptide, which is in stark
contrast to the different ADP-ribosylation sites observed in cell
culture (Supplementary Fig. 1b). Collectively, these results
strongly suggest that the ADP-ribosylation sites observed in our
cell culture analysis were not caused by glycation.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms12917
4 NATURE COMMUNICATIONS | 7:12917 | DOI: 10.1038/ncomms12917 | www.nature.com/naturecommunications
RESULTS
39
To further validate Lys residue ADP-ribosylation in vivo, we
biochemically confirmed the Lys modification sites identified on
FEN1, CEBPB and SSRP1 in cells using an in vitro PARylation
assay. To this end, recombinant proteins for these target
substrates were purified as wild type (WT) and potentially
modification-deficient mutant variants, with the latter harbouring
K-to-A mutations at Lys residues that we found to be modified
(K354A for FEN1, K133A for CEBPB and K640A for SSRP1)
(Supplementary Data 1). All proteins were incubated with
purified ARTD1 in the presence of [32P]-NADþ and a DNA
fragment to measure the incorporation of NADþ radioactivity by
autoradiography37. Activation of ARTD1 was confirmed by a
a
b
c
1.5
2
Forward Reverse
0
0.5
1
SI
LA
C 
ra
tio
 (lo
g2
)
n = 38 (D=9, E=12, K=10, R=7)
D
is
tri
bu
tio
n,
 %
Asp Glu Lys Arg
30
40
50
0
10
20
PARylome Genome
P32
CB
ARTD1
FEN1 CEBPB SSRP1
ARTD1
* *
*
* *
*
Density:
ARTD1
K354Awt K133Awt K640Awt
TAF15
SRSF1
CBX4
d
WC
L
IP:
 GF
P
IP:
Af1
52
1 
97 kDa
IB: GFP
H2O2: + + + +
Olaparib: +
IP:
Af1
52
1 
WC
L
IP:
 GF
P
IP:
Af1
52
1 
97 kDa
IB: GFP
+ + + +H2O2:
Olaparib: +
IP:
Af1
52
1 
WC
L
IP:
 GF
P
IP:
Af1
52
1 
64 kDa
IB: GFP
H2O2: + + + +
Olaparib:
– – –
+
IP:
Af1
52
1 
WC
L
IP:
 GF
P
IP:
Af1
52
1 
64 kDa
IB: GFP
H2O2: + + + +
Olaparib: +
IP:
Af1
52
1 
SRSF2
Asp Glu Lys Arg
0.841.000.181.00
– – –
– – –
– – –
Figure 2 | Lysine residues are in vivo targets of ADP-ribosylation in human cells. (a) Distribution of ADP-ribosylation acceptor sites compared with their
distribution in the genome. (b) Assessment of peptide glycation by free ADP-ribose. Distribution of log2 transformed SILAC ratios, and ADP-ribosylation
acceptor sites, from forward and reverse SILAC experiments as outlined in Supplementary Fig. 2a. No increased SILAC ratios were observed for the
different acceptor sites when cells were treated with PAR, supporting the notion, that the observed modifications are not derived from glycation.
(c) In vitro PARylation of identified protein targets. Purified full-length human ARTD1 was incubated with recombinantly expressed proteins in the presence
of 32P-NADþ and double-stranded DNA oligomer. Samples were resolved by SDS–PAGE, stained with Coomassie (CB; lower panel) and 32P-incorporation
was detected by autoradiography (P32; upper panel). (d) HeLa cells stably expressing SRSF1, SRSF2 CBX4 or TAF15 as GFP-fusion proteins were
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strong automodification (Fig. 2c, upper panel). Using ARTD1
we detected strong ADP-ribosylation signals for all three WT
protein candidates, confirming that these are ADP-ribosylation
substrates. When Fen1, CEBPB or SSRP1 were trans-modified
with either ARTD1, ARTD1þ PJ34, ARTD1 Y907A/C908R
(catalytically dead) or ARTD1 E988K (1.25% of wild-type
activity; only monomers are added), modification of the
substrates was not observed (Supplementary Fig. 3), confirming
that glycation is not a problem in our in vitro assays.
However, in our data set we observed several other
ADP-ribosylation sites in this protein, although these had lower
localization scores. These findings suggest that the K640
modification may only contribute a low percentage of the total
ADP-ribosylation levels for SSRP1. Conversely, for the K133A
mutant of CEBPB9, we observed a 16% decrease in the
ADP-ribosylation signal. Analogously, when K354 was mutated
to Ala in FEN1, a reduction in total PAR signal was also observed,
thus confirming that this residue constitutes an ADP-ribosylation
site. Altogether, these findings demonstrate that Lys residues
are indeed specific targets of ADP-ribosylation. In addition,
we confirmed SRSF1, SRSF2, TAF15 and CBX4 as in vivo
ADP-ribosylated protein substrates using western blot (WB)
analysis (Fig. 2d). These targets were selected for three reasons:
TAF15 is a known ADP-ribosylated substrate during oxidative
stress9,20 and serves to demonstrate the ability of the
methodology to confirm known targets. For SRSF1, the
identified modification sites were observed with localization
scores of 0.5, and therefore do not constitute bona fide
high-confident sites (Supplementary Data 1). Importantly, we
demonstrate that the data obtained could still be used to infer that
SRSF1 is an ADP-ribosylation target substrate as WB confirmed
the MS results. Finally, both SRSF2 and CBX4 are novel
ADP-ribosylation targets harbouring high-confident modifications
sites.
ADP-ribosylation and PAR formation dynamics correlate.
Since the established enrichment approach requires PARG
enzymatic conversion of ADP-ribosylated acceptor sites into their
MARylated counterparts, we examined the dynamics of the
H2O2-induced ADP-ribosylation sites identified using SILAC. For
this, Light SILAC cells were stimulated for only a few seconds
with 500mM H2O2 (B0min), while heavy SILAC cells were
treated with the same concentration of H2O2 for various
durations (0, 5, 10, 30, 60 and 120min) (Supplementary Fig. 4a).
Using this approach, we investigated the effect oxidative stress
(H2O2 treatment) has on the abundance of ADP-ribosylation sites
determined by quantitative MS: if the identified ADP-ribosylation
site is induced on oxidative stress, then the relative SILAC peptide
intensity ratio between light and heavy peaks will be higher in the
heavy isotope encoded sample, thereby exhibiting an increased
SILAC ratio. Following MS analysis of H2O2-treated SILAC
samples, we extracted and compared the temporal SILAC ratios
of identified ADP-ribosylation sites, and observed the highest
SILAC ratios at early time points (5 and 10min H2O2 treatment)
(Fig. 3a). To examine whether changes in SILAC ratios correlate
with the dynamics of cellular PAR formation, we compared the
SILAC readout signal (Fig. 3a) to the PAR signals analysed by
immunofluorescence in the same cells. Although the employed
antibody primarily recognizes only longer PAR chains, the
employed approach constitutes a widely used methodology to
evaluate relative differences (that is, dynamic changes) in cellular
PAR formation38–40 (Fig. 3b; Supplementary Fig. 4b). From
triplicate IF experiments a good temporal and kinetic correlation
between the measured SILAC ratios (Fig. 3a) and PAR IF signals
was observed (Fig. 3b), with both analyses exhibiting the highest
increase at 5–10min of H2O2 treatment. Moreover, the
dynamic changes observed are similar to results obtained from
immuno-slot-blot analysis of PAR formation (Supplementary
Fig. 4c), and to those reported in mouse embryonic fibroblasts
treated with 100mM H2O2. Also in these experiments a peak of
PAR formation was observed after 5min, with subsequent
turnover after 15–20min (ref. 39). Collectively, these data show
that the upregulation of ADP-ribosylation sites determined by
SILAC ratios correlates with the increase in PAR formation using
IF analysis.
Determination of endogenous ADP-ribosylation stoichiometry.
Today, large-scale proteomics experiments have been very
successful in determining the relative abundance of PTMs
between different cellular states11. However, an inherent
challenge in PTM analyses is the estimation of stoichiometry,
referred to as the fraction of a given protein modified with a
particular PTM at a given amino acid. To obtain stoichiometry
information, we used the information gathered in our
H2O2-treated SILAC experiments (Fig. 3a and Supplementary
Data 1), and combined it with data characterizing general protein
regulation during H2O2 treatment41. Briefly, ADP-ribosylated
peptides have opposite ratios of their unmodified counterparts,
which can be used to calculate the absolute stoichiometry of
modified sites from any two SILAC states. This calculation is
made under the assumption that the sum of modified and
unmodified peptides remains constant between SILAC states41.
From a single experiment, we obtained stoichiometry values
for 55 ADP-ribosylation sites, revealing that half of the
ADP-ribosylation sites have less than 11% stoichiometry on
H2O2 treatment (that is, the fraction of a given modification site
occupied by ADP-ribosylation; Supplementary Fig. 4d). In line
with the overall transient nature of the modification, these
findings suggest a tight enzymatic regulation of ADP-ribosylation
stoichiometry. Moreover, several of the arginine residue
ADP-ribosylation sites were measured with high stoichiometry
(Supplementary Fig. 4e, Supplementary Data 4). Whether these
represent protein targets modified by ARTs other than ARTD1
and 2, or represent MARylation rather than PARylation remains
to be determined.
Comparing this ADP-ribosylome to Asp/Glu ADP-ribosylomes.
With the wide range of ADP-ribosylated proteins identified,
we sought to compare our list of modified proteins with the
previously reported proteins ADP-ribosylated at Asp/Glu (ref. 9).
Although these analyses were conducted in different cell lines and
under different physiological conditions, we found that 36 per
cent of the reported Asp/Glu ADP-ribosylated proteins were also
modified in our data set (Fig. 3c). Similarly, 38% of the targets
identified in our previous report using the Af1521 domain for
identification of ADP-ribosylated proteins20 were also identified
with the current methodology (Supplementary Fig. 4f).
This overlap increased to 52 percent when only H2O2-induced
ADP-ribosylation substrates were compared, supporting the
notion that differences in the substrates identified do not stem
from the methodologies but from differences in cellular
conditions (Supplementary Fig. 4f). Similarly, when comparing
our data set with an in vitro analysis where 8-Bu(3-yne)T-NADþ
was incubated with cell lysates and mutated analogue-sensitive
ARTDs42 an overlap of only 30% was observed (Fig. 3d). These
findings suggest that in vivo and in vitro strategies target different
ARTD substrates.
To further investigate the comparability of the different
enrichment strategies, we performed SILAC experiments in
which the PARP inhibitor olaparib was introduced before
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Figure 3 | SILAC ratios of ADP-ribosylation sites. (a) Boxplot analysis of logarithmized H/L SILAC ratios from six SILAC experiments representing HeLa
cells treated with H2O2 in a temporal manner (see Supplementary Fig. 2a). Strongest regulation of ADP-ribosylation sites is observed when cells are treated
for 5–10min of genotoxic stress. (b) Densiometric evaluation of IF analysis of HeLa cells treated with H2O2 for different time points. The strongest
abundance in PAR signal is observed after 5–10min treatment of H2O2, in good correlation with observed increase in SILAC ratios on MS analysis (Fig. 2a).
Experiments were performed in triplicates. (c) Venn diagram depicts overlap between identified ADP-ribosylated proteins compared with previously
reported Asp and Glu ADP-ribosylated proteins. (d) Venn diagram depicts overlap between identified ADP-ribosylated proteins compared with previously
reported Asp and Glu ADP-ribosylated proteins using an in vitro strategy. (e) Comparison of identified ARTD1 ADP-ribosylation sites across different
experiments as indicated. (f) Multi-scatter plot of measured peptide signal intensities from triplicate ADP-ribosylation experiments. A strong Pearson
correlation signifies high reproducibility in the measured abundance of ADP-ribosylated peptide species. (g) Abundance measurement for seven
ADP-ribosylation sites, demonstrating that lysine residue K498 is abundantly modified in ARTD1. Error bars are 95% confidence intervals with n¼ 3.
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oxidative stress and compared the outcome with the analogous
ADP-ribosylome experiment9. In two SILAC experiments, both
light and heavy SILAC cells were treated with H2O2, while only
light SILAC cells were treated with olaparib (1 mM or 10mM)43.
A strong Pearson correlation in SILAC ratios between the
experiments (R¼ 0.69) signifies that the ADP-ribosylation sites
identified were similarly affected by the employed olaparib
concentrations (Supplementary Fig. 4g). Using the STRING
database of physical and functional interactions44, we found that
the proteins harbouring ADP-ribosylation sites regulated by
olaparib were strongly connected with ARTD1 and ARTD2
(Supplementary Fig. 5a). Moreover, the regulated proteins were
also strongly associated with biological processes known to
involve ARTDs (Supplementary Fig. 5b) and therefore most
probably constitute ADP-ribosylated candidates.
Next, we compared the protein distribution of identified
modification sites between this data set and the above-mentioned
methodology. In the Asp/Glu ADP-ribosylome9, a total of 1,048
ADP-ribosylation sites residing on 320 proteins were identified,
which corresponds to 3.3 modifications per identified substrate.
In contrast, our combined data set includes 958 ADP-ribosylation
sites on 565 proteins, or 1.7 modifications per identified substrate.
Considering that only half of the identified sites in our data set
reside on Glu or Asp residues (Fig. 2a), the boronic acid
approach, which employs non-physiological siPARG conditions,
identifies more ADP-ribosylation sites per identified substrate.
Notably, this increase is analogous to the observed increase in
overall PAR signal on siPARG treatment (Fig. 1b).
We then compared the ADP-ribosylation sites only identified
on ARTD1. In the Asp/Glu ADP-ribosylome analysis by Zhang
et al.9, a total of 37 ADP-ribosylation sites were reported for
ARTD1 (Fig. 3e), of which 23 resided on Glu residues, which
corresponds to 31% of the total number of Glu within human
ARTD1. In contrast, the Af1521 analysis only identified
ADP-ribosylation in a total of 11 amino acid acceptor sites
across all experiments (Fig. 3e). To investigate whether the
differences in the number of identified ADP-ribosylation sites
might be abundance-driven, we performed an analysis of HeLa
lysates without Af1521 enrichment. In addition, we performed a
similar analysis with recombinant ARTD1, where automodified
ARTD1 was treated with PARG but not enriched by Af1521.
From these experiments, we solely found K498 to be modified in
the non-enriched HeLa sample, whereas both K498 and K505
were identified on recombinant ARTD1 (Fig. 3e). These data
suggest that certain Lys residues within the auto-modification
domain of ARTD1 are most abundantly present in the analysed
samples, which is similar to previous mutational observations
for ARTD1 (ref. 7). We observed a strong reduction in the
in vitro PAR signal when the three lysine residues within the
automodification domain of ARTD1 (K498R, K521R and K524R)7
were mutated. Thus, indicating that these sites are indeed relevant
for automodification of ARTD1 and supporting our observations
that K498 is a major PAR acceptor site of ARTD1.
To quantify ARTD1 modification sites in more detail, we next
compared the peptide signal abundance between replicate Af1521
analyses (Fig. 1e). To this end, the intensity values for all
identified peptide sequences were compared across replicate
samples. A strong Pearson correlation between replicates
(R40.89) demonstrates that the measured peptide signal
intensities can be used as a reliable measure for modification
site abundance (Fig. 3f). To further investigate quantification of
ADP-ribosylation sites, we performed abundance assessment for
seven modification sites on ARTD1 that were reliably identified in
two out of the three replicate experiments (Fig. 3g). The analysis
revealed that ADP-ribosylation located on lysine K498 yielded the
strongest signal abundance. Although peptides from the same
protein might exhibit different ‘flyability’45, an observed 34-fold
and 420-fold difference in signal intensity compared with nearby
modification sites residing on glutamic acids E520 and E488,
respectively, suggests that K498 is an abundant auto-modification
site on ARTD1. Besides, ADP-ribosylation on K498, both E488
and E491 reside on comparable tryptic peptide sequences within
ARTD1, so that the observed differences in abundance cannot
be attributed to different peptide ionization propensities. We
observed that quantified ADP-ribosylation sites preferentially
reside within the auto-modification domain of ARTD1 under
physiological conditions (Fig. 3g,e).
Analysing endogenous ADP-ribosylation sites in mouse liver.
Tissues can contain many different cell types that display a wide
range of protein concentrations, which poses challenges to pro-
teomic identification and the analysis of PTMs. Moreover, many
tissues contain a broad range of different mono-ARTs, including
members of the ARTD family, SIRTs and ARTCs (ref. 46). To
further explore the general applicability of the new method,
we characterized the endogenous ADP-ribosylome of mouse liver,
a tissue that has already been described to regulate cellular
processes in an ADP-ribosylation-dependent manner47. Three
C57BL/6 mice were killed before their livers were collected and
frozen in liquid nitrogen. The tissue was then ground up and
processed as described for the HeLa cells (Fig. 4a). In triplicate
analyses, we identified 901 modified peptides with unique
ADP-ribosylation acceptor sites, of which 414 were identified in
at least two different liver samples (Fig. 4b, Supplementary
Data 5). The distribution of ADP-ribosylation sites was similar to
the cell culture analysis, with 70% of identified proteins
harbouring only one modification site (Fig. 4c). Strikingly, the
majority (86%) of identified ADP-ribosylation acceptor sites in
the mouse liver were Arg, while Lys, Asp and Glu were detected
only at very low levels compared with HeLa cells (Fig. 4d).
Notably, several Lys residues modified with ADP-ribosylation
were also found on cytoplasmic proteins in this analysis
(Supplementary Data 5), providing evidence that lysine residues
being in vivo targets of ADP-ribosylation under physiological
conditions.
GO analysis of the modified proteins revealed a high
enrichment in mitochondrial, cytoplasmic, nuclear and mem-
brane proteins (Fig. 4e). Among the identified ADP-ribosylated
proteins, we found several previously reported ADP-ribosylated
proteins. These included ARTD12 (formerly PARP12), which has
been described to have MAR and auto-ADP-ribosylation activity;
ARTC2, which is a GPI-anchored arginine-specific MARylating
enzyme that can be shed and circulated in the blood; and
glutamate dehydrogenase 1, which is known to be regulated
through ADP-ribosylation by SIRT4 (refs 48,49). In agreement
with experiments done in HeLa cells, we also found that
histone H2B and several RNA helicases were modified. These
results indicate that the established enrichment protocol
can readily be employed to investigate the non-induced
ADP-ribosylomes of tissues, which include both intra- and
extra-cellular ADP-ribosylated proteins.
Discussion
Here, we describe the establishment of a robust and highly
reproducible technology for the first unbiased proteome-wide
view of a mammalian ADP-ribosylome, which includes the exact
identification of endogenous ADP-ribose acceptor sites under
different physiological conditions in cells and for the first time
also in organ tissue. We show that PARG treatment of peptides
before enrichment with Af1521, allows specific identification of
ADP-ribosylated amino acids and highly sensitive identification
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of the corresponding proteins. And we demonstrate that the
detected modifications are not derived from non-enzymatic
glycation and, contrary to previous claims50, Af1521 does not
hydrolyse the modification under the applied conditions. Besides,
this method supports the identification of ADP-ribosylated
proteins without complementing cell lysates or organelles
with NADþ analogues and mutated ARTDs (ref. 18) and is,
consequently, able to analyse the ADP-ribosylome under different
cellular conditions derived from endogenous ARTD protein and
NADþ levels in both cells and tissue.
The streamlined methodology led to the identification of more
than 900 endogenous ADP-ribosylation sites belonging to more
than 500 proteins in both culture and tissue cells. Our results
suggest that this methodology could be used in combination with
high-throughput screening techniques to identify endogenous
proteins affected by ADP-ribosylation and/or those modulated
by ADP-ribosylation inhibitors (also called PARP inhibitors).
ARTD1 is a key regulator within the DDR (ref. 33), which has
recently become a highly attractive target for cancer therapy51,52.
Although not specific for ARTD1, several ADP-ribosylation
inhibitors have been approved or are currently being evaluated in
clinical trials as mono-therapeutic or combination therapy agents.
Our ability to now analyse the endogenous ADP-ribosylome from
different cancer cells or tissues constitutes a promising approach
that should advance of our understanding of ADP-ribosylation in
a clinical setting.
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FEN1 is a structure-specific nuclease with 50-flap endonuclease
and 50–30 exonuclease activities involved in DNA replication
and repair, and ARTD1 recruits FEN1 to DNA damage
intermediates53. The K354 reside of FEN1 becomes acetylated
through the acetyltransferase p300, which reduces the
DNA-binding activity of FEN1 (ref. 54), while ubiquitylation of
the same lysine mediates the proteosomal degradation of FEN1
during G2/M phase55. These PTM-based regulatory mechanisms
support the notion that ADP-ribosylation at K354 might relate to
a currently uncharacterized regulatory function of FEN1.
The observed ADP-ribosylation of the SUMO-protein ligase
CBX4 suggests nuclear cross-talk between PARylation and
SUMOylation, which might be more widely occurring than
previously anticipated. Such cross-talk could be analogous to
previously reported ADP-ribosylation-dependent ubiquitylation
(PARdu)56. In fact, CBX4 is known to mediate SUMO
conjugation in the DDR, and the recruitment of CBX4 to sites
of DNA lesions is dependent on ADP-ribosylation57. Thus,
our observation that CBX4 becomes ADP-ribosylated during
oxidative stress strongly suggests that we have identified a
previously uncharacterized DDR regulatory mechanism
controlled by PARylation-dependent SUMOylation (PARsu).
The presented methodology is suitable for the identification of
key endogenous ADP-ribosylation events in biological processes.
We find that ADP-ribosylated proteins are on average less
modified under physiological conditions than reported under
siPARG treatment9, which suggests that deregulation of PARG
alters physiological ADP-ribosylation homoeostasis (Fig. 1b)13,39.
Moreover, our MS analysis supports that Lys residues K498 and
K505 are major acceptor sites in ARTD1, which follows previous
mutational analysis of ADP-ribosylation sites on ARTD1 (ref. 7).
Our analysis indicates that under physiological conditions
ARTD1 is activated in cis58, contradicting the observed in trans
activation of ARTD1 under siPARG treatment9.
Comparison of the SILAC and IF data obtained from HeLa
cells revealed that the dynamic changes induced by H2O2 for
these two data sets correlate well with each other. The relative
increase in peptide abundance may thus suggest that the
ADP-ribosylation sites detected reflect PARylation, at least
partially. However, since the methodology described here
cannot discriminate between MAR and PAR, each regulated
ADP-ribosylation site will require follow-up experiments to
determine whether they are indeed PARylated or MARylated.
The importance of tissue-specific protein ADP-ribosylation
mapping is underscored by the substantial differences in
ADP-ribosylation observed between cell culture and tissue (that
is, liver). In mouse liver tissue the majority of ADP-ribosylated
proteins localize to compartments containing enzymes with MAR
activity, such as ARTD10, ARTD8, ARTC and SIRT4, suggesting
that these proteins are primarily MARylated rather than
PARylated (Fig. 4e). These observations are further supported
by the increased levels of modified Arg residues, and membrane
and extracellular proteins, which might stem from ARTC activity.
Moreover, our data substantiates initial studies where
ADP-ribosylation was observed on Arg residues within rat liver
proteins59. From the analysed liver extracts, ARTD1 was not
found to be auto-ADP-ribosylated, highlighting the fact that the
enzyme is mainly inactive under normal, non-stressed conditions.
Our organ analysis of ADP-ribosylation provides evidence that
the modification is involved in multiple physiological functions.
For example, KEGG pathway analysis reveals that proteins
involved in actin cytoskeleton and endoplasmic reticulum
regulation are enriched in ADP-ribosylation (Supplementary
Fig. 5c). These pathways have previously been associated with
ADP-ribosylation60,61, but the mechanism by which the
modifications are catalysed (that is, ARTDs or ARTCs (ref. 62))
remains to be investigated. NADþ can be released on necrosis or
mechanic stress in tissue, which in turn likely activates ARTCs
during organ collecting63. Considering that ARTCs have higher
affinity for NADþ compared with ARTD1, this renders ARTCs
more prone to activation following NADþ release during tissue
collecting. Moreover, we find that proteins involved in metabolic
processes, oxidative-reduction processes and mitochondrial
content are distinctly enriched in ADP-ribosylation targets
(Fig. 4e and Supplementary Fig. 5f), which suggests these
processes may be influenced by the modification. While the
exact mechanisms are not well understood, inhibition of ARTDs
is known to enhance these processes64. With ARTD1 activation
known to affect cellular metabolism via direct PARylation events,
transcriptional reprogramming, or alterations in cellular NADþ
levels64, our tissue analysis supports the hypothesis that metabolic
consequences on ADP-ribosylation inhibition might occur via
alterations in NADþ levels65. This is based on ARTD1 being an
avid NADþ consumer, and that ADP-ribosylation inhibition
increases the cellular levels of NADþ available for other
ARTDs (ref. 65), in a manner reminiscent of the reported
interplay between ARTD1 activity and deacetylase SIRT1
(ref. 66). Furthermore, with immortalized cell lines exhibiting
mitochondria and metabolic processes deficiencies67, hereby
rendering them impractical for ADP-ribosylation inhibition/
activation and cellular metabolism investigations, highlights
that methodologies allowing proteomics-based whole tissue
analyses are required to investigate this antagonistic interplay in
more detail.
In conclusion, our novel methodology allows for the unbiased
and sensitive characterization of ADP-ribosylation sites under
physiological conditions, while the data presented here
extends current ADP-ribosylation knowledge and highlights the
widespread occurrence of the modification. Although the
methodology presented cannot currently distinguish between
MARylated and PARylated peptide species, adjustment of the
binding reaction stringency and combining the enrichment
with specific MAR-binding domains, will most likely facilitate
dissecting peptide MAR- versus PARylation in a more specific
manner68. Importantly, the approach presented supports
comprehensive and quantitative evaluation of the mammalian
ADP-ribosylome of cell lines and tissue samples. Thus, allowing
downstream interrogation of disease pathways in which ARTs are
implicated.
Methods
Cell culture and transfection. HeLa cells were grown in Dulbecco’s modified
Eagle’s medium (D-MEM; Invitrogen) supplemented with 10% foetal bovine serum
and penicillin/streptomycin (100Uml# 1) (Gibco). Stable HeLa-Kyoto cells
expressing CBX4, SRSF2, SRSF1 and FUS tagged with C-terminal GFP under the
control of an endogenous promoter were generated by transfecting BAC transgenes
and were kindly provided by Prof Anthony Hyman (Max Planck Institute, Dres-
den). Selection was maintained by adding 400 mgml# 1 G418 (Sigma Aldrich) to
the culture medium. SILAC HeLa cells were grown in SILAC D-MEM (Invitrogen)
supplemented with 10% dialyzed foetal bovine serum, L-glutamine, penicillin/
streptomycin, and either L-lysine and L-arginine, L-lysine 4,4,5,5-D4 and
L-arginine-U-13C6, or L-lysine-U-13C6-15N2 and L-arginine-U-13C6-15N4
(Cambridge Isotope Laboratories)36. The siRNA oligonucleotides against
endogenous PARG (ID: 4390826) was purchased from Ambion as well as Negative
Control siRNA#1. SiRNA transfections were performed using Lipofectamine
RNAiMAX (Invitrogen) according to the manufacturer’s protocol and lysed 48 h
after transfection. All HeLa cells used for experiments were tested negative for
mycoplasma.
Sample preparation. Cells were stimulated with H2O2 (Sigma Aldrich) for 10min
in PBS at 37 !C, collected by washing with ice-cold PBS and lysed in modified RIPA
buffer (50mM Tris pH 7.5, 400mM NaCl, 1mM EDTA, 1% Nonidet P-40, 0.1%
Na-deoxycholate), protease inhibitor mixture (Roche) supplemented with 2mM
Na-orthovanadate, 5mM NaF, 5mM Glycero-2-phosphate, 1 mM ADP-HPD
(Millipore) and 40mM PJ-34 (Enzo Life Sciences) and cleared by high-speed
centrifugation. Proteins were precipitated by adding fourfold excess volumes of
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ice-cold acetone and stored at # 20 !C overnight. Subsequently, proteins were
solubilized in a urea solution (6M urea/2M thiourea/10mM HEPES pH 8.0).
Protein concentrations in lysates were measured using Bradford assay (Bio-Rad).
Next, proteins were reduced by adding dithiothreitol to a final concentration of
1mM, and alkylated with chloroacetamide at 5.5mM. Proteins were digested using
endoproteinase Lys-C (1:100 w/w) and modified sequencing grade trypsin (1:100
w/w) after a fourfold dilution in 50mM ammonium bicarbonate solution. Protease
digestion was terminated by slow addition of trifluoroacetic acid to pH 2.
Precipitates were removed by centrifugation for 10min at 3,000g. Peptides were
purified using reversed-phase Sep-Pak C18 cartridges (Waters). Peptides were
eluted off the Sep-Pak with 50 and 80% acetonitrile.
GST-protein expression and purification of Af1521. BL21 was used for long
transformation. Briefly, 1 ml of cooled plasmid was added to BL21 and left on ice
for 15min. Bacteria were heat shocked at 42 !C for 45 sec, incubated for 1min on
ice and then mixed with SOC for 40min at 37 !C. Bacteria were streaked onto
Amp-plates and left overnight at 37 !C. The following day a single colony was
inoculated in LB media and grown overnight at 37 !C. The starter culture was
diluted and grown to an OD600 of 0.55–0.65. Protein expression was induced by
adding IPTG to final concentration of 0.5mM and incubated for 5–6 h. Bacteria
were spun down and pellet frozen at # 80 !C.
The bacterial pellet was thawn and incubated for 20min in lysis buffer (50mM
Tris–HCl, pH 7.5, 150mM NaCl, 1mM MgCl2, 1mM dithiothreitol, 1$Bug
Buster (Novagen), 1 ml ml# 1 Benzonase (Sigma Aldrich), 200mgml# 1 lysozyme
(Sigma Aldrich), protease inhibitor mixture (Roche)). After breaking cells by
vortexing with glass beads, cell debris was pelleted by centrifugation. The cleared
lysate was incubated for 4 h at 4 !C rolling with equilibrated glutathione sepharose
4B (Sigma Aldrich). Beads were washed four times in wash buffer (50mM
Tris–HCl, pH 7.5, 150mM NaCl and 1mM dithiothreitol), resuspended in wash
buffer and kept at 4 !C for up to 3 weeks.
Enrichment of ADP-ribosylated peptides. After eluting off Sep-Pak, appropriate
amounts of IP buffer (50mM Tris–HCl, pH 8, 10mM MgCl2, 250 mM
dithiothreitol and 50mM NaCl) was added before the acetonitrile and the volume
was reduced by vacuum centrifugation. PAR complexity was reduced by incubation
with PARG (4.2 mg per sample) for 3 h at 37 !C. The peptide mixture was cooled
down before it was incubated rotating for 2 h at 4 !C with the purified Af1521
macro domain. The peptides were washed three times in ice-cold IP buffer followed
by one wash in water, and modified peptides were eluted with 2$ 100 ml 0.15%
TFA in Milli-Q water. Peptide eluates were desalted on reverse phase C18
StageTips69.
Mass spectrometric analysis. All MS experiments were performed on a
nanoscale EASY-nLC 1000 UHPLC system (Thermo Fisher Scientific) connected
to an Orbitrap Q-Exactive Exactive equipped with a nanoelectrospray source
(Thermo Fisher Scientific). Each sample was eluted off the StageTip, auto-sampled
and separated on a 15 cm analytical column (75 mm inner diameter) in-house
packed with 1.9-mm C18 beads (Reprosil Pur-AQ, Dr Maisch) using a 3 h
gradient ranging from 5 to 64% acetonitrile in 0.5% formic acid at a flow rate of
200 nlmin# 1. The effluent from the high-performance liquid chromatography was
directly electrosprayed into the mass spectrometer. The Q Exactive Plus mass
spectrometer was operated using data-dependent acquisition, with all samples
being analysed using a ‘sensitive’ acquisition method22 and a normalized
collision energy of 28. Back-bone fragmentation of eluting peptide species were
obtained using HCD which ensured high-mass accuracy on both precursor and
fragment ions.
Mass spectrometry analysis of ADP-ribosylation sites by ETD. ETD spectra of
ADP-ribosylated peptides were acquired on an Orbitrap Fusion Lumos mass
spectrometer (Thermo Scientific) operating in positive ion mode. Full MS scans
(m/z 300–1,500) were performed at 120,000 resolution (m/z 200) in the Orbitrap,
with the AGC target set at 4e5. Precursor selection was prioritized on the basis of
highest charge state followed by highest intensity. Peptides (charge states from 3þ
to 6þ ) were selected by the quadrupole (1.3 m/z isolation window) before reaction
with fluoranthene radical anions (ETD reagent target 4e5). ETD reaction times
were set at 1.7t for each charge state. MS/MS spectra were acquired using a normal
ion trap scan rate with a maximum injection time of 50ms (AGC target 2e5).
A Venn diagram comparing identified protein targets derived from the ETD with
HCD analysis is shown in Supplementary Fig. 6a.
In vitro TOF-MS analysis of H2B peptide sequence. 1 mg of HK326 peptide
(PQPAKSAPAPKKG) was incubated with 1mM ADP-ribose in 50mM sodium
phosphate buffer (pH 7.5 and pH 9.5) for 1 h or overnight at 37 !C. Samples were
desalted using Reversed-phase m-C18 ZipTips (for MALDI-MS) and eluted
with MALDI matrix solution (a-cyano-4-hydroxycinnamicacid in 0.3mM
di-ammonium hydrogen citrate (Fluka), 60% acetonitrile in H2O) directly on the
target plate. MALDI analyses were performed on a 4800 MALDI TOF/TOF system
in linear mode.
Identification of peptides and proteins. All raw data analysis was performed
with MaxQuant software suite version 1.3.0.5 supported by the Andromeda
search engine70. Data were searched against a concatenated target/decoy
(forward and reversed) version of the UniProt Human fasta database encompassing
71,434 protein entries (downloaded from www.uniprot.org on 2013-07-03).
Mass tolerance for searches was set to maximum 7 p.p.m. for peptide masses
and 20 p.p.m. for HCD fragment ion masses. Data were searched with
carbamidomethylation as a fixed modification and protein N-terminal acetylation,
methionine oxidation and mono-ADP-ribosylation (m/z 541,06110:
C10H13N5O9P2) on lysine, arginine, glutamic and aspartic acids as variable
modifications. A maximum of three mis-cleavages was allowed while requiring
strict trypsin specificity, and only peptides with a minimum sequence length of
seven were considered for further data analysis. Peptide assignments were
statistically evaluated in a Bayesian model on the basis of sequence length and
Andromeda score. Only peptides and proteins with a false discovery rate of o1%
were accepted, estimated on the basis of the number of accepted reverse hits, and
false discovery rate values were finally estimated separately for modified and
unmodified peptides. Protein sequences of common contaminants such as human
keratins and proteases used were added to the database. For SILAC quantification a
minimum of two ratio-counts was required.
Enrichment of GFP-tagged and ADP-ribosylated proteins. Cells expressing the
tagged versions of the proteins of interest were collected by washing with PBS and
lysed in modified RIPA buffer (50mM Tris pH 7.5, 400mM NaCl, 1mM EDTA,
1% Nonidet P-40, 0.1% Na-deoxycholate), protease inhibitor mixture (Roche)
supplemented with 2mM Na-orthovanadate, 5mM NaF, 5mM Glycero-2-
phosphate, 1 mM ADP-HPD (Millipore) and 40 mM PJ-34 (Enzo Life Sciences).
Lysates were diluted in modified RIPA without salt and then cleared by high-speed
centrifugation.
GFP-immunoprecipitaion was performed with 20 ml GFP-Trap_A agarose
beads (Chromotek). 1mg of protein mixtures were incubated for 2 h rotating at
4 !C before washing and subsequent elution with 2$ Laemmli sample buffer
(Thermo Fisher Scientific) at 90 !C. Pull down of ADP-ribosylated proteins was
performed similarly but using 200 ml crosslinked Af1521 macro domain and 2mg
of protein mixtures.
Western blotting. The following antibodies were used in this study: rabbit
polyclonal PAR 1:1,000 (ALX-210–890A, Enzo Life Science) and mouse
monoclonal GFP 1:1,000 (11814460001, Roche).
Total cell lysates together with the eluates were resolved on 4–12% gradient
SDS–PAGE gels (Thermo Fisher Scientific) and proteins were transferred onto
nitrocellulose membranes (Sigma Aldrich). Membranes were blocked using 5%
BSA solution in PBS supplemented with Tween-20 (0.1%). Secondary antibodies
coupled to horseradish peroxidase (Jackson ImmunoResearch Laboratories)
were used for immunodetection. The detection was performed with Novex ECL
Chemiluminescent Substrate Reagent Kit (Invitrogen). For slot blot analysis, PAR
polymer (Trevigen) was incubated with different concentrations of PARG and
spottet directly onto PVDF membranes (Millipore) using the slot blot chamber
(Fisher Scientific) according to manufacturer’s protocol. Cropped WBs presented
in Fig. 2d have been included as uncropped scans in Supplementary Fig. 6b.
Immunofluorescence microscopy. HeLa cells were seeded on coverslips and the
following day stimulated for indicated time points with H2O2. After washing with
PBS, cells were fixed in methanol/acetic acid solution and incubated for 5min at
37 !C. Coverslips were blocked in 5% milk powder, transferred to a humid chamber
and incubated with rabbit polyclonal PAR (Enzo Life Science) for 1 h at 37 !C and
with secondary antibody Alexa Fluor 488 (Invitrogen) for 1 h at 37 !C, stained with
DAPI for 2min, washed in PBS and mounted. Images were acquired on a DFC345
FX microscope (Leica) and analysed using ImageJ.
Immuno-slot-blot. For the immuno-slot-blot analysis, HeLa cells were treated and
lysed as described in sample preparation, and proteins were vacuum aspirated onto
a Hybond P 0.2 PVDF (Amersham Biosciences) using a slot-blot manifold
(Amersham Biosciences). The membrane was blocked with 5% milk powder in
10mM Tris–HCL (pH 8.0), 150mM NaCl and 0.05% (v/v) Tween 20 (TBST
buffer) and incubated with polyclonal PAR antibody (Enzo Life Science) diluted
1:1,000 in 5% milk powder in TBST for 1 h at RT and with secondary antibody
IRDye 800CW goat anti-rabbit IgG (LI-COR) 1:15,000 in TBST for 1 h at RT.
Signals were detected by the Odyssey infrared imaging system (LI-COR) and the
immunoblot signal was quantified using GelEval (FrogDance Software).
In vitro radiography assay. 10 pmol of ARTD1 and ARTD10 were automodified
with 100 nM NADþ for 10min at 37 !C, respectively, hereby inducing short PAR
chains on ARTD1 and MAR on ARTD10 through auto-catalysis29. Samples were
filtered through G50 columns to remove excess amount of unincorporated NADþ ,
and subsequently treated with 10 pmol PARG for additional 1 h at 37 !C. Using
autoradiography assays the hydrolysis of attached radioactive 32 P-NADþ of the
protein substrates were subsequently monitored. For transmodification reactions,
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50 pmol of target protein was incubated with 10 pmol ARTD1 for 10min at 37 !C.
The reaction was stopped by adding Laemmli buffer and boiling for 5min at 95 !C.
After separation of samples by SDS–PAGE, the radiolabelled ADP-ribosylation
signal was determined by GelEval (FrogDance Software).
Preparation of mouse liver extracts. Male 9-week-old C57BL/6 mice were
maintained on a 12-h light–dark cycle with regular unrestricted diet. Mice were
killed in a CO2 chamber. Excised livers were washed in PBS and shock frozen in
liquid nitrogen. Ice-cold modified RIPA buffer (supplemented with PARP-, PARG-
and protease inhibitors as described before) was added to the shock frozen livers
and they were lysed operating the Tissue Lyser II (Qiagen) device at 30HZ for
4$ 30 s. The lysate was further sonicated until it became fluid and all liver pieces
were dissolved. The lysate was cleared by high-speed centrifugation and processed
similar as described for the cell culture samples. 20mg of liver protein was used as
starting material for the digest.
Bioinformatic analyses. Statistical analysis and hierarchical clustering was
performed using the Perseus software suite (Max Planck Institute of Biochemistry,
Department of Proteomics and Signal Transduction, Munich). Significantly
enriched Gene Ontology terms were determined using the Functional Annotation
Tool of the DAVID Bioinformatics database. Protein interaction networks were
analysed using the interaction data from the STRING database (v. 9.05) and
visualized using Cytoscape (v. 2.8.3). Protein abundance assessment was performed
using a deep proteome reference data set for HeLa cells. All Venn diagrams were
generated using the online Venny program (http://bioinfogp.cnb.csic.es/tools/
venny/).
Comments related to animal study. C57BL/6J mice were bread at the animal
facility of the University of Zurich. No randomization or blinding were used for
these studies, and no animals had to be excluded. All animal experiments were
carried out in accordance with the Swiss and EU ethical guidelines and have been
approved by the local animal experimentation committee of the Canton of Zurich
under licence #2012207 and following the 3R guidelines.
Data availability. The mass spectrometry proteomics data have been deposited to
the ProteomeXchange Consortium via the PRIDE partner repository71 with the
data set identifier PXD004245. The additional data that support the findings of this
study are available from the corresponding author on request.
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ABSTRACT: Protein adenosine diphosphate (ADP)-ribosylation is a
physiologically and pathologically important post-translational mod-
iﬁcation. Recent technological advances have improved analysis of this
complex modiﬁcation and have led to the discovery of hundreds of
ADP-ribosylated proteins in both cultured cells and mouse tissues.
Nevertheless, accurate assignment of the ADP-ribose acceptor site(s)
within the modiﬁed proteins identiﬁed has remained a challenging task.
This is mainly due to poor fragmentation of modiﬁed peptides. Here,
using an Orbitrap Fusion Tribrid mass spectrometer, we present an
optimized methodology that not only drastically improves the overall
localization scores for ADP-ribosylation acceptor sites but also boosts
ADP-ribosylated peptide identiﬁcations. First, we systematically
compared the eﬃcacy of higher-energy collision dissociation (HCD),
electron-transfer dissociation with supplemental collisional activation
(ETcaD), and electron-transfer/higher-energy collision dissociation
(EThcD) fragmentation methods when determining ADP-ribose acceptor sites within complex cellular samples. We then
tested the combination of HCD and EThcD fragmentation, which were employed in a product-dependent manner, and the
unique fragmentation properties of the ADP-ribose moiety were used to trigger targeted fragmentation of only the modiﬁed
peptides. The best results were obtained with a workﬂow that included initial fast, high-energy HCD (Orbitrap, FT) scans, which
produced intense ADP-ribose fragmentation ions. These potentially ADP-ribosylated precursors were then selected and analyzed
via subsequent high-resolution HCD and EThcD fragmentation. Using these resulting high-quality spectra, we identiﬁed a
xxxxxxKSxxxxx modiﬁcation motif where lysine can serve as an ADP-ribose acceptor site. Due to the appearance of serine within
this motif and its close presence to the lysine, further analysis revealed that serine serves as a new ADP-ribose acceptor site across
the proteome.
Protein adenosine diphosphate (ADP)-ribosylation is areversible post-translational modiﬁcation (PTM) that
results from hydrolysis of nicotinamide adenine dinucleotide
(NAD+) and, subsequently, covalent conjugation of a mono-
ADP-ribose unit (MAR) to the acceptor protein (MARylation
reaction) or to an ADP-ribose moiety already attached to the
protein, forming poly-ADP-ribose (PAR; PARylation reac-
tion).1 The enzyme diphtheria toxin-like ADP-ribosyltransfer-
ase 1 (ARTD1) and other ARTD family members [also known
as poly ADP-ribosyltransferases (PARPs)] are the major
enzymes responsible for catalyzing this reaction in cells.2,3
Lysine (K), arginine (R), and aspartic (D) and glutamic (E)
acids are the main acceptors of ADP-ribosylation.2 Additionally,
cysteine, diphthamide, phosphoserine, and asparagine serve as
possible ADP-ribosylation acceptor sites.4 ADP-ribosylation
regulates several important cellular functions, including stress
responses,5 epigenetic transcriptional regulation,6,7 RNA
splicing and transport,8 and cell fate determination.7,9
The introduction of mass spectrometry (MS)-based
techniques drastically improved the ability to detect ADP-
ribosylated proteins and their modiﬁcation site(s). Several MS-
based approaches have been described;10−12 unfortunately,
despite these advances, accurate mass spectrometric ADP-
ribose acceptor site localization remains challenging. This may
be due to the poor ionization capacity and hampered
fragmentation properties of the modiﬁed peptides, especially
PARylated peptides. To tackle this, several strategies have been
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developed to reduce PAR complexity and to improve
identiﬁcation accuracy. Zhang et al.11 applied boronic acid
enrichment with a chemical elution approach in which the
ADP-ribosylated peptides are exposed to hydroxylamine.
Unfortunately, this method is limited to ADP-ribosylated
glutamic (E) and aspartic (D) acids. Several acceptor-site-
independent enzymatic conversion approaches, including the
use of phosphodiesterases [i.e., snake venom phosphodiesterase
(SVP)13] or ADP-ribosylhydrolases [i.e., poly-ADP-ribose
glycohydrolase (PARG)14], have also been recently developed.
Phosphodiesterase treatment converts PAR and MAR into
phosphoribose (212.01 Da), while PARG treatment converts
PAR into MAR (541.06 Da). Indeed, these MAR and PAR
modiﬁcation size reductions improve the ionization capacities
of all modiﬁed peptides. However, the ADP-ribosyl group and
its fragmentation pattern provide interesting features that can
be used during MS measurement and downstream bioinfor-
matic analysis. Upon higher-energy collision dissociation
(HCD), the ADP-ribose moiety fragments into characteristic
marker ions that are mainly represented by adenine+ (136.06),
adenosine−H2O+ (250.09), AMP+ (348.07), and ADP+
(428.03) (Figure S1A).15 The presence of these ADP-
ribosylation marker ions can be exploited during the measure-
ment process to trigger product-dependent MS events.
Moreover, the presence of marker ions in MS/MS spectra
validates the presence of ADP-ribosylation on the precursor ion
and allows for accurate scoring of its assignment with a search
engine. Unfortunately, in some cases, these ions dominate the
spectra and obstruct proper precursor fragmentation. Thus,
optimization of the applied normalized collision energy (NCE)
should be performed to balance precursor fragmentation and
marker ions’ intensity.
Hengel et al.16 suggested that electron-transfer dissociation
with supplemental collisional activation (ETcaD) fragmenta-
tion could enhance precise ADP-ribose acceptor site local-
ization. When comparing ETcaD to HCD fragmentation, we
found that the HCD method identiﬁed ADP-ribosylation sites
with the same localization probability as ETcaD.15 Never-
theless, when HCD and ETcaD fragmentation were combined
in one run (so-called “product-dependent method”) on an
LTQ Orbitrap Velos mass spectrometer, the identiﬁcation of
ADP-ribosylation sites in in vitro ADP-ribosylated samples
increased.
New-generation Orbitrap Fusion and Orbitrap Lumos
Tribrid mass spectrometers (Thermo Scientiﬁc) introduced
an electron-transfer/higher-energy collision dissociation
(EThcD) peptide fragmentation methodology that combines
HCD and ETcaD into one fragmentation event. This has the
advantage that peptide backbone fragmentation is improved
and that dual fragmentation generates data-rich MS/MS spectra
containing both b/y and c/z ions, which ultimately improves
peptide sequence coverage and PTM localization conﬁdence.17
EThcD fragmentation has already proven beneﬁcial for
unambiguous phosphorylation site localization, even on
peptides with several possible amino acid acceptors.18
In this study, we strove to exploit these features of the
Orbitrap Fusion Tribrid mass spectrometer for analysis of
ADP-ribosylated peptides. As a model system, we used HeLa
cells challenged with oxidative stress in combination with
Af1521 peptide enrichment.14 First, individual HCD, ETcaD,
and EThcD fragmentation performances were evaluated by
comparing the quality and quantity of identiﬁed ADP-
ribosylated peptides and ADP-ribosylation site assignment
accuracy. Overall, we found that HCD and EThcD
fragmentation methods identiﬁed complementary ADP-ribosy-
lated peptide sets and outperformed ETcaD. In a second step,
we exploited the ADP-ribose marker ion properties and
evaluated how combining HCD and EThcD into one
product-dependent method performed relative to the individual
fragmentation methods. This led to the development of a
specialized ADP-ribosylation analysis workﬂow on the Orbitrap
Fusion, which signiﬁcantly augmented our ability to globally
characterize the cellular ADP-ribosylome and conﬁdently assign
ADP-ribosylation sites.
■ EXPERIMENTAL SECTION
ADP-Ribosylated Peptide Enrichment. HeLa cells
(Kyoto) were cultured in Dulbecco’s modiﬁed Eagle’s medium
[DMEM, supplemented with 10% fetal calf serum (FCS) and
1% penicillin/streptavidin] at 37 °C with 5% CO2. Cells were
treated for 10 min with 1 mM H2O2 to induce PAR formation
and then further processed and enriched with Af1521
macrodomain protein as previously described.14
Liquid Chromatographic/Mass Spectrometric Anal-
ysis. Mass spectrometric analysis was performed on an
Orbitrap Fusion mass spectrometer, which combines three
mass analyzers (Orbitrap, quadrupole, and ion trap), coupled to
a nano EasyLC 1000 liquid chromatograph (Thermo Fisher
Scientiﬁc). Solvent compositions in channels A and B were
0.1% formic acid in H2O and 0.1% formic acid in acetonitrile,
respectively. Self-made 75 μm × 150 mm columns, packed with
reverse-phase C18 material (ReproSil-Pur 120 C18-AQ, 1.9
μm, Dr. Maisch GmbH), were used, and aliquots (4 μL) of
peptide solution were loaded onto the columns and eluted over
80 min at a ﬂow rate of 300 nL/min. An elution gradient
protocol from 2% to 25% B, followed by two steps, 35% B for 5
min and 95% B for 5 min, was used. The mass spectrometer
(Tune page v2.0) was set to acquire full-scan MS spectra (300−
1500 m/z) at 120 000 resolution at 200 m/z; precursor
automated gain control (AGC) target was set to 200 000.
Charge-state screening was enabled, and precursors with +2 to
+5 charge states and intensities >50 000 were selected for
tandem mass spectrometry (MS/MS). Ions were isolated by
use of the quadrupole mass ﬁlter with a 2 m/z isolation
window. Wide quadrupole isolation was used, and injection
time was set to 50 ms. The cycle time was set to 3 s (top speed
mode). In total, ﬁve diﬀerent MS/MS acquisition methods
were performed in randomized order and their performances
were compared. These included (a) Orbitrap HCD MS/MS
(HCD only); (b) Orbitrap ETcaD MS/MS (ETcaD only); (c)
Orbitrap EThcD MS/MS (EThcD only); (d) data-dependent
HCD followed by EThcD MS/MS when more than one ADP-
ribose fragment peak (136.0623, 250.0940, 348.07091, and
428.0372) was observed in the HCD scan (HCD-PD-EThcD;
where PD = product-dependent); (e) low-resolution and high-
energy data-dependent HCD (named preview HCD), followed
by high-quality HCD and EThcD MS/MS when more than two
ADP-ribose fragment peaks (136.0623, 250.0940, 348.07091,
and 428.0372) were observed in the HCD scan (HCD-PP-
HCD-EThcD, where PP = product preview). The parameters
for MS/MS fragmentations changed according to the method
applied. The AGC values for MS/MS analysis were set to
500 000 and the maximum injection time was 240 ms for all
experiments. For the HCD preview scan (method e) only,
AGC target was set to 50 000 and injection time was set to 60
ms. With the exception of the HCD preview scan, whose
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normalized collision energy (NCE) was set to 38% in order to
obtain higher marker ion intensities, all other HCD
fragmentations were performed at an NCE of 35%. For
ETcaD and EThcD fragmentations, the “use-calibrated charge-
dependent parameter” option was selected. In all cases,
precursor masses previously selected for MS/MS measurement
were excluded from further selection for 30 s, and the exclusion
window was set at 10 ppm. All measurements were acquired
using internal lock mass calibration on m/z 371.1010 and
445.1200. A complete description of all tandem MS experi-
ments employed in this study can be found in Table S1.
Data Analysis. MS and MS/MS spectra were converted to
Mascot generic format (MGF) by use of Proteome Discoverer,
v2.1 (Thermo Fisher Scientiﬁc, Bremen, Germany). When
multiple fragmentation techniques (HCD, ETcaD, or EThcD)
were utilized, separate MGF ﬁles were created from the raw ﬁle
for each type of fragmentation. All MS/MS spectra were
deconvoluted by use of the MS Spectrum Processor (http://
ms.imp.ac.at/?goto=ms2spectrumprocessor). In the ETcaD and
EThcD spectra, the precursor, charge-reduced precursor(s),
and neutral loss peaks were removed within a 0.5 Da window.
The MGFs were searched against the UniProtKB human
database (taxonomy 9606, version 20140422), which included
35 787 Swiss-Prot entries, 37 802 TrEMBL entries, 73 589
decoy hits, and 260 common contaminants. Mascot 2.5.1.3
(Matrix Science) was used for peptide sequence identiﬁcation
with previously described search settings.15 Brieﬂy, a peptide
tolerance of 10 ppm and MS/MS tolerance of 0.05 Da were
used. For the HCD runs, singly charged b and y ion series,
immonium ions, water loss, and ammonia loss ion series were
searched. For ETcaD, singly charged c, y, z, (z + 1), and (z + 2)
series were considered. For EThcD, singly charged b, c, y, z, (z
+ 1), and (z + 2) ion series, immonium ions, and water and
ammonia loss ion series were used. Enzyme speciﬁcity was set
to trypsin, and up to four missed cleavages were allowed. Decoy
hits were used to control false discovery rates (FDR) on the
peptide and protein levels. The ADP-ribose variable mod-
iﬁcation was set diﬀerently for HCD, EThcD, and ETcaD
spectra searches. For HCD and ETcaD MGFs, the modiﬁcation
was set as previously described.15 For EThcD MGFs, the
modiﬁcation was set to a mass shift of 541.0611 and marker
ions at m/z 428.0372, 348.0709, 250.0940, and 136.0623 were
ignored for scoring. An ADP-ribosylated peptide was
considered to be correctly identiﬁed when the Mascot score
was >20 and the expectation value was <0.05. To deﬁne ADP-
ribosylation site localizations, Mascot site localization analysis19
was used, and sites with a Mascot-derived site localization
conﬁdence of ≥95% were considered as correctly assigned. To
obtain site localization information, the searches were subjected
to analysis via B-fabric.20
To screen the spectra for the presence of ADP-ribose marker
ions (m/z = 136.0623, 250.0940, 348.0709, and 428.0372), all
of the Mascot output.dat ﬁles were further analyzed by use of
PTM MarkerFinder contained in the The Comprehensive R
Archive Network (CRAN) package protViz (available through
https://cran.rproject.org/package=protViz).21 Spectra contain-
ing >2 marker ions and marker ion intensity sum ≥3% (for
HCD > 10%) of the total ion intensities were considered as
putative ADP-ribosylated modiﬁed peptide spectra.
Finally, peptide coverage information was obtained by use of
an in-house R script using the CRAN protViz package. The
“.dat” ﬁles were screened for the presence of the in silico-
computed m/z peak of fragment ions. Ion intensity was set to
5% of total spectrum intensity with a mass tolerance of 10 ppm.
Motif Discovery by Use of Scaﬀold PTM. Identiﬁcation
of ADP-ribosylation motifs was carried out by use of Scaﬀold
PTM software, v.2.1.3 (Proteome Software). All ﬁles were
imported into Scaﬀold software, v.4.2.0 (Proteome Software),
and ﬁltered according to a 0.1% FDR peptide threshold and a
3% FDR protein threshold.
■ RESULTS AND DISCUSSION
EThcD Complements HCD Identiﬁcation of ADP-
Ribosylated Peptides. In this study, we analyzed the ADP-
ribosylome of HeLa cells during oxidative stress, which was
triggered by treating the cells with 1 mM H2O2 for 10 min.
Oxidative stress is a well-known and very potent inducer of
protein ADP-ribosylation. This is thought to be catalyzed by
nuclear ADP-ribosyltransferase (ARTD1, ARTD2, and/or
ARTD3) activation.5,22,23 Following H2O2 treatment, cells
were lysed in the presence of PARP and PARG inhibitors. The
recovered proteins were digested with trypsin, PAR mod-
iﬁcations were reduced to MARs via PARG treatment, and
ADP-ribosylated peptides were aﬃnity-puriﬁed by use of the
Af1521 macrodomain.14 Initial parameter optimizations on the
Orbitrap Fusion Tribrid mass spectrometer, with HCD
fragmentation, revealed that an NCE of 35 was ideal for the
fragmentation of ADP-ribosylated peptides. In addition,
spectral quality increased when higher numbers of ions
(AGC 5 × 105) were accumulated over longer periods of
time (240 ms) (Figure S1B). These optimized acquisition
settings were implemented in all further HCD-based MS
applications. Due to the presence of phosphate groups in the
MAR, we tried to include the fragmentation of +1 charge state
precursors, but overall identiﬁcation were decreased due to the
fragmentation of chemical contamination precursors. The
performance of HCD to identify ADP-ribosylated peptides,
compared to ETcaD or EThcD fragmentation, was evaluated
on these HeLa cell-derived samples (n = 4/MS method). Each
fragmentation method was evaluated on the basis of the ADP-
ribose fragmentation pattern and the number and properties of
the identiﬁed ADP-ribosylated peptides. As previously
reported,15 initial spectra analyses revealed that primary HCD
spectra signals for ADP-ribosylated peptides were generated
from ADP-ribose fragmentation (Figure 1).
Applying the PTM Markerﬁnder tool21 to the spectra
generated by HCD fragmentation, we identiﬁed 5313 spectra
with ≥2 ADP-ribose marker ions with total intensities >10%
(Figure S1C). The adenine+ (136.0618) marker ion was the
most intense ion identiﬁed, while all other marker ions were
Figure 1. Intensity distribution of marker ions in HCD and EThcD
fragmentation. Spectra where the marker ions represented at least 3%
of total intensity and with ≥2 marker ions were analyzed.
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produced with about 10 times lower intensities (Figure 1 and
Figure S1D). In contrast, ETcaD fragmentation failed to
generate any ADP-ribose marker ion-containing spectra, even
when the total ion intensity threshold was decreased to 3%.
The absence of marker ions in ETcaD spectra was expected on
the basis of the mild nature of this fragmentation method, as
well as the fact that modiﬁcations are kept intact during this
fragmentation.24 ADP-ribose marker ions were, however,
observed in the EThcD analysis, but they represented only
3−5% of total ion intensities. Decreasing the marker ion
intensity threshold to 3% for HCD- and EThcD-produced
spectra signiﬁcantly increased the number of spectra containing
marker ions for EThcD: 1212 total MS/MS spectra versus 8164
spectra for HCD (Figure 1). However, out of the total marker
ion-containing spectra, around 70% were multiple spectra from
the same precursors (i.e., duplicate spectra). After these
duplicates had been removed, 380 and 2291 MS/MS spectra
belonging to unique precursors were identiﬁed by EThcD and
HCD, respectively. The adenosine−H2O+ (250.0935) ion had
the lowest marker ion intensity in EThcD, while HCD
fragmentation-generated marker ions (except 136.06 ion) all
had similar intensities (Figure 1). Overall, the relative average
abundance of ADP-ribose fragments following EThcD
fragmentation was about 5-fold lower than in HCD spectra.
Thus, the EThcD- and HCD-produced marker ion proﬁles
could be used to validate ADP-ribosylated identiﬁcation. We
were not able deﬁne amino-acid-speciﬁc marker ion intensity
patterns that could be used to characterize modiﬁcation
acceptor sites; instead, the marker ions enabled ADP-ribose-
containing peptide-spectrum match (PSM) spectral identiﬁca-
tion. Next, we compared the fragmentations by the number of
unique identiﬁed peptides. A unique peptide was deﬁned as a
peptide with a unique modiﬁcation site. In this case, two
peptides with identical amino acid sequence but with diﬀerent
site localization were considered as two unique peptides. In
agreement with our previous ﬁndings, ETcaD fragmentation
failed to identify large numbers of ADP-ribosylated peptides15
(Table 1, Figure 2A).
In contrast, HCD identiﬁed twice as many unique ADP-
ribosylated peptides (52 for ETcaCD vs 105 for HCD) and
ETcaD fragmentation required longer acquisition times than
HCD, which decreased the overall number of MS/MS spectra
generated (total number of MS/MS spectra 45 532 vs 65 795).
The overall decrease in identiﬁed spectra may partially
explain why fewer ADP-ribosylated peptides were identiﬁed by
the ETcaD fragmentation method. EThcD fragmentation,
which generated 47 112 spectra, identiﬁed 70 unique ADP-
ribosylated peptides. This ﬁnding highlights the superior
performance of this fragmentation method when compared to
ETcaD. Comparative analysis of peptides identiﬁed by the
diﬀerent fragmentation methods revealed that EThcD identi-
ﬁed 42 unique ADP-ribosylated peptides (gain of 26% total)
that were not detected with HCD fragmentation (Figure 2B).
Seventeen of these EThcD-unique ADP-ribosylated peptides
were also assigned in the ETcaD run. Moreover, ETcaD
identiﬁed 13 unique ADP-ribosylated peptides (19% gain) that
were not present in either the EThcD or HCD runs. Further
investigation into the physical properties of the identiﬁed ADP-
ribosylated peptides (charge, length, and chemical composi-
tion) revealed that ETcaD demonstrated a clear preference for
higher charge-state precursors (3+ and 4+). We did not,
however, observe any diﬀerences in average ADP-ribosylated
peptide length or chemical composition for the tested
fragmentation methods (Figure S2). In conclusion, as judged
by the number of PSMs and unique identiﬁed ADP-ribosylated
peptides, HCD fragmentation performed best. EThcD
fragmentation performed less favorably but identiﬁed additional
modiﬁed peptides. These ﬁndings suggested that a combination
of HCD and EThcD could be beneﬁcial for in-depth ADP-
ribosylome characterization. For HCD, around 40% of unique
ADP-ribose marker ion-containing spectra were assigned by the
Mascot search. The unassigned spectra might be partially
explained by the poor fragmentation of ADP-ribosylated
peptides, peptides that are shorter or longer than the set
threshold, peptides that fall under the applied scoring threshold
in Mascot, and/or a not fully optimized search algorithm. This
suggests the possibility for further improvements in the
bioinformatics analysis pipeline, including the development of
algorithms that score the presence of marker ions.
HCD and EThcD Localize ADP-Ribose Acceptor Sites
with High Conﬁdence. Previous studies reported the beneﬁt
of EThcD to accurately localize serine and threonine
phosphorylation sites.18 Therefore, we compared how the
diﬀerent fragmentation methods performed when attempting to
conﬁdently assign four described ADP-ribosylation acceptor
sites: lysine (K), arginine (R), glutamic acid (E), and aspartic
acid (D) HCD, ETcaD, and EThcD localized all four acceptor
amino acids with high conﬁdence. For HCD fragmentation
measurements, the modiﬁcation acceptor sites were assigned
with conﬁdence >95% for 63.8% of the identiﬁed unique ADP-
ribosylated sites. ETcaD assigned 51.9% of the unique ADP-
ribosylated sites with similar conﬁdence (Table 1). EThcD
performed comparably to HCD, assigning 60.5% of the unique
ADP-ribosylated sites with >95% conﬁdence. Moreover,
acceptor sites identiﬁed with a localization probability of less
than 60% represented only 4% of all ADP-ribose acceptor sites
identiﬁed with EThcD, whereas they comprised 18% of the
ADP-ribosylated sites identiﬁed with HCD (Figure 2C). This
fact points to better peptide fragmentation with EThcD in
comparison to HCD.
To understand the localization probabilities in more detail,
we compared the peptide coverage information obtained from
all fragmentation methods and looked for the presence of
characteristic ions, which were deﬁned as the ﬁrst fragment ions
carrying the modiﬁcation. To evaluate peptide sequence
coverage, the number of ions used by Mascot for scoring was
normalized to the length of the peptide (the presence of a full
ion series corresponds to a coverage ratio of 1). In agreement
with the localization probability assignments, HCD and EThcD
performed comparably, with slightly better fragmentation than
ETcaD (Figure S1E). Furthermore, each fragmentation method
was compared on the basis of the presence of acceptor-site-
Table 1. Analysis of ADP-Ribosylated Peptides Identiﬁed by
HCD, ETcaD, and EThcD Fragmentations
ADP-
ribosylated
PSMsa
ADP-
ribosylated
peptides ADP-ribosylated sites
method total total total
loc probability >95% (%
total identiﬁcations)
HCD 276 105 92 60 (63.8)
ETcaD 113 52 40 20 (51.9)
EThcD 195 70 56 30 (60.5)
aPSM, peptide-spectrum match.
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characterizing ions (Figure 2E). For each fragmentation,
characteristic y/b or z/c ions were not observed (only in
1.8% c-ion series generated by EThcD but not with other
fragmentations). However, HCD and EThcD often produced
ions before the modiﬁcation site, whereas ETcaD did not
generate ions close to the assigned modiﬁcation site.
Overall, ETcaD performed signiﬁcantly worse than HCD and
EThcD for ADP-ribosylation site identiﬁcation and localization.
For this reason, ETcaD was excluded from further analysis. In
agreement with previous phosphoproteomics studies,18,25 we
found that the localization probabilities for ADP-ribosylation
showed a general improvement when EThcD fragmentation
methods were used. Together, ADP-ribosylated peptides with
localization probabilities >95% represented ∼60% of all HCD-
and EThcD-identiﬁed acceptor sites. EThcD did, however,
provide slightly better-quality spectra. In a previous study,
performed on an Orbitrap Velos, only 10% of the identiﬁed
acceptor sites had localization probabilities >95%.15 Thus, this
study showed a signiﬁcant improvement in unambiguous site
assignment, which was largely due to technological improve-
ments and the development of new fragmentation techniques.
Together, these ﬁndings suggest that both HCD and EThcD
could be used to conﬁdently localize ADP-ribosylated acceptor
sites.
ADP-Ribose Marker-Ion-Dependent Combination of
HCD and EThcD Improves ADP-Ribosylated Peptide
Identiﬁcation. Our previous study,15 together with the
ﬁndings presented above, suggest that combining diﬀerent
fragmentation methods in an ADP-ribose marker ion product-
dependent manner could increase the number of ADP-
ribosylated peptides identiﬁed by use of the Orbitrap Fusion.
The observation that the EThcD fragmentation-identiﬁed sites
were complementary to those identiﬁed via HCD, combined
with excellent localization scores generated from both
fragmentation methods, prompted us to develop a method
that would combine HCD and EThcD into a single
measurement. Furthermore, to optimize measurement eﬃ-
ciency and focus speciﬁcally on ADP-ribosylated peptides, we
integrated a precursor selection criterion that is based on the
detection of ADP-ribose marker ions, whose presence triggers
subsequent product-dependent EThcD and/or HCD. For this
product-dependent method (HCD-PD-EThcD), HCD MS/
MS spectra were generated as described for the single HCD
method. When at least one ADP-ribose marker ion was
observed during the HCD MS/MS scan, the same precursor
was selected again and fragmented by EThcD. The HCD-PD-
EThcD methodology signiﬁcantly increased ADP-ribosylated
PSMs (429 vs 276 for HCD alone; Figure 3A and Table 2).
Despite this increase, only a 20% increase in unique ADP-
ribosylated peptides identiﬁcations was observed (126 unique
ADP-ribosylated peptides vs 105 for HCD alone). This could,
Figure 2. Evaluation of HCD, ETcaD, and EThcD fragmentation performance for ADP-ribosylated peptide identiﬁcation. (A) Number of ADP-
ribosylated peptide spectrum matches (PSMs) and unique peptides identiﬁed by each fragmentation. (B) Venn diagram showing overlap in the
unique peptide identiﬁed by each fragmentation method. (C) Distribution of ADP-ribosylated localization probability of unique ADP-ribosylated
peptides identiﬁed with each fragmentation method. Values were normalized to total numbers of unique ADP-ribosylated peptides. (D) Distribution
of amino acid acceptor sites from unique ADP-ribosylated peptides. Only peptides with localization probability >95% were considered. (E) Presence
of modiﬁcation-characteristic ions in the spectra of ADP-ribosylated peptides. Characteristic ions were deﬁned as the ﬁrst fragment ions carrying the
modiﬁcation. The number close to the ion shows the frequency at the ion was observed with the speciﬁed fragmentation method.
Figure 3. Evaluation of HCD-PD-EThcD and HCD(FT)-PP-EThcD
performance for ADP-ribosylated peptide identiﬁcation. (A) Number
of PSMs and unique peptides (score >20, expectation <0.05) identiﬁed
by each product-dependent method. (B) Contribution of HCD and
EThcD fragmentations in product-dependent methods for identi-
ﬁcation of ADP-ribosylated peptides. (C) Putative ADP-ribosylation
motif for lysine as ADP-ribose acceptor site. ADP-ribosylated
modiﬁcation motif for K sites was identiﬁed with Scaﬀold PTM.
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potentially, result from mass spectrometer speed capacity
saturation.
To fully exploit the advantages of this dual fragmentation
method, we aimed to optimize the instrument’s cycle time and
implement a new method called HCD-PP-HCD/EThcD. In
this workﬂow, every MS1 spectrum acquisition was followed by
a product preview (PP) HCD MS/MS scan, performed in the
Orbitrap (FT acquisition) at low resolution (30K) with high
NCE (38). These settings resulted in fast MS/MS lower-quality
spectra acquisitions that gave very intense ADP-ribose marker
ion signals. Given that PP FT-HCD injection times are 4 times
shorter than FT-HCD injection times, these alterations
generated 4 times more scans per duty cycle. After initial PP-
FT-HCD scans, the instrument was then programmed to select
precursors with >2 ADP-ribose marker ions to record
additional MS/MS spectra via high-quality HCD and EThcD
fragmentation. When compared to the HCD-PD-EThcD
method described above, this new HCD-PP-HCD/EThcD
strategy identiﬁed an additional 42% unique ADP-ribosylated
peptides (Figure 3A), and it identiﬁed 70% more when
compared to HCD alone. The contribution of EThcD
fragmentation to the identiﬁcation of ADP-ribosylated peptides
in these product-dependent methods was similar to the
performance of EThcD alone and contributed to at least 22%
of all identiﬁcations (Figure 3B and Table 2).
Given these positive results, we also attempted to implement
an HCD (IT)-PP-HCD/EThcD method. Unfortunately, we
found that the preview scan in the ion trap (IT) led to a high
proportion of false positives and the overall performance of this
method was worse than other product-dependent methods
(data not shown). Product-dependent methods, which combine
HCD and ETcaD fragmentations, have been previously
reported for analysis of complex post-translational modiﬁca-
tions, as in glycoproteins.26,27 Therefore, we optimize machine
duty time and tested whether use of ADP-ribose marker-ion-
triggered product-dependent MS/MS measurements would
promote eﬃcient ADP-ribosylation acceptor site identiﬁcation.
To this end, we found that the fast, high-energy, low-resolution
preview HCD MS/MS scans, which triggered subsequent MS/
MS (>2 ADP-ribose fragmentation ions), optimized machine
capacity and eﬃciently selected the appropriate ADP-
ribosylated precursors. Moreover, when combined with
subsequent HCD and EThcD, this strategy signiﬁcantly
enhanced ADP ribosylated peptide identiﬁcations compared
to HCD or EThcD alone.
Improved ADP-Ribosylation Site Assignments Identi-
ﬁed a Lysine ADP-Ribosylation Motif. Next, we assessed
the distribution of known ADP-ribose acceptor sites (K, R, D,
E) that were identiﬁed with high localization conﬁdence
(localization probability >95%) by the diﬀerent fragmentation
methods. Interestingly, K was the most abundant acceptor
amino acid identiﬁed in this analysis, representing 45% of total
unique sites for both HCD and EThcD and 52% for ETcaD.
We also found that R was more often observed as acceptor site
in ETcaD or EThcD fragmentation methods and that the
identiﬁcation of E and D acceptor sites was underrepresented in
the ETcaD fragmentation data sets (Figure 2D and Figure
Table 2. Identiﬁcation of ADP-Ribosylated Peptides via
Product-Dependent Methods Including Contribution of
HCD and EThcD to Total Assignment
ADP-ribosylated PSMsa
ADP-
ribosylated
peptides
ADP-
ribosylated
sites
method total total % total %
HCD-PD-EThcD 429 126 99
including HCD 265 69 55 58 59
EThcD 164 30 24 22 22
overlap 27 21 19 19
HCD-PP-EThcD 450 179 141
including HCD 349 97 54 86 61
EThcD 196 49 27 31 22
overlap 33 19 24 17
aPSM, peptide-spectrum match.
Figure 4. (A) Distribution of amino acid acceptor sites of unique ADP-ribosylated peptides. Only peptides with localization probability >95% were
considered. The number of unique peptides is indicated. (B) ADP-ribosylation motif for S sites. (C) Distribution of ADP-ribosylated localization
probability of unique ADP-ribosylated peptides identiﬁed with each fragmentation method. (D) EThcD fragmentation of an ADP-ribosylated
peptide modiﬁed on S.
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S3A). These high-quality ADP-ribosylated peptide spectra and
their corresponding acceptor site identiﬁcations prompted us to
further analyze the peptide sequences for potential ADP-
ribosylation motifs. When the lysine acceptor sites were
studied, 48% of the modiﬁcation sites (44 out of 90) contained
a xxxxxxKSxxxxx motif and 20% had a xxxxxxSKxxxxx motif (19
out of 90) (Figure 3C and Figure S3B and Table S2). We were
not able to detect any consensus modiﬁcation sequences for D,
E, or R acceptor sites in our data set.
Proteomewide Identiﬁcation of Serine ADP-Ribosyla-
tion Sites. The appearance of serine adjacent to the lysine
acceptor site at the xxxxxxKSxxxxx motif prompted us to re-
evaluate our data and determine whether serine could also be a
potential ADP-ribose acceptor site. Indeed, including serine as a
ﬁfth potential ADP-ribose acceptor site increased ADP-
ribosylated PSM detection (additional 524 PSMs for HCD-
PP-HCD/EThcD method; Figure S3C) and led to the
identiﬁcation of 137 additional unique ADP-ribosylated
precursors. Analysis of conﬁdently identiﬁed ADP-ribose
acceptor sites suggests that serine is a major target for ADP-
ribosylation (Figure 4A). These ﬁndings are in agreement with
a recent study that reported that histones were predominantly
ADP-ribosylated at serine residues.28 Further analyses of the
ADP-ribosylated serine spectra conﬁrmed the existence of a
xxxxxxKSxxxxx motif (Figures 3C and 4B). Additionally, a novel
xxxxxxRSxxxxx motif was also identiﬁed in 21 unique serine-
ADP-ribosylated peptides (Figure 4B and Table S3). Of the
assigned modiﬁed serines, 24% were without an adjacent K or
R.
Importantly, the quality of the spectra remained high, but
inclusion of serine within our analysis pipeline increased the
number of peptides with localization probabilities around 50%
(Figure 4C). This could be associated with the presence of the
xxxxxxKSxxxxx or xxxxxxRSxxxxx motifs in the identiﬁed
peptides, which makes it diﬃcult to conﬁdently assign the
ADP-ribosylation site, as only two fragment ions (HCD) or
four fragment ions (EThcD) discriminated these sites. In
support of this, we found that, within the HCD-PP-HCD/
EThcD data, ∼75% of the unique peptides with localization
probabilities <60% also had at least one additional possible
ADP-ribose acceptor site adjacent to the assigned modiﬁcation
site, while 58% of the unique peptides with localization
probabilities >60% had no adjacent possible acceptor site. We
obtained highly conﬁdent assignments for serine ADP-ribose
acceptor sites located adjacent to lysine residues (Figure 4D).
In fact, when serine was included as a potential ADP-ribose
acceptor site in our searches, signiﬁcantly lower numbers of
ADP-ribosylated lysines were assigned and those identiﬁed
were mainly supported by HCD spectra (Figure S3D). Overall
we observed proteomewide occurrence of serine ADP-
ribosylation, due to novel assigned ADP-ribosylated precursors
as well as a partial shift of previously assigned lysine-ADP-
ribosylation to a proximal serine (Figure 4A). Interestingly, the
use of EThcD fragmentation allowed us to identify a new
peptide species that carries two ADP-ribose moieties (Figure
S4). Another ARTD1 dual-modiﬁed precursor had been
previously identiﬁed following MS analysis of in vitro-modiﬁed
ARTD1.13 Initially the two sites were assigned to K508 and
E520 as acceptor sites (Figure S4A), and after inclusion of S as
a potential acceptor site in the Mascot search parameters, the
modiﬁcations were then assigned to S507 and either S519 or
E520 (only S507 was conﬁdently assigned) (Figure S4B).
■ CONCLUSIONS
Several techniques to enrich, process, and analyze ADP-
ribosylated peptides from complex samples have been
published. These techniques, however, usually employ standard
mass spectrometric methods. The analysis of complex PTMs
like ADP-ribosylation, however, requires an optimized method-
ology that tackles the speciﬁc features of the PTM and resulting
modiﬁed peptides. Here, we harnessed the full MS potential of
the Orbitrap Fusion Tribrid and exploited the unique
properties of ADP-ribose fragmentation to establish an ADP-
ribosylome customized MS workﬂow. Parameter optimization
and systematic performance comparisons of HCD, ETcaD, and
EThcD fragmentation of endogenous ADP-ribosylated peptides
revealed that HCD alone identiﬁed the most modiﬁed peptides.
Importantly, we also discovered that EThcD fragmentation
identiﬁed 42 unique ADP-ribosylated peptides that were not
present in the HCD data set. These ﬁndings suggested that a
combination of HCD and EThcD fragmentation would allow
in-depth characterization of the cellular ADP-ribosylome. To
this end, we established a HCD-PP-HCD/EThcD method that
supported robust ADP-ribosylome discovery studies. The
method consists of several important implementations: (1)
initial fast, high-energy HCD scans that promote generation of
ADP-ribose marker ions and allows preselection of potential
ADP-ribosylated peptide precursors and (2) two high-
resolution HCD and EThcD measurements of the preselected
precursors. This method signiﬁcantly improved the eﬃcient
identiﬁcation of ADP-ribosylated peptides, and high quality
MS/MS spectra were acquired that allowed the accurate
localisation of ADP-ribose acceptor sites within the peptide. To
our knowledge, this HCD-PP-HCD/EThcD workﬂow is the
most optimized and eﬃcient method for ADP-ribosylation site
identiﬁcation in complex samples. Importantly, the improve-
ments described here generated a unique and highly accurate
data set that allowed us to deﬁne the ﬁrst modiﬁcation motif for
K and S as ADP-ribose acceptor sites.
Identiﬁcation of ADP-ribosylation motifs would greatly
beneﬁt the eﬀort to identify potential ADP-ribosylation targets,
as was seen in the phosphorylation ﬁeld. It remains to be
clariﬁed if and what the biological relevance of the identiﬁed
motif is, since this might help to determine the target speciﬁcity
of the ARTD enzymes. Furthermore, the techniques for
proteomewide ADP-ribosylation site mapping are only started
to develop.
Applying diﬀerent fragmentation techniques to ADP-
ribosylated peptides led to the recognition of serine as ADP-
ribose acceptor across the proteome. This discovery suggests
that additional amino acid ADP-ribose acceptor sites could be
present in vivo. Importantly, this novel methodology produces
high-quality spectra for ADP-ribosylated peptides. This is
critical to the identiﬁcation of all possible ADP-ribose acceptor
amino acids via thorough bioinformatic analysis and subsequent
biochemical validation.
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SUMMARY
Chromatin ADP-ribosylation regulates important
cellular processes. However, the exact location and
magnitude of chromatin ADP-ribosylation are largely
unknown. A robust and versatile method for assess-
ing chromatin ADP-ribosylation is therefore crucial
for further understanding its function. Here, we pre-
sent a chromatin affinity precipitation method based
on the high specificity and avidity of twowell-charac-
terized ADP-ribose binding domains to map chro-
matin ADP-ribosylation at the genome-wide scale
and at specific loci. Our ADPr-ChAP method re-
vealed that in cells exposed to oxidative stress,
ADP-ribosylation of chromatin scales with histone
density, with highest levels at heterochromatic sites
and depletion at active promoters. Furthermore, in
growth factor-induced adipocyte differentiation,
increased chromatin ADP-ribosylation was observed
at PPARg target genes, whose expression is ADP-ri-
bosylation dependent. In combination with deep-
sequencing and conventional chromatin immuno-
precipitation, the established ADPr-ChAP provides
a valuable resource for the bioinformatic comparison
of ADP-ribosylation with other chromatin modifica-
tions and for addressing its role in other biologically
important processes.
INTRODUCTION
Protein ADP-ribosylation is an ancient post-translational protein
modification with high biochemical complexity (i.e., different
length and branching of ADP-ribose polymers) that consists of
the transfer of the ADP-ribose moiety from NAD+ to specific
amino acid residues on substrate proteins and to ADP-ribose
itself (Hottiger, 2015). The reaction is catalyzed by various ADP-ri-
bosyltransferases (ARTs) and a subgroup of NAD+-dependent sir-
tuins (Aravind et al., 2014; Hottiger et al., 2010; Houtkooper et al.,
2012). From the existing 18 intracellular diphtheria toxin-like ADP-
ribosyltransferases (ARTDs, formerly known as poly (ADP-ribose)
polymerases [PARPs]), ARTD1 (PARP1) and ARTD2 (PARP2) are
found in the nucleus, whereas the other ARTDs are found in the
nuclear and cytoplasmic, or only in the cytoplasmic compartment
(Hottiger, 2015). Currently, little is known about the substrate
specificity of ARTDs and the mechanisms directing this speci-
ficity. Protein ADP-ribosylation can be divided into two subtypes:
mono-ADP-ribosylation (MARylation), which defines a reaction
where only mono-ADP-ribose (MAR) is transferred to the amino
acid of a target protein, and poly-ADP-ribosylation (PARylation),
which involves the transfer and elongation of the initial ADP-ribose
moiety to generate poly-ADP-ribose chains (Alvarez-Gonzalez
and Mendoza-Alvarez, 1995).
Protein ADP-ribosylation is recognized by different protein do-
mains (readers) and reversed by ADP-ribosylhydrolases (erasers).
Among the recently identified readers, some recognize both
mono-ADP-ribosylated (MARylated) and poly-ADP-ribosylated
(PARylated) proteins (e.g., Af1521macrodomain), whereas others
only bind to PARylated proteins (e.g., WWE domain) (Hottiger,
2015). The WWE domain is a globular domain that contains
two conserved tryptophans (W) and a glutamate (E) residue
and is usually found as a single or double domain. Crystal and so-
lution NMR structures of individual WWE-domains have been
described for the E3 ubiquitin-protein ligase RNF146 (Wang
et al., 2012), as well as for ARTD11 and ARTD8 (He et al., 2012).
WWE domains have a strong affinity for iso-ADP-ribose within
the PAR chain and have been proposed to be involved in ADP-ri-
bosylation signaling (Aravind, 2001; He et al., 2012; Wang et al.,
2012).
At the molecular level, ADP-ribosylation affects the function of
themodified proteins or provides a scaffold for the recruitment of
regulatory proteins (Gibson and Kraus, 2012; Izhar et al., 2015). A
large body of studies has been performed to elucidate the
cellular functions of the nuclear ARTD family members. In higher
organisms, ADP-ribosylation regulates important cellular pro-
cesses such as DNA replication and repair, telomere mainte-
nance, gene transcription, chromatin architecture, proteasomal
functions, cell morphology, cell viability, cell cycle, and cell death
(reviewed in Gibson and Kraus, 2012; Hassa et al., 2006; Kraus
and Hottiger, 2013; Leung, 2014; Schreiber et al., 2006; Vira´g
et al., 2013).
ADP-ribosylation has gained much attention in recent years,
because its pharmacological inhibition by PARP inhibitors has
been shown to induce synthetic lethality in certain cancer cells
and to be therapeutically beneficial against certain forms of
ovarian cancer (Benafif and Hall, 2015; Rouleau et al., 2010;
474 Molecular Cell 61, 474–485, February 4, 2016 ª2016 Elsevier Inc.
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Chapter 10
Identification of ADP-Ribose Acceptor Sites on In Vitro 
Modified Proteins by Liquid Chromatography–Tandem 
Mass Spectrometry
Mario Leutert*, Vera Bilan*, Peter Gehrig, and Michael O. Hottiger
Abstract
Protein ADP-ribosylation is a covalent, reversible posttranslational modification (PTM) catalyzed by ADP- 
ribosyltransferases (ARTs). Proteins can be either mono- or poly-ADP-ribosylated under a variety of physi-
ological and pathological conditions. To understand the functional contribution of protein ADP-ribosylation 
to normal and disease/stress states, modified protein and corresponding ADP-ribose acceptor site identi-
fication is crucial. Since ADP-ribosylation is a transient and relatively low abundant PTM, systematic and 
accurate identification of ADP-ribose acceptor sites has only recently become feasible. This is due to the 
development of specific ADP-ribosylated protein/peptide enrichment methodologies, as well as technical 
advances in high-accuracy liquid chromatography–tandem mass spectrometry (LC-MS/MS). The stan-
dardized protocol described here allows the identification of ADP-ribose acceptor sites in in vitro ADP- 
ribosylated proteins and will, thus, contribute to the functional characterization of this important PTM.
Key words ADP-ribosylation, ADP-ribosylome, ARTD, PARP, PARG, Mass spectrometry, 
Ti4+-IMAC enrichment, Phosphoenrichment
1 Introduction
Protein ADP-ribosylation is a covalent posttranslational modifica-
tion (PTM) catalyzed by different ADP-ribosyltransferases (ARTs). 
These enzymes use nicotinamide adenine dinucleotide (NAD+) as 
a substrate to transfer the ADP-ribose (ADPr) moiety onto specific 
amino acid side chains, a process termed protein mono-ADP- 
ribosylation (MARylation). ARTs can also mediate poly-ADP- 
ribosylation (PARylation) by transferring the ADPr moiety onto 
an existing protein-bound ADP-ribose unit. Currently, 22 cellular 
human ARTs are known. They are subdivided into ARTCs (C for 
C2/C3 toxin like) and ARTDs (D for diphtheria toxin like, also 
*These authors contributed equally to this chapter.
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called PARPs). While ARTCs are membrane-associated or secreted 
ARTs, human ARTDs form a family of 18 intracellular enzymes 
with confirmed or putative mono- or poly-ADP-ribosyltransferase 
activity [1–3].
Several enzymes that remove ADP-ribose from mono- and 
poly-ADP-ribosylated substrates have also been identified, render-
ing ADP-ribosylation a fully reversible PTM. Several mammalian 
ADP-ribosylhydrolases have been characterized so far, including 
poly-ADP-ribose glycohydrolase (PARG), ADP-ribosylhydrolase 3 
(ARH3), both of which are able to hydrolyze poly-ADP-ribose, 
and the mono-ADP-ribosylarginine hydrolase 1 (ARH1). In addi-
tion, the macrodomain-containing proteins MacroD1, MacroD2, 
and C6orf130 have recently also been shown to exhibit mono- 
ADP- ribosylhydrolase activity [4–6].
To elucidate the functional role of protein ADP-ribosylation, 
systematical analysis of all ADP-ribosylated proteins and identifica-
tion of their ADP-ribose acceptor sites are necessary. Comparable 
to many other PTMs, the fraction of ADP-ribosylated cellular pro-
teins is very low. Thus, studying this group of modified proteins 
requires specific ADP-ribosylated protein/peptide enrichment 
methodologies. Mass spectrometry (MS)-based proteomics is 
probably the most powerful tool for the analysis of PTMs. However, 
the analysis of this PTM has proven to be very challenging for sev-
eral reasons, including the highly transient nature and the low 
abundance of ADP-ribosylated proteins, the special physicochemi-
cal properties of the PTM (bulky, highly charged, heterogeneous 
structure, labile), and the number of different amino acids that 
were reported to be modified (acidic and basic amino acids with a 
primary amino group on the side chain) [7]. Characterization of 
ADP-ribose acceptor sites by MS has significantly improved fol-
lowing the development of high-resolution mass spectrometers 
and novel fragmentation techniques.
In the past few years, several methods for the identification of 
ADP-ribose acceptor sites on in vitro and in vivo ADP-ribosylated 
proteins have been published. Zhang et al. [8] established an 
enrichment protocol based on the isolation of ADP-ribosylated 
peptides by boronate affinity chromatography and subsequent 
modified peptide elution using hydroxylamine (NH2OH). This 
methodology leaves a characteristic mass signature of 15.01 Da at 
the ADP-ribose acceptor site [8]. A major drawback of this proto-
col is that the chemical reaction employed here limits the detection 
of ADP-ribosylated amino acids to glutamates and aspartates only. 
Other groups have also used boronate affinity enrichment, but in 
combination with acidic elution, which leaves the ADP-ribose 
moiety intact and leads to a release of all bound peptides. This, 
unfortunately, resulted in high background of unmodified pep-
tides. Additionally, hydroxylamine treatment has also been used as 
a stand-alone procedure without any enrichment, but this method 
only seems useful for strongly ADP-ribosylated targets [9, 10].
Mario Leutert et al.
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Phosphoproteomic approaches were also found to co-enrich 
ADP-ribosylated peptides, and protocols have been optimized for 
the specific enrichment of ADP-ribosylated or phosphoribosylated 
peptides [11–14]. Chapman et al. [13] and Daniels et al. [14] used 
phosphodiesterases to reduce the mono- and poly-ADP- 
ribosylation modification (MAR or PAR, respectively) to a protein-
bound phosphoribose. The resulting phosphoribosylated peptides 
are subsequently enriched using either Fe(III)-immobilized metal 
ion affinity chromatography (IMAC) or TiO2 microspheres. The 
conversion of protein-bound MAR or PAR to phosphoribose leads 
to a detectable mass signature of 212.01 Da.
The most recent enrichment approach published by Martello 
et al. [15] makes use of PARG enzymatic treatment to convert 
in vivo PARylated peptides into MARylated peptides, which are 
subsequently enriched by the ADP-ribose binding protein Af1521 
and described in the Chap. 11 of this book. This technique allows 
the accurate and reproducible identification of ADP-ribose accep-
tor sites in vivo. However, this enrichment strategy has so far not 
been tested or optimized for in vitro modified proteins.
Here, we thus describe an updated protocol using a Ti4+-IMAC 
enrichment based on the work done by Chapman et al. [13] and 
Daniels et al. [14] to map ADP-ribose acceptor sites on in vitro 
ADP-ribosylated proteins. This protocol is more readily applicable 
to a variety of different samples than the boronate affinity 
chromatography- based protocol described by our group in the 
previous edition of this book for in vitro modified proteins [9]. 
More importantly, this new methodology is not biased against spe-
cific ADP-ribose acceptor sites. The problem that phosphorylated 
peptides might co-enrich with phosphoribosylated/ADP- 
ribosylated peptides and interfere with the sensitivity of the detec-
tion is not an obstacle due to the low complexity of in vitro 
modified samples.
2 Materials
All solutions prepared with type 1 analytical grade water.
 1. hARTD1 is expressed and purified from insect cells as carboxyl- 
terminal His-tagged protein and stored in liquid nitrogen.
 2. hPARG is expressed and purified from insect cells as carboxyl- 
terminal His-tagged protein and stored in liquid nitrogen 
(see Note 1).
 3. 10 mM β-Nicotinamide adenine dinucleotide (NAD+) (>99% 
Sigma–Aldrich as hydrate) stored at −80 °C.
 4. 10 mM PJ-34 (≥98% Sigma-Aldrich as hydrochloride hydrate) 
stored at −20 °C.
2.1 ADP-Ribosylation 
Assay and PARG 
Treatment
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 5. ADP-ribosylation buffer (always prepare freshly): 50 mM Tris–
HCl pH 8.0, 4 mM MgCl2, 250 μM DTT, and cOmplete™ 
EDTA-free Protease Inhibitor Cocktail.
 1. 5× disulfide bond reduction buffer: 250 mM DTT, 250 mM 
Tris–HCl pH 8.2, and 5 M urea.
 2. 0.5 ml Microcon 30 kDa centrifugal filter units with Ultracel- 30 
membranes (Millipore, MRCF0R030).
 3. Urea buffer: 8 M urea in 50 mM Tris–HCl pH 8.2.
 4. Iodoacetamide solution: 0.05 M iodoacetamide in urea buffer 
(kept protected from light).
 5. 0.5 M NaCl.
 6. 0.05 M ammonium bicarbonate (prepare freshly).
 7. Sequencing grade modified trypsin (Promega).
 1. MagReSyn® Ti4+-IMAC from ReSyn Biosciences.
 2. 70% ethanol.
 3. Loading Buffer: 1 M glycolic acid in 80% acetonitrile.
 4. Wash buffer: 80% acetonitrile and 0.1% acetic acid in H2O.
 5. Elution buffer: 50 mM Tris–HCl pH 8, 10 mM diammonium 
hydrogen phosphate, and 5% acetonitrile.
 1. C18 Empore high-performance extraction disks (3 M).
 2. 100% methanol.
 3. Stage Tip Solution A: 0.5% acetic acid in H2O.
 4. Stage Tip Solution B: 80% acetonitrile and 0.5% acetic acid 
in H2O.
 5. Stage Tip Elution Solution: 60% acetonitrile and 0.5% acetic 
acid in H2O.
 1. HPLC solvent A: H2O containing 0.1% formic acid.
 2. HPLC solvent B: Acetonitrile containing 0.1% formic acid.
 3. Frit column (inner diameter 75 μm, length 15 cm) packed 
with reversed phase material (C18-AQ, particle size 1.9 μm, 
pore size 120 Å, Dr. Maisch GmbH, Germany).
 4. Instrumentation: Orbitrap Fusion Tribrid mass spectrometer 
(Thermo Scientific, San Jose, CA), connected to an Easy-nLC 
1000 HPLC system (Thermo Scientific) (see Note 2).
3 Methods
In vitro auto- and especially trans-ADP-ribosylation reactions are 
often not efficient and lead to a low abundance of ADP-ribosylated 
proteins. We, therefore, recommend ADP-ribosylated peptide 
2.2 FASP Trypsin 
Digestion
2.3 ADP-Ribosylated 
Peptide Enrichment
2.4 Stage Tip 
Desalting
2.5 Mass 
Spectrometry
3.1 Overview 
of the Protocol
Mario Leutert et al.
RESULTS
61
141
enrichment following a previously described phosphoenrichment 
technique that is based on immobilized titanium ion affinity chro-
matography [16]. This protocol facilitates modified peptide enrich-
ment and increases the possibilities of a successful analysis, including 
ADP-ribosylation site determination. In vitro reactions should be 
carried out according to the optimized protocols for the different 
ADP-ribosyltransferases. The original protocol used phosphodies-
terases to reduce mono- and poly-ADP-ribosylation modifications 
(MAR or PAR, respectively) to a protein-bound phosphoribose 
and to enrich subsequently phosphoribosylated peptides. We have, 
however, found that treatment of ADP-ribosylated proteins with 
poly(ADP-ribose) glycohydrolase (PARG), which reduces the 
complexity of PAR to protein-bound mono-ADP-ribose, works 
very reliable and allows efficient ADP-ribose enrichment as well. 
PARG-treated proteins are further digested with trypsin using 
filter- aided sample preparation (FASP) protocol [17]. The ADP- 
ribosylated peptides are finally enriched with magnetic micro-
spheres with chelated Ti4+ ions. This protocol is optimized to use 
only very mild buffers for the binding, washing, and peptide elu-
tion steps in order to preserve the ADP-ribose and its linkage to 
the modified amino acid residue. Samples are desalted using a C18 
Stage Tip protocol [18] and analyzed on an Orbitrap Fusion 
Tribrid mass spectrometer. HCD fragmentation has previously 
been shown to lead to reproducible identification of ADP- 
ribosylated peptides, and this method allows the accurate identifi-
cation of the modified amino acid [19]. Mascot searches are 
performed to identify ADP-ribose acceptor sites by setting ADP- 
ribosylation as a variable modification for lysine, arginine, gluta-
mate, and aspartate. A representative, annotated spectrum of an 
identified ADP-ribosylated ARTD1 peptide after the Ti4+ IMAC 
enrichment and the HCD ADP-ribose fragmentation pattern are 
shown in Fig. 1.
 1. For in vitro auto-ADP-ribosylation of ARTD1, incubate 20 pmol 
hARTD1 in the presence of 10 pmol annealed double- stranded 
oligomer (5-GGAATTCC-3) and 100 nM NAD+ in ADP-
ribosylation buffer (see Note 3). Reaction volume: 50 μl, reac-
tion conditions: 15 min, 30 °C. Terminate the reactions by 
adding PJ-34 (ADP-ribosylation inhibitor) to a final  concentration 
of 10 μM. To generate larger amounts of modified target pro-
tein, several reactions can be run in parallel (see Note 4).
 2. To reduce the complexity of PAR and generate MARylated 
proteins, samples are incubated with 5 pmol hPARG. Adjust 
the MgCl2 and NaCl buffer concentrations to 10 mM and 50 
mM, respectively, and incubate for 1 h at 37 °C.
 3. For the identification of ADP-ribose acceptor sites in peptides, 
proceed immediately with the FASP trypsin digestion, or, 
alternatively, freeze the proteins at −20 °C.
3.2 ADP-Ribosylation 
Assay and PARG 
Treatment
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 1. Add 5× reduction buffer to the protein sample to achieve 1×, 
and incubate at 37 °C for 30 min to reduce the disulfide bonds.
 2. Load up to 250 μl of reduced sample onto the Microcon-30 
kDa centrifugal filter unit. Centrifuge at 14,000 × g for ~15–
20 min at room temperature (RT). Repeat until the sample is 
completely loaded onto the filter.
 3. Add 200 μl of urea buffer to the filter unit. Centrifuge at 
14,000 × g for ~20 min at RT.
 4. Add 100 μl iodoacetamide solution to the filter unit. Gently 
shake for 5 min and centrifuge at 14,000 × g for ~15–20 min 
at RT.
 5. Add 100 µl of urea buffer to the filter unit. Centrifuge at 
14,000 × g for ~ 15 min at RT. Repeat step twice.
 6. Add 100 μl of 0.5 M NaCl to the filter unit. Centrifuge at 
14,000 × g for ~15–20 min at RT. Repeat step once.
 7. Add 100 μl of ammonium bicarbonate solution to the filter 
unit. Centrifuge at 14,000 × g for ~15–20 min at RT. Repeat 
step twice.
3.3 FASP Trypsin 
Digestion
200 400 600 800 1000 1200 1400 1600
0
10
20
30
40
50
90
100
R
el
at
iv
e 
Ab
un
da
nc
e 
% 136.06
z=1
Ad
en
in
e+
y(
1)
175.12
z=1
(A
de
no
si
ne
 - 
H
2O
)+
250.09
z=1
288.20
z=1
y(
2)
294.15
z=1
b(
3)
AM
P+
348.07
z=1
381.18
z=1
b(
4)
500.26
z=2
524.06
z=1
504.28
z=1
b(
9) (A
D
Pr
- H
2O
)+
y(
4)
-(A
D
Pr
)
AD
P+
428.04
z=1
614.31
z=2 650.37
z=1
b(
6)
y 0
(6
)-(
AD
Pr
)
708.37
z=1
y(
6)
-(A
D
Pr
)
717.36
z=3
[M
+3
H
-A
D
Pr
]3+
659.33
z=3
787.43
z=1
b(
7)
823.39
z=1
855.45
z=2
b*
(1
8)
-(A
D
Pr
)
928.97
z=2
y(
16
)-(
AD
Pr
)
y0
(1
6)
-(A
D
Pr
)
929.96
z=2
999.51
z=1
b(
9)
1150.57
z=1
y(
10
)-(
AD
Pr
)
1098.58
z=1
b(
10
)
1075.54
z=2
[M
+3
H
-A
D
Pr
]2+
1227.62
z=1
b(
11
)
1265.60
z=1
y(
11
)-(
AD
Pr
)
1362.65
z=1
y(
12
)-(
AD
Pr
)
1326.69
z=1
b(
12
)
b(
13
)
1441.71
z=1 1499.71
z=1
y(
13
)-(
AD
Pr
)
1481.70
z=1
b*
(1
4)
1645.80
z=?
b(
15
)
FTMS + p NSI d Full ms2 897.7209@hcd35.00 [110.0000-2000.0000]
m/z
ARTD1 / PARP1 - E76-ADP-ribosylation
V G H S
y1
6
b3
I
b4
R H
y1
3
b6
P D V E V
b1
1
D G
y6
b1
3
F S
b1
5
E L
y2
R
y1
b1
8
y1
2
b7
AD
Pr
y1
0
b1
0
y1
0
B9 b1
2
B1
4
y4
m1+ +
m3+ +
m6+
+
m8+
+
m10+
: 136.06 adenine
: 250.09 adenosine-H2O
: 348.05 adenosine-mono phosphate (AMP )
: 428.02 adenosine-di phosphate (ADP )
: 542.07 ADP-ribose  (ADPr )+
O O
P
O
O
OH
P
HO
OH
HO
O
O O
OH
OH
N
NN
N NH2
m6 m3m8
m1
A B
+
+
+
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 8. Transfer the filter units to new collection tubes.
 9. Add 120 μl of trypsin (1:25 trypsin to protein), dissolved in 
ammonium bicarbonate solution, to the filter unit, and gently 
shake for 1 min.
 10. Incubate the filter units at RT overnight in a humidity chamber.
 11. The next day, centrifuge the filter units at 14,000 × g for ~15–
20 min. The flow-through contains the digested proteins.
 12. Re-elute the column with 80 μl of ammonium bicarbonate 
solution.
 13. Dry the eluted peptides in a vacuum concentrator (see Note 5).
 1. Thoroughly resuspend MagReSyn® Ti4+-IMAC microspheres 
to ensure homogeneous suspension.
 2. Transfer 25 μl (0.5 mg) MagReSyn® Ti4+-IMAC to a 2 ml 
microcentrifuge tube.
 3. Place the tube on a magnetic separator, allow 10 s for the 
microspheres to clear, and discard the storage solution.
 4. Wash the microspheres, with gentle agitation, in 200 μl of 70% 
ethanol for 5 min.
 5. Place the tube on the magnetic separator, and allow the micro-
spheres to clear. Discard the ethanol solution.
 6. Repeat steps 4 and 5.
 7. Add 50 μl loading buffer to microspheres, and let stand for 60 
s to equilibrate.
 8. Place the tube on the magnetic separator and allow the micro-
spheres to clear. Remove the loading buffer. Important: The 
microspheres equilibration step should be performed immedi-
ately before sample loading.
 9. Repeat the equilibration process two additional times.
 10. Mix dried protein digests with 100 μl of loading buffer, incu-
bate for 5min at RT and add mixture to the equilibrated 
microsphere pellet (see Note 6).
 11. Incubate at room temperature for 30 min with continuously 
shaking to ensure adequate sample and microsphere interaction.
 12. Place the tube on the magnetic separator and allow the micro-
spheres to clear. Discard the coupling supernatant.
 13. Remove unbound sample by washing microspheres with 100 
μl loading buffer for 30 s with gentle agitation.
 14. Place the tube on a magnetic separator, and allow 10 s for the 
microspheres to clear. Remove the supernatant.
 15. Remove nonspecifically bound peptides by resuspending the 
microspheres in 100 μl wash buffer for 2 min with gentle 
agitation.
3.4 Enrichment 
of ADP-ribosylated 
Peptides
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 16. Place the tube on a magnetic separator, and allow 10 s for the 
microspheres to clear and remove the supernatant.
 17. Repeat steps 15 and 16 twice for a total of three washes.
 18. Elute the bound peptides from the microspheres by adding 60 
μl elution buffer and letting stand for 15 min. Ensure that the 
microspheres remain in suspension by gently agitating the 
tube.
 19. Place the tube on the magnetic separator and allow the micro-
spheres to clear. Remove the eluate and transfer it to a new 
tube.
 20. Repeat the elution steps 18 and 19 twice for a final elution 
volume of 180 μl.
 1. Prepare Stage Tips by plugging two C18 disks in a 200 μl 
pipette tip (see Note 7).
 2. Make a hole in the lid of a 1.5 ml Eppendorf tube and fit stage 
tip in. The tip should be tightly attached to the lid, and the tip 
should not touch the bottom of the tube.
 3. Activate the Stage Tip by adding 200 μl 100% methanol to the 
stage tip, and centrifuge at 1000 × g for approx. 3 min.
 4. Add 200 μl Stage Tip Solution B to the stage tip, and centri-
fuge at 1000 × g for approx. 3 min.
 5. Add 200 μl Stage Tip Solution A to the stage tip, and centri-
fuge at 1000 × g for approx. 3 min.
 6. Add 200 μl of your peptide sample, and centrifuge at 1000 × g 
for approx. 3 min. Repeat step until the whole sample is loaded.
 7. Wash Stage Tip by adding 50 μl of Stage Tip Solution A, and 
centrifuge at 1000 × g for approx. 3 min until Stage Tip is 
completely dry.
 8. Elute Stage Tip by adding 20 μl of Stage Tip Elution solution, 
and centrifuge at 1000 × g for approx. 1 min. Repeat elution 
step once more and combine elutions.
 9. Partially dry the eluted samples in a vacuum concentrator 
(see Note 5). The samples can be stored at −20 °C or directly 
proceed by LC-MS/MS.
All data are acquired on an Orbitrap Fusion Tribrid mass 
spectrometer connected to an Easy-nLC 1000 HPLC system 
(see Note 2). 4 μl of peptide sample in 0.1% formic acid are loaded 
and separated at a flow rate of 300 nl per min. The following LC 
gradient was applied: 0 min: 2% HPLC solvent B, 60 min: 30% B, 
70 min: 97% B, and 80 min: 97% B.
Survey scans were recorded in the Orbitrap mass analyzer in 
the range of m/z 350–1800, with a resolution of 120,000 and a 
maximum injection time of 50 ms. Higher-energy collisional 
3.5 Stage Tip 
Desalting
3.6 LC-MS/MS
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dissociation (HCD) spectra were acquired in the Orbitrap mass 
analyzer. A maximum injection time of 240 ms, an AGC target 
value of 5e5, and a resolution of 120,000 were used. The precur-
sor ion isolation width was set to m/z 2.0, and the normalized 
collision energy was 35%. Charge state screening was enabled, and 
charge states 2–5 were included. The threshold for signal intensi-
ties was 5e4, and precursor masses already selected for MS/MS 
acquisition were excluded for further selection during 30 s.
MS data are analyzed as previously described [19]. MS and MS/
MS spectra are converted into Mascot generic format (mgf) 
using Proteome Discoverer, v2.1 (Thermo Fisher Scientific, 
Bremen, Germany). All high-resolution HCD MS/MS spectra 
are deconvoluted using MS Spectrum Processor, v0.9 [21]. 
Searches were performed against the UniProtKB human data-
base (taxonomy 9606, version 20140422), which includes 
35′787 Swiss-Prot, 37′02 TrEMBL entries, 73′589 reversed 
sequences, and 260 common contaminants. Mascot 2.5.1 
(Matrix Science) is used for peptide identification using the fol-
lowing search settings: singly charged b and y ion series, immo-
nium ions, and water and ammonia loss ion series are searched. 
Enzyme specificity is set to trypsin, allowing up to four missed 
cleavages. The ADP-ribose variable modification is set to a mass 
shift of 541.0611, with scoring of the neutral losses equal to 
347.0631 and 249.0862. The marker ions at m/z 428.0372, 
348.0709, 250.0940, 136.0623 are ignored for scoring. Lysine, 
arginine, and glutamic and aspartic acid are set as variable ADP-
ribose acceptor sites. Peptides are considered correctly identified 
when a Mascot score >20, and an expectation value <0.05 are 
obtained. To assess the location of the ADP-ribose acceptor 
sites, we use the site localization analysis provided by Mascot, 
which is based on the work by Savitski et al. [21] and was devel-
oped especially for phosphorylation. Due to the lack of a better 
estimate, we define correctness as having a confidence of ≧95% 
in the Mascot site localization analysis (see Note 8).
4 Notes
 1. As an alternative to PARG treatment, enzymes converting 
ADP-ribose to phosphoribose (e.g., nudix hydrolases, snake 
venom phosphodiesterase I) can be used, but these require 
individually optimized reaction conditions and are expensive in 
the case of snake venom phosphodiesterase I [14, 22]. None of 
the available methods to date are capable of distinguishing 
between mono- and poly-ADP-ribose acceptor sites. We envi-
sion that a specific set of binding proteins with affinities for 
3.7 Database 
Analysis 
and Configuration 
of Mascot 
Modifications
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either PAR or MAR or conversion of PAR in to a specific moi-
ety could solve this problem in the near future.
 2. We measured all our samples on an Orbitrap Fusion Tribrid 
mass spectrometer, but it is also possible to conduct a similar 
analysis on other mass spectrometers with optimized machine 
settings.
 3. Higher NAD+ concentrations can trigger the generation of 
very long ADP-ribose polymers that might interfere with 
trans- ADP- ribosylation or subsequent analysis.
 4. We started our analysis with 50 μg ARTD1 and ended up with 
enough material for nine mass spectrometry injections. The 
amount of initial starting protein and the peptide solution that 
is injected into the mass spectrometer need to be optimized 
depending on the efficiency of the ADP-ribosylation reaction, 
the HPLC, and the mass spectrometer used for the analysis.
 5. Partial drying of the peptides (leave 1–2 μl) increases the over-
all yield.
 6. To control for the enrichment and MS analysis, standard phos-
phopeptides can be added into the sample prior to sample 
preparation.
 7. Video tutorial describing how to build and use the stage tips 
[18]: https://www.biochem.mpg.de/226863/Tutorials.
 8. This method is not optimized for ADP-ribosyl modifications 
due to the lack of standard peptides with known modification 
sites. For this reason, even if Mascot states a correctness of 95% 
for the site localization, this value is arbitrary and cannot be 
validated experimentally. If required, other amino acid accep-
tor sites can be included as variable modification sites.
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Chapter 11
Proteome-Wide Identification of In Vivo ADP-Ribose 
Acceptor Sites by Liquid Chromatography–Tandem Mass 
Spectrometry
Sara C. Larsen*, Mario Leutert*, Vera Bilan, Rita Martello, 
Stephanie Jungmichel, Clifford Young, Michael O. Hottiger, 
and Michael L. Nielsen
Abstract
ADP-ribosylation is a posttranslational modification (PTM) that affects a variety of cellular processes. In 
recent years, mass spectrometry (MS)-based proteomics has become a valuable tool for studying ADP- 
ribosylation. However, studying this PTM in vivo in an unbiased and sensitive manner has remained a 
difficult challenge. Here, we describe a detailed protocol for unbiased analysis of ADP-ribosylated proteins 
and their ADP-ribose acceptor sites under physiological conditions. The method relies on the enrichment 
of mono-ADP-ribosylated peptides using the macrodomain Af1521 in combination with liquid chroma-
tography–high-resolution tandem MS (LC-MS/MS). The 5-day protocol explains the step-by-step enrich-
ment and identification of ADP-ribosylated peptides from cell culture stage all the way through to data 
processing using the MaxQuant software suite.
Key words ADP-ribosylation, ADP-ribosylome, Mass spectrometry, Proteomics, Af1521 macrodomain 
enrichment, Affinity purification, PARG
1 Introduction
Protein ADP-ribosylation is a posttranslational modification 
(PTM) where an ADP-ribose moiety is transferred from NAD+ to 
the amino acid side-chains of target proteins (mono-ADP- 
ribosylation, MARylation), which subsequently can serve as an 
attachment point for additional ADP-ribose moieties (poly-ADP- 
ribosylation, PARylation). ADP-ribosylation is primarily catalyzed 
*These authors equally contributed to this work.
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by ADP-ribosyltransferases (ARTs) and certain Sirtuin deacetylases 
[1, 2]. A detailed understanding of the molecular mechanisms and 
functions regulated by ADP-ribosylation remains elusive. This is 
partially due to the fact that the amino acid residues modified 
in vivo by ADP-ribosylation remains unclear. Current experimental 
evidence suggests that ADP-ribosylation in eukaryotes occurs pri-
marily on the side chains of the following four amino acids; Lys 
[3], Arg [4], Asp and Glu residues [5]. In addition, Cys residues 
were reported to be MARylated not only by bacterial toxins, but 
also by certain ARTDs [6, 7].
Protein ADP-ribosylation is a low abundant and rapidly 
degraded PTM. To overcome the challenge posed by rapid ADP- 
ribosylation turnover, cellular poly(ADP-ribosyl) glycohydrolase 
(PARG) have been knocked down by siRNA or abolished by 
genetic deletion (i.e., using PARG knockout cells) [5, 8]. 
Unfortunately, these conditions establish a non-physiological cel-
lular setting that induces physiological alterations in the investi-
gated cells and tissues [9–11]. Thus, it is more than questionable 
whether studying ADP-ribosylation and its associated mechanisms 
of action under these conditions is biologically relevant.
High-resolution mass spectrometry (MS) has become a valuable 
tool for comprehensive identification of PTMs [12]. Two MS-based 
approaches for mapping ADP-ribose acceptor sites in vivo were 
recently published. Unfortunately, these techniques are limited as 
they can only identify Glu and Asp modifications [5] or lack sensitiv-
ity due to co-enrichment of phosphorylated peptides [8]. In addi-
tion, a chemical genetic discovery-based method for ARTD target 
identification was recently reported [13]. However, this approach 
does not support the identification of ARTD-specific substrates 
under different cellular conditions or physiological NAD+ levels. To 
address the limitations of these approaches, we have developed a 
novel and straight forward methodology that allows unbiased map-
ping of endogenous ADP-ribose acceptor sites in proteins under 
physiological cellular conditions [14]. Importantly, this new meth-
odology represents a major advancement in the detection of in vivo 
ADP-ribose acceptor sites and the identification of cellular processes 
regulated by ADP-ribosylation.
2 Materials
We recommend preparing all buffers using sequencing grade 
chemicals and Milli-Q water.
 1. Cells of interest. The protocol described here has been success-
fully applied to HeLa cells.
 2. Dulbeccos Modified Eagle’s Medium (D-MEM) supple-
mented with 10% fetal bovine serum (FBS) and 
penicillin/streptomycin (100 U/mL).
2.1 Cell Culture 
and Lysis
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 3. Phosphate-buffered saline (PBS).
 4. Hydrogen peroxide or alternative ADP-ribosylation-inducing 
agent of interest.
 5. Modified RIPA buffer (high salt): 50 mM Tris–HCl, pH 7.5, 
400 mM NaCl, 1 mM EDTA, 1% NP-40, 0.1% Na- 
deoxycholate, 40 μM PJ-34, 1 μM ADP-HPD (see Note 1), 
protease inhibitor cocktail.
 6. Modified RIPA buffer (no salt): 50 mM Tris–HCl, pH 7.5, 
1 mM EDTA, 1% NP-40, Protease inhibitor cocktail.
 7. 100% Acetone.
 8. Equipment: Cell lifters.
 9. Equipment: Centrifuge (with cooling) including a swinging 
bucket rotor.
 1. Denaturation buffer: 6 M urea, 2 M thiourea, 10 mM HEPES, 
pH 8.0.
 2. Bradford reagent or alternative assay for measuring protein 
concentration.
 3. Reduction buffer: 1 M dithiothreitol (DTT).
 4. Alkylation buffer: 550 mM chloracetamide (CAA).
 5. Lys-C protease.
 6. Digestion buffer: 25 mM ammonium bicarbonate (ABC).
 7. Sequencing grade modified trypsin.
 8. 10% trifluoroacetic acid (TFA)
 9. Equipment: Centrifuge (with cooling) including a swinging 
bucket rotor.
 10. Equipment: Thermomixer.
 1. 100% acetonitrile.
 2. 0.1% TFA.
 3. Equipment: Centrifuge including a swinging bucket rotor.
 4. Equipment: Sep-Pak C18 Classic Cartridges.
 1. Bacterial expression plasmid containing N-terminal GST-fused 
macrodomain Af1521 [15].
 2. BL21 chemically competent E. coli cells.
 3. Super Optimal broth with Catabolite repression (SOC).
 4. LB-Agar plates containing ampicillin (Amp-plates).
 5. Lysogeny broth (LB) medium.
 6. Terrific Broth (TB) medium.
 7. Isopropyl-beta-D-thiogalactopyranoside (IPTG).
2.2 In-Solution 
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 8. Lysis buffer: 50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 1 mM 
MgCl2, 1 mM DTT, 1× BugBuster, 1 μL/mL benzonase, 
200 μg/mL lysozyme, protease inhibitor cocktail.
 9. Glass beads.
 10. Glutathione Sepharose 4B.
 11. Wash buffer: 50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 
1 mM DTT.
 12. Equipment: Centrifuge (with cooling) including a fixed angle 
rotor for eppendorf tubes.
 13. Equipment: Centrifuge (with cooling) including a swinging 
bucket rotor.
 1. 50% acetonitrile.
 2. 80% acetonitrile.
 3. 5× affinity precipitation (AP) buffer: 250 mM Tris–HCl, pH 
8.0, 50 mM MgCl2, 1.25 mM DTT, 250 mM NaCl. (For 1× 
AP buffer dilute 5× AP buffer in Milli-Q).
 4. hPARG is expressed and purified from insect cells as carboxyl- 
terminal His-tagged protein and stored in liquid nitrogen.
 5. Purified Af1521.
 6. 0.15% TFA.
 7. Equipment: Vacuum concentrator (SpeedVac).
 8. Equipment: NanoDrop or alternative assay for measurement 
of peptide concentration.
 9. Equipment: Centrifuge (with cooling) including a fixed angle 
rotor for eppendorf tubes.
 10. Tabletop centrifuge.
 1. C18 material.
 2. Methanol.
 3. Buffer B: 80% acetonitrile, 0.5% acetic acid.
 4. Buffer A: 0.5% acetic acid.
 5. Equipment: StageTip adapters for microcentrifuge tubes.
 6. Equipment: Centrifuge including a fixed angle rotor for eppen-
dorf tubes.
 1. StageTip elution buffer 1: 40% acetonitrile, 0.5% acetic acid.
 2. StageTip elution buffer 2: 60% acetonitrile, 0.5% acetic acid.
 3. Buffer A*: 5% acetonitrile, 0.1% TFA.
 4. C18-packed nanospray column. We use 15 cm analytical col-
umns (75 μm inner diameter) pulled and packed in-house with 
1.9 μm C18 beads (Reprosil Pur-AQ, Dr. Maisch, Germany).
2.5 Enrichment 
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 5. Equipment: Liquid chromatography (LC) system, e.g., 
nanoscale UHPLC system EASY-nLC1200.
 6. Equipment: Nanospray column heater (Sonation GmbH).
 7. Equipment: Mass spectrometer, e.g., a Q Exactive HF (Thermo 
Fisher Scientific).
 8. Data analysis software such as the freely available MaxQuant 
software suite (www.maxquant.org).
3 Methods
Here, we describe a sensitive and unbiased method for the identi-
fication of in vivo ADP-ribosylated peptides and amino acid accep-
tor sites using high-resolution LC-MS/MS. This methodology 
facilitates the study of basal ADP-ribosylation levels as well as their 
changes upon stimulation. In principle, the protocol is applicable 
to any cell line, as long as enough material can be collected. Basal 
in vivo ADP-ribosylation levels are low, but can be enhanced via 
genotoxic stress-mediated activation of ARTDs [16]. Thus, despite 
fast and gentle sample handling, DNA shearing during cell lysis 
was shown to cause artifactual PAR formation [17]. Therefore, it 
is crucial to complement the lysis buffer with PARP and PARG 
inhibitors to preserve the physiological ADP-ribosylome and avoid 
lysis-induced artifacts. To enhance identification of ADP- 
ribosylation sites, the isolated proteins are first digested to peptides 
and then treated with PARG, which converts all PARylated amino 
acids to their MARylated counterparts. While PARG treatment 
does not allow distinguishing between PARylation and MARylation, 
the conversion allows for feasible MS analysis. The resulting 
MARylated peptides are then unbiasedly enriched using ADP- 
ribose- specific binder, such as the Af1521 macrodomain, which 
has a Kd of ~0.13 μM to ADP-ribose [15, 17, 18]. Finally, the 
enriched modified peptides and their ADP-ribose acceptor sites are 
identified by high-resolution LC-MS/MS.
The protocol described here can be divided into the following 
parts: (1) culture and lysis of cells, (2) digestion of proteins, (3) 
concentration of peptide solution, (4) expression and purification 
of the Af1521 macrodomain, (5) enrichment of ADP-ribosylated 
peptides, (6) purification of samples for MS analysis, and (7) analy-
sis of the peptide mixture using LC-MS/MS. A scheme of the 
workflow is depicted in Fig. 1.
The protocol described below has been optimized for ADP- 
ribose acceptor site identification of in vivo modified proteins from 
cultured cells. However, this method is with optimization of the 
extraction conditions also suitable for whole tissue ADP-ribosylome 
characterization.
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 1. Seed cells into eight 150 mm cell culture dishes per condition 
and grow to ~80% confluency. This will yield approximately 
30–40 mg of total protein.
 2. Wash cells once with warm PBS. Add H2O2 (0.5–1 mM) in 
PBS and incubate for 5–10 min at 37 °C (see Note 2).
 3. Carefully wash the cells briefly with ice-cold PBS. Make sure to 
remove all PBS.
 4. Place the washed 150 mm cell culture dishes on ice. Add 0.2 
mL ice-cold modified RIPA (high salt) to each plate and incu-
bate on ice for 5 min. Scrape the cells off the bottom of the 
plate and transfer the entire content of the plate into a 15 mL 
Falcon tube placed on ice.
 5. Centrifuge at 5000 × g for 20 min at 4 °C to clear the lysate. 
Transfer supernatant to a 50 mL Falcon tube for acetone 
precipitation.
 6. Dilute sample with salt-free RIPA to obtain a final NaCl con-
centration of 133 mM (this makes the pellet easier to dissolve 
in urea) (see Note 3).
 7. Precipitate the proteins by adding a fivefold volume of ice-
cold acetone (80% acetone final concentration) and incubate 
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Fig. 1 Schematic overview of the peptide-based purification strategy. Cell culture is treated with genotoxic 
stress (or other stimuli) and cells are subsequently lysed with PARP and PARG inhibitors present in the lysis 
buffer. Proteins are digested into peptide species using trypsin, and treated with PARG enzyme to convert 
multimeric ADP-ribosylation into monomeric counterparts. The ADP-ribosylated peptides are then enriched 
using the GST-AF1521 macrodomain, and enriched peptides are subsequently analyzed and the acceptor sites 
identified using high resolution LC-MS/MS. For improved identification of ADP-ribosylated peptides diagnostic 
ions related to the specific fragmentation pattern of the ADP-ribose moiety are used. Following this, the 
acquired data is further processed by bioinformaticssoftware tools
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overnight at −20 °C. Samples in acetone can be stored at 
−20 °C for several weeks.
 1. Centrifuge acetone-precipitated proteins at 1000 × g for 5 min 
at 4 °C and carefully discard all of the acetone.
 2. At room temperature, add denaturation buffer (urea) to the 
50 mL Falcon tube containing the protein pellet and resus-
pend. The added volume depends on the pellet size; ideally the 
protein concentration should be ~5 mg/mL (see Note 4).
 3. Determine protein concentration for example by Bradford 
assay.
 4. Reduce disulfide bridges and unwind proteins by adding 
1/1000 volume of reduction buffer, mix well and shake at 
500 rpm for 60 min at room temperature.
 5. Alkylate the free –SH groups by adding 1/100 volume of 
alkylation buffer and shake at 500 rpm in the dark for 60 min 
at room temperature.
 6. Digest the precipitated proteins to peptides by adding Lys-C 
(1 μg per 100 μg protein) to the sample and shake for 3–4 h at 
room temperature. Lys-C will cleave at the carboxyl side of 
lysine.
 7. Dilute the sample 1:4 with 25 mM ABC to reduce urea con-
centration to <2 M. Make sure the pH is 8.0–8.5; if the pH is 
too high, add water.
 8. Add trypsin (1 μg per 100 μg protein) and shake overnight at 
room temperature. Trypsin will cleave at the carboxyl side of 
lysine and arginine.
 9. Terminate trypsin digestion by dropwise (carefully!) adding 
10% TFA until peptide solution reaches pH 2.
 1. Clarify the peptide mixture by centrifugation at 1800 × g for 
5 min at room temperature. Transfer supernatant to fresh tube.
 2. Insert the Sep-Pak C18 column into a 10 mL syringe. The 
capacity of the Sep-Pak is approximately 5% (wt/wt) of pack-
ing material.
 3. Add 5 mL of 100% acetonitrile to pre-wet the Sep-Pak 
cartridge.
 4. Wash column two-times with 4 mL 0.1% TFA. Use a P-200 
pipette to remove bubbles at the top of the Sep-Pak; this will 
ensure even flow through the Sep-Pak material.
 5. Load ~5 mL of the peptide mixture onto the Sep-Pak column 
(the column might turn yellow), remove any bubbles that form 
at the top of the Sep-Pak and allow gravity flow of the sample 
3.2 In-Solution 
Digestion
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through the column. Repeat until the entire sample has entered 
the Sep-Pak C18 column.
 6. Wash the column three-times with 5 mL water. Measure the 
pH of the flow-through. It must be >6, otherwise more washes 
with water are required. Store the Sep-Pak at 4 °C (for up to 
several months) until further use.
 1. Add 1 μg of cooled Af1521 WT plasmid to freshly thawed 
chemically competent BL21 cells, stir carefully, and leave on 
ice for 15 min.
 2. Heat shock for 45 s at 42 °C.
 3. Incubate for 1 min on ice.
 4. Add 900 μL SOC and shake vigorously for 40 min at 37 °C.
 5. Centrifuge at 2000 × g for 2 min at room temperature and 
discard approximately 600 μL of the supernatant.
 6. Resuspend the cells in the remaining media, spread the sus-
pension to LB + Amp plates, and incubate overnight at 37 °C.
 7. Inoculate 5 mL of LB media containing ampicillin (100 μg/
mL) with a single colony of AmpRBL21 cells and incubate 
overnight at 37 °C, 230 rpm.
 8. Dilute overnight culture 1:500 into 100 mL of pre-warmed 
TB media containing ampicillin (100 μg/mL) in a 0.5 mL 
flask (see Note 5).
 9. Incubate at 37 °C, 230 rpm and measure OD600 every 30 min.
 10. When the culture has reached an OD600 of 0.55–0.65, induce 
protein expression by adding freshly thawed IPTG (0.5 mM).
 11. Express proteins by incubating for 5–6 h at 30 °C, 230 rpm.
 12. Pour 50 mL of the bacteria suspension into a 50 mL Falcon 
tube and centrifuge at 3000 × g for 15 min at room 
temperature.
 13. Discard the supernatant and repeat step 12 with another 50 
mL of the bacteria.
 14. Freeze pellet at −80 °C. Pellets can be stored at −80 °C for 
several months.
 15. Thaw pellet at room temperature and resuspend in 4 mL fresh 
lysis buffer. Incubate rotating at room temperature for 20 min.
 16. Break cells by adding glass beads and vortex for approximately 
30 s.
 17. Transfer lysate to microcentrifuge tubes and pellet cell debris 
by centrifugation at 14,500 × g for 5 min at 4 °C.
 18. Transfer 2 mL of Glutathione Sepharose 4B slurry to a 15 mL 
Falcon tube.
3.4 GST-Protein 
Expression 
and Purification 
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 19. Add 8 mL of wash buffer and centrifuge at 2000 × g for 2 min 
at 4 °C.
 20. Discard supernatant, add 9 mL of wash buffer, and centrifuge 
at 2000 × g for 2 min at 4 °C.
 21. Discard supernatant, transfer the cleared GST-Af1521 lysate 
to the 15 mL Falcon tube containing the equilibrated beads, 
and incubate at 4 °C for 4 h with head-over-tail rotation.
 22. Centrifuge the slurry at 2000 × g for 2 min at 4 °C and discard 
the supernatant.
 23. Wash beads four-times with wash buffer. Mix by inverting the 
tube five-times. Centrifuge at 2000 × g for 2 min at 4 °C 
between each wash step.
 24. Discard final supernatant and resuspend beads in wash buffer 
to give a final volume of 10 mL. Bead-coupled proteins can be 
stored at 4 °C for several weeks (see Note 6).
 1. Elute the peptides off the Sep-Pak (from Subheading 3.3, step 6) 
with 3 mL 50% acetonitrile, followed by 1.5 mL 80% acetoni-
trile. Pool peptide eluates.
 2. Aliquot the 4.5 mL pooled peptide elution into four 1.5 mL 
microcentrifuge tubes. Add 40 μL of 5× AP buffer to each 
tube, mix by pipetting up and down.
 3. Reduce the volume of each aliquot to 200 μL via vacuum cen-
trifugation at 45 °C. This will take ~60 min.
 4. Pool the four concentrated aliquots into a single tube 
(~800 μL final volume).
 5. Clear concentrated peptide solution via centrifugation at 
1800 × g for 5 min at 4 °C. Store supernatant on ice.
 6. Determine peptide concentration by for example using a 
NanoDrop at 280 nm. Use ~10 mg of peptides for enrich-
ment of ADP-ribosylated peptides. Keep 100 μg of unenriched 
peptides for proteome analysis.
 7. To degrade PAR to MAR, add 4.2 μg PARG per 10 mg of 
peptides and incubate for 3 h at 37 °C, 300 rpm.
 8. Cool peptide mixture on ice.
 9. Add 500 μL of the bead-coupled GST-Af1521 macrodomain 
slurry (Subheading 3.4, step 24) and incubate for 2 h at 4 °C 
with head-over-tail rotation.
 10. Centrifuge at 1000 × g for 1 min at 4 °C and remove 
supernatant.
 11. Wash beads three-times with 1 mL of ice-cold 1× AP buffer. 
Mix by inverting tubes three-times and immediately centri-
fuge at 1000 × g for 1 min at 4 °C and remove supernatant.
3.5 Enrichment 
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 12. Wash beads three-times with 1 mL of ice-cold water. Mix by 
inverting tubes five-times and immediately centrifuge at 
1000 × g for 1 min at 4 °C and remove supernatant.
 13. Elute the enriched ADP-ribosylated peptides by adding 
100 μL 0.15% TFA to the beads. Tap the bottom of the tube 
several times (do not vortex) and let stand at room tempera-
ture for 10 min.
 14. Tap the bottom of the tube again, pellet beads via quick (a few 
seconds) centrifugation, remove the supernatant using a gel- 
loading tip and transfer to a new, labeled microcentrifuge tube.
 15. Repeat elution step with an additional 100 μL of 0.15% TFA 
for 10 min, combine the eluates and load onto an activated 
and equilibrated C18 stage tip (see below for preparation).
 1. Prepare one C18 StageTip per sample. The making of StageTips 
is described in Rappsilber et al. [19]. We recommend stacking 
two C18 discs on top of each other for each StageTip.
 2. Activate the discs by adding 100 μL 100% methanol to the 
StageTips and passing through the C18 material via centrifu-
gation at 600 × g for approximately 2 min at room tempera-
ture. Do not let the material dry.
 3. Condition the discs by adding 100 μL Buffer B and centrifuga-
tion at 600 × g for approximately 2 min at room temperature.
 4. Equilibrate the discs by adding 100 μL Buffer A and centrifuga-
tion at 600 × g for approximately 2 min at room temperature.
 5. Load the eluted peptides (Subheading 3.5, step 15) onto the 
activated StageTip and centrifuge at 600 × g at room tempera-
ture untilthe entire sample has entered the StageTip (~4 min).
 6. Wash the StageTips by adding 50 μL Buffer A and centrifuge 
at 600 × g at room temperature until the StageTip is dry (~3 
min). Dried StageTips can be stored at 4 °C for several months.
 1. Elute enriched ADP-ribosylated peptides from the StageTip by 
adding 20 μL of StageTip elution buffer 1, followed by 20 μL 
of StageTip elution buffer 2 into a 96-well plate suitable for 
the LC autosampler.
 2. Remove acetonitrile from the eluates via vacuum centrifuga-
tion until volume is approximately 7 μL. This will take approx-
imately 25 min at 30 °C. If less than 7 μL are left, top up to 7 
μL with Buffer A.
 3. Add 1 μL of Buffer A* to all wells.
 4. For peptide separation, we typically use an in-house packed 
analytical LC column made from 15 cm long fused silica (75 
μm inner diameter) and packed with 1.9 μm C18 beads (Dr. 
Maisch, Germany).
3.6 Purification 
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 5. Program an LC method with nLC gradient of 60 min or more. 
We recommend analyzing each sample using a 180 min 
reverse-phase gradient ranging from 5% to 64% acetonitrile in 
0.5% formic acid at a flow rate of 250 nL/min (see Note 7).
 6. Injection volume should be kept to ≦5 μL for each sample 
(see Note 8).
 7. To facilitate the identification of the ADP-ribosylated pep-
tides, we recommend analyzing the samples on a Q-Exactive 
mass spectrometer using the “sensitive settings” as described 
in [20] (see Note 8). Briefly, the sensitive settings use a “top 
10 method” on the Q Exactive with 60,000 MS resolution 
and 60,000 MS/MS resolution.
 8. Set the scan range of the MS to 400–1600 m/z, and the MS/
MS fixed first mass to 100 m/z.
 9. Set the automatic gain control (AGC) target of the MS should 
to 1e6 or higher and to 1e5 (10× lower) for MS/MS.
 10. Keep maximum injection time at 45 ms for MS and 110 ms for 
MS/MS.
 11. Normalized collisional energy should be set to a value between 
25 and 30, we recommend 28 as safe median.
 12. Set the dynamic exclusion to 30 s.
 13. Process raw files using the MaxQuant software suite supported 
by the Andromeda search engine. We recommend the follow-
ing settings:
Fixed modifications: Carbamidomethyl (C)
Variable modifications: Oxidation (M), Acetyl (Protein N-term), 
mono-ADP-ribosylation (C10H13N5O9P2) on lysine, arginine, 
glutamic acid, and aspartic acid.
To increase the confidence of ADP-ribosylated peptide identifica-
tions, we typically add neutral losses and diagnostic ion masses 
in the MaxQuant search parameters (see Note 9).
Max. missed cleavages: 3
Min. peptide length: 7
Protein FDR: 0.01; Peptide FDR: 0.01; Site FDR: 0.01.
4 Notes
 1. The stability of ADP-HPD in solution is critical. Following 
reconstitution of the powder, aliquots are only stable for up to 
1 week at −20 °C.
 2. We recommend inducing ADP-ribosylation by treating the 
cells for example with H2O2 for 5–10 min, because this signifi-
cantly increases the number of ADP-ribosylated targets that 
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can be detected. However, several other stimuli/DNA damage- 
inducing agents can be used.
 3. Protein concentration can be determined after lysis (e.g., by 
Bradford) and an aliquot of the protein lysate can be kept for 
western blotting. If stable isotope labeling by amino acids in 
cell culture (SILAC) is applied, we recommend mixing the 
heavy and light SILAC samples prior to acetone precipitation 
(Subheading 3.1, step 7). Alternatively, samples can be mixed 
following resuspension in urea (Subheading 3.2, step 2).
 4. It is important to perform the urea protein pellet resuspension 
step at room temperature (Subheading 3.2, step 2). At low 
temperatures, urea will crystalize and at high temperatures 
urea can induce artifacts [21].
 5. We recommend making several starting cultures for prepara-
tion of a large batch of Af1521.
 6. For western blotanalysis, we recommend cross-linking the 
GST- Af1521 macrodomain to the GST-sepharose beads. In 
brief, wash resin three-times with 10 mL 0.2 M borate-NaOH, 
pH 9.0, centrifuge at 2000 × g for 2 min at room temperature 
between each wash. Add 10 mL fresh DMP solution (20 mM) 
and incubate for 60 min at room temperature with head-over- 
tail rotation. Centrifuge at 2000 × g for 2 min at room tem-
perature. Stop the cross-linking reaction by adding 10 mL 
0.2 M ethanolamine. Wash resin three-times with 0.1 M gly-
cine-HCl, pH 2.5 to remove any remaining non-covalently 
linked molecules. Cross-linking can be verified by SDS-PAGE. 
GST-protein should only elute from the resin prior to addition 
of DMP.
 7. The described LC settings are applied for the analysis of 
enriched ADP-ribosylated peptides from treated cells. The LC 
gradient needs to be adjusted depending on the complexity of 
the sample and instrument used.
 8. An injection volume of 5 μL will take approximately 20 min to 
load onto the column at a constant pressure of 500 bars. An 
injection volume of more than 5 μL will result in longer load-
ing times. By using a nanoscale UHPLC system, e.g., EASY- 
nLC1200 (Thermo Fisher Scientific) the loading pressure can 
be increased and the loading time thereby shortened.
 9. To help assign ADP-ribosylated peptides in MaxQuant, the 
following parameters can be added to the Andromeda search 
engine:
Monoisotopic mass: 541.0611088074.
Composition: H(21)C(15)N(5)O(13)P(2).
Position: notCterm.
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NeutralLoss: H(21)C(15)N(5)O(13)P(2) for lysine, arginine, 
aspartic acid and glutamic acid.
Diagnostic peak: H(5)C(5)N(5), H(11)C(10)N(5)O(3), 
H(14)C(10)N(5)O(7)P, H(15)C(10)N(5)O(10)P(2), 
H(21)C(15)N(5)O(13)P(2) for lysine, arginine, aspartic 
acid and glutamic acid.
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In a recent issue of Science, Gibson et al. (2016) describe an in vitro chemical genetic approach that maps the
specific ADP-ribosylation sites targeted by the ADP-ribosyltransferases PARP-1, PARP-2, and PARP-3 and
demonstrate that PARP-1 regulates RNA polymerase II promoter-proximal pausing.
The human genome encodes 17 intra-
cellular ADP-ribosyltransferases, called
PARPs (also known as ARTDs), that
regulate different biological processes
via post-translational modification of
proteins with a single (MARylation) or mul-
tiple (PARylation) ADP-ribose units from
NAD+ (Hottiger, 2015). The identification
of PARP-specific targets has been
hampered by technical challenges for
many years. Gibson et al. now report
the development and application of
an elegant in vitro chemical genetic meth-
odology that allowed the identification of
protein targets specific for PARP-1,
PARP-2, or PARP-3 (Gibson et al., 2016).
All three are DNA-dependent nuclear
proteins that PARylate (PARP-1/2) or
MARylate (PARP-3) their targets. The
method is based on the combined use
of a newly developed NAD+ analog,
8-Bu(3-yne)T-NAD+, and analog-sensitive
PARP-1, PARP-2, and PARP-3 mutant
isoforms (asPARPs). Analog sensitivity
was achieved by modifying the PARP
active site to accommodate the bulky
8-Bu(3-yne)T-NAD+. Importantly, the
modification of proteins using this NAD+
analog allowed downstream azide-alkyne
cycloaddition (‘‘click’’ chemistry), which
enabled PARP target labeling and purifi-
cation. In contrast to previous attempts
(Carter-O’Connell et al., 2014; Jiang
et al., 2010), screening of an NAD+ analog
library with systematically mutated
PARP-1 isoforms identified functional
combinations that promote PARylation.
Using this approach, HeLa cell nuclear
extracts were co-incubated with purified,
salmon sperm DNA-activated asPARP-1,
PARP-2, or PARP-3 and 8-Bu(3-yne)T-
NAD+. The asPARP-modified protein
targets were purified by ‘‘click’’ chemis-
try-based azide-agarose crosslinking,
trypsin digested, and identified by liquid
chromatography-tandem mass spec-
trometry (LC-MS/MS) (Figure 1A). Asp
and Glu ADP-ribosylated peptides were
eluted with hydroxylamine (NH2OH) and
the ADP-ribosyl modification sites identi-
fied by LC-MS/MS (Zhang et al., 2013).
The same workflow was also applied to
nuclei isolated from Parp1!/! mouse em-
bryonic fibroblasts (MEFs) overexpress-
ing asPARP-1. A total of 467 in vitro
ADP-ribosylated proteins were identified.
Using the same chemical strategy, the
authors developed a ‘‘Click-ChIP-seq’’
method and mapped the asPARP-1-
mediated genomic ADP-ribosylation sites
in MEF nuclei (Figure 1B). Sites of
asPARP-1-mediated chromatin ADP-ri-
bosylation co-localized with actively tran-
scribed (H3K4me3-enriched) gene pro-
moters and actively transcribing Pol II
(from GRO-seq data). ADP-ribosylation
was found to contribute to negative elon-
gation factor (NELF) complex function,
and components of NELF were identified
as ADP-ribosylation targets of asPARP-1
and asPARP-3. ADP-ribosylation of
NELF-E was also shown for authentic
PARP-1 and found to be dependent on
CDK9/P-TEFb-mediated NELF-E phos-
phorylation, which results in release of
Pol II promoter pausing. asPARP-1-medi-
ated chromatin ADP-ribosylation posi-
tively correlated with PARP-1 and NELF-
B binding at actively transcribed pro-
moters with high CDK9 occupancy.
GRO-seq analysis in PARP-1 knockdown
or PARP inhibitor-treated MCF-7 cells
confirmed the functional relevance of
these observations. In both cases,
paused Pol II accumulated at promoter
regions, and corresponding gene body
transcriptional elongation decreased.
Similar findings were obtained by CDK9
inhibition or NELF knockdown, suggest-
ing that PARP-1-dependent NELF-E
ADP-ribosylation reinforces P-TEFb-
mediated Pol II pause release and pro-
ductive transcriptional elongation.
A caveat of this methodology is that
8-Bu(3-yne)T-NAD+, like NAD+, is not
cell permeable, and can only be used in
in vitro or isolated nuclei-based ADP-ribo-
sylation reactions. ADP-ribosylation is a
reversible, highly dynamic, and low abun-
dant PTM. Thus, it will be interesting to
see whether 8-Bu(3-yne)T-NAD+-derived
modifications are as reversible as
authentic ADP-ribosyl modifications (Yu
et al., 2006). Furthermore, exogenous
addition of asPARPs and the NAD+ analog
may cause off-target modifications due to
concentrations being non-physiological.
Although in vivo ADP-ribosylation by
PARP-1 was confirmed for NELF, addi-
tional asPARP-1, asPARP-2, and as-
PARP-3 ADP-ribosylation targets need
to be tested to see whether the method
is able to faithfully predict in vivo PARP
targets.
Due to technical limitations of the
method used to map ADP-ribosylation
acceptor sites, only Asp and Glu sites
were identified (Zhang et al., 2013).
Thus, potential modifications of other
amino acids, e.g., Lys or Arg (Altmeyer
Molecular Cell 63, July 21, 2016 ª 2016 Elsevier Inc. 181
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et al., 2009), could not be identified. Sur-
prisingly, Gibson et al. (2016) identified
considerable overlaps between the tar-
gets modified by PARP-1, PARP-2, and
PARP-3 (Figure 1C). This is intriguing,
given that these PARPs have different bio-
logical functions. Furthermore, asPARP-3
generated the largest number of unique
ADP-ribosylated targets, which is an
interesting finding for a nuclear,
MARylating enzyme that is not as well
characterized as PARP-1 or PARP-2.
The authors observed also partial overlap
between their targets and those identified
in previous studies. Some variation is ex-
pected due to different sample prepara-
tion and enrichment techniques, and the
untargeted mass spectrometry measure-
ments. The study is difficult to compare
to previous ones (reviewed in Daniels
et al., 2015), as it is unclear how exoge-
nous addition of PARPs compares to
studies using stimulated cells. While the
initial discovery experiments used artifi-
cially activated asPARPs, subsequent ex-
periments with purified nuclei were
considered to have identified targets un-
der unstimulated conditions. This raises
the question as to how asPARP activity
is regulated under these conditions and
whether these nuclei truly represent unsti-
mulated conditions. Previous ADP-ribo-
sylation proteomic screens found that
PARP activity is tightly regulated in vivo,
and that successful target identification
requires genotoxic stress (Jungmichel
et al., 2013) and/or PARG knockdown
(Zhang et al., 2013). Finally, it would be
interesting to see whether the number of
ADP-ribosylated targets increases when
the asPARP-8-Bu(3-yne)T-NAD+ tech-
nique is used in conjunction with MS
workflows that identify all ADP-ribosyl
acceptor amino acids.
PARP-1 knockdown or inhibition
caused an accumulation of paused Pol II
at gene promoters. Remarkably, Pol II
pausing was observed genome-wide,
even at genes that had not been previ-
ously reported to be regulated by ADP-
ribosylation. This suggests that ADP-
ribosylation regulates transcription in a
highly complex manner. The genomic
ADP-ribosylation profiles identified by
Click-ChIP-seq were rather large (>5 kb)
chromatin domains. This lack of resolu-
tion makes it difficult to define exact sites
of ADP-ribosylation and assess their rela-
tion to PARP-1 binding. Intriguingly, the
analysis also identified loci with significant
PARP-1 binding but little or no ADP-ribo-
sylation. A recently published in vivo
ADP-ribosylated chromatin affinity purifi-
cation (ADPr-ChAP) methodology found
associations between oxidative stress,
PARP1-mediated chromatin ADP-ribosy-
lation, histone density, and heterochro-
matic histone marks (Bartolomei et al.,
2016). These findings are not contra-
dictory to the ones reported here, but
rather suggest that ADP-ribosylation pat-
terns are dependent upon cell type and
stimulation.
In the paper by Gibson et al. (2016),
PARP-1-mediated ADP-ribosylation of
NELF-E was dependent on P-TEFb activ-
ity, which points to a potential functional
link between ADP-ribosylation and phos-
phorylation. Increased Pol II pausing
was observed when cells were comple-
mented with an ADP-ribosylation-defi-
cient NELF-E mutant. However, ADP-
ribosylation-dependent release of Pol II
pausing was only observed for less than
half of the NELF-E-regulated genes.
Further experiments are therefore
required to fully substantiate a link. Finally,
NELF-E was also identified as a PARP-3
target but not investigated further.
Thus, additional studies are required to
determine whether PARP-3 also regulates
gene expression.
To provide novel therapeutic options
and translate these, and emerging new in-
sights, into patient benefits, it will be
important to: (1) identify and validate pro-
tein targets for all PARP family members
in vivo using the relevant cell culture and
animal models, (2) define the molecular
pathways regulated by the different
PARPs, and (3) determine how and to
what extent PARPs contribute to disease
development. This knowledge will expe-
dite the development of isozyme-specific
PARP inhibitors that provide therapeutic
benefits for diseaseswhere one PARP pri-
marily causes the pathophysiological
condition.
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In this issue of Molecular Cell , Wang et al. (2016a) report crystal structures of the core of the METTL3/
METTL14 m 6A methyltransferase complex and propose how the two subunits interact and cooperate to
bind and methylate RNA.
N6-methyladenosine (m 6A) is the most
abundant modification in eukaryotic
messenger RNA. Through its impact on
protein binding, m 6A influences every
step in the lifespan of an mRNA molecule,
from splicing and export to translation and
decay ( Liu and Pan, 2016; Maity and Das,
2016; Yue et al., 2015 ). A single m 6A
methyltransferase complex is responsible
for making all the m 6A modifications
in mRNA. The core of the complex is a
heterodimer of two proteins, METTL3
and METTL14. Each of the two proteins
has a methyltransferase domain and can
methylate RNA in vitro, yet the METTL3/
METTL14 complex has much greater
m6A methyltransferase activity than either
subunit alone ( Liu et al., 2014 ). In this
issue, Wang et al. (2016a) shed light on
the structural and biochemical basis
for the interdependence and synergy of
METTL3 and METTL14.
Wang et al. (2016a) determined the
minimal components of METTL3 and
METTL14 necessary for stable complex
formation and then solved three struc-
tures of the resulting complex: in
apo form, with the cofactor S -adenosyl-
methionine (SAM), and with the
cofactor product S -adenosylhomocys-
teine (SAH). These structures reveal
detailed features of the interactions be-
tween METTL3, METTL14, and SAM/
SAH and provide insights on how this
enzyme interacts with the RNA substrate.
The authors also used biochemical as-
says to examine how mutations in
METTL3 or METTL14 affect methyltrans-
ferase activity.
Since bothMETTL3 andMETTL14 have
methyltransferase homologous domains,
either subunit could potentially catalyze
m6A methylation in the METTL3/
METTL14 complex. However, the crystal
structures only showed SAM and SAH
densities in the catalytic cavity of
METTL3, indicating that METTL3 is
the sole catalytic subunit ( Figure 1 ,
feature 1). In contrast, the catalytic cavity
of METTL14 adopted a closed con-
formation that could not accommodate
SAM. In addition, a mutation in the cata-
lytic site of METTL3 completely abolished
methyltransferase activity of the complex,
whereas mutating the putative catalytic
site derived from the protein sequence
of METTL14 had no effect. These findings
are similar to those of Wang et al.
(2016b) , who also crystallized a complex
of the METTL3/METTL14 methyltransfer-
ase domains and its complexes with
SAM/SAH and performed mutational
analysis ( Wang et al., 2016b ). Both
studies provide structural and biochem-
ical evidence that METTL3 is the unique
catalytic subunit in the METTL3/METTL14
complex.
Although METTL3 is the catalytic sub-
unit, its activity is strongly dependent
on METTL14. The METTL3/METTL14
complex has much higher activity than
the isolated METTL3 protein in vitro ( Liu
et al., 2014 ), and knockdown of either
METTL3 or METTL14 decreases m 6A
levels to a similar degree ( Wang et al.,
2014 ). The observation that METTL3
and METTL14 depend on each other for
protein stability in vivo ( Wang et al.,
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ABSTRACT 
 
Despite recent biochemical and mass spectrometry (MS)-based breakthroughs, 
comprehensive ADP-ribosylome identification and accurate ADP-ribose-site localization 
remain challenging. Here we report the establishment of an unbiased, multistep ADP-
ribosylome data analysis workflow, where bioinformatic analyses were combined with manual 
spectra validation, that identified tyrosine as a novel in vivo ADP-ribose-acceptor. Using 
shRNA-based knockdown studies, we provide proteome-wide evidence demonstrating that 
genotoxic stress strongly and specifically induces ARTD1-dependent serine and tyrosine 
ADP-ribosylation in vivo. Site-directed mutagenesis and in vitro ADP-ribosylation assays 
confirmed that tyrosine functions as an ADP-ribose-acceptor amino acid in RPS3A and HPF1. 
ARTD1-mediated tyrosine modification was dependent on HPF1. Moreover, these studies 
revealed that ADP-ribosylation of HPF1 on Y238 is required for its activity as ADP-ribosylation 
cofactor. Together, our findings validate the functional importance of tyrosine as novel ADP-
ribose-acceptor amino acid and demonstrate the broad and far-reaching influences low 
abundant ADP-ribosylation, like HPF1-Y238, can have on the cellular ADP-ribosylome. 
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INTRODUCTION 
Protein ADP-ribosylation is a physiologically and pathologically important post-
translational modification (PTM) that regulates cellular activities by chemically modifying 
proteins with a single (MARylation) or multiple (PARylation) ADP-ribose (ADPr) units from 
NAD+1,2. The human genome encodes 17 intracellular ADP-ribosyltransferases (ARTDs or 
PARPs) that are distributed in different cellular compartments1,3. While ARTDs are structurally 
homologous, and resemble the diphtheria toxin, the molecular mechanisms by which they 
modify target proteins are not fully defined. It is not yet clear if each ARTD has enzymatic 
activity towards all or a specific subset of the known ADPr-acceptor amino acids or if they are 
all capable of modifying the same amino acid(s) within a given target protein.   
For many years, technical challenges have limited the number of identified ARTD-
specific target proteins. But, the introduction of mass spectrometry (MS)-based ADP-
ribosylation optimized methodologies4-7 and the development of MARylated-peptide 
enrichment and/or ADPr labeling techniques prior to MS analysis drastically improved the 
detection and identification of ADP-ribosylated proteins8-12. Our group and others have shown 
that genotoxic stress conditions strongly and specifically induce the ADP-ribosylation of 
hundreds of proteins. These studies identified ARTD1 and histones to be the main acceptors 
of ADPr under these conditions10,11,13,14. ARTD1 and ARTD2 are considered the two main 
ARTDs that “write” nuclear PARylation1,3. A recent permeabilized cell-based chemical 
proteomics study using NAD+ analogues demonstrated as well that ARTD1 and ARTD2 ADP-
ribosylate several hundred proteins and revealed a significant target protein12. Although these 
groundbreaking studies have significantly advanced our understanding of cellular ADP-
ribosylation, unfortunately it still remains unclear what the bona fide ADP-ribosylation targets 
of these ARTDs are in vivo. 
Proteomics studies have also identified several ADPr-acceptor amino acids in 
mammalian cells, namely lysine (K), arginine (R), aspartic acid (D), glutamic acid (E), cysteine 
(C) and serine (S)1,5,6,9,11,15,16. Unfortunately, accurate ADPr acceptor site(s) localization 
remains challenging partially due to the fact that MS-search engines require the user to 
predefine all possible ADPr-acceptor amino acids. This can introduce bias, which was 
recently highlighted by the unexpected identification of S as the prominent genotoxic stress 
induced ADPr-acceptor7,15. Using ARTD1 as the writer of in vitro ADP-ribosylation 
modifications, a few of the described ADPr-acceptor amino acid have been biochemically 
validated by site directed mutagenesis or Edman sequencing1,3,5,11. Following the 
identification of S-ADP-ribosylation on histones and ARTD115, Bonfiglio et al. found that 
Histone PARylation Factor 1 (HPF1, previously C4orf27) functions as a cofactor for ARTD1 
and ARTD2 that directs ADP-ribosylation specifically towards S-ADPr acceptor sites5. HPF1, 
was first identified as a regulator of ADP-ribosylation signaling in the DNA damage response 
via ARTD1-dependent recruitment to DNA lesions, which subsequently leads to ARTD1-
dependent ADP-ribosylation of histones17.  
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Here, we took advantage of the high-quality MS datasets that our group recently 
generated using an ADPr-optimized HCD-PP-EThcD/HCD MS workflow7 and re-analyzed 
these data using several different variable ADPr search parameters. By expanding the ADPr-
acceptor amino acid specificity search parameters, we identified Y-ADPr-acceptor sites. 
Using powerful, label-free quantitative proteomics methods we demonstrate that ARTD1 
functions as the proteome-wide writer of H2O2-induced S-ADPr and Y-ADPr protein 
modifications. Biochemical assays, coupled with site-directed mutagenesis, confirm that 
ARTD1 ADP-ribosylates the MS-identified Y-ADPr acceptor sites of RPS3A (Y155) and HPF1 
(Y238). Finally, in depth investigation of functional consequences of HPF1 ADP-ribosylation 
reveal that Y238 ADP-ribosylation drives all HPF1 ADP-ribosylation activities and that loss of 
this PTM obstructs the enzymatic activities of ARTD1. 
 
RESULTS
90
 5 
RESULTS 
Opening Mascot-based MS search parameters for ADPr variable modifications 
identifies tyrosine as a novel potential ADPr-acceptor site. 
To investigate whether new ADPr-acceptor amino acids could be identified within our 
high-quality ADPr-enriched MS datasets, a revised Mascot searches were used7. The data 
used here were acquired from biological replicate H2O2-treated HeLa cell samples (n=4) using 
an ADPr-optimized HCD-PP-EThcD/HCD MS workflow (Figure 1a). For these new searches, 
we opened the variable ADPr PTM search parameters to include all 20 amino acids as 
potential ADPr-acceptor sites (Table S1). Potential ADP-ribosylated peptides were 
considered for further analysis and validation when Mascot scores >20 and expectation 
values <0.05 were obtained. The individual searches returned ~700 ADPr-site localizations 
per search (Table S2). Interestingly, these open search parameters returned ~500 ADPr 
modifications that localized to “new” potential ADPr-acceptor amino acids. The semi-repetitive 
search parameters used here returned several ADPr-site localizations for the same spectra. 
As a result, the spectra annotations were validated manually to determine which of the 
assigned ADPr-sites was most likely correct for each of the spectra. Prior to manual review, 
an additional ion score filter was applied (Figure 1b) and ADPr-site localizations for spectra 
with ion scores >0.5 (448 unique spectra/117 unique peptides) were validated. This identified 
288 high quality spectra (181 EThcD and 107 HCD spectra) in which the ADPr-site was 
confidently localized within the ADPr-peptide. In agreement with previous studies 7,11,15,18, 
these spectra support the attachment of ADPr to known ADPr-acceptors (S, D, E, R, and K) 
and further supported previous findings that S is the prominent ADPr-acceptor amino acid in 
vivo (Figures 1c and S1a). In addition, several previously unidentified ADPr-acceptor amino 
acids were found including alanine (A), leucine (L), asparagine (N), glutamine (Q), valine (V) 
and tyrosine (Y) (Figures 1c and S1a, and Table S3).   
Several of the side chains of these new potential ADPr-acceptors are biochemically inert. 
Moreover, all but Y were only identified in HCD spectra (Figure S1a) and, while high-
resolution HCD fragmentation methods successfully and confidently identify ADP-ribosylated 
peptides, the inherent fragility of the ADPr modification under these conditions severely limits 
confident ADPr site localization5,7,11,15. We, therefore, reasoned that some of these new ADPr-
acceptors were false positives. To tease this out, we used the 288 high-quality spectra (Table 
S3) to build a spectra library for ADPr-site localization training. The ADPr-site Localization 
Spectra Database (ADPr-LSD) (Supplementary Information) was then used to iteratively 
refine the search parameters to define the full ADP-ribosylome (peptide/protein), confidently 
and accurately assign the ADPr-site within each modified peptide and identify all biologically 
relevant ADPr-acceptor amino acids. Two search parameter refinement steps were carried 
out using Mascot where the ADPr-acceptor amino acid groups were varied (SDERKY or 
SRY). The refined peptide identification and ADPr-site localization results were compared 
(computationally and manually) with each other and the original assignments (Figures 1c and 
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S1a). Throughout this process, we found that ADPr-site localization scores increased as the 
search parameters were refined to only include amino acids that could be confirmed by 
manual spectra annotation (Table S3). Moreover, the step-wise bioinformatic and manual 
validation workflow presented here led to the identification of Y as an ADPr-acceptor amino 
acid. The improved spectra fragment ion assignments also confirmed all of the other potential 
“new” ADPr-acceptors (A, L, N, Q and V) as false positives (Table S3 and ADPr-LSD). 
To assess the performance of our improved ADPr-search parameters on the full data 
set, rather than just the ADPr-LSD spectra, we extended our analyses and compared our 
SDERKY and SRY results. In line with results published by Bilan et al.7, each of our searches 
identified ~180 unique ADPr-peptides with perfect peptide identification overlaps (Figure 1d, 
Tables 1 and S4). Comparison of the ADPr-site localizations returned by the SDERKY and 
SRY searches revealed >60% ADPr-site localization agreement for EThcD fragmentation-
based spectra (Figure 1d) and ~35% agreement for HCD spectra (Figure S1b). Half of the 
ADPr-peptides were identified by both HCD and EThcD fragmentation methods. For these 
peptides, the ADPr-site localizations were in agreement ~50% of the time (Figure 1e). Finally, 
and most intriguingly, these comparative analyses identified 7 proteins that carry potential Y-
ADPr modifications (Table 2). Thus, validating Y as a novel, albeit low abundant, in vivo 
ADPr-acceptor amino acid. 
 
ARTD1 is the main writer of genotoxic stress induced ADP-ribosylome 
To dissect the contributions of ARTD1 and ARTD2 on the observed ADP-ribosylome, we 
inhibited their expression in HeLa cells via stable expression of shARTD1, shARTD2 or 
shControl siRNAs (Figure S2a). The engineered cell lines were treated in biological triplicate 
with H2O2 or left untreated and the resulting ADP-ribosylomes defined using HCD-based MS 
as previously described11. The resulting datasets were analysed for variable SDERKY or SRY 
ADP-ribosylation using Mascot. In general, while the untreated ADP-ribosylomes of each cell-
line were quite similar, specific and significant decreases in the total number of ADP-
ribosylated spectra and proteins identified were observed in H2O2-treated shARTD1 cells 
(Figures 2a and S2b, Table S5). In fact, shARTD1 ADP-ribosylation levels were most similar 
to untreated shControl or shARTD2 cells (Figure S2b). These findings confirmed that ARTD1 
is the main driver of nuclear PARylation19 Moreover, our data suggest that ARTD2 does not 
functionally complement ARTD1 in vivo and demonstrate that ARTD1 is the main enzyme that 
catalyzes of genotoxic stress induced nuclear de novo ADP-ribosylation. Finally, our findings 
also indicate that ARTD1 and ARTD2 only marginally contribute to the steady-state 
(untreated) ADP-ribosylome and that ARTD2 does not, in fact, significantly contribute to H2O2-
induced ADP-ribosylation in HeLa cells (Figures 2a and S2b). To address a potential 
crosstalk between ARTD1 and ARTD2, we quantified the identified ADPr-sites using MS1-
based label-free quantification (LFQ). While quantified relative ADPr-peptide abundances 
were consistent among biological replicates (Spearman rank’s correlation coefficients 0.71-
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0.83), poor correlation between the shARTD1 and the shControl or shARTD2 samples were 
observed (Figure S2c-d). Taken together, these findings suggest that ARTD1 is the main 
writer of HeLa cell cellular ADP-ribosylation following H2O2 treatment.  
 
Proteome-wide S- and Y-ADP-ribosylation is mediated by ARTD1 
To determine proteome-wide ARTD1 ADPr-acceptor amino acid specificity, comparative 
analysis of our optimized ADPr search parameters (SDERKY vs SRY) revealed a slight 
(~15%) increase in the number of unique peptides identified in the SRY search, while 
comparable numbers of ADPr spectra matches were identified (Figure S3a-b). Overall the 
increased search space (SDERKY) did not lead to a significant decrease in R-ADP-
ribosylation, but reduced S-ADP-ribosylation assignments in favor of K-ADP-ribosylation, D-
ADP-ribosylation and E-ADP-ribosylation (Figure S3c-d). These searches demonstrated that 
R is the primary steady-state ADPr-acceptor amino acid. Following H2O2 treatment, the major 
modification site identified was S and, to a much lesser extent, Y. Interestingly, our data 
indicates that both of these modifications required ARTD1 (Figure S3c-d). Quantification of 
the site-specific ADP-ribosylation changes in response to ARTD1 or ARTD2 knockdown, via 
volcano blot analyses and annotation of EThcD localized ADPr sites, further confirmed that S-
ADP-ribosylation and Y-ADP-ribosylation were dependent on ARTD1, and specifically and 
strongly induced upon H2O2 treatment, while R-ADP-ribosylation remained uninfluenced by 
genotoxic stress (Figure 2b). 
 
Pathway analysis identifies links between the ADP-ribosylome, cellular functions and 
the phospho-proteome 
GO analysis of the ADPr-ribosylated proteins identified revealed that S-ADP-ribosylated 
and Y-ADP-ribosylated proteins are typically nuclear proteins that interact with RNA and/or 
DNA and play a role in chromatin organization (Figure 2c and Table S5). In contrast, R-ADP-
ribosylated proteins localized to endomembranes and function in protein folding and/or 
endoplasmic reticulum (ER) stress-associated processes, similar to our previous studies19. 
Studies have demonstrated that ~90% of the phosphorylation-sites observed in mammalian 
cells localize to S20. Given that our studies identified S and Y as the main H2O2-induced 
ADPr-acceptor, we investigated the potential link between protein ADP-ribosylation and 
phosphorylation modifications. Comparison of our datasets with those recently published by 
Sharma et al.20 found that 18% of our S-ADPr-sites could also serve as phosphorylation sites 
in Hela cells (Figure 2d and Table S6), which tentatively suggests that cross-talk between 
phosphorylation and O-linked ADP-ribosylation may control key cellular stress response 
pathways. 
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RPS3A-Y155 is ADP-ribosylated by ARTD1 in presence of HPF-1. 
Our extensive bioinformatics analyses identified 7 proteins that are potentially ADP-
ribosylated on Y residues in vivo (Table 2). Moreover, the LFQ-based data presented above  
indicated that these novel Y-ADP-ribosylations are written by ARTD1. The low abundance of 
these modifications, relative to S-ADP-ribosylation, and the uncertainty surrounding ADP-
ribosylation sites localized using HCD spectra5 prompted us to independently validate Y as an 
ADPr acceptor amino acid using in vitro ADP-ribosylation assays. For these studies, we 
proceeded with RPS3A, as several high quality EThcD spectra supporting Y155-ADPr 
modification were identified at each phase of our bioinformatic analyses (Figure 3a and 
ADPr-LSD (KTSYAQHQQVR)). Full-length recombinant wild-type RPS3A (RPS3A-WT) and 
Y155F mutant (RPS3A-Y155F) proteins were constructed for these studies. Strong and 
relatively indistinguishable amounts of [32P]-ADPr were incorporated into full-length RPS3A-
WT and RPS3-Y155F when the modification reactions were carried out with ARTD1 alone 
(Figure 3b). Recent studies have demonstrated that the in vitro enzymatic activity of ARTD1 
can be promiscuous and that addition of HPF1 to these reactions changes the modified ADPr-
acceptor specificity on histones and ARTD1 from E, D, R and K residues to S residues5,17.  
We reasoned that Y-ADP-ribosylation should be biochemically similar to O-linked S-
ADP-ribosylation, thus addition of HPF1 could provide the ARTD1 enzymatic specificity 
required to confirm Y-ADP-ribosylation. Based on the incorporation of [32P]-ADPr, we found 
that HPF1 augmented ARTD1 auto-modification and damped trans-modification of RPS3A 
(Figure 3b). Importantly, HPF1-mediated modulation of ARTD1 trans-ADP-ribosylation 
activity significantly reduced RPS3A-Y155F mutant protein ADP-ribosylation (~40%) relative 
to RPS3A-WT (Figure 3b). Together, these data demonstrate that RPS3A is ADP-ribosylated 
by ARTD1 at Y155, confirm that Y can act as an ADPr-acceptor amino acid and show that 
HPF1 provides Y-ADP-ribosylation specificity.  
 
ADP-ribosylation of Y238 of HPF1 is important for its ADP-ribosylation cofactor 
functions 
The addition of HPF1 to the in vitro ADP-ribosylation assays presented in Figure 3 
revealed that ARTD1 also ADP-ribosylates HPF1. This finding was, in fact, supported by the 
MS data presented above (Table S4), in which a single ADPr-peptide from HPF1 
(TFHGAGLVVPVDKNDVGYRELPETDADLKR) was identified which resulted in the 
identification of one ADPr-site – Y238 (Figure S4). The identification of Y238, which together 
with the adjacent R239 is highly conserved in all C4orf27 orthologues, led us to wonder if not 
just the amino acid itself, but ADP-ribosylation of Y238 controls HPF1 ADP-ribosylation 
cofactor functions; particularly given the large, aromatic and pH dependent charged state of Y 
amino acid side chain and the bulkiness an ADPr modification would add to HPF1.   
To explore this, we first set out to determine if Y238 of HPF1 is ADP-ribosylated. We 
generated HIS-tagged recombinant wild-type HPF1 and mutant proteins in which Y238 was 
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mutated to a phenylalanine (Y238F) to maintain the aromatic structure of the amino acid at 
this position. The adjacent R239 was additionally mutated either alone to alanine (R239A) or 
together with Y238 (Y238F/R239A). In vitro ADP-ribosylation assays with these HPF1 
isoforms and ARTD1 demonstrated strong incorporation of 32P-ADPr into HPF1-WT (Figure 
4a). In contrast, very weak modification of HFP1-Y238F was observed and quantification 
analysis revealed a ~75% decrease in the modification HPF1-Y238F relative to WT (Figure 
4a), suggesting that Y238 is indeed an ADPr-acceptor. We found that HPF1-R239A was 
modified to almost wild-type levels (>80%) and, unexpectedly, observed ADP-ribosylation of 
the double mutant (HPF1-Y238F/R239A) under these conditions. While HPF1-Y238F/R239A 
modification was stronger than that observed for HPF1-Y238F, it was weaker than that 
observed for HFP1-WT or HPF1-R239A (Figure 4a). This suggests that, under these 
conditions, ADP-ribosylation of HPF1-Y238F/R239A could reflect promiscuous ARTD1 
enzymatic activity. Moreover, the dramatic boost in ARTD1 auto-ADP-ribosylation observed in 
presence of HPF1-WT (350% +/-7%), was completely lost when the modification assays were 
carried out in the presence of any of the HPF1 mutants (Figure 4a). Quantification analysis 
ARTD1 ADP-ribosylation revealed that, relative to ARTD1 auto-modification in the absence of 
HPF1, HPF1-Y238F, HPF1-R239A and HPF1-Y238F/R239A inhibited ARTD1 auto-
modification by ~20% (Figure 4a). This suggests that both of Y238-ADP-ribosylation and 
R239 are required for HPF1 to enhance ARTD1 auto-modification. 
Unfortunately, it remains unclear whether the lack of modification of HPF-Y238F mutant 
resulted from ADPr-site mutagenesis (i.e. lack of ADP-ribosylation) or general loss-of ARTD1 
binding. Moreover, modification of HPF1-Y238F/R239A suggested that nonspecific 
interactions with ARTD1, different from wild-type HPF1-ARTD1 interactions, facilitated 
promiscuous ADP-ribosylation of this HPF1 mutant. Defining the interactions between ARTD1 
and our isoforms of HPF1 are of particular importance as previous in vivo 
immunoprecipitation-based with HPF1 mutants (HFP1-Y238A, HPF1-R239A and HPF1-
Y238A/R239A) demonstrated that all of these mutations abolished ARTD1-HFP1 protein-
protein interactions under unstressed conditions17. To explore this and determine if ADP-
ribosylation alters ARTD1-HFP1 interactions, HPF1 proteins were pre-incubated with 
recombinant ARTD1 under non-modifying conditions or in the presence of NAD+/Activating 
DNA to induce ADP-ribosylation. Purification of ARTD1-HPF1 protein complexes using !-
ARTD1 protein A sepharose beads demonstrated that the interaction between ARTD1 and 
HPF1-WT was not dependent on ADP-ribosylation, but was augmented following ADP-
ribosylation (Figure S5a). Interestingly, we discovered that while unmodified ARTD1 (i.e. in 
absence of NAD+) was unable to interact with HFP1-Y238F or HFP1-Y238F/R239A, it did 
interact weakly with HPF1-R239A (Figure S5b-d). These findings suggest that Y238 provides 
a beneficial interface for ARTD1-HPF1 interactions. Furthermore, we found that ADP-
ribosylation not only enhanced the interaction between ARTD1 and HPF1-R239A but also 
facilitated weak interactions between ARTD1 and HPF1-Y239F and HFP1-Y238F/R239A 
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(Figure S5b-d). Taken together, these findings indicate that Y238 provides a beneficial 
interface for ARTD1-HPF1 interactions, that ADP-ribosylation of ARTD1 and/or HPF1 
stabilizes the protein-protein complex. It is possible that ADP-ribosylation of Y238 itself (in 
presence of the R239A mutation) provides the critical structural framework required to 
stabilize ARTD1-HFP1 interactions. Finally, we also confirm that R239 also contributes, 
although to a lesser extent, to ARTD1-HPF1 complex formation.  
 
ADP-ribosylation of HPF1 at Y238 is required for its function as a trans-ADP-
ribosylation cofactor. 
Given that both ADP-ribosylation of Y238 and the presence of R239 are required for 
HPF1 to enhance the auto-modification enzymatic activity of ARTD1 (Figure 4a), we 
wondered whether ADP-ribosylation of HPF1 would also affect its trans-ADP-ribosylation 
cofactor functions. To this end, recombinant RPS3A-WT or RPS3A-Y155F proteins were 
ADP-ribosylated in vitro in the presence of ARTD1 alone or with ARTD1 and HPF1-WT, 
HPF1-Y238F, HPF1-R239A or HPF1-Y238F/R239A. In agreement with Figure 3, the HFP1-
WT dampened the trans-ADP-ribosylation activities of ARTD1, which provides ADPr-
ribosylation specificity (Figure 4b). Intriguingly, a dramatic and specific decrease in ARTD1 
trans-ADP-ribosylation activity of was observed in the presence of HPF1-Y238F. 
Quantification of [32P]-ADPr incorporation into RPS3A-WT and RPS3A-Y155F, relative to 
RPS3A-WT modified by ARTD1 alone, revealed a >75% decrease in ARTD1 trans-ADP-
ribosylation activity (Figure S6). In stark contrast to this, the modification levels of both 
RPS3A proteins observed with HFP1-R239A or HFP1-Y238F/R239A were comparable to 
those achieved with ARTD1 alone (Figure 5 and S6). Together, these findings suggest that 
ADP-ribosylation of HPF1 at Y238 is critical for the trans-ADP-ribosylation cofactor functions 
and, together with R239, provides amino acid ADPr-acceptor site specificity. 
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DISCUSSION 
Here we report the establishment of a MS data analysis workflow for identifying the ADP-
ribosylome that was developed using an alternative, multistep approach that combined 
bioinformatic analyses with manual validation of the spectra annotations to confidently 
localize the ADPr-sites within the identified ADP-ribosylated peptides. In addition to identifying 
spectra that strongly support the in vivo ADP-ribosylation of S and R, this approach led to the 
first identification of Y-ADP-ribosylation. Using shRNA-based knockdown studies, we have 
demonstrated that genotoxic stress strongly and very specifically induces proteome-wide S- 
and Y-ADP-ribosylation in vivo and that these PTMs are ARTD1 dependent. Site-directed 
mutagenesis and in vitro ADP-ribosylation methods biochemically confirmed Y-ADPr protein 
modifications for RPS3A and HPF1. Like O-linked S-ADP-ribosylation, we found that the 
HPF1 cofactor activity was also required for Y-ADPr modification specificity. Finally, and most 
intriguingly, in vitro biochemical validation methodologies provide strong evidence that ADP-
ribosylation of HFP1-Y238 is required for HPF1’s ARTD1-associated trans-ADP-ribosylation 
cofactor function.  
As indicated above, analyzing ADP-ribosylome MS data is challenging and bias can be 
introduced when attempting to accurately localize ADP-acceptor sites. Indeed, earlier reports 
from our group identified K-ADPr-sites within a KS modification motif7,11. Interestingly, re-
evaluation of the data to include S as an ADPr-acceptor amino acid led to the reassignment of 
most of the K-ADPr assignments to S-ADPr5,7. These findings suggested that new ADPr-
acceptor amino acid potentially awaited discovery. We approached this by developing an 
alternative analysis workflow where all possible amino acids were queried as ADPr-acceptors 
and all peptides with strong theoretical spectra library annotations were validated manually for 
correct ADPr-site localization. Subsequent re-analysis of the same data for ADP-ribosylation 
on only those amino acids confirmed by manual spectra validation (S, D, E, R, K and Y) 
improved our ADPr search outcomes and assigned ADPr-sites with greater confidence. 
Importantly, this approach also revealed that Y functions as an ADPr-acceptor amino acid in 
vivo.   
We have made great strides towards overcoming the bioinformatic challenges 
associated with analyzing ADP-ribosylome MS datasets, but improvements are still required. 
Confident ADPr-site localizations were only made for ~50% of the HCD and ~75% of the 
EThcD identified ADPr-peptides. We, therefore, needed to evaluate these spectra where the 
ADPr-site was not assigned to determine if new site determining ions can be identified that 
could facilitate ADPr-site localization. It will also be important to explore other MS search 
engines and data analysis pipelines identify more ADPr-peptides and assign ADPr-sites with 
greater confidence21-23. Moreover, our ability to confidently assign only S-ADPr, R-ADPr and 
Y-ADPr modifications in vivo raises concerns as to why E-ADPr and D-ADPr were not 
detected; especially given that other studies provide strong evidence that these modifications 
are written in vivo and in vitro 9,10,12. It could simply be that AF1521-based ADPr-enrichment 
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and/or the peptide fragmentation (EThcD versus CID24,25) methods used here limit D-ADPr 
and E-ADPr modification identifications. T-ADP-ribosylation modifications were not identified, 
suggesting that T may not be ADP-ribosylated or that T-ADPr modifications are not detectable 
using our methodologies. Additional studies are required to clarify these potential biases. 
It has remained unclear until now which ARTDs specifically write the in vivo ADP-
ribosylome that has thus far been identified. Here, we demonstrate that H2O2-stress 
specifically induces S-ADPr and Y-ADPr protein ADP-ribosylation in vivo and that ARTD1, not 
ARTD2, catalyzes of these modifications. These findings are in agreement with earlier in vitro 
reports using microarrays26,27 or purified histones5. We also demonstrate that R is the main 
steady-state ADP-ribosylation acceptor in HeLa cells. The ART responsible for this 
modification is not yet known but the cytoplasmic localization of proteins suggests that a 
cytoplasmic ART(s) writes these modifications. Previous studies observed PAR formation in 
ARTD1 knockout cells and suggested that ARTD2 may be responsible for these 
modifications28. Here, we found that ARTD1 and ARTD2 do not modify the same ADP-
ribosylation target proteins in H2O2-treated HeLa cells. Indicating that ARTD2 does not 
compensate for ARTD1 in HeLa cells and is likely regulated by a different stress stimuli than 
ARTD1. Nevertheless, ARTD1−/−/ARTD2−/− mice are not viable29; thus, it is possible that 
ARTD1 and ARTD2 functionally compensate for each indirectly by modifying different target 
proteins that function in the same cellular processes. 
In vitro ADP-ribosylation assays revealed that ARTD1 can ADP-ribosylate RPS3A, and 
site-directed mutagenesis studies confirmed Y155 of RPS3A as an ADPr-site. ADP-
ribosylation of RPS3A was not completely lost on RPS3A-Y155F mutant proteins, but our MS 
data analyses indicated the RPS3A may also be ADP-ribosylated on S154 (EThcD/HCD) and 
K152 (HCD). Thus, the residual ADP-ribosylation observed here likely reflects the in vitro 
modification of these and/or other additional RPS3A ADPr-sites. Importantly, we also 
established demonstrated HPF1 provides ARTD1 with the trans-ADP-ribosylation specificity 
required to specifically and accurately write Y-ADPr (and possibly S-ADPr) modifications on 
RPS3A. This elaborates on the S-specific ADP-ribosylation functions identified for HPF15 and 
indicates that HPF1 functions to tune the enzymatic activity of ARTD1 towards O-linked S- 
and Y-ADP-ribosylation.   
Our HPF1 site-directed mutagenesis studies not only confirmed that Y238 is the ADPr-
site in HPF1, but also teased out the functional contributions Y238 and R239 make to HPF1 
ADP-ribosylation cofactor activities. Previous studies demonstrated that Y238 and R239 
single and double HPF1 mutants failed to purify ARTD1 from unstressed cellular extracts, 
which suggested that both amino acids were required for ARTD1-HPF1 complex formation17. 
Using less complex binding conditions and more structurally relevant HPF1 mutant proteins, 
we demonstrate that unmodified ARTD1 mainly interacts strongly with HPF1-WT and weakly 
with the ADP-ribosylation proficient HFP1-R239A mutant. Interactions were not observed 
between unmodified ARTD1 and HPF1-Y238F (i.e. ADP-ribosylation deficient) or HPF1-
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Y238F/R239A. Interestingly, we also demonstrate that ADP-ribosylation intensifies HPF1-WT 
and HPF1-R239A interactions and that ARTD1 auto-modification supports weak protein-
protein interactions between HPF1-Y238F and HPF1-Y238F/R239A and ARTD1. Subsequent 
in vitro ADP-ribosylation assays revealed two important molecular mechanisms associated 
with HPF1 ADP-ribosylation cofactor functions. We found that Y238 ADP-ribosylation and 
R239 (which is not modified) were required for HPF1 to augment ARTD1 auto-modification. In 
addition, we discovered that Y238 ADP-ribosylation provides an important interface that 
controls the trans-ADP-ribosylation enzymatic activities of ARTD1 that together with R239, 
which appears to provide an additional interaction point, “clicks” the CAT domain of ARTD1 
into the trans-ADP-ribosylation conformation required to specifically write O-linked ADPr 
modifications on hundreds of target proteins.  
For researchers embarking on similar ADP-ribosylomics studies, we think that this study 
has clarified some of the bioinformatics challenges associated with ADP-ribosylomics and 
hope they take advantage of the insights gained. We recommend that ADPr-MS datasets be 
searches in duplicate with variable ADPr modifications on S, D, E, R, K and Y and on just S, 
R and Y. Comparative analyses of these results will identify ADPr-sites that are common to 
both searches and those that differ. While ADPr-site localizations that differ between these 
searches require manual validation of the spectra annotations, common assignments can 
confidently be considered “correct”. Finally, the ADPr-site Localization Spectra Database 
(ADPr-LSD) that we provide here is the first, and most comprehensive, HCD and EThcD 
ADPr spectra resource that has been made public to the research community. Not only does 
it provide spectral references for ADPr-sites identified within, but it can also be used by 
researchers as a training resource to improve high-quality ADPr-spectra identifications and 
ADPr-site localizations. 
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Figure Legends 
 
Figure 1: Refining MS search parameters for variable ADP-ribose peptide modifications 
identifies tyrosine as a novel ADPr-amino acid acceptor.  a. Schematic of the sample 
preparation and HCD-PP-EThcD/HCD MS acquisition method workflow employed by Bilan et 
al.7 to generate the high quality EThcD and HCD datasets used here.  b. Schematic of the 
bioinformatics workflow employed here.  In the initial phase of these analyses, variable ADPr 
PTM search parameters were opened to include all 20 amino acids as potential ADPr-
acceptor sites. Ion scores were then calculated to help identified the best quality ADPr-site 
localizations within modified peptides and peptides for manual validation of ADPr-site 
localization.  Based on these manual validations, the search parameters were refined to 
include S, D, E, R, K and Y (SDERKY) or S, R and Y (SRY) as ADPr-acceptor amino acids 
and the workflow re-applied.  c. The ADPr-site localization results from the initial (20aa) 
searches and refined searches were compared.  The flow chart depicts how ADPr-acceptor 
amino acid identifications changed for the 181 EThcD ADPr-localization training spectra as 
the variable ADPr search parameters were refined. Importantly, these analyses identified 
novel tyrosine (Y) ADPr modifications at each phase of our analyses. d. Comparison of total 
number of unique ADP-ribosylated peptides and unique ADPr-sites identified (Mascot 
localization probability >60%) in the SDERKY and SRY searches.  e. Comparison of the 
ADPr-site localizations (Mascot localization probability >60%) for ADP-ribosylated peptides 
that were identified by both EThcD and HCD fragmentation methods. 
 
Figure 2: ARTD1 mediates proteome-wide S and Y ADP-ribosylation.  a. Venn diagrams 
indicate the overlap of ADP-ribosylated proteins identified in untreated and H2O2 treated HeLa 
cells following ARTD1 or ARTD2 knockdown. b. Volcano plots comparing ADP-ribosylated 
peptides identified in the different cell lines and conditions (t-test with Permutation-based FDR 
< 0.05 and fold change of 2, indicated by the black line).  ADP-ribosylation sites confirmed by 
EThcD spectra are color coded for S-ADPr (blue), Y-ADPr (green) and R-ADPr (red) 
modifications.  Serine (DDX21), tyrosine (RPS3A) and arginine (PDIA3) modifications that 
were identified using our ADPr-localization training spectra library are annotated. The black 
hyperbolic line represents a permutation-based False Discovery Rate (FDR) of 5% and a 
minimal fold change of 2.  c.  Gene ontology cellular localisation annotation of ADP-
ribosylated proteins following H2O2 treatment, SRY ADP-ribosylated proteins were considered 
with a Mascot localisation score >90% .d. Comparison of the S,Y-ADP-riboslyome identified 
here with the HeLa phosphoproteome identified by Sharma et al.20. 
 
Figure 3:  Biochemical validation of RPS3-Y155 ADPr modification.  a. High-resolution 
EThcD fragmentation spectrum of an RPS3A peptide modified with ADP-ribose on Y155. b. 
Recombinant RPS3A-WT or RPS3A-Y155F were in vitro ADP-ribosylated with [32P]-NAD+, 
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activated DNA and recombinant ARTD1 in the presence or absence of recombinant HPF1. 
Samples were resolved by SDS-PAGE and analyzed by autoradiography. top: Coomassie 
Blue-stained poly-acrylamide gel; middle: raw-scan of autoradiograph; bottom: 
autoradiograph with levels adjusted to enhance exposure. Relative percentages of the in vitro 
ADP-ribosylation (radioactive signal) of ARTD1 (relative to radioactive signal with [32P]-NAD+ 
and activated DNA alone), RPS3A-WT and RPS3A-Y155F (relative to radioactive signal for 
RPS3A-WT for each condition) are indicated (n = 3). Values in brackets represent the 
standard deviation of the mean. 
 
Figure 4:  ARTD1/HPF1 protein-protein interactions and the serine and tyrosine ADP-
ribosylation co-factor functions of HPF1 are dependent on HPF1 ADP-ribosylation on tyrosine 
238. a. Recombinant wild-type HPF1 (HPF1-WT) and HPF1 mutant (HPF1-Y238F, HPF1-
R238A or HPF1-Y238F/R239A) proteins were in vitro ADP-ribosylated with [32P]-NAD+, 
activated DNA and recombinant ARTD1 (n = 3). b. Recombinant RPS3A-WT and or RPS3A-
Y155F were in vitro ADP-ribosylated with [32P]-NAD+, activated DNA and recombinant ARTD1 
(Trevigen, Gaithersburg, MD, USA) in vitro ADP-ribosylation assays were performed with 
[32P]-NAD+, DNA and recombinant ARTD1 without HPF1 or with recombinant HPF1-WT and 
HPF1-Y238F, HPF1-R239A, or HPF1-Y238F/R239A proteins (n = 2). For in vitro ADP-
ribosylation assays, the samples were resolved by SDS-PAGE and analyzed by 
autoradiography (top: Coomassie Blue-stained poly-acrylamide gel; middle: raw-scan of 
autoradiograph; bottom: autoradiograph with levels adjusted to enhance exposure). Relative 
percentages of in vitro ADP-ribosylation (radioactive signal) of ARTD1 (relative to radioactive 
signal with [32P]-NAD+ and activated DNA alone) RPS3A-WT and RPS3A-Y155F (relative to 
radioactive signal for RPS3A-WT for each condition) and the HFP1 protein isoforms (relative 
to radioactive signal for HPF1-WT) are indicated. Values in brackets represent the standard 
deviation of the mean. c.  Summary of the ARTD1 binding capacities of wild-type and mutant 
HFP1 proteins and the ADP-ribosylation cofactor activities of each of the isoforms of HFP1.  
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TABLE 1. Summary of ADPr-peptides and ADPr-sites identified using different variable ADPr 
localization parameters 
 
Unique ADPr-Peptides 
  SDERKY SRY 
HCD-PP-EThcD 188 182 
Unique EThcD 33 40 
Unique HCD 74 67 
overlap 81 75 
Unique ADPr-Peptides with loc. 
probability >60% 
  SDERKY SRY 
HCD-PP-EThcD 145 129 
EThcD 36 31 
HCD 54 45 
overlap 55 53 
Unique ADPr-sites with loc. 
probability >60% 
  SDERKY SRY 
HCD-PP-EThcD 187 140 
EThcD 70 45 
HCD 85 64 
overlap 32 32 
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TABLE 2. Y-ADPr modified Proteins  
Gene Name Peptide Sequence_ADPr-site 
Y-ADPr Site 
on Protein 
Spectra 
Type 
RPS3A KTSYAQHQQVR_Y4 Y155 EThcD 
HPF1 TFHGAGLVVPVDKNDVGYRELPETDADLKR_Y18 Y239 EThcD/HCD 
HNRNPA1 NQGGYGGSSSSSSYGSGR_Y5 Y252 HCD 
HNRNPA2B1 NMGGPYGGGNYGPGGSGGSGGYGGR_Y6 Y319 HCD 
HDGF STANKYQVFFFGTHETAFLGPK_Y6 Y38 HCD 
YY1 KSYLSGGAGAAGGGGADPGNKKWEQK_Y3 Y185 HCD 
P4HB LAKVDATEESDLAQQYGVRGYPTIK_Y16 Y94 HCD 
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ONLINE METHODS 
Generation of stable shARTD1 and shARTD2 cell lines 
Virus generation and HeLa cell transduction was carried out as previously described 30.  
Briefly, short hairpin RNAs (shRNAs) targeting the mRNA coding sequences ARTD1 
(CCGAGAAATCTCTTACCTCAA) or ARTD2 (TCTGAATCCAGATGGTTATA), or a scramble 
shRNA (CCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGGGCGACTTAACCTTAGG) were 
cloned into pRDI292. These vectors were then used to generate replication incompetent 
retroviruses in HEK-293 cells.  HeLa cells (Kyoto) were infected with the resulting retroviruses 
for 8 hours, cultured for 48 hours without selection and placed under selective growth 
conditions (2µg/mL puromycin) to select for transduced cells. ARTD1 and ARTD2 knockdown 
was confirmed on the mRNA and protein levels via qPCR and Western blot analyses, 
respectively. 
 
Cell culture conditions and ADPr Peptide enrichment 
shControl, shARTD1 and shARTD2 HeLa cells (Kyoto) were cultured in Dulbecco’s 
modified Eagle’s medium [DMEM, supplemented with 10% fetal calf serum (FCS) and 1% 
penicillin/streptavidin] at 37°C with 5% CO2. Cells were either untreated or treated in 
triplicated with 1mM H2O2 in PBS containing and 1mM MgCl2.  Cells were lysed and 
processed for MS analysis as previously described 7,11. 
 
Liquid Chromatography and Mass Spectrometry Analysis 
The ADP-ribosylomes of shControl, shARTD1 and shARTD2 HeLa cells were identified 
using an Orbitrap Q Exactive HF mass spectrometer (Thermo Fisher Scientific) coupled to a 
nano EasyLC 1000 (Thermo Fisher Scientific). The peptides were loaded into the MS using a 
reverse-phase C18 (ReproSil-Pur 120 C18-AQ, 1.9 μm, Dr. Maisch GmbH) packed self-made 
column (75 μm × 150 mm) that was connected to an empty Picotip emitter (New Objective, 
Woburn, MA). Peptides were injected into the MS at a flow rate of 300nL/min and were 
separated using a 90 minute gradient of 2% to 25% buffer B. Solvent compositions of buffer A 
and buffer B were 0.1% formic acid and 0.1% formic acid/99.9% acetonitrile, respectively. 
For mass spectrometer (MS) analysis, the MS was set to acquire full-scan MS spectra 
(300–1700 m/z) at a resolution of 60,000 after accumulation to an automated gain control 
(AGC) target value of 3 × 106. Charge state screening was enabled, and unassigned charge 
states and single charged precursors were excluded. Ions were isolated using a quadrupole 
mass filter with a 2 m/z isolation window. The maximum injection time was set to of 240 ms 
and HCD fragmentation performed at 28% normalized collision energy (NCE). Finally, 
selected ions were dynamically excluded for 20 seconds. 
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MS Data analysis  
For the bioinformatic analyses aimed at identifiying novel ADPr-acceptor amino acids, 
raw files from Af1521-enriched H2O2-treated HeLa samples measured by the HCD-PP-
EThcD/HCD method 7 were used. These files can be accessed via ProteomeXChange 
(PXD004676). MS and MS/MS spectra were converted to Mascot generic format (MGF) using 
Proteome Discoverer, v2.1 (Thermo Fisher Scientific, Bremen, Germany). Separate MGF files 
were created from the raw file for each type of fragmentation and the files processed further 
as previously described 7.   
The resulting MGF files were searched against UniProtKB human database (taxonomy 
9606, version 20140422) using Mascot 2.5.1.3 (Matrix Science) as previously described 7 
(Supplementary Table 1). For HCD fragmentation, ADP-ribosylation was defined as 
previously described by Rosenthal et al 18. For EThcD fragmentation, the modification was 
defined similarly, but marker ions at m/z 428.0372, 348.0709, 250.0940, 136.0623 were 
ignored for scoring.  For initial analysis, the files were searched with fixed 
carbamidomethylation (C), except for the search with C as a potential ADPr-acceptor where C 
carbamidomethylation was set as variable, and variable oxidation (M). ADP-ribosylation was 
set as a variable modification and 14 separate searches for each MGF file were performed to 
cover all 20 amino acid acceptors: individual searches allowed ADPr modifications to be 
localized on the 5 experimentally validated ADPr-acceptor amino acids (S, D, E, R and K) and 
on one additional amino acid. Upon completion, all search results were integrated and the 
spectra filtered based on the presence of at least two of the known ADPr marker ions31. 
Peptides were considered correctly identified when a Mascot score >20 and an 
expectation value <0.05 was obtained. Prior to manual spectra validation, we applied an ion 
score filter to reduce the spectra for manual validation to properly fragmented peptides. The 
ion score was based on observed peptide fragment ions in the b, y, c and z ion series 
normalized to the maximum number of observable theoretical ions. We manually curated 
ADPr peptide spectra with an ion score > 0.5. 
Using this filter, we identified 448 unique spectra in which the ADPr-localization was 
validated manually.  Following manual validation, the files were searched again using Mascot 
with fixed carbamidomethylation (C), variable oxidation (M) and variable ADP-ribosylation on 
S, D, E, R, K and Y (SDERKY) or S, R and Y (SRY). All ADPr-site localizations mentioned in 
the text had Mascot localization scores >60%, unless otherwise stated.   
 
Label-free Quantification MS Analysis of shControl, shARTD1 and shARTD2 ADP-
ribosylomes 
Progenesis QI software (v. 3.0.6039.34628, Nonlinear Dynamics, Purham, NC) was 
used for MS1 precursor-based label-free quantification of the shControl, shARTD1 and 
shARTD2 ADP-ribosylomes.  For these analyses, the raw data were imported into Progenesis 
and aligned based on MS1 peak retention time.  Sample loading variations were normalized 
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based on total signal intensity and the results obtained exported as MGFs.  These MGFs 
were then searched for variable ADPr modifications (SDERKY and SRY) using Mascot as 
described above. The Mascot search results were then imported into Scaffold software 
(v.4.7.2) and filtered for protein and peptide False Discovery Rates (FDRs) ≤0.01. When 
multiple charge-state precursors were sequenced for the same peptide, total peptide amounts 
were calculated by summing individual charge-state values. To most confidently localized 
ADPr-sites within the identified ADPr-peptides, the HCD ADPr-peptides were compared to the 
EThcD ADPr-peptides identified in the Bilan et al. dataset presented above. All identified 
ADPr-peptides were included in this analysis, but only ADPr-peptides for which we had 
corresponding high quality EThcD fragmentation spectra were assigned a modification site. 
Volcano plot analysis of the quantified ADPr-peptides and their non-modified counterparts 
was performed using two-sample testing in Perseus, with permutation-based FDRs of 5% and 
minimal fold change of 2 32. Gene ontology analysis was performed using the PANTHER data 
base 33. 
 
Cloning and protein purification 
Human HPF1 (pET21a), human RPS3A-WT (pGEX6P-3) and human RPS3A-Y155F 
(pGEX-6P3) bacterial expression vectors were constructed by Genscript (Piscataway, NJ, 
USA). HPF1 mutants were generated via PCR-based site-directed mutagenesis using the 
following oligonucleotides: HPF1-Y238F sense 5’-GATGTTGGGTTCCGAGAGCTCCCTG-3’; 
HPF1-Y238F antisense 5’-CAGGGAGCTCTCGGAACCCAACATC-3’; HFP1-R239A sense 5’-
GATGTTGGGTACGCAGAGCTCCCTG-3’; HPF1-R239A antisense 5’-
CAGGGAGCTCTGCGTACCCAACATC-3’; HPF1-Y238F/R239A sense 5’- 
GATGTTGGGTTCGCAGAGCTCCCTG-3’; HPF1-Y238F/R239A antisense 5’- 
CAGGGAGCTCTGCGAACCCAACATC-3’. Sequencing of plasmids was performed at 
Microsynth.  Plasmids were transformed into BL21 E. coli, and protein expression induced by 
adding 1 mM IPTG at OD600 0.4-0.6 for 3 h at 30 °C. Batch purification of GST-tagged or His-
tagged proteins were carried out using glutathione sepharose 4B beads (GE Healthcare) or 
ProBond™ Nickel-Chelating Resin (ThermoFisher Scientific) according to the manufacturer’s 
manual. Expression and purification of all recombinant proteins was analyzed by sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) followed by Coomassie 
staining. 
 
In vitro ADP-ribosylation assay with recombinant proteins 
In vitro ADP-ribosylation assays were performed based on previously described methods 
5,17. Briefly, recombinant RPS3A (50pmol) and HPF1 (50pmol) proteins were mixed as 
indicated with ARTD1 (2.5pmol; Trevigen, Gaithersburg, MD, USA) in 1x PARP1 buffer 
(Trevigen). Activated DNA (Trevigen) and [32P]NAD+ (6.25µM, 0.3µCi/µl; Perkin Elmer) were 
then added to the reactions at final concentrations of 40ng/µL and 100nM, respectively. 
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Reactions were incubated at 25ºC for 20 min.  Reactions were stopped via addition of SDS-
PAGE sample buffer to 1x final concentration and heat denaturation at 95ºC for 10min. The 
reaction volume for all in vitro ADP-ribosylation assays was 25µL.  Samples were resolved by 
SDS-PAGE and analyzed by autoradiography. 
 
ARTD1/HPF1 in vitro binding assays 
Rabbit !-human-PARP1 polyclonal rabbit antibodies (in-house), obtained from rabbits 
immunized with human ARTD1 expressed and purified as previously described34 were 
immobilized on protein A Sepharose 4 Fast Flow resin (GE Healthcare Life Sciences, 
Glattbrugg, Switzerland) following the manufacturer’s instructions.  The resulting !-hPARP1-
pA beads were stored at 4ºC in in vitro binding buffer (IVB; 20mM Sodium Phosphate pH8.0, 
50mM NaCl, 2mM "-Mercaptoethanol, 0.1% NP-40) with 0.01% sodium azide. 
For the in vitro binding experiments, 10µg (200pmol) of each HIS-tagged HPF1-WT, 
HPF1-Y238F, HPF1-R239A and HPF1-Y238F/R239A fusion protein was incubated either 
alone or with 1.15µg (10pmol) ARTD1 (Trevigen) in 1x PARP1 buffer (Trevigen) in the 
presence or absence of 5µM NAD+ and 200nM of double-stranded 40 bp DNA 
oligonucleotides (40mer; 5'-TGCGACAACGATGAGATTGCCACTACTTGAACCAGTGCGG-
3') for 20 min at 25°C. Each reaction was diluted with 1mL ice-cold IVB buffer and incubated 
with !-hPARP1-pA beads overnight at 4ºC. The beads were collected by centrifugation and 
the unbound proteins removed. The beads were then washed three times with IVB buffer for 
10 min at 4ºC with end-over-end rotation and the bound proteins were eluted with 1x SDS-
PAGE sample buffer. All samples were heat denatured at 75ºC for 20min and resolved in 
10% SDS-PAGE gels. HPF1 protein isoforms were visualized by Coomassie Blue staining 
and ARTD1 was detected via western blot analysis with an !-ARTD1 antibody.  
 
Western Blot Analysis  
For Western blot analyses, protein samples were resolved using standard SDS-PAGE 
methods and transferred to nitrocellulose membranes (Merck Millipore). Membranes were 
then blocked for 3hrs at room temperature with blocking buffer (25 mM Tris-HCl pH 7.5, 150 
mM NaCl, 0.1% Tween 20 and 3% bovine serum albumin) and probed overnight with primary 
antibodies, diluted in blocking buffer, at 4ºC. Membranes were then washed with TBS-T (25 
mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1% Tween-20) and incubated at room temperature for 
with IR-Dye-conjugated secondary antibodies (1:15’000, LI-COR). Blots were visualized using 
the Odyssey infrared imaging system (LI-COR). Dilutions used for the primary antibodies 
were: 1:1000 !-ARTD1 (H-250 sc-7150, Santa Cruz); 1:1000 !-ARTD2 (Active motif); 1:1000 
!-PAR 10H (in house).  
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Manual inspection of MS spectra  
Candidate spectra were visualized using lorikeet, a JavaScript-based viewer35. Using a 
custom python script, one HTML-document was created per candidate peptide, and each 
peptide page display all collected spectra (regardless of the source file) in a vertically stacked 
fashion to allow for fast comparison. 
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SUPPLEMETARY INFORMATION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S1: HCD spectra ADPr-site localizations change considerably as the Mascot searches 
were refined. a. ADPr-site localization results from the initial (20aa) searches and refined 
searches were compared.  The flow chart depicts how ADPr-acceptor amino acid 
localizations changed for the 107 HCD ADPr-localization training spectra as the variable 
ADPr search parameters were refined. b. Comparison of total number of unique ADP-
ribosylated peptides and unique ADPr-sites identified (Mascot localization probability >60%) 
from HCD spectra in the SDERKY and SRY searches.  
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Figure S2: Analysis of shControl, shARTD1 and ARTD2 knockdown HeLa cells. a. !-ARTD1, 
!-ARTD2 and !-PAR western blot analysis of untreated and H2O2 treated shControl, 
shARTD1 and shARTD2 HeLa cell lysates confirms specific knockdown of ARTD1 or ARTD2 
and specific inhibition of H2O2-induced PAR following loss-of ARTD1. b. Number of ADPr-
PSMs identified in untreated and H2O2 treated HeLa cells following ARTD1 or ARTD2 
knockdown.  c. Heat map of spearman’s rank correlation coefficient and multi-scatter plots 
showing reproducibility between cell line ADP-ribosylome identifications. d. Heat map of 
unsupervised clustering of the z-score of ADPr site abundance in the different cell lines. 
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Figure S3: Comparison of SRY and SDERKY ADPr searches following ARTD1 and ARTD2 
knockdown reveals that ARTD1 is the writer of cellular Ser-ADPr and Try-ADPr modifications. 
a. Venn diagram depicts the overlap of total number of unique ADPr-peptides identified by 
Mascot-based searches that considered S, R and Y or S, D, E, R, K, and Y as variable ADPr-
acceptor amino acids following H2O2 treatment. Note that ADPr-site localization within the 
peptide was ignored for this analysis. b. Total number of ADPr-modified peptide spectrum 
matches (PSMs) identified in untreated or H2O2-treated shControl, shARTD1 and shARTD2 
cells by SRY and SDERKY variable ADPr Mascot searches. c-d. Total number of ADPr-sites 
localized (Mascot localization score > 60%) in the SDERKY (c) and SRY (d) searches. 
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Figure S4: Spectral evidence supporting HPF1-Y238 ADP-ribosylation. High-resolution 
EThcD fragmentation spectrum of an HPF1 peptide modified with ADP-ribose on Y238. 
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Figure S5:  ARTD1/HPF1 protein-protein interactions are dependent on ADP-ribosylation. 
ARTD1/HPF1 in vitro binding assays were carried out with unmodified or ADP-ribosylated 
recombinant ARTD1 and HPF1-WT (a.), HPF1-Y238F (b.), HPF1-R238A (c.) or HPF1-
Y238F/R239A (d.) using !-ARTD1-pA-speharose resin. Samples were resolved by SDS-
PAGE and stained with Coomassie Blue. I = input (5%); B = bead-bound (25%) 
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Figure S6 Relative quantification of in vitro ADP-ribosylation of ARTD1, HPF1 and RPS3A. 
The absolute amounts of in vitro ADP-ribosylation (radioactive signal) observed in Figure 4 for 
ARTD1, RPS3A protein isoforms and HFP1 protein isoforms were quantified.  Relative 
quantification of ARTD1 modification was achieved by quantifying the modifications observed 
(radioactive signal) in the presence of trans-ADPr target proteins (HPF1 and/or RPS3A) 
relative to that observed with 32P-NAD+ and activated DNA alone (considered baseline 
modification; Figure 4a). Relative quantification of RPS3A-WT and RPS3A-Y155F 
modifications was achieved by quantifying the modifications observed in the presence of 
HPF1 recombinant protein isoforms relative to that observed for RPS3A-WT with ARTD1, 32P-
NAD+, and activated DNA alone (Figure 4b). Relative quantification of HFP1 protein isoform 
modifications was achieved by quantifying the modifications observed with variants of HPF1 
and RPS3A relative to that observed for HFP1-WT with ARTD1, 32P-NAD+, and activated 
DNA (n=2). Error bars depict standard deviations of the mean. 
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Supplementary Table 1:  Description of Mascot variable-ADPr search parameter settings. 
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Supplementary Table 2:  Summary of number of ADPr-site localizations returned by each of 
the Mascot searches performed. 
 
 
 
 
 
 
 
Supplementary Table 3:  Peptide information and ADPr-site localization summaries for 
ADPr-site localization training library spectra. 
 
SupTable3.xlsx 
 
Supplementary Table 4:  Full protein, peptide and ADPr-site localization information for 
SDERKY and SRY search results. 
 
SupTable4.xlsx 
Supplementary Table 5:  List of ADPr-peptides identified in untreated and H2O2-treated 
shControl, shARTD1 and shARTD2 cell-lines. 
 
SupTable 5.xlsx 
Supplementary Table 6:  Serine ADP-ribosylated proteins that share Phospho Acceptor 
sites. 
 
SupTable 6.xlsx 
 
ADPr-site Localization Spectra Database (ADPr-LSD)  
 
The spectra provided here can be visualized by opening the spectra.html file in a web 
browser. 
 
ADPr-LSD.zip 
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Abstract 
ADP-ribosylation is a posttranslational modification that exists in monomeric and polymeric forms. 
Whereas the writers (e.g. ARTD1/PARP1) and erasers (e.g. PARG, ARH3) of poly-ADP-ribosylation 
(PARylation) are relatively well described, the enzymes involved in mono-ADP-ribosylation 
(MARylation) have been less well investigated. While erasers for the MARylation of 
glutamate/aspartate and arginine have been identified, the respective enzymes with specificity for 
serine are still missing. Here, we report that in vitro, ARH3 specifically binds and demodifies proteins 
and peptides that are MARylated. Molecular modeling and site-directed mutagenesis of ARH3 
revealed that numerous residues are critical for both the mono- and the poly-ADP-ribosylhydrolase 
activity of ARH3. Notably, a mass spectrometry approach showed that ARH3-deficient MEFs are 
characterized by a specific increase in serine-ADP-ribosylation in vivo under untreated conditions as 
well as following hydrogen-peroxide stress. Together, our results establish ARH3 as a serine mono-
ADP-ribosylhydrolase and as an important regulator of the basal and stress induced ADP-ribosylome. 
 
Keywords: Mono-ADP-ribosyl(-acceptor) hydrolases, serine, post-translation modification, PARG, 
ARH3, PARP, proteomics  
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Abstract 
Mammalian ecto-ADP-ribosyltransferases (ecto-ARTs or also ARTCs) catalyze the ADP-ribosylation 
of cell surface proteins using extracellular nicotinamide adenine dinucleotide (NAD+) as substrate. By 
this post-translational protein modification, ecto-ARTs modulate the function of various target 
proteins. A functional role of ARTC2 has been demonstrated for peripheral immune cells such as T 
cells and macrophages. Yet, little is known about the role of ecto-ARTs in the central nervous system 
and on microglia. Here, we identified ARTC2.1 as the major ecto-ART expressed on murine 
microglia. ARTC2.1 expression was strongly upregulated on microglia upon co-stimulation with LPS 
and an ERK1/2 inhibitor or upon IFNβ stimulation. We identified several target proteins modified by 
ARTC2.1 on microglia with a recently developed mass spectrometry approach, including two 
receptors for immunoglobulin G (IgG), FcγR1 and FcγR2B. Both proteins were verified as targets of 
ARTC2.1 in vitro using a radiolabeling assay with 32P-NAD+ as substrate. Moreover, ADP-
ribosylation of both targets strongly inhibited their capacity to bind IgG. In concordance, ARTC2.1 
induction in WT microglia and subsequent cell surface ADP-ribosylation, significantly reduced the 
phagocytosis of IgG-coated latex beads, which was unimpaired in NAD+/DTT treated microglia from 
ARTC2.1ko mice. Hence, induction of ARTC2.1 expression under inflammatory conditions, and 
subsequent ADP-ribosylation of cell surface target proteins could represent a hitherto unnoticed 
mechanism to regulate the immune response of murine microglia. 
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ABSTRACT/Summary 
 
ADP-ribosylation has thus far been studied on the proteomic level mainly in cell lines and in combination 
with genotoxic stress. The clostridium-like ADP-ribosyltransferases (i.e. ARTC) are GPI-anchored or 
secreted proteins that are expressed in a highly tissue specific manner. Transcriptomic data revealed that 
ARTC1 is expressed in skeletal muscle and heart tissue. Although ARTC1 is highly active in vitro, 
identification of ARTC1 targets in vivo and subsequent characterization of ARTC1-regulated cellular 
processes on the proteome level has been challenging and only a few ADP-ribosylated targets are known. 
Using a new MS-based workflow, we provide the thus far most extensive identification of endogenous 
ADP-ribosylomes with hundreds of ARTC1-ADP-ribosylated proteins in C2C12 myotubes and in skeletal 
muscle and heart tissues from wild type and newly generated ARTC1 knockout mice. These proteins are 
ADP-ribosylated on arginine residues and mainly located on the cell surface or in the extracellular space. 
They are associated with signal transduction, transmembrane transport and muscle function. Validation of 
hemopexin (HPX) as a newly identified ARTC1-target protein confirmed the functional importance and 
prevalence of ARTC1-mediated extracellular arginine ADP-ribosylation on the organism level. Together 
we provide the first comprehensive systems-level analysis of endogenous ADP-ribosylation in two 
different muscle tissues revealing a widespread function of ARTC1 and its targets. 
 
 
 
 
Key words: ADP-ribosylation, proteomics, mass spectrometry, ARTC1, Arg, muscle, heart, hemopexin 
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INTRODUCTION 
  
Protein ADP-ribosylation is an ancient post-translational modification (PTM) found in a wide range of 
species1-3. Protein ADP-ribosylation has been shown to regulate several cellular processes by altering the 
function of the modified protein and/or providing a scaffold for the recruitment of other proteins. ADP-
ribosylation is a complex PTM that can be divided into two subtypes: mono-ADP-ribosylation 
(MARylation), in which only a single ADP-ribose (ADPr) is transferred to an amino acid of a target 
protein, and poly-ADP-ribosylation (PARylation), which involves the addition of further ADP-ribose 
moieties to generate poly-ADP-ribose (PAR)4. These modifications are enzymatically mediated by ADP-
ribosyltransferases (ARTs). In mammalians, ARTs are divided into the two families of ARTC (C2/C3 
toxin-like, also ecto-ARTs) and ARTD (diphtheria toxin-like, formerly PARPs) enzymes5. While all 
known enzymes catalyzing PARylation belong to the ARTD family, and MARylation has traditionally 
been the domain of the ARTC transferases, it has recently been appreciated that some ARTDs and even 
some family members of the structurally unrelated sirtuin family can also mediate MARylation6. 
 Four human (ARTC1, 3, 4, 5, formerly also hART1-5) and six mouse (ARTC1, 2.1, 2.2, 3, 4, 5, 
formerly also mART1-5) ARTC genes have been identified. For both species, ARTC1 is expressed mainly 
in skeletal and heart muscles, non-lactated mammary gland, brown adipocytes, epithelial cells or activated 
granulocytes7-9. The human and mouse ARTC family members, ARTC1-ARTC4, are expressed as GPI-
anchored ecto-enzymes5,7,8,10. ARTC1, comparable to 2 and 5 contain the characteristic cholera toxin R-S-
E catalytic motif in their active center. R and S are important for NAD+ binding and E has a catalytic 
function11. Arginine-specific mono-ADP-ribosylation activity has been confirmed for human and mouse 
ARTC1, the two mouse isoforms of ARTC2 and for human and mouse ARTC58.  
 An important question when examining the biological function of ARTCs is the endogenous 
source of extracellular NAD+ under normal and pathophysiological conditions, since NAD+ is not cell 
membrane permeable. The concentration of extracellular NAD+ in serum has been reported to range from 
0.1 to 0.3  µM, while intracellular NAD+ concentrations are much higher (400–500 µM)12. Moreover, 
plasma NAD+ concentrations are approximately five-fold lower than that required in vitro to observe 
ARTC2.2-mediated ADP-ribosylation events13,14. Several studies have, however, demonstrated that NAD+ 
can be released from intracellular sources during lytic processes like tissue damage and necrosis14-16. 
Furthermore, it is thought that NAD+ and other nucleotides are released by controlled mechanisms during 
hypoxia and inflammation17,18. In line with this, acute inflammation was reported to be associated with the 
liberation of significant amounts of NAD+ (1–10  µM range) into the extracellular milieu17. Moreover, 
extracellular NAD+ has a longer half-life compared to ATP (15 min vs. only a few seconds in 
plasma)15,19,20. Hence, upon its release into the extracellular space at sites of inflammation or following 
cell injury, extracellular NAD+ can either be used by ARTCs to covalently modify specific ADP-
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ribosylation target proteins or be degraded into smaller metabolites. Hence, the net biological effect of 
extracellular NAD+ depends on the amount of NAD+ released into the extracellular space, the quality and 
quantity of specific receptors/enzymes expressed by surrounding cells, and on the activities of the 
catabolising-enzymes14,21. Such a balance between local production of a signalling molecule that is 
normally absent from the extracellular space and its rapid degradation/consumption is characteristic of the 
class of molecules that mediates ‘‘danger signals’’ and that can alert immune cells22.  
 Functional consequences of eukaryotic arginine ADP-ribosylation have mainly been studied for 
ARTC2.2 targets. One of the ARTC2.2 targets on T cells is the P2X7 ion channel. MARylation of R125 
of P2X7 leads to its activation, which induces the influx of Ca2+ and Na+ as well as the efflux of K+23. 
Downstream effects of P2X7 activation include inflammasome activation, processing and cytokine release 
(IL-1β, IL-18, IL-1 receptor antagonist and IL-36α), release and activation of proteases (mainly ADAM10 
and 17) resulting in the shedding of cell-surface molecules, including ARTC2.2 itself 24,25. Prolonged 
activation of P2X7 stimulates T cell death, also called NAD+-induced cell death (NICD)17. ARTC1 was 
found in bronchoalveolar lavage fluid from smokers. Here, it modifies the defensin human neutrophil 
peptide 1 (HNP1) on Arg14 and Arg24, which specifically reduces its antimicrobial and cytotoxic 
activities26,27. ARTC1 ADP-ribosylation was also found to have a role in endoplasmic reticulum stress 
responses28. In addition, ARTC1 ADP-ribosylates members of the integrin family of adhesion molecules 
on skeletal muscle cells and leukocytes29. ADP-ribosylation of integrin α7 (ITGA7) by ARTC1 modulates 
the binding of integrin α7β1 to laminin30. It is proposed that an arginine residue located in the central 
region of ITGA7 is involved in the interaction with a negative region of ITGB1 and, at low NAD+ 
concentrations (10 µM), this arginine is ADP-ribosylated to repel ITGB1 and induce the formation of a 
high affinity conformer. In contrast, increasing NAD+ concentrations (100 µM) lead to ADP-ribosylation 
of additional site(s) located in the headpiece of ITGA7, where the ligand-binding site is located, that 
sterically hinder and directly inhibit ligand binding31. However, it is not clear if ARTC1 has other 
functions and targets on myotubes. Furthermore, it is also not known if ARTC1 mediated ADP-
ribosylation has any role under steady-state conditions. 
 Despite these recent discoveries, the substrates of the different ARTCs as well as their 
implications in cellular processes are still not very well understood. This is in large due to the fact that 
mass spectrometry (MS) based methods were only developed for and applied to the identification of ADP-
ribosylated proteins and their ADP-ribose acceptor site in cultured cells. Very recently we developed an 
approach that allowed the analysis of ADP-ribosylated proteins in the liver, a tissue that has already been 
described to regulate cellular processes in an ADP-ribosylation-dependent manner32. This characterization 
identified 901 modified peptides with unique ADP-ribosylation acceptor sites32-35. The majority (86%) of 
the identified ADP-ribosylation acceptor sites in the mouse liver were Arg residues and associated with 
plasma membrane or cytoplasmic proteins. Interestingly, ARTC2.2 was found among the modified 
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targets. Moreover, we have shown that the GPI-anchored ARTC2.2 is restricted to a small subset of target 
proteins by virtue of its association with lipid rafts, but promiscuously modifies many different targets 
upon detergent solubilization of the plasma membrane11,36. It remained so far unclear whether ARTC1 has 
a comparable target spectrum, or whether it would only modify a few specific target proteins, as it has 
been observed for the bacterial ART toxins. 
 Here, we analyzed the ARTC1-specific ADP-ribosylome in C2C12 myotubes as well as skeletal 
and heart muscle of wildtype and ARTC1-deficient mice, which were generated to facilitate systems-level 
analyses. These studies revealed that ARTC1 is essential for the modification of numerous membrane 
proteins under basal conditions, which provides strong evidence for the physiological importance of 
ARTC1. In particular, we confirm that ARTC1-dependent ADP-ribosylation of hemopexin (HPX) on 
Arg218 strongly reduces its capacity to bind heme, which is likely highly relevant for the function of this 
strongest known heme binding protein. 
 Together we provide the first comprehensive systems-level analysis of ARTC1-mediated ADP-
ribosylation in two different muscle tissues. The identification of the site-specific profile of the ARTC1 
dependent ADP-ribosylome provides evidence for a widespread contribution of ADP-ribosylation on the 
cell surface and the extracellular space and provides an extensive resource that allows to further discover 
the functional relevance of ADP-ribosylation in muscle physiology and pathophysiology.  
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RESULTS 
 
ARTC1 mediates widespread extracellular ADP-ribosylation in C2C12 myotubes 
 To assess the extent of ARTC1-mediated ADP-ribosylation and to identify ADP-ribosylated 
proteins, we first verified the expression of ARTC1 in differentiating C2C12 by quantitative reverse 
transcription PCR (RT-qPCR) and could confirm previous reports29 showing that ARTC1 is specifically 
expressed in mouse heart tissue and fully differentiated C2C12 myotubes (Suppl. Figure 1A). The other 
active membrane-bound extracellular ART expressed in mice is ARTC237. We were, however, unable to 
detect ARTC2 in C2C12 by RT-qPCR (data not shown), which is in agreement with the reports that 
ARTC2 is predominantly expressed in immune cells8,38. Hence, ARTC1 is likely the only active 
ectopically expressed ADP-ribosyltransferase in differentiated C2C12 myotubes.  
 To investigate whether ARTC1 is enzymatically active in C2C12 myotubes and to assess its target 
space, we treated in vitro differentiated C2C12 myotubes with NAD+ and subsequently mapped site 
specific ADP-ribosylation using our established ADP-ribosylome proteomic workflow32,39. While only a 
few peptides were identified under basal (i.e. untreated) conditions, we identified a strong increase in 
ADP-ribosylation sites following NAD+ treatment (144 vs. 9 unique ADP-ribosylated peptides (Figure 
1A); 84 vs. 8 ADP-ribosylated proteins (Suppl. Figure 1B) corresponding to 120 ± 47 vs 9 ± 1 ADP-
ribosylated peptide spectra matches (Suppl. Figure 1C). Under these conditions, arginine was identified 
as the main ADPr-acceptor amino acid (Figure 1B). Gene ontology analyses revealed that the NAD+-
treatment dependent ADP-ribosylation targets are predominantly extracellular and plasma membrane 
proteins having a molecular function in extracellular matrix binding and receptor activity and participating 
in biological processes associated with cell adhesion, muscle contraction and regulation of signal 
transduction (Figure 1C).  
 To quantitatively assess the observed increase of ADP-ribosylation, we performed label-free MS1 
based quantification of all identified ADP-ribosylated peptides using three biological replicates of 
untreated and NAD+-treated C2C12 myotubes. A good Pearson correlation among untreated (R>0.76) and 
NAD+-treated (R>0.87) replicates, respectively, demonstrated that the measured ADP-ribosylated peptide 
signal intensities could be used as a reliable measure for modification site abundance (Suppl. Figure 1D). 
Most detected ADP-ribosylated targets were strongly induced upon NAD+ treatment and, importantly, are 
novel ARTC1 targets (Figure 1D and Suppl. Table 1). The heat map representation of the ADP-
ribosylation site abundance reveals three minor clusters of sites that were already ADP-ribosylated under 
basal conditions (Figure 1D). From the indicated clusters, the ADP-ribosylated peptides of the top and 
lower cluster were more abundantly modified after NAD+ treatment, and included four members of the 
integrin family (ITGA7, ITGA6, ITGAV and ITGB5) (Figure 1D), with ITGA7 representing the only 
previously reported ARTC1 target29. A small portion of the ADP-ribosylation sites identified remained 
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largely unchanged following NAD+ treatment as visualized in the middle cluster. This cluster included 
histone H2B, which however is unlikely a target of ARTC1, since the two proteins are not in the same 
cellular compartment32,40. Interestingly, most of the proteins of this small middle cluster (approx. 80%) 
were annotated to be localized to the endomembrane system, and thus likely not affected by addition of 
exogenous NAD+. 
To understand if whole protein complexes are targeted by ADP-ribosylation we mapped and 
visualized high confidence interactions (minimum required interaction scores >0.7) between the ADP-
ribosylated proteins identified above using the STRING database of physical and functional protein 
interactions41. The analysis identified several ADP-ribosylated protein complexes, but revealed no 
significant enrichment of fully ADP-ribosylated protein complexes. We could unravel an interaction 
network of 13 ADP-ribosylated proteins with a high enrichment in extracellular matrix (ECM)-receptor 
interactions, suggesting that ADP-ribosylation of this ECM interaction complex might specifically 
modulate the function of protein complexes involved in cell adhesion and ECM-receptor signaling 
(Figure 1E). The other interacting protein groups that were identified function in cell-cell adhesion, 
calcium ion trans membrane transport and vesicular transport (Figure 1E). In summary, these data show 
that ARTC1 is expressed in differentiated muscle cells and demonstrated that these cells exhibit NAD+-
inducible ADP-ribosylation responses that mainly affect plasma membrane and/or extracellular proteins. 
 
ARTC1 knockout animals are viable and develop normally, but show reduced skeletal muscle ADP-
ribosylation 
 To ascertain whether ARTC1 is the predominant in vivo writer of the ADP-ribosylome in muscle 
cells, we generated ARTC1-deficient (Artc1-/-) mice. This was achieved via insertion of loxP sites into the 
Artc1 gene (Suppl. Figure 2A-D), transgene-positive offspring were mated with a deleter strain, which 
resulted in the generation of Artc1-/- knockout animals. Artc1 gene deletion was confirmed by PCR and 
Western blotting of a glycoprotein-enriched muscle extract (Suppl. Figure 2E, Figure 2A). Artc1-/- mice 
were fertile and did not show any overt phenotype. The overall body constitution as judged by body 
weight did not seem to be overtly impaired (Figure 2B). We did observe a slight reduction in circadian 
movement, which could be due to muscle weakness (Figure 2C). Consistently, Artc1-/- mice showed signs 
of muscle weakness in an accelerated Rotarod test (Figure 2D), suggesting that the lack of ARTC1 affects 
the skeletal or heart muscle function. Next, we wanted to confirm the importance of ARTC1 for muscle 
cell ADP-ribosylation. To this end, primary myoblasts from WT and Artc1-/- mice were differentiated in 
vitro and treated with radioactively labeled NAD+. Autoradiograms showed complete absence of surface 
protein ADP-ribosylation in Artc1-/- myoblasts, while WT and heterozygous animals displayed an Artc1 
gene dose dependent ADP-ribosylation signal (Figure 2E). Furthermore, the dominant band at 120 kD, 
presumably corresponding to integrin alpha 7, is undetectable in the Artc1-/- samples (Figure 2D). 
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Together, these results confirm that ARTC1 is essential in differentiated muscle cells for ADP-
ribosylation of cell surface proteins and hint at a functional in vivo relevance for ARTC1-mediated ADP-
ribosylation in skeletal and heart muscle.  
 
ARTC1 is essential for the skeletal muscle ADP-ribosylation in vivo 
 Having established the Artc1-/- mice, we aimed to define the in vivo ARTC1-dependent ADP-
ribosylome of murine skeletal muscle. Total skeletal muscle protein extracts were prepared in a denaturing 
Guanidine-HCl lysis buffer from unstressed WT and Artc1-/- mice, the ADP-ribosylated fraction enriched 
and subsequently analyzed by MS as described earlier32. Importantly, these animals were perfused with 
the ARTC inhibitor novobiocin prior to muscle extraction to inhibit stress-induced ADP-ribosylation. MS 
analyses identified a very large basal ADP-ribosylome that consisted of 1295 unique ADP-ribosylated 
peptides (Figure 3A, Suppl. Table 2). Good correlations were observed between biological replicates 
(Suppl. Figure 2F). Moreover, a >20-fold reduction in the number of unique ADPr-peptides in Artc1-/- 
muscle tissues was observed, strongly indicating that ARTC1 is the main writer of skeletal muscle ADP-
ribosylation under endogenous conditions (Figure 3A). The importance of ARTC1 for the muscle ADP-
ribosylome was further validated by ADPr-acceptor site specificity analyses. As expected for ARTC1 
targets42, the vast majority of the ADPr-acceptor sites identified in wild-type tissues were Arg residues, 
which were almost completely absent in the corresponding Artc1-/- samples (Figure 3B). In fact, the 
remaining ADP-ribosylated proteins observed in Artc1-/- muscles were modified on Ser, Lys, Glu or Asp 
residues. Over 70% of the ADP-ribosylated proteins in wild-type muscle tissues carried only a single 
modification (Figure 3C), which suggests that ARTC1-dependent ADP-ribosylation is a tightly controlled 
and very specific process. These findings were further substantiated by gene ontology analyses, which 
demonstrated that the identified ADP-ribosylated proteins almost exclusively localized to the 
extracellular/membrane and/or mitochondrial compartments and function in transmembrane transport, 
calcium signaling and/or ATP metabolic processes (Figure 3D). ADP-ribosylated proteins from Artc1-/- 
muscle only showed a significant enrichment in mitochondrial proteins having a role in ATP-metabolic 
processes.  
 Together these experiments provide evidence that ARTC1 modifies a defined set of proteins 
already under unstressed conditions and that the observed skeletal muscle ADP-ribosylome is rather 
stable. When comparing the ADP-ribosylomes of WT skeletal muscle and C2C12 myotubes, we found 
that around 15% of the ADP-ribosylated proteins identified in NAD+-treated C2C12 myotubes were also 
modified in the skeletal muscle (Suppl. Figure 2G).  
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The ARTC1-dependent heart and skeletal muscle ADP-ribosylomes differ  
 To investigate whether ARTC1 activity or the obtained skeletal muscle ADP-ribosylome is 
specific to this tissue or shares similarities with heart tissue, proteome analyses were performed on mouse 
hearts from WT and Artc1-/- mice. Compared to the skeletal muscle, less ADP-ribosylation sites were 
identified in wild-type hearts under basal conditions, however Arg was still the most abundant ADP-
ribosylation site and was strongly reduced in the corresponding Artc1-/- tissues (Figure 4A, Suppl. Figure 
3A, Suppl. Table 3). Around 85% of the observed ADP-ribosylation sites were dependent on ARTC1 
(Figure 4A). The performed MS analyses were reproducible with 70% and 60% of the ADP-ribosylated 
proteins identified in at least two biological replicates for the WT and the Artc1-/- tissue samples 
respectively (Suppl. Figure 3B). The variation in the measurement of non-ARTC1 mediated targets was 
significantly bigger than of ARTC1 targets. Closer analyses of the ADP-ribosylation sites revealed 
preferential modification of Arg residues in wild-type heart tissues only, while Ser, Lys, Glu or Asp 
residues were the only sites identified in Artc1-/- hearts (Figure 4B). Similar to what was observed in 
skeletal muscle (Figure 3C), approximately 70% of the modified proteins that were identified in mouse 
hearts were ADP-ribosylated at only one site (Figure 4C).  
 To characterize the mouse heart ADP-ribosylome in more detail, the ADP-ribosylome data were 
subjected to gene-ontology analysis, which produced a pattern of term enrichment similar to what was 
observed for skeletal muscle. WT heart samples were enriched for proteins that localize to the plasma 
membrane and/or extracellular space, function in receptor binding and/or transporter activity and are 
involved in the regulation of muscle contraction and apoptotic processes. In contrast, these terms were 
absent from the ADP-ribosylomes identified in the Artc1-/- samples, which only showed enrichment for 
mitochondrial proteins and proteins involved in the TCA cycle and ATP synthesis (Figure 4D). This 
suggests that ARTC1 most probably manifests its functionality by ADP-ribosylation of a broad array of 
membrane associated protein targets. To analyze whether specific protein complexes would be ADP-
ribosylated and whether the modified proteins functionally co-regulate certain cellular processes, STRING 
analyses based protein-protein interactions were carried out for ADP-ribosylated proteins identified either 
exclusively in WT (Figure 4E) or Artc1-/- animals (i.e. ARTC1-independent targets, Suppl. Figure 3C). 
Nine high confident ADP-ribosylated protein interaction networks were identified exclusively in the WT 
heart muscle samples (Figure 4E). These interaction networks mostly contained extracellular and plasma 
membrane proteins that are involved in stress responses. Similar to the C2C12 cells, we found an 
interaction network of ADP-ribosylated proteins that mediates ECM-receptor interactions, but also 
identified heart specific functional interaction networks. Interestingly we identified an ADP-ribosylated 
protein network that plays a role in oxidative phosphorylation and is situated in the mitochondria, however 
these proteins were not modified at Arg and therefore unlikely ARTC1 targets. In fact, this network fits 
better to the pattern observed in the Artc1-/- animals. There we identified three ARTC1 independent ADP-
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ribosylated protein networks for mostly mitochondrial and some cytosolic proteins that function in 
oxidative phosphorylation, TCA cycle and fatty acid degradation (Suppl. Figure 3C).  
 Despite the fact that we started our analysis with the same amount of tissue (i.e. heart and skeletal 
muscle tissue) and we observed quite a large overlap (60%) of ADP-ribosylated proteins identified in the 
heart compared to the skeletal muscle tissues (compare Figure 3A to Figure 4A and Suppl. Figure 3D), 
4 times more ADP-ribosylated proteins were identified in skeletal compared to heart muscle tissues. To 
test our sample-handling regime that was focused on eliminating ADP-ribosylation reactions due to 
sample preparation, we tested lysis of the tissue under different conditions (Suppl. Figure 3E). The lysis 
was performed either with a modified RIPA buffer43 or a denaturing 6M guanidine-HCl buffer44 in 
combination with Novobiocin perfusion, as already performed previously with the skeletal muscle 
samples. In addition, animals were pretreated with Novobiocin (intra venous (i.v.), 30 min, before 
sacrifice). MS-analysis of these three samples revealed that guanidine-HCl lysis buffer prevented lysis-
induced ADP-ribosylation since pretreatment with Novobiocin (i.v.) did not reduce the observed amount 
of modification. On the other hand, modified RIPA buffer alone was not able to prevent lysis-induced 
ADP-ribosylation, which resulted in an increased number of ADP-ribosylation identifications, consistent 
with our previous findings for ARTC2.236 (Supp. Figure 3E).  
 The reduced ADP-ribosylation in the heart could also be due to different plasma membrane 
compositions (i.e. affecting ARTC1 complex formation) in heart and muscle, which might affect ARTC1 
activity and affinity to NAD+ or due to overall less NAD+ in the heart tissue. To test whether the lower 
amount of ADP-ribosylation is due to lack of substrate in healthy unstressed mouse hearts, animals were 
pretreated with NAD+ (i.v.) 30 min before sacrifice, the hearts were harvested and ADP-ribosylome MS 
analysis performed. Injection of NAD+ did not increase the overall number of identified unique ADP-
ribosylated peptides significantly, neither in WT nor in Artc1-/- background (Suppl. Figure 4A). 
Moreover, NAD+ pretreatment did neither alter the ADPr acceptor site profile nor the number of unique 
ADPr acceptor sites significantly (Suppl. Figure 4B). To strengthen this aspect, we aimed at detecting 
potential quantitative changes after NAD+-treatment by applying a label free MS1 quantification 
approach. Replicate comparison of ADP-ribosylated peptide intensities revealed a very strong Pearson 
correlation among the triplicates of untreated and NAD+ treated WT tissue (>0.92) and a lower but 
acceptable correlation among the Artc1-/- replicates (>0.73), respectively (Suppl. Figure 4C). Also 
untreated versus NAD+ treated WT and Artc1-/- samples correlated well (>0.8 and >0.73) (Suppl. Figure 
4C). Principal component analyses of ADP-ribosylated peptide abundance revealed that the ADP-
ribosylomes of untreated and NAD+ pre-treated WT hearts differed and segregated in two groups, whereas 
the Artc1-/- heart samples were much more variable and the treatment did not seem to induce distinct 
changes in ADP-ribosylated peptide abundances (Figure 4F). Quantitative MS analysis of three 
independent samples confirmed that NAD+ treatment of WT mice induces only little de novo ADP-
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ribosylation but leads to quantitative changes of discrete ADP-ribosylation sites, most of them already 
present in untreated hearts (Figure 4G, Suppl. Figure 4D). Interestingly, this analysis showed that 12 
ADP-ribosylation sites were significantly more abundant after the NAD+-treatment, including integrin 
alpha 7 and hemopexin (HPX), as well as five ADP-ribosylation sites which were less abundant after the 
treatment, including on ARTC1 itself (Figure 4G). The NAD+ treatment only changed the degree of the 
ADP-ribosylation at specific sites of these proteins, however total protein level remained constant for the 
ones we could detect (Suppl. Figure 5). Integrin alpha 7, which has been shown before in vitro to be a 
target of ARTC1 shows the most significantly induced ADP-ribosylation (on Arg896 and Arg608) after 
NAD+ treatment, which is in line with our results from NAD+ treated C2C12 cells. Also, integrin alpha 7 
interacting extracellular matrix proteins LAMB2 showed a significant increase of ADP-ribosylation at two 
sites (Arg103 and Arg1458). Moreover, a significantly increased proportion of ADP-ribosylation on the 
two soluble extracellular proteins Hemopexin (HPX) and Fibronectin1 (FN1) could be detected upon 
NAD+ treatment (Figure 4G). In contrast, ARTC1 itself, ARTC3, GPC1, NECTIN2, CSPG4 and EFNB3, 
all of them plasma membrane proteins, were less abundantly modified after NAD+-treatment. The 
reduction in modification on these proteins could be due to shedding by metalloproteases which would 
sequester them from the membrane-bound ARTC1 25,45-48.  
 
Arginine ADP-ribosylation marker ions and motifs.  
Studies of in vitro modified peptides have suggested that ADP-ribosylated Arg residues can give rise to an 
Arg-specific ADP-ribose marker ion (ADPr-carbodiimide, Figure 5A) during MS2 fragmentation49. ADP-
ribose marker ions can be extracted from MS2 spectra without applying peptide search engines and/or 
matching the spectra to a specific peptide sequence, and have proven beneficial in the identification of 
ADP-ribosylated peptides50. Observation of ADPr-carbodiimide ions in our samples would allow an 
alternative estimation and validation of Arg-ADP-ribosylation levels. To this end, we screened MS2 
spectra from the measured heart samples using the PTM marker finder software to extract ADPr maker 
ions51. Indeed, when we looked at spectra containing at least 4 ADPr maker ions we could identify 361 
spectra containing an ADPr-carbodiimide ion (10% of spectra) in the WT samples and only 3 in Artc1-/- 
samples (0.9% of spectra) (Figure 5B). As expected ADPr-carbodiimide ions showed a lower intensity 
than the other marker ions, however in many cases they were readily identified and could be used to 
estimate the Arg-specific ADP-ribosylation levels (Figure 5C, Supplementary Figure 4E).  
 Next we attempted to identify an Arg-ADP-ribosylation consensus motif as previously identified 
for nuclear Ser-ADP-ribosylation 33,52. Analysis of 21 amino acid windows with the identified Arg-ADP-
ribosylation sites in the middle for the different samples revealed five significantly enriched motifs 
(p<0.0005, binomial test), comprising 78%, 30% and 63% of all identified Arg-ADP-ribosylation sites in 
C2C12, skeletal and heart muscle, respectively (Figure 5C). The most prominent motif identified 
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consisted of an R(-ADPR)G motif (in all sample types), followed by an RR(-ADPR) motif (in skeletal and 
heart muscle).  
 
ADP-ribosylation of hemopexin at Arg218 reduces its capacity to bind heme 
 To validate our findings, we investigated the functional relevance of HPX ADP-ribosylation on 
Arg218 in heart and skeletal muscle tissue. HPX plays a crucial role during inflammatory conditions53 and 
is the strongest known heme binder53. To confirm that HPX is a direct ARTC1 target, recombinant HPX 
was incubated with ARTC1 and radiolabeled NAD+. We found that recombinant ARTC1 modified HPX 
in vitro and that no glycation or passive attachment of NAD+ to HPX occurs (Figure 6A). ARTC1 
dependent HPX modification was sensitive to ARTC inhibitor Novobiocin and slightly decreased in the 
presence of heme (Figure 6B). MS analysis of the in vitro reaction confirmed the ADP-ribosylation of 
Arg218 in vitro and additionally identified ADP-ribosylation on R83. Manual annotation of HCD and 
EThcD fragmentation spectra for in vivo and in vitro modified HPX peptides confirmed ADP-ribosylation 
on Arg218 and revealed Arg-ADP-ribosylation specific marker ions and neutral losses (Figure 6C). 
Arg218 faces the heme binding pocket of HPX and might therefore interfere with heme binding upon 
ADP-ribosylation (Figure 6D). To test this possibility, a heme binding assay measuring the HPX-heme 
protein complex formation absorbance at 413 nm was established. ADP-ribosylated HPX was strongly 
impaired in its heme binding capacity as compared to unmodified HPX (Figure 6E and F), indeed 
suggesting that the ADP-ribosylation of HPX might regulate its heme binding capacity and might 
therefore be a physiologically relevant function.   
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DISCUSSION: 
 In this study, we investigated the targets of ARTC1 in C2C12 myotubes, as well as in skeletal and 
heart muscle tissues at the systems-level. These proteome-profiling studies, which compared tissues from 
WT and newly generated Artc1-/- mice, uncovered a very large previously unidentified ARTC1-dependent 
ADP-ribosylome composed of several membrane and secreted proteins that were most often modified on a 
single Arg. Ser, Lys, Glu and Asp modifications were also identified, but these ADP-ribosylation events 
were not dependent on ARTC1. We showed that Arg-specific ADP-ribosylation could be additionally 
confirmed using a diagnostic ADPr-carbodiimide ion specific for the modified Arg, thereby expanding the 
toolbox of ADP-ribose marker ions to the screening of complex samples. Comparison of the identified 
peptides revealed sequence motifs with enriched Gly and Arg adjacent to the modified Arg within ARTC1 
target proteins. 
 Based on the proteins identified under steady-state conditions in vivo, ARTC1 seems to be 
constitutively active and to play a role under steady-state conditions. The very strong drop in the number 
of detectable ADP-ribosylation sites in Artc1-/- compared to WT mice strongly suggests that ARTC1 is the 
main contributor to the skeletal and heart ADP-ribosylome under untreated conditions (Figure 2 – Figure 
3). The only additional active and cell bound ARTC family member in mouse, ARTC2.2 is not expressed 
in C2C12 or the tested tissues. Interestingly, the large number of identified ADP-ribosylated proteins 
showed that the applied Af1521 enrichment method is suitable for Arg-ADP-ribosylated proteins.  
NAD+ can be released upon necrosis or mechanical stress in tissue, which could activate ARTCs 
during organ collecting12. Considering that ARTCs have higher affinity for NAD+ compared to 
intracellular ARTDs, ARTCs are more prone to activation following NAD+ release during tissue 
collecting12. However, the ADP-ribosylomes we profiled were quite stable and constrained to the 
extracellular compartment, the plasma membrane and the mitochondria with modification of many low 
abundant proteins. The finding of some cytoplasmic and mitochondrial Arg-ADP-ribosylated proteins 
indicates that the applied extraction procedure might still lead to ADP-ribosylation of intracellular proteins 
due to tissue damage induced upon excising the tissues, as previously reported for ARTC2.2 36. It will be 
interesting to test if ARTC1 mediated ADP-ribosylation also has a function in endogenously occurring 
tissue damage. Besides cell necrosis or physical tissue damage, another reason for intracellular Arg-ADP-
ribosylation could be the modification of proteins during their maturation (ER and Golgi) as both ARTC1 
and its target proteins are processed in and traffic through these compartments. Furthermore, 
mitochondrial proteins might be non-enzymatically ADP-ribosylated due to the high NAD+ concentration 
in the mitochondria 12. 
 The remarkable stability of the observed ARTC1-mediated ADP-ribosylomes contrasts to the 
observed ADP-ribosylomes catalyzed by ARTD1 upon oxidative stress, which can be detected only 
during a few minutes 32. Reversibility of cell surface ADP-ribosylation was previously studied on integrin 
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alpha 7 revealing that surface ADP-ribosylation is not readily reversed by ADP-ribosylhydrolases 54. 
These findings suggested that the responsible erasers operate outside the postulated ADP-ribosylation 
cycle. ARH1, the only known arginine specific ADP-ribosylhydrolase, is solely expressed within the cell, 
but not secreted. It is thus tempting to speculate that the extracellular ADP-ribosylation could only be 
removed from the cell membrane proteins by internalization and protein degradation or shedding, 
potentially rendering the removal of Arg-ADP-ribosylation a slow process. Alternatively, ADP-ribose can 
also be processed by extracellular phosphodiesterases, thereby converting it to phospho-ribosylated 
proteins. However, with the applied enrichment method we can unfortunately not anticipate the level of 
phospho-ribosylated proteins 54. 
 Comparison of ADP-ribosylated proteins in the three sample types revealed a 40% overlap 
between the C2C12 sample and the in vivo samples and a 44% overlap between the two in vivo muscle 
samples. Although the proteome of C2C12 is different from skeletal muscle (44% of the proteins show a 
different expression profile55), this does not explain the small overlap of the ADP-ribosylomes but rather 
suggests that ARTC1’s activation, specificity and expression levels are different in cell culture compared 
to in vivo. These differences could stem from variations in the extracellular matrix and local fluids that 
control ARTC1 activity. In analogy to ARTC2, it is possible that the targets of ARTC1 are also restricted 
to raft associated target proteins36. Alternatively, differential concentrations of available NAD+ could lead 
to a different ADP-ribosylome.  
 Computational analysis of all modified peptide sequences revealed motifs for many Arg-ADP-
ribosylation sites and showed that often another Arg or a Gly residue is positioned adjacent to a modified 
Arg (Figure 5C). The Arg/Arg motif might provide a beneficial environment for the catalytic ART 
process or might serve as a positively charged protein-protein interaction patch whose functionality could 
be annihilated by ADP-ribosylation of one of the arginines. A double Arg motif was already observed for 
individual proteins in in vitro ARTC2.2 assays23. Interestingly, the Ser modified by ARTD was also found 
to be adjacent to a positively charged Lys or Arg residue33, suggesting that a positively charged amino 
acid beside the ADPr acceptor site might be important for the biochemical reaction independent whether 
the modification is catalyzed by ARTC or ARTD family members. The Gly/Arg and Arg/Gly motifs 
might render the Arg more accessible to ARTC1. Interestingly, an Arg/Gly/Asp motif in proteins 
constitutes a major recognition system for cell adhesion and half of all integrins recognize and bind 
protein ligands containing this motif 56. Together with the previous findings and the analysis provided in 
this study this strongly suggests that ARTC1 is involved in modulating cell adhesion. 
 The identification of the relatively intense Arg-specific ADPr-carbodiimide marker ion for Arg-
ADP-ribosylated peptides in complex samples opens the possibility to include the marker ion in product 
dependent MS methods33,40,49,57. This will be beneficial while studying ARTC targets in complex 
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backgrounds by specifically targeting Arg-ADP-ribosylated peptides for fragmentation and thereby 
acquiring high quality spectra.  
 In ARTC1-/- samples, also a residual ARTC1-independent ADP-ribosylome could be detected 
which was not affected by NAD+ pretreatment. Our data reveal that these proteins were mainly modified 
at Ser, Lys, Glu or Asp. However, these sites were by far less abundant than the identified ARTC1 targets. 
Compared to the arginine-modified sites, it was much more difficult to obtain good localization for these 
alternative modification sites, probably due to their labile ADPr-peptide bond upon MS2 fragmentation 52. 
These proteins with ARTC1–independent ADP-ribosylation were involved in metabolic processes, 
oxidative-reduction processes and mainly localized to the mitochondria, suggesting that these processes 
may be influenced by the modification.  As mentioned above, the high NAD+ concentration found in 
mitochondria (approx. 0.5mM) might also favor non-enzymatic ADP-ribosylation for these proteins 12. 
NAD+ i.v. injection (i.e. a DAMP signal) did not markedly alter the total amount of ADP-ribosylated sites 
of the analyzed heart tissues, however changed their quantitative composition. It is likely that NAD+ 
treatment induces a metalloprotease (e.g, ADAM17) 25, which would lead to shedding of plasma 
membrane proteins. Indeed, GPC1 as well as NECTIN4, the close relative of NECTIN2, are known to be 
shed by ADAM17 45,46. CSPG4 and EFNB3 can be cleaved by ADAM10, the close relative of ADAM17 
46-48 The soluble form of these proteins might be less efficiently targeted by membrane bound ARTC1. 
ARTC2.2, the close relative of ARTC1 and 3, has been shown to be released by ADAM17 25. 
Interestingly, the region close to the GPI-anchor where ARTC2.2 is cleaved is conserved in GPI-anchored 
ARTC1 as well as in ARTC3, indicating that they might also be shed25. Release of ARTC1 itself might 
lead to a shift in its activity towards soluble proteins such as HPX and FN1 as shown previously for 
ARTC2.2 25. So far it is not clear which targets are modified by soluble ARTC2.2.  
 Moreover, we characterized and functionally validated the ADP-ribosylation of hemopexin (HPX) 
at Arg218 using purified recombinant proteins and observed that in vitro modification of HPX strongly 
interfered with its capacity to bind heme (Figure 6). HPX is a soluble protein that it is usually found in 
heart and skeletal muscle tissue55,58. After acute hemolysis (e.g. after post-ischemic reperfusion or sepsis) 
excess heme is bound by HPX59. HPX-heme complexes are taken up by macrophages or hepatocytes and 
heme is degraded60. HPX is also important for heme export from cells, by accepting heme from export 
proteins, indicating that HPX also has a function directly at the plasma membrane, placing it in the 
potential vicinity of ARTC161. The inhibitory role of ARTC1 mediated ADP-ribosylation on the HPX-
heme complex might thus play a role in heme homeostasis by shifting the binding of heme to other 
proteins and reduce heme degradation under non-stressed conditions. Interestingly, a recent report 
provides evidence that post-translational oxidative modification of HPX’s Tyr199, which is in close 
structural proximity to R218, also impairs heme binding62.  
RESULTS
140
 16 
 The identified ARTC1 target proteins seem to be involved in various pathways controlling muscle 
function, which might explain the observed reduced endurance of the muscle activity in Artc1-/- mice. 
Whether this observation is only due to skeletal, heart or both muscle tissues needs to be further 
addressed. Moreover, we could identify different protein interaction clusters of which several proteins 
were modified by ARTC1. ARTC1 is GPI-anchored and seems to be concentrated in lipid rafts at the cell 
surface. This topology could regulate ARTC1’s specificity to other membrane proteins associated with 
lipid rafts16. The STRING analyses surprisingly identified a modified protein network in the mitochondria 
in WT tissue, which was not detected in Artc1-/- tissue. We found that these mitochondrial ADP-
ribosylation sites are lower abundant than the extracellular ARTC1 targets making them more prone to 
biological as well as sample and measurement variations.  
 Together, using a new MS-based workflow, we identified and compared the ADP-ribosylomes of 
the murine skeletal muscle and heart tissue and we showed that they are largely ARTC1-dependent. 
Furthermore, our system level analyses show that, in vivo, ARTC1 has an immense target space, which is 
remarkably stable. Ultimately, we also provided evidence for a functional role of ARTC1-mediated ADP-
ribosylation in muscle by showing that heme-binding of HPX is sensitive to ADP-ribosylation and that 
Artc1-/- mice exhibit reduced endurance. We provide a rich resource for ARTC mediated ADP-ribosylation 
research, which was so far limited to a few targets and cumbersome biochemical identification of sites by 
site directed mutations and in vitro experiments. The ADPr-acceptor site localization database that we 
provide here is the first, and most comprehensive HCD and EThcD ADPr spectra resource of primary 
tissue that has been made public to the research community and can also be used by researchers as a 
resource to further investigate the functional implication of ADP-ribosylation in muscle tissues.  
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Material and Methods 
All chemicals were purchased from Sigma unless otherwise stated.  
 
Generation and characterization of Artc1-/- mice 
Mice were obtained from the Animal Resources Units of the University of California at San Francisco and 
the University Hospital, Hamburg. A targeting vector for the Art1 locus was constructed in which loxP 
sites were introduced up- and downstream of the Art1-encoding exons 3 and 4 and a pgk-neomycin 
resistance cassette. The targeting construct was linearized with NotI and transfected into RF8 ES cells. 
Neomycin resistant clones were screened by Southern Blot analyses using informative 5' and 3' flanking 
probes. Two of 600 tested clones showed additional bands indicating homologous recombination at the 
target locus. Following injection of these ES cells into B6 blastocysts, chimeric male and female mice 
were obtained. Germline transmission of the targeted locus was obtained for both clones upon mating of 
chimeric and B6 mice. PCR analyses using primers flanking the distal loxP site confirmed the presence 
and Mendelian inheritance of this site. Art1 floxed mice were mated with mice expressing the cre 
recombinase under control of the ß-actin promoter (deleter mice). PCR analyses using primers from the 
neomycin gene and the 3' flanking region of the ART1 gene yielded a diagnostic band in progeny but not 
parental mice, indicating deletion of exons 3 and 4 in the targeted Art1 allele. Artc1-/- mice were 
backcrossed onto the C57Bl/6 background for 12 generations. Sex and age matched adult WT and Artc1-/- 
mice were monitored for voluntary activity using the Mouse E-Motion universal mobile datalogger system 
(INFRA-E-MOTION GmbH, Hamburg, Germany). Mice were placed in individual cages and movements 
were recorded in three consecutive 12 h light/12 h dark cycles. Endurance of muscle activity was assessed 
using the rotarod performance system (TSE systems, Bad Homburg, Germany). For this, mice were 
adapted to the rotarod at low speed (4 rpm) in trials 1 and 2. Trials 3-5 were then performed at an 
accelerated speed (8 rpm) with a pause of 45 min between each trial. Trial 6 was performed the next day at 
the accelerated speed. The maximum duration of mice on the rotarod was 5 min.  
 
Cell Culture and Treatments 
The mouse skeletal muscle cell line C2C12 was maintained below 60% confluence in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 20% fetal calf serum and 1x 
penicillin/streptomycin (Invitrogen). For differentiation into myotubes, growth medium was exchanged 
for DMEM supplemented with 0.5% fetal calf serum and 1x penicillin/streptomycin (Invitrogen). For the 
NAD+ treatment cells were washed twice with serum free DMEM and subsequently treatment was 
performed for 30min in serum free DMEM containing 50 µM NAD+.  
 Primary myoblasts were isolated from hindlimbs and forelimbs of neonatal mice (2-5 days old). 
The muscle tissue was incubated in Dulbecco’s phosphate-buffered saline (DPBS) with 1% collagenase II 
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(Invitrogen), 2.4U/ml dispase II (Roche) and 2.5 mM CaCl2 for 45 minutes at 37°C, and then passed 
through 100µm-nylon mesh filter (BD Biosciences). The filtrate was centrifuged, the cell pellet was 
suspended in Ham’s F-10 medium (Cambrex) containing 20% FBS and 1% penicillin/streptomycin, pre-
plated for 30 minutes on collagen I-coated plates, and then plated on tissue culture-treated plastic plates. 
To stimulate differentiation of myoblasts to myotubes, 90-100% confluent myoblasts were incubated for 3 
days in medium containing 2% horse serum. 
 
Mouse treatment and organ harvesting for proteomic experiment. 
WT and ARTC1-/- C57BL/6 mice were maintained on a 12-h light-dark cycle with regular unrestricted diet. 
WT (male, 15weeks) and ARTC1-/- (male, 9 weeks) mice were injected with 10 mg NAD+ or stayed 
untreated and sacrificed after 30 min. Mice (n=3 per group) were anesthetized with isofluran and perfused 
with PBS containing 1 mM Novobiocin. Heart and skeletal muscle from legs were collected and 
immediately snap-frozen in liquid nitrogen. All samples were stored at -80°C. In order to optimize the 
analysis and to rule out ADP-ribosylation artifacts induced by stress and lysis, we evaluated different 
sample preparation methods and decided for a strongly denaturing Gnd-HCl lysis protocol and in vivo 
perfusion with the ARTC inhibitor Novobiocin. An additional Novobiocin treatment 30 min before 
euthanasia of the animals did not lead to further reduction in the ARTC1-dependent ADP-ribosylome and 
was thus judged to be unnecessary (Suppl. Figure 3E). 
 
Gene expression 
RNA extraction was performed with the NucleoSpin RNA II kit (Macherey-Nagel). Mouse tissue samples 
were lysed using a tissue lyser II (Qiagen) with the provided lysis buffer. C2C12 myotubes cells were 
washed with PBS, before lysis with the same buffer. After RNA extraction RNA was quantified with a 
NanoDrop (Thermo Fisher Scientific) and reverse transcribed according to the supplier’s protocol (High 
Capacity cDNA Reverse Transcription Kit, Applied Biosystems). Quantitative real-time polymerase chain 
reactions (qPCR) were performed with KAPA SYBR fast (Kapa Biosystems) and a Rotor-Gene Q 2plex 
HRM System (Qiagen). 
 
Immunoblotting 
Three-month old wild-type and Artc1-/- mice were euthanized by CO2 inhalation in accordance with a 
protocol approved by the Kansas State University Institutional Animal Care and Use Committee. Hind 
limb muscles were excised, ground, and homogenized in 50 mM Tris-Cl, pH 7.4, 150 mM NaCl, 50 mM 
octylglucoside, 1 mM AEBSF, 5 mg/ml aprotinin, 5 mg/ml leupeptin, 5 mg/ml pepstatin A (5 ml 
homogenization buffer/1 g tissue). The homogenate was centrifuged at 13,000g for 20 min, the 
supernatant was filtered through a 0.45 mm filter, and incubated with 0.2 ml of Concanavalin A agarose 
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beads at 4°C for 2 h with gentle shaking. The beads were washed with 5 ml of homogenization buffer and 
eluted with SDS-PAGE loading buffer, the eluate was resolved by SDS-PAGE and transferred to a 
nitrocellulose membrane. The membrane was blocked with 3% (w/v) dry milk and 0.3% (v/v) Tween-20 
in DPBS, then incubated with goat anti-ART1 antibody (Santa Cruz, S-15; 1:200 dilution in blocking 
buffer), followed by incubation with horseradish peroxidase-labeled secondary antibody and detection 
using the WestPico chemiluminescence kit (Pierce). 
 
ADP-ribosylation reaction on cells  
Differentiated primary myoblasts (myotubes) were washed with DPBS and incubated for 30 min in DPBS 
(with Ca2+ and Mg2+) containing 5 mM [adenylate-32P] NAD+ and 1 mM ADP-ribose. Cellular proteins 
were extracted with extraction buffer (50mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM ADP-ribose, 1% 
Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 1 mM 4-(2-aminoethyl)-benzene-sulfonylfluoride 
hydrochloride (AEBSF), 5 mg/ml aprotinin, 5 mg/ml leupeptin, 5 mg/ml pepstatin A, 10 mM 1,10-
phenanthroline; 0.5 ml extraction buffer/well in a 6-well plate). Cell extracts were centrifuged at 21,000g 
for 15 min, and supernatants were analyzed by autoradiography after SDS-PAGE under reducing 
conditions. 
 
ADP-ribosylation reaction with recombinant proteins 
Recombinant mouse ARTC1 was purified from DC27.10 lymphoma cells stably transfected with FLAG-
tagged ARTC163. DC27.10_ARTC1 cells were incubated with Phospholipase C (Sigma) for 1 h at 37°C. 
Cell supernatants were clarified by centrifugation (20 min, 2000 3 g) and ARTC1 was purified by affinity 
chromatography on agarose immobilized anti-FLAG mAb M2 (Sigma). The column was washed with 
PBS, 1% Triton X-100 and ARTC1 was eluted with 100 mM glycine, 10 mM Tris (pH 2.7). The eluate 
was neutralized with one-tenth volume of 1 M Tris (pH 9.0) and the buffer was exchanged to PBS by gel 
filtration (PD-10 columns; Pharmacia). ARTC1 was concentrated using centrifugal filters (Millipore; 
molecular weight cutoff 10 kDa). Recombinant mouse hemopexin was purchased from Sino Biological. 
To monitor trans ADP-ribosylation of HPX by radiography we incubated 50nM ARTC1 with 2.5 µM 
HPX using 0.5 µCi [32P]-NAD+ (Perkin Elmer) in PBS and incubated at 37 °C for 30min or 60min. For 
some reactions 10µM Novobiocin or 10µM heme was added. Reactions were stopped by adding SDS-
loading buffer, with subsequent boiling at 95 °C for 5 min. Samples were run on an SDS-PAGE gel, 
stained with Coomassie blue, photographed, destained, and exposed on phosphorscreens overnight. 
Images were taken with a Typhoon FLA 9400 phosphorimager (GE Healthcare). 
 For the Heme-HPX binding assay as well as for subsequent MS analysis 10 µM HPX was 
incubated with 100 µM NAD+ with or without 250 nM ARTC1 in PBS, overnight at 37 °C. The next day, 
indicated amounts of heme were added to the reaction, incubated at 37 °C and absorbance was measured 
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with a NanoDrop (Thermo Fisher Scientific) and the OD at 413 nM was quantified for the different 
reactions. All reactions were done and measured as independent triplicates.  
 
ADPr-peptide enrichment 
C2C12 cells were washed twice with PBS and subsequently lysed and scraped by adding 95°C Gnd-HCL-
lysis buffer (6 M guanidine-hydrochloride, 5 mM tris(2-carboxyethyl)phosphine (TCEP), 10mM 
chloroacetamide (CAA), in 100 mM Tris pH 8). Frozen murine heart and skeletal muscle samples were 
added to 95 °C Gnd-HCL-lysis buffer and ground in a tissue lyser II (Qiagen), for 3min at 30hz. Samples 
were subsequently incubated at 95 °C for 10min and sonicated for 1min at an amplitude of 30%. Lysate 
was cleared by centrifugation at 4000g, ten times diluted with 25 mM Tris pH 8, and digested with 
sequencing grade trypsin (Promega). The peptide mixture was treated with PARG enzyme to reduce 
potentially PARylated peptide to MARylated peptides, and the peptides were enriched using an Af1521 
macrodomain affinity enrichment and prepared for MS analysis as described previously32. The in vitro 
modified HPX protein was processed using filter aided sample preparation (FASP) protocol using 
Microcon-30-kDa-cutoff filter units (Milipore) and sequencing grade trypsin (Promega)64.  
 
Liquid chromatography and mass spectrometry analysis 
Identification of ADP-ribosylated peptides from C2C12, skeletal muscle, heart and recombinant HPX was 
performed on an Orbitrap Fusion Tribrid mass spectrometer (Thermo Fisher Scientific), coupled to a nano 
EasyLC 1000 liquid chromatograph (Thermo Fisher Scientific). We applied an ADP-ribose product-
dependent method called HCD-PP-EThcD33 Briefly, the method includes high-energy data-dependent 
HCD, followed by high-quality HCD and EThcD MS/MS when two or more ADP-ribose fragment peaks 
(136.0623, 250.0940, 348.07091, and 428.0372) were observed in the HCD scan. A detailed description of 
the MS parameters can be found in33. Solvent compositions in channels A and B were 0.1% formic acid in 
H2O and 0.1% formic acid in acetonitrile, respectively. Peptides were loaded onto an Acclaim PepMap 
100 (Thermo Scientific) trap column, 75 µm x 2 cm, packed with C18 material, 3 µm, 100 Å, and 
separated on an analytical EASY-Spray column (Thermo Scientific, 75 µm × 500 mm) packed with 
reverse-phase C18 material (PepMap RSLC, 2 µm, 100 Å ). Peptides were eluted over 110 min at a flow 
rate of 300 nL/min. An elution gradient protocol from 2% to 25% B, followed by two steps, 35% B for 5 
min and 95% B for 5 min, was used. 
 Heart samples were additionally analyzed using an Orbitrap Q Exactive HF mass spectrometer 
(Thermo Fisher Scientific) coupled to a nano EasyLC 1000 (Thermo Fisher Scientific). The peptides were 
loaded onto a reverse-phase C18 (ReproSil-Pur 120 C18-AQ, 1.9 µm, Dr. Maisch GmbH) packed self-
made column (75 µm × 150 mm) that was connected to an empty Picotip emitter (New Objective, 
Woburn, MA). Peptides were injected into the MS at a flow rate of 300 nL/min and were separated using a 
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90 minute gradient of 2% to 25% buffer B. The MS was set to acquire full-scan MS spectra (300–
1700 m/z) at a resolution of 60,000 after accumulation to an automated gain control (AGC) target value of 
3 × 106. Charge state screening was enabled, and unassigned charge states and single charged precursors 
were excluded. Ions were isolated using a quadrupole mass filter with a 2 m/z isolation window. The 
maximum injection time was set to 240 ms and HCD fragmentation performed at 28% normalized 
collision energy. Finally, selected ions were dynamically excluded for 20 seconds. 
 
Raw mass spectrometry data analysis and label free quantification 
MS and MS/MS spectra were converted to Mascot generic format (MGF) by use of Proteome Discoverer, 
v2.1 (Thermo Fisher Scientific, Bremen, Germany). When multiple fragmentation techniques (HCD and 
EThcD) were utilized, separate MGF files were created from the raw file for each type of fragmentation. 
MGF files were further processed33. The MGFs were searched against the UniProtKB mouse database 
(taxonomy 10090, version 20160902), which included 24’905 Swiss-Prot, 34’616 TrEMBL entries, 
59’783 reverse sequences, and 262 common contaminants. 
 Mascot 2.5.1.3 (Matrix Science) was used for peptide sequence identification with previously 
described search settings and some modification for the EThcD searches33. Enzyme specificity was set to 
trypsin, allowing up to 4 missed cleavages. The ADP-ribose variable modification was set to a mass shift 
of 541.0611, with scoring of the neutral losses equal to 347.0631 and 249.0862. The marker ions at m/z 
428.0372, 348.0709, 250.0940, 136.0623 were ignored for scoring. Ser, Arg, Lys, Asp and Glu residues 
were set as variable ADP-ribose acceptor sites. Carbamidomethylation was set as a fixed modification on 
C and oxidation as a variable modification on M. Peptides are considered correctly identified when a 
Mascot score >20 and an expectation value <0.05 are obtained. For the ADP-ribosylation site analyses, 
peptides identified with EThcD fragmentation, having a mascot localization score > 90% were used if not 
stated otherwise.   
 To perform label-free quantification based on the MS1 precursor peak area of the identified 
peptides and proteins, Progenesis QI software (v. 3.0.6039.34628, Nonlinear Dynamics, Purham, NC) was 
applied. Raw data was imported into Progenesis and aligned based on the MS1 peak retention time. All 
samples were normalized based on the total signal intensity. The obtained results were exported as MGF 
and searched with Mascot as indicated above. The Mascot search results were imported into Scaffold 
software (v.4.7.2) and filtered for protein and peptide FDR values of 1% and 0.5% respectively. When 
multiple precursors were observed for the same peptide, the values were summed up to obtain the total 
level of the peptide.  
 
Bioinformatic analyses 
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Statistical analysis, volcano plot analysis, principal component analysis and hierarchical clustering were 
performed using the Perseus software suite (Max Planck Institute of Biochemistry, Department of 
Proteomics and Signal Transduction, Munich). Normalized LFQ intensities were imported and missing 
values were imputed.  
 For GO enrichment analyses the GOrilla online tool65 was applied, using a C2C12 myotube, a 
mouse skeletal muscle or a mouse heart proteome as background 55,58. A p-value threshold of 10-3 was set 
and higher-ranking terms were chosen from GO Biological Processes, GO Molecular Functions, GO 
Cellular Compartments or Kyoto Encyclopedia of Genes and Genomes (KEGG) for display. 
Protein-protein interactions in between ADP-ribosylated protein were analyzed using the interaction data 
from the STRING database (v. 10.5) using high confidence interaction scores (≥0.7) and hiding 
disconnected ADP-ribosylated nodes from the network. Significantly enriched, interesting GO Biological 
Processes and KEGG pathway terms were annotated according to the STRING database and GO Cellular 
Compartments were annotated using the PANTHER database.  
The heart samples measured on the Q Exactive HF MS, using a non-product dependent HCD 
fragmentation method, were used to extract MS2 ADP-ribose marker ion patterns from the Mascot 
ouput.dat files. For this we used the PTM marker finder tool and following marker ions were included 
136.0618, 250.0935, 348.0704, 428.0367 and 584.0901 51. Only spectra were considered where at least 
four marker ions were identified with an intensity of at least 5% of the highest peak and a mascot score of 
>20.	
For the ADP-ribosylation site motif analysis we used the web-based motif-x program66. We 
included all Arg-ADPr sites identified with a localization score >90% for the analysis. A p-value threshold 
<0.0005 was chosen for the binomial probability and a 21 amino acid window with the ADP-ribosylation 
site in the center was analyzed against the whole mouse proteome as a background.  All identified motifs 
were reported as a 13 amino acid windows. Their fraction to all analyzed sites is indicated as well as the 
motif score. The motif score is the sum of the negative log probabilities used to fix each position of the 
reported motif. The higher the score the more statistically significant and specific the motif.  
 The protein structure of HPX 67 was visualized an annotated using PyMOL v1.7.4. All Venn 
diagrams were generated using biovenn (http://www.biovenn.nl). 
 
Data availability 
The mass spectrometry proteomics data for the C2C12 cells, the mouse skeletal and heart muscle tissues, 
including the RAW files, peak list files (MGFs), and result files (mzIdent) have been deposited to the 
ProteomeXchange Consortium via the PRIDE68 partner repository with the dataset identifier PXD008041 
and 10.6019/PXD008041. The additional data that support the findings of this study are available from the 
corresponding author on request.  
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Figure legends: 
Figure 1 – Profiling of ADP-ribosylation in mouse myotubes 
A) Increase in unique ADP-ribosylated peptides after NAD+ treatment of C2C12 myotubes. Venn diagram 
of identified unique ADP-ribosylated peptides in C2C12 myotubes left untreated or treated with 50 µM 
NAD+. 
B) R-ADP-ribosylation is specifically induced upon NAD+ treatment of C2C12 myotubes. Identified 
unique ADP-ribose acceptor sites in C2C12 myotubes left untreated or treated with 50 µM NAD+ (n=3; 
bar graph represents mean and SD).  
C) Term-enrichment analysis displaying significantly enriched (P<0.001) gene ontology terms of the 
identified ADP-ribosylated proteins (n=85) according to their cellular localization, molecular function and 
the biological processes. Term enrichment is calculated relative to a deep C2C12 myotube proteome 
(n=8476) 55. Numbers in parentheses indicate participation size and category size, respectively. 
D) Unsupervised hierarchical clustering analysis of normalized intensity values determined by MS1 based 
label free quantification of detected ADP-ribosylation sites. A black cell corresponds to not present or a 
relatively low abundant ADP-ribosylation site, blue indicates a site of intermediate abundance and green a 
highly abundant site. Protein names for three indicated clusters, where ADPr peptides are observed 
already under untreated conditions are indicated. Names in bold correspond to proteins with a function in 
biological adhesion. 
E) STRING database analysis of high confidence protein interactions (interaction score >0.7) between 
identified ADP-ribosylated proteins in C2C12 cells. Only ADP-ribosylated proteins with at least one 
interaction with another ADP-ribosylated protein are shown. Subcellular localization and biological 
process are annotated. 
 
Figure 2 – Characterization of the Artc1-/- mouse 
A) Western blotting of glycoprotein-enriched muscle extracts using anti-ART1 antibody confirmed the 
absence of the 39-kDa ART1 protein in Art1c-/- mice. Two different mice of WT and Artc1-/- genotype 
were analyzed. 
B) Adult male Artc1-/-  mice (n= 8) have similar average weights as their WT litter mates (n=9; bar graph 
represents mean and SD).  
C) Monitoring of voluntary activity using the Mouse E-Motion system. Mice were placed in individual 
cages and movements were recorded in three consecutive 12 h light/12 h dark cycles. Data points 
represent the activity of individual mice over 72 h, expressed as the movement index +/- SEM (student's t-
test).  
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D) Endurance of muscle activity was assessed using the rotarod performance system. Mice were adapted 
to the rotarod at low speed (4 rpm) in trials 1 and 2. Trials 3-5 were then performed at an accelerated 
speed (8 rpm) with a pause of 45 min between each trial. Trial 6 was performed the next day at the 
accelerated speed. The maximum duration of mice on the rotarod was 5 min. The latency to fall for each 
group is expressed as mean +/- SEM (student's t test p < 0.05 = *; p < 0.01 = **). 
E) Primary myoblasts isolated from 6 littermate pups (genotypes shown at the top, mice numbers at the 
bottom), differentiated (D) in vitro into myotubes or undifferentiated (U), were incubated with [32P]-
NAD+ and analyzed by SDS-PAGE and autoradiography (left panel) or Coomassie blue-staining (right 
panel). Position of ADP-ribosylated integrin α7 is indicated by arrow, molecular weight markers (kDa) are 
on the right. 
 
 
Figure 3 – Analysis of skeletal muscle 
A) The ADP-ribosylome of skeletal muscle is strongly dependent on ARTC1. Venn diagram of unique 
identified ADP-ribosylated peptides in skeletal muscle tissue from WT and Artc1-/- mice (3 animals per 
group).  
B) R-ADP-ribosylation in skeletal muscle tissue is strongly ARTC1-dependent. Identified ADP-ribose 
acceptor sites in WT and Artc1-/- skeletal muscle tissue (n=3; bar graph represents mean and SD).  
C) Histogram analysis shows that the majority (78%) of ADP-ribosylated skeletal muscle proteins carry 
only one ADPr modification.   
D) Term-enrichment analysis displaying significantly enriched (P<0.001) gene ontology terms of the 
identified ADP-ribosylated proteins in WT (n=573) and Artc1-/- (n=33) tissue according to their cellular 
localization and the biological processes. Term-enrichment is calculated relative to a deep mouse skeletal 
muscle proteome (n=5647) 55. Numbers in parentheses indicate participation size and category size, 
respectively. 
 
 
Figure 4 – Profiling of the mouse heart ADP-ribosylome 
A) The ADP-ribosylome of the heart tissue is strongly dependent on ARTC1. Venn diagram of unique 
identified ADP-ribosylated peptides in heart muscle tissue from WT and Artc1-/-  mice (3 animals per 
group). 
B) R-ADP-ribosylation in skeletal muscle tissue is strongly ARTC1-dependent. Identified ADP-ribose 
acceptor sites in WT and Artc1-/- skeletal muscle tissue (n=3; bar graph represents mean and SD).  
C) Histogram analysis shows that the majority (71%) of ADP-ribosylated skeletal muscle proteins carry 
only one ADPr modification.  
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D) Term-enrichment analysis displaying significantly enriched (P<0.001) gene ontology terms of the 
identified ADP-ribosylated proteins in WT (n=131) and Artc1-/- (n=26) tissues according to their cellular 
localization, molecular function and the biological processes. Term enrichment is calculated relative to a 
deep mouse heart proteome (n=3157) 58. Numbers in parentheses indicate participation size and category 
size, respectively. 
E) STRING database analysis of high confidence interaction (interaction score >0.7) between identified 
ADP-ribosylated proteins in heart tissue, dependent on ARTC1 expression. Only ADP-ribosylated 
proteins with at least one interaction with another ADP-ribosylated protein are shown. Subcellular 
localization and biological process are annotated. 
F) Principal component analysis of ADP-ribosylated peptide abundance separates WT and Artc1-/- hearts 
as well as untreated and NAD+ treated WT samples (3 animals per group). Analysis done with Perseus. 
G) Volcano plot analysis of WT heart untreated versus NAD+ treated. Significantly different sites are 
shown in black (FDR<0.5) and ADP-ribosylation sites annotated. 
 
 
Figure 5 – Arginine ADP-ribosylation marker ions and motifs.  
A) MS2 fragmentation pattern of an ADP-ribosylated arginine, indicating ADP-ribose marker ions that 
should theoretically be generated when using HCD fragmentation, including partial fragmentation of the 
Arg side chain giving rise to an R-ADPr specific ADPr-carbodiimide marker ion (marked in red).  
B) Count of peptide spectra containing ADP-ribose marker ions in measurements of WT and Artc1-/-  heart 
samples (3 animals per group). Only spectra containing at least four ADP-ribose marker ions, with an 
intensity of at least 5% of the highest peak and a mascot score of >20 were considered. Log10 based 
intensities of specific ADP-ribose marker ions are plotted in a box plot. The Arg specific ADP-ribose 
marker ion is marked in red and its contribution to the total number of ADP-ribosylated spectra is 
indicated.  
C) R/G and R/R motifs identified at Arg-ADP-ribosylation sites with a localization probability >90% in 
C2C12 cells, WT muscle and heart tissue compared against the whole mouse proteome as background 
(binomial test, p< 0.0005) using x-motif 66. Percentage of all Arg-ADP-ribosylation sites containing the 
motif and motif score are shown on top of the respective sequence motif.  
 
Figure 6– ARTC1 mediated ADP-ribosylation of HPX interferes with heme binding 
A) Autoradiography of mouse hemopexin (HPX) in vitro ADP-ribosylation by recombinant mouse 
ARTC1 or NAD+ alone. Heme (10µM) was added to some reactions. 
B) Autoradiography of mouse hemopexin (HPX) in vitro ADP-ribosylation by recombinant mouse 
ARTC1. Heme (10µM) or Novobiocin (10µM) were added to some reactions.  
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C) Manual annotation of high resolution HCD (top) and EThcD (bottom) MS2 fragmentation spectrum of 
a HPX peptide confirms ADP-ribosylation on R218. Spectra were retrieved from measured WT heart 
tissue and in vitro modified HPX, respectively. Y and z ion series are shown in green, b and c ion series in 
blue, ADP-ribose specific marker ions and neutral losses are indicated in red.  
D) Crystal structure of HPX bound to heme (red)67 with indicated ADP-ribosylation sites. The ADPr sites 
on Arg218 detected in WT heart and skeletal muscle might interfere with HPX ability to sequester heme 
due to its very close proximity to the heme-binding site. ADP-ribosylated Arg218 and Arg83 are 
highlighted.  
E) Absorbance measurement of non-modified HPX (HPX incubated with NAD+) or ADP-ribosylated 
HPX (HPX incubated with NAD+ and ARTC1) incubated in the presence of different concentrations of 
heme. Average absorbance measurement from 300-600 nm for the different reactions in triplicates are 
shown, the HPX-heme complex absorbs light at 413nm.  
F) ARTC1 mediated ADP-ribosylation of HPX inhibits heme binding in vitro. Binding was assessed as in 
E) and OD413 is shown as a bar plot for triplicate measurement of the indicated reactions. (n=3; bar graph 
represents mean and SD, t-test ** p<0.01). 
 
 
Supplementary Figure 1 - ADP-ribosylation in myotubes 
A) RT-qPCR analysis of ARTC1 expression in C2C12 myoblast, C2C12 myotubes and in the mouse 
heart. The expression of ARTC1 is expressed relative to the house-keeping gene RPS12.   
B) Venn diagram of all identified ADP-ribosylated proteins in untreated and NAD+ treated C2C12 
myotubes. 
C) Count of identified ADP-ribosylated peptide spectra matches (PSMs) for untreated and NAD+ treated 
C2C12 myotubes (n=3;bar graph represents mean and SD).  
D) Multi-scatter plot and Pearson correlation coefficients of measured ADP-ribosylated peptide signal 
intensities from triplicate ADP-ribosylome measurements. 
 
 
Supplementary Figure 2 – Generation of the Artc1-/- mouse 
A) Schematic diagram of the conditional Artc1 targeting construct (tc) in which the neomycin resistance 
cassette was inserted into the second intron of the ART1 gene. The 3' arm of homology was assembled by 
PCR, thereby incorporating lox P sites (arrowheads) up- and downstream of the main ART1-encoding 
exons 3 and 4. The neo cassette and 3' loxp site contained diagnostic NcoI and EcoRI sites, respectively. 
The targeting construct was linearized with NotI and transfected into RF8 ES cells.  
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B) Neomycin resistant clones were screened by Southern Blot analyses using informative 5' and 3' 
flanking probes. Two of 600 tested clones showed additional EcoR1 and Nco1 bands indicating 
homologous recombination at the target locus.  
C) PCR analysis for floxed allel. Following injection of these ES cells into B6 blastocysts, chimeric male 
and female mice were obtained. Germline transmission of the targeted locus was obtained in both cases 
upon mating of chimeric and B6 mice. PCR analyses using primers flanking the distal loxP site confirmed 
the presence and Mendelian inheritance of this site (lanes a: 260 bp band = floxed ART1 vs. 250 bp band 
= wt ART1). The floxed ART1 site is co-inherited with the linked neo cassette (lanes b).  
D) PCR analysis for deleted allel. ART1 floxed mice were mated with mice expressing the cre 
recombinase under control of an unbiquitous promoter (deleter mice). PCR analyses using primers from 
the neomycin gene and the 3' flanking region of the ART1 gene yielded a diagnostic 1.5 kb band in 
progeny but not parental mice, indicating deletion of exons 3 and 4 in the targeted ART1 allele (lanes c).  
E) Mice genotyping. PCR reaction with primer set "a" (Art1.3 and Art1.4) yields a diagnostic band of 250 
bp for the wild-type and no band for the targeted allele. PCR reaction with primer set "b" (NF1 and 
Art1.4) yields a diagnostic band of 1.5 kb for the targeted allele and no band for the wild-type allele. 
Positions of the molecular weights (bp) are shown on the right.  
F) Venn diagram comparing unique ADP-ribosylated peptides in triplicates of WT skeletal muscle tissue.  
G) Venn diagram comparing unique ADP-ribosylated proteins in skeletal muscle and C2C12 myotubes. 
 
 
Supplementary Figure 3 – ADP-ribosylation in the mouse heart 
A) Count of identified ADP-ribosylated PSMs for untreated and NAD+ treated WT and Artc1-/- hearts 
(n=3; bar graph represents mean and SD) .  
B) Venn diagram comparing unique ADP-ribosylated proteins identified in triplicates of WT and Artc1-/-  
heart tissue, respectively.  
C) STRING database analysis of high confidence protein interactions between identified ADP-ribosylated 
proteins in Artc1-/- heart tissue. Only ADP-ribosylated proteins with at least one interaction with another 
ADP-ribosylated protein are shown. Subcellular localization and biological process are annotated.  
D) Venn diagram of all identified ADP-ribosylated proteins in C2C12, skeletal and heart muscle tissue.   
E) Count of identified ADP-ribosylated PSMs for different sample preparation protocols for the analysis 
of endogenous ADP-ribosylated proteins from heart extracts. 
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Supplementary Figure 4 – ADP-ribosylation in the mouse heart after NAD+ treatment 
A) Count of identified ADP-ribosylated PSMs for untreated and NAD+ treated WT and Artc1-/- hearts (n=3 
per condition; mean and SD).  
B) Identified ADP-ribose acceptor sites in untreated and NAD+ treated WT and Artc1-/- hearts (n=3 per 
condition; mean and SD).  
C) Multi-scatter plot and Pearson correlation coefficients of measured peptide signal intensities in 
untreated and NAD+ treated WT and Artc1-/- hearts (n=3 per condition). A Pearson correlation close to 1 
signifies high reproducibility in the measured abundance of ADP-ribosylated peptide species.  
D) Unsupervised hierarchical clustering analysis of normalized intensity values determined by MS1 based 
label free quantification of ADPr-peptides detected across all heart samples. 
E) LC-MS2 overview of a representative sample for WT and Artc1-/- heart samples, respectively. Peptide 
charge states are color-coded and peptide spectra containing at least four ADP-ribose marker ions are 
indicated with a black square. ADP-ribosylated peptides show mainly 2+ and 3+ charges.  
 
 
Supplementary Figure 5 – Total protein levels remain unchanged, whereas the ADP-ribosylation 
site abundance changes for selected proteins identified in untreated and NAD+ treated hearts 
Low-high bar graphs with indicate means of total protein or APD-ribosylated peptide abundances in hearts 
of untreated or NAD+-treated WT animals are shown. Data was produced using MS1 label free 
quantification of non-enriched or Af1521 enriched samples, respectively (3 animals per group). Unpaired 
t-test was performed (*P<0.05, **P <0.01, ***P <0.001) 
 
Supplementary Tables 1-3 
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Figure 3 - Profiling of ADP-ribosylation in skeletal muscle
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AFigure 4 - Profiling of the mouse heart ADP-ribosylome 
WT          ARTC1 KO
230      29   8
ADPr peptides
1 2 3 4 more
0
20
40
60
80
Count of ADPr sites per protein%
 o
f A
D
Pr
 p
ro
te
in
s
Arg
Ser
Lys/Glu/Asp
0
10
20
30
40
50
ARTC1 KO
B
0
10
20
30
40
50
un
iq
ue
 A
D
Pr
-s
ite
s 
WT
B
D
4
Transmembrane
transporter activity
Substrate-specific
transporter activity
Receptor
binding
0 1 2 3 4 5
0 5 10 15 20 25
Term-enrichment
Cation-
transporting 
ATPase activity
0 10 20 30 40 50
ATP synthesis 
coupled 
proton transport
Tricarboxylic acid
 cycle
0 2 4 6 8
Regulation of 
apoptotic process
Regulation of cardiac
muscle contraction
0 1 2 3
Mito-
chondrion
Extracellular
space
Mito-
chondrion
GO: Cellular compartment GO: Molecular function GO: Biological process
WT ARTC1 KO
Eci1Acaa2Efnb3 Efna1
Snap23
Pdia3
Vdac1 Ppif
Aifm1
Timm50
Phb
Dsc2 Eef1a1 Eef1a2
Tomm40lEndog
Dsg2
Ndufaf2
Ndufa8
Uqcrc2
Atp5f1
Ndufb5
Uqcrfs1
Cox6b1Atp5e
AdipoqCdh2
Apoe
Cdh13
Lpl
Gpc1
Cspg4
Atp2a2
PlnNppa
Tnni3
Tpm1 Ldb3
P4hb
Serpina3k Actn4Kng1 Itga7 Lama2
AhsgC3 Nid1
Plg
Col6a3Apool Lamb2
Chchd3
E
B C
un
iq
ue
 A
D
Pr
-s
ite
s
lo
c.
 s
co
re
 >
90
%
 
WT ARTC1 KO
Term-enrichment
Plasma
membrane
40 1 2 3
(26/305)
(41/593)
(70/904)
(22/904)
(24/293)
(19/192)
(17/149)
(5/26)
(9/131)
(25/316)
(4/26)
(8/15)
Term-enrichment
Oxidative
phosphorylation
Subcellular localization
ECM-receptor
interaction
Response 
to stress
Regulation of 
heart rate
Regulation
in response 
to wounding
Extracellular 
& cell surface
Mitochondrion
Biological process
-3
0
-2
0
-1
0
0
10
C
om
po
ne
nt
 4
 (3
.3
%
)
-60 -40 -20 0 20 40 60
Component 1 (79.7%)
WT unt
WT NAD+
ARTC1 KO unt
ARTC1KO NAD+
Difference of means ADPr sites (log2)
untreated NAD+
Itga7 - R896
Fn1 - R2334
Slc3a2 - R246
Hpx - R218
Dsg2 - R408
Nid1 - R318
P
-v
al
ue
 (l
og
10
)
-10                 -5                   0                   5                  10      
0
4
3
2
1
Art1 - R167
Gpc1 - R510
Nectin2 - R104 
Efnb3 - R172
Cspg4 - R2110
Art3 - R263
Lamb2 -R103
Nid1 - R349
Itga7 - R608
Lamb2 - R1458
Fgb 
Il1rap - R86
F G
RESULTS
162
AO O
P O
O
OH
P
HO
OH
HO
O
O O
OH
OH
N
NN
N NH2
N
NH
HN
136.06 adenine
250.09 adenosine-H2O
348.07 AMP
428.02 ADP
542.06 
ADPr-H2O 
584.09 ADPr- 
+carbodiimide
+
+
+
+
+ 3693
3688 3694 3681
207 361
329
328
326
109
329
10%
3
0.9%
lo
g1
0 
ba
se
d 
m
ar
ke
r i
on
 in
te
ns
ity
10
2
10
4
10
6
5x
10
2
5x
10
3
5x
10
4
5x
10
5
136.06
250.09
348.07
428.03
542.06
584.09
ADPr-marker ion m/z
136.06
250.09
348.07
428.03
542.06
584.09
ADPr-marker ion m/z
B
WT heart ARTC1 KO heart
-6 -5 -3 -2 -1 0-4 +1 +2 +4 +5 +6+3
-6 -5 -3 -2 -1 0-4 +1 +2 +4 +5 +6+3
-6 -5 -3 -2 -1 0-4 +1 +2 +4 +5 +6+3 -6 -5 -3 -2 -1 0-4 +1 +2 +4 +5 +6+3
-6 -5 -3 -2 -1 0-4 +1 +2 +4 +5 +6+3
-6 -5 -3 -2 -1 0-4 +1 +2 +4 +5 +6+3
WT skeletal muscle WT heart
-6 -5 -3-4 -2 -1 0 +1 +2 +4 +5 +6+3
-6 -5 -3 -2 -1 0-4 +1 +2 +4 +5 +6+3
C2C12 + NAD+
46% - 4.52
32% - 3.85
12% - 5.47
10% - 4.27
8% - 4.02
32% - 9.04
19% - 4.80
12% - 3.35
Figure 5 - Arginine ADP-ribosylation marker ions and motifs 
C
RESULTS
163
HPX
R218-ADPr
in vivo: heart &
muscle 
& in vitro
Heme
R83-ADPr
in vitro
CA
E
Figure 6 - ARTC1 mediated ADP-riboslyation of HPX inhibits heme binding. 
130kD--
●        ●        ●               
●               ●              
             ●                   
         
HPX                   
ARTC1
Heme
70kD--
100kD--
55kD--
130kD--
70kD--
100kD--
55kD--
32P
Coomassie
--HPX
--HPX 70kD--
130kD--
35kD--
55kD--
70kD--
130kD--
35kD--
55kD--
32P
Coomassie
--HPX
--ARTC1
--HPX
--ARTC1
HPX                   
ARTC1
Heme
Novo
●       ●       ●               ●       ●       ●
●       ●       ●               ●       ●       ●
       ●                            ●       
   ●                  ●
30min 60min
30min
B
200 400 600 800 1000 1200 1400 1600 1800 2000
0
5
10
15
20
25
100
A
de
ni
ne
+
z +
1(1
)
z +
1(2
)
y(
2) b
(2
)
A
M
P
+
z +
1(3
)
b(
3)
A
D
P
+
z +
1(4
)/b
(4
) c(
4) b(
5)
c(
5)
c(
6)
z +
1(6
)
y(
15
)3+
c(
7)
y(
9)
2+
[M
+3
H
]3+
b(
8)
y(
10
)2+
y(
12
)2+
y(
13
)2+
y(
15
)2+
[M
+3
H
-A
M
P
]2+
[M+3H]2+
[M
+3
H
-N
H
3]2
+
y(
9)
-A
M
P
y(
9)
-A
de
no
si
ne
 - 
H
2O
z +
1(7
)
y(
7) y(
9)
z +
1(1
0)
c(
11
)
z +
1(1
1)
z +
1(1
2)
y(
12
)
z +
1(1
3)
A
D
P
r-
ca
rb
od
iim
id
e
≈
F N P
y1
5
b2
V
b3
T
y,z
13
b,c
4
G
y,z
12
b,c
5
E
y1
1
c6
V
z,y
10
c7
P
y9
b8
P
ADPr
R
y,z
7
Y
z6
c1
1
P L
z4
b1
3
D
z3
A
y,z
2
R
z1
0
5
10
15
20
25
30
y(
2)
b(
2)
b(
3)
y(
3)
y(
9)
2+
-A
D
P
r-
ca
rb
od
iim
id
e
y(
5)
y(
9)
2+
-A
M
P
y(
10
)2+
-A
M
P
y(
6)
y(
13
)2+
-A
M
P
y(
15
)2+
-A
M
P
y(
9)
-A
D
P
r-
ca
rb
od
iim
id
e
y(
12
)-
A
D
P
r-
ca
rb
od
iim
id
e
y(
13
)-
A
D
P
r-
ca
rb
od
iim
id
e
y(
15
)-
A
D
P
r-
ca
rb
od
iim
id
e
b(
4)
b(
7) b(
8)
A
D
P
+
45
65
100 Ad
en
ine
+
F N P
y1
5
V
b3
T
y1
3
b4
G E V
y1
0
b7
P
y9
b8
P R Y
y6
P
y5
L D
y3
A R
b2
ADPr
y1
2
A
M
P
+
(A
de
no
sin
e-H
2
O)
+
≈
≈
≈
(A
de
no
si
ne
-H
2O
)+
re
la
tiv
e 
ab
un
da
nc
e
re
la
tiv
e 
ab
un
da
nc
e
m/z
heart HPX R218-ADPr - HCD
in vitro HPX R218-ADPr  - EThcD
D
0 μM 10 μM 25 μM 50 μM  
[Heme]
HPX NAD+
ARTC1 NAD+ HPX
F
0.0
0.1
0.2
0.3
**
**
O
D
 4
13
nm
P
V
P
V
T
P
V
TG
E
P
V
TG
E
V
P
V-
C
O
y(
15
)2+
-A
M
P
300 400 500 600
0.0
0.1
0.2
0.3
ARTC1 HPX 50μM Heme
HPX 50μM Heme
ARTC1 HPX 25μM Heme
HPX 25μM Heme
HPX 10μM Heme
ARTC1 HPX 10μM Heme
nm
O
D
RESULTS
164
Supplementary Figure 1 - ADP-ribosylation in myotubes.
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Supplementary Figure 2 - Generation of ARTC1-KO mice. 
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Supplementary Figure 3 - ADP-ribosylation in the mouse heart. 
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Supplementary Figure 4 - ADP-ribosylation in the mouse heart after NAD+
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Supplementary Figure 5 – Total protein level and levels of ADP-ribosylated 
peptides for selected proteins identified in untreated and NAD+ treated hearts. 
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4 Unpublished	Results	The	established	MS	workflow	was	also	applied	to	different	other	organs,	cell	type	or	samples	to	elucidate	the	potential	of	the	technology,	but	also	to	get	first	insights	of	the	 different	 ADP-ribosylomes.	 The	 validation	 and	 functional	 analysis	 of	 the	identified	ADP-ribosylated	proteins	is	currently	under	investigation	or	still	has	to	be	done.		
4.1 ADP-ribosylation	in	NASH	liver	is	sensitive	to	PARPi	and	NR	treatment	One	 very	 interesting	 area	 of	 therapeutic	 NAD+	 intervention	 is	 non-alcoholic	 fatty	liver	disease	(NAFLD).	NAFLD	includes	pathophysiologies	ranging	from	simple	fatty	liver	 (steatosis),	 to	 non-alcoholic	 steatohepatitis	 (NASH),	 cirrhosis,	 hepatocellular	carcinoma	and	may	finally	cause	death.	NAFLD	is	considered	the	most	common	liver	disease	 in	 the	 Western	 world	 and	 without	 approved	 pharmacological	 treatment	[138].	 It	 is	known	that	the	expression	of	several	ARTDs	is	 increased	in	the	liver	of	mouse	 NAFLD	 or	 NASH	 models	 and	 it	 was	 shown	 that	 PARP	 inhibitor	 or	 NR	treatment	 restored	 the	 hepatic	 NAD+	content,	 opposing	 the	 decrease	 in	 SIRT1	activation,	 which	 has	 been	 identified	 as	 a	 disease	 driver	 [139,	 140].	 The	 positive	outcome	of	both	treatments	(PARP	inhibitor	and	NR)	was	linked	to	beneficial	effects	on	 the	metabolic-,	 inflammatory-,	 and	oxidative	stress-related	conditions	 [139].	 In	collaboration	with	Prof.	Johan	Auwerx	(EPFL)	we	aimed	to	determine,	whether	the	beneficial	 effect	would	 correlate	with	 changes	 of	 the	 ADP-ribosylome	 in	 the	 liver	and	whether	ADP-ribosylation	targets	could	be	identified	that	might	be	functionally	important	in	the	context	of	disease	progression.		Mice	were	 fed	with	a	chow	diet	or	a	methionine-	and	choline-deficient	diet	(MCD),	as	a	model	for	NASH	[139],	complemented	with	either	nothing,	PARPi	or	NR,	and	liver	samples	prepared	from	three	individual	mice	for	every	tested	condition.	In	order	to	measure	the	ADP-ribosylome,	tissues	samples	were	lysed	using	an	8M	Urea	lysis	 buffer	 and	 the	 ADP-ribosylated	 peptide	 subsequently	 enriched	 using	 the	Af1521	approach	[57].	Around	25	proteins	were	found	to	be	ADP-ribosylated	in	all	tested	samples.	One	protein	cluster	was	ADP-ribosylated	in	all	samples,	whereas	the	chow	diet	and	MCD	diet	additionally	induced	characteristic	ADP-ribosylated	protein	
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clusters	 (Figure	 10A,	 B).	 Treatment	with	NR	 or	 PARPi	 strongly	 reduced	 the	ADP-ribosylomes	in	both	tested	cases	(Figure	10A,	B).		
	
Figure	 10	 ADP-ribosylated	 proteins	 in	 NASH	 liver	 are	 sensitive	 to	 PARPi	 and	 NR	 treatment.	 A)	 ADP-ribosylated	proteins	detected	in	at	least	two	out	of	three	biological	replicates.	Columns	correspond	to	biological	samples,	 consisting	of	 three	 individual	mouse	 livers	 respectively;	 a	 blue	 cell	 indicates	 that	 the	 corresponding	protein	was	 found	to	be	modified.	B)	ADP-ribosylated	proteins	detected	 in	at	 least	 two	out	of	 three	biological	replicates	shown	as	a	Venn	diagram.			 ARTD1	was	not	found	to	be	ADP-ribosylated,	indicating	that	it	is	not	strongly	induced	upon	the	 tested	conditions	and	another	ART	might	be	responsible	 for	 the	observed	 ADP-ribosylation	 sites.	 In	 the	 NASH	 model,	 one	 of	 the	 most	 biological	interesting	 ADP-ribosylated	 proteins	 was	 apoptosis	 regulator	 BAX	 that	 was	specifically	 modified	 on	 R37,	 but	 was	 not	 modified	 anymore	 after	 NR	 or	 PARPi	treatment,	 indicating	 that	 it	 is	most	 probably	ADP-ribosylated	 by	 an	ARTD	 family	member	 activated	 by	 the	 MCD	 diet.	 This	 is	 moreover	 interesting,	 since	 it	 was	already	reported	that	BAX	and	ARTD1	act	 in	the	same	molecular	pathway	through	calpain	 [141],	 resulting	 in	 the	 translocation	 of	 BAX	 form	 the	 cytosol	 to	 the	mitochondria,	subsequently	facilitating	the	release	of	AIF,	which	translocates	to	the	nucleus	to	induce	necrosis	[141].	Moreover,	BAX	can	also	localize	to	the	nucleus	to	exhibit	yet	unknown	nuclear	functions,	placing	it	to	the	same	cellular	compartment	of	ARTD1,	2	or	3	[142].	It	is	unclear	which	ARTD	is	ADP-ribosylating	BAX	and	what	the	 functional	 consequence	 of	 this	 modification	 is.	 To	 address	 which	 ART	 is	responsible	 for	 the	 ADP-ribosylation	 of	 BAX,	 in	 vitro	 modification	 assays	 with	different	 recombinant	 ARTDs	 could	 be	 performed.	 In	 addition,	 BAX	 ADP-
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ribosylation	could	be	monitored	by	targeted	proteomics	under	basal	conditions	and	different	disease	models	in	WT	as	well	as	ARTD1/2	KO	mice.			 It	 is	 surprising	 that	 after	 NR	 treatment,	 less	 ADP-ribosylation	 sites	 were	observed,	 since	NR	 is	known	 to	 increase	 intracellular	NAD+	 levels.	An	explanation	for	the	low	number	of	ADP-ribosylation	sites	could	also	be	that	NAD+	consumption	by	ARTD	enzymes	does	not	necessarily	correlate	with	the	amount	of	PARylation	or	numbers	of	ADP-ribosylation	sites,	since	these	are	also	very	much	dependent	on	the	activity	of	ADP-ribosylhydrolases	[143].	It	would	be	interesting	to	measure	in	NASH	liver	 beside	 protein	 ADP-ribosylation	 the	 expression	 levels	 of	 different	 ADP-ribosylhydrolases	 as	 well	 as	 the	 turnover	 of	 ADPr	 metabolites	 to	 further	characterize	the	molecular	effects	of	ARTD	inhibition	or	restoration	of	NAD+	in	the	context	of	NASH.		
4.2 Widespread	ARTC2.2	dependent	ADP-ribosylation	in	the	spleen	Mouse	ARTC2.2	 is	mainly	 expressed	 in	 the	 spleen,	 on	 immune	 cells	 and	 in	 lymph	nodes	 [25].	 Although	 not	many	 ADP-ribosylation	 targets	 have	 been	 identified	 for	ARTC2.2,	it	is	expected	that	it	modifies	a	broad	range	of	proteins,	since	addition	of	labeled	 NAD+	 to	 cells	 expressing	 ARTC2.2	 led	 to	 the	 detection	 of	 many	 ADP-ribosylated	proteins	[99].	 In	collaboration	with	Prof.	Friedrich	Koch-Nolte	we	thus	aimed	to	profile	the	ADP-ribosylome	of	the	spleen	from	WT,	ARTC1	KO	and	ARTC2.2	KO	animals.	Spleens	from	untreated	mice	were	isolated,	samples	prepared	and	ADP-ribosylated	 peptides	 enriched	 using	 the	 AF1521	 approach	 [57].	 151	 ADP-ribosylated	proteins	were	identified	in	the	WT	spleen,	mostly	modified	on	R.	While	183	 ADP-ribosylated	 proteins	 were	 found	 in	 the	 ARTC1	 KO,	 only	 5	 modified	proteins	 were	 identified	 in	 the	 ARTC2.2	 KO	 spleen	 (Figure	 11A),	 suggesting	 that	ARTC2.2	is	indeed	responsible	for	the	ADP-ribosylation	of	the	majority	of	identified	proteins.	 The	 observation	 that	 more	 ADP-ribosylated	 proteins	 are	 observed	 in	ARTC1	KO	samples	can	potentially	be	explained	by	higher	extracellular	NAD+	levels	in	 these	animals,	however	 this	 is	 so	 far	only	speculation.	PANTHER	gene	ontology	analysis	of	the	modified	proteins	in	WT	spleen	revealed	that	the	modified	proteins	
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are	mainly	 localized	on	 the	 cell	 surface	 and	 in	 the	 extracellular	 space,	 involved	 in	stress	responses,	immune	system	processes	and	signal	transduction	(Figure	11B,	C).	
	
Figure	 11	 Arginine	 ADP-ribosylation	 in	 spleen	 is	 dependent	 on	 ARTC2.2.	A)	Venn	diagram	of	 identified	ADP-ribosylated	 protein	 observed	 in	 untreated	 spleen	 samples	 from	WT,	 ARTC1	KO	 and	ARTC2	KO	mice.	 B)	PANTHER	 gene	 ontology	 analysis	 of	 proteins	 detected	 in	 the	WT	 spleen	 of	 their	 cellular	 localization	 and	 C)	biological	processes.		
4.3 Identification	of	the	ARTC2.2	specific	ADP-ribosylation	of	T	Cells	Although	ARTC2.2	is	known	to	be	specifically	expressed	on	mouse	T	cells	and	a	few	ARTC2.2	 ADP-ribosylation	 targets	 were	 previously	 identified,	 such	 as	 IL-2ra	 and	P2X7,	 and	 followed	up	by	 functional	 studies	 [97,	99,	144],	 the	T	 cell	 surface	ADP-ribosylome	was	so	 far	not	systematically	analyzed.	 In	collaboration	with	Dr.	Björn	Rissiek	(Medical	Center	Hamburg-Eppendorf),	we	mapped	the	ADP-ribosylation	of	T	cells	isolated	from	mice	under	untreated	conditions	or	after	ex	vivo	treatment	with	NAD+.	CD3+	T	cells	were	FACS	sorted	from	spleen	or	liver	of	7	C57BL/6	mice.	50μM	exogenous	 NAD+	 was	 added	 to	 one	 aliquot	 of	 the	 isolated	 splenic	 T	 cells	 and	incubated	 for	 15min.	 All	 cells	 were	 subsequently	 treated	 with	 ARTC2.2-blocking	Nanobody	 (i.e.	 s+16a)	 for	 15min	 and	 lysed	 with	 denaturing	 RIPA	 buffer.	 100	 μg	protein	 from	each	 sample	were	processed	using	 the	PARG-FASP-Af1521	approach	described	 in	 the	method	section	and	analyzed	on	a	Fusion	MS	[145].	While	only	3	ADP-ribosylated	 proteins	were	 observed	 in	 the	 liver	 T	 cells,	 18	were	 found	 to	 be	modified	 in	 the	 splenic	 T	 cells	 under	 untreated	 conditions	 and	 57	 after	 NAD+	treatment,	 corresponding	 to	 3,	 24	 or	 75	 unique	 ADP-ribosylated	 peptides	respectively	(Figure	12A).	
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Figure	12	Identified	ADP-ribosylomes	in	mouse	T	cells.	A)	Venn	diagram	of	ADP-ribosylated	proteins	found	in	T	cells	sorted	from	liver	tissue,	left	untreated	or	sorted	from	splenic	tissue	left	untreated	or	treated	with	NAD+	
ex	vivo.	Particularly	 interesting	identified	proteins	are	marked	B)	PANTHER	gene	ontology	annotation	of	ADP-ribosylated	 proteins	 found	 in	 splenic	 liver	 cells	 treated	 with	 NAD+	 for	 molecular	 function	 and	 C)	 biological	function.	Gene	ontology	analysis	for	molecular	and	biological	function	was	performed	for	the	identified	 ADP-ribosylated	 proteins	 in	 splenic	 T	 cells	 treated	 with	 NAD+	 and	revealed	that	these	proteins	are	mainly	associated	with	trans	membrane	receptors	involved	 in	 signal	 transduction,	 cell	 adhesion	 molecules	 and	 overall	 proteins	associated	 with	 T	 cell	 activation	 and	 immune	 system	 processes	 (Figure	 12B,C).	When	 applying	 an	 ADP-ribosylation	 site	 localization	 score	 of	 >80%,	 only	 R	 sites	were	 found	 to	 be	 ADP-ribosylated,	 except	 for	 one	 S	 site.	 Based	 on	 the	 current	knowledge	of	ARTC2.2	functions	and	considering	that	an	extracellular	rise	in	NAD+	concentration	 is	 possible	 upon	 stress	 conditions,	 these	 results	 strongly	 suggest	 a	broad	 role	 of	ARTC2.2	ADP-ribosylation	 regulating	T	 cell	 responses	 [35,	 97,	 144].	While	ARTC2.2	 itself	was	ADP-ribosylated	 in	untreated	 splenic	T	 cells	 on	one	 site	(R206),	 NAD+	 treatment	 induced	 an	 additional	 ADP-ribosylation	 site	 (R173).	 It	 is	not	 yet	 clear	 if	 ARTC2.2	 auto-modification	 has	 a	 regulatory	 effect	 on	 ARTC2.2	activity.	 To	 further	 investigate	 this	 aspect,	 the	 identified	 sites	 should	 be	mutated	and	ARTC2.2	 activity	 tested	 in	vitro	 or	 by	 genetically	 complementing	ARTC2.2	KO	cells	with	a	modification	deficient	ARTC2.2	mutant	in	vivo.	Remarkably,	 the	heteromeric	 IL-2	receptor	subunits,	 IL2ra,	 IL2rb	and	Il2rγ,	were	all	found	to	be	ADP-ribosylated	after	addition	of	NAD+.	The	receptor	complex	forms	 if	 either	 two	 of	 these	 proteins	 or	 all	 three	 assemble.	 The	 different	combinatorial	 assemblies	 of	 the	 receptor	modulate	 its	 affinity	 for	 binding	 to	 IL-2,	
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with	 the	 receptor	 containing	 all	 three	proteins	 showing	 the	highest	 affinity	 [146].	Upon	 IL-2	 signaling	 regulatory	 T	 cells	 start	 proliferating	 [146].	 Although	 it	 was	reported	that	IL2ra	is	ADP-ribosylated	by	ARTC2.2	and	that	this	tunes	IL2	signaling,	ADP-ribosylation	 might	 impact	 IL-2	 signaling	 more	 than	 previously	 anticipated,	since	also	 IL2rb	and	 Il2rγ	were	 found	 to	be	ADP-ribosylated	 [144].	Also	 the	 IL-18	receptor	 was	 ADP-ribosylated.	 IL-18	 receptor	 signaling	 induces	 the	 release	 of	interferon-γ	(IFNγ),	which	plays	a	role	in	promoting	cell-mediated	immunity	[147].	Investigating	 the	 functional	 relevance	 of	 IL-18	 receptor	 ADP-ribosylation	 on	 IFNγ	associated	processes	would	be	very	interesting	and	could	be	tested	using	WT	versus	ARTC2.2	T	cells,	treated	with	IL-18	and	quantifying	IFNγ	levels	by	qPCR	or	ELISA.			 Interestingly,	the	only	high	confident	ADP-ribosylation	site	not	localized	on	R	was	S842	of	ARTD8	in	splenic	T	cells	untreated	as	well	as	 treated	with	NAD+.	 It	 is	very	 likely	 that	 this	 site	 is	 an	ARTD8	auto-modification	 site,	 however	 it	 is	 not	 yet	clear	 what	 its	 function	 might	 be.	 Interestingly	 ARTD8	 was	 previously	 associated	with	 immunological	 processes	 trough	 ADP-ribosylation	 of	 STAT1	 and	 subsequent	induction	of	pro-inflammatory	gene	expression	in	macrophages	[148].	It	remains	to	be	tested	if	ARTD8	has	a	similar	role	in	T	cells	and	if	the	identified	modification	site	plays	a	role	in	ARTD8	activity	and	STAT1	modification.		
4.4 Determining	ADP-ribosylation	in	thrombocytes	Thrombocytes,	 also	 called	 platelets,	 are	 blood	 cells	 and	 responsible	 for	 clumping	and	 clotting	 of	 the	 blood	 during	 vessel	 injuries	 [149].	 Their	 activation	 and	aggregation	 is	 involved	 in	 arterial	 thrombosis	 and	 in	 the	 pathophysiology	 of	ischemic	 stroke	 [85,	150].	PARPi	 showed	beneficial	outcomes	 in	animal	models	of	ischemic	stroke	potentially	due	to	the	effect	of	PARPi	on	thrombocyte	activation	[85,	151,	152].	Since	thrombocytes	do	not	have	a	nucleus	it	is	unlikely	that	they	contain	ARTD1-3,	although	older	studies	reported	ADP-ribosylation	in	thrombocytes	[153].	An	 alternative	 proposed	 mechanism	 why	 PARPi	 would	 still	 be	 beneficial,	 is	 that	PARPi,	 as	 NAD+	 analogues,	 might	 bind	 to	 ADP-receptors	 on	 the	 surface	 of	thrombocytes,	 therefore	 influencing	 their	 function	 in	 an	 ADP-ribosylation	independent	 manner	 [152].	 To	 clarify	 if	 ADP-ribosylation	 can	 be	 detected	 in	
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thrombocytes	and	if	these	ADP-ribosylation	sites	might	contribute	to	the	observed	PARPi	 effect,	 we	 measured	 the	 ADP-ribosylome	 using	 our	 proteomic	 method.	Untreated	thrombocytes	of	pooled	buffy	coats	or	treated	thrombocytes	with	either	4	U/ml	thrombin	at	37	°C	for	10min,	which	leads	to	thrombocyte	activation,	or	with	1mM	H2O2	 to	 activate	 several	ARTDs	were	 prepared	 and	 their	 proteome	 isolated,	trypsin	digested,	enriched	by	Af1521	as	well	as	analyzed	on	a	Q	Exactive	MS	[57].	We	identified	19	ADP-ribosylated	proteins	with	only	a	minor	increase	upon	H2O2	or	thrombin	treatment	(Figure	13).	
	 		
Figure	13	ADP-ribosylation	was	detected	 in	 thrombocytes.	 Identified	ADP-ribosylated	proteins	are	shown	on	the	left	and	the	table	shows	the	corresponding	number	of	identified	unique	ADP-ribosylated	peptides	for	the	different	treatments.		Most	 of	 the	 identified	 ADP-ribosylated	 proteins	 did	 not	 correlate	 with	classical	ARTD1	or	2	 targets	 identified	previously.	 Several	modified	proteins	were	cytoskeletal	 and	 structural	 proteins,	 including	 Actin.	 Actin	 ADP-ribosylation	 by	bacterial	 toxin	was	 reported	 to	 degrade	 the	 cytoskeleton	 [16],	 however	 the	 ADP-ribosylation	sites	identified	in	this	study	on	Actin	were	localized	to	a	different	part	of	 the	protein,	 and	 could	 therefore	 have	 a	 different	 effect.	 A	 few	extracellular	 cell	surface	proteins	were	identified	to	be	ADP-ribosylated	as	well,	which	could	point	at	the	 presence	 of	 an	 endogenous	 or	 co	 purified	 ARTC.	 ARTC	 mediated	 ADP-ribosylation	 could	 be	 confirmed	 by	 including	 the	 ARTC	 inhibitor	 Novobiocin	 or	
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treating	 the	 cells	 with	 NAD+	 to	 stimulate	 ARTC	 ADP-ribosylation.	 To	 investigate	whether	the	modified	sites	are	indeed	sensitive	to	PARPi	treatment,	the	experiment	should	be	repeated	with	PARPi	pre-treatment.	
4.5 Identifying	ADP-ribosylation	targets	of	bacterial	toxins	Many	different	prokaryotic	toxins	ADP-ribosylate	specific	host	proteins	in	order	to	promote	bacterial	pathogenesis.	Unlike	ARTDs,	 they	are	thought	to	ADP-ribosylate	very	specifically	only	one	single	amino	acids	of	the	target	protein	(see	introduction	chapter	 3.1)	 [16].	 Photorhabdus	 luminescens	 belongs	 to	 the	 family	 of	
Enterobacteriaceae	and	produces	ADP-ribosylating	toxins,	which	have	been	shown	to	be	deadly	for	insect	[120].	Several	human	pathogens	produce	structurally	related	toxins	[120].	Dr.	Alexander	E.	Lang	and	Prof.	Klaus	Aktories	(University	of	Freiburg)	have	 identified	 two	presumably	ADP-ribosylating	bacterial	 toxins	belonging	 to	 the	TccC4	 protein	 class	 from	 two	 Photorhabdus	 luminescens	 strains	 (i.e.	 “W014”	 and	“TT01”).	W014	and	TT01	have	different	amino	acid	sequences	and	it	is	currently	not	clear,	if	they	are	acting	in	a	similar	manner.	Dr.	Alexander	E.	Lang	had	expressed	and	purified	the	recombinant	His-tagged	enzymatic	domains	of	both	toxins.	 Incubation	of	HeLa	cell	lysate	with	the	toxins	in	presence	of	32P-NAD+	let	to	ADP-ribosylation	of	two	 unknown	 distinctive	 proteins.	 In	 a	 collaborative	 approach	 we	 aimed	 at	determining	 the	 eukaryotic	 targets	 of	 these	 toxins	 in	vivo.	We	 infected	HeLa	 cells	with	either	one	of	the	toxins	in	presence	of	the	protective	antigen	(PA)	from	Bacillus	
anthracis,	 to	 allow	 internalization	 of	 the	 toxins	 [120].	 Optimal	 intoxication	conditions	 (i.e.	 dose	 and	 time)	were	determined	by	microscopy	 readout	using	 the	shape	 change	 of	 the	 cells	 (Figure	 14A).	 Infected	 and	 control	 cells	 were	 lysed,	proteins	were	 digested,	 enriched	with	Af1521	 and	modified	 peptides	 analyzed	 by	MS	measurement	[145].		To	identify	potential	toxin	mediated	ADP-ribosylation	sites	MS	 searches	 were	 performed	 in	 an	 error	 tolerant	 mode	 or	 by	 taking	 every	theoretically	modifiable	amino	acid	into	account	(described	in	[62])(Figure	14B,	C).		
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Figure	14	ADP-ribosylation	in	HeLa	cells	after	infection	with	TccC4	related	toxins	W014	and	TT01	from	
two	different	Photorhabdus	luminescens	strains.	A)	Light	microscopic	pictures	of	infected	and	control	HeLa	cells	 show	 the	 effect	 of	 the	 toxins	 on	 cell	 shape.	 B)	 Overlap	 of	 identified	 ADP-ribosylated	 proteins.	 C)	 ADP-ribosylated	proteins	specifically	observed	after	infection	with	the	individual	toxins.	Proteins	labeled	in	red	were	subjected	to	in	vitro	ADP-ribosylation	by	the	respective	toxin.		Although	several	targets	were	selected	(ie.	MAGT1,	PON2,	LRPAP1,	KDELC2,	LMAN1)	 and	 validated	 using	 in	 vitro	 ADP-ribosylation	 assays	 of	 purified	recombinant	 protein	 or	 overexpression	 cell	 lysate	with	 TccC4	 toxins,	 none	 of	 the	selected	targets	could	be	confirmed	to	be	a	bona	fide	toxin	target.	We	do	currently	not	 know	 if	 any	 of	 the	 identified	 ADP-ribosylated	 proteins	 are	 the	 real	 targets	 of	toxin	ADP-ribosylation	or	whether	they	are	ADP-ribosylated	by	an	endogenous	ART,	as	a	consequence	of	toxin	internalization.	This	could	be	elucidated	by	repeating	the	experiments	with	enzymatically	inactive	mutants	of	the	toxins.	The	other	identified	proteins	 remain	 to	 be	 confirmed	 as	 toxin	 targets.	 Should	 none	 of	 the	 identified	proteins	 be	 confirmed,	 alternative	 proteomic	 approaches	 should	 be	 considered.	Limitations	 of	 the	 current	 MS	 assay	 include	 the	 sensitivity	 of	 the	 global	 ADP-
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ribosylome	 approach	 and	 a	 certain	 constrain	 regarding	 the	 tryptic	 digestion.	 One	possibility	that	would	overcome	this	obstacle	would	be	different	proteases	(such	as	Glu-C	or	Lyc-C)	in	combination	with	the	current	workflow	or	the	application	of	ADP-ribosylated	protein	affinity	purification,	as	described	in	[50].		
4.6 Targeted	proteomic	measurement	of	ADP-ribosylation	sites	on	
immunopurified	proteins.	To	 detect	 protein	 ADP-ribosylation	 in	 complex	 samples,	 such	 as	 cell	 lysates,	 it	 is	necessary	to	apply	ADP-ribosylation	specific	enrichment	methods	(see	introduction	chapter	9).	However,	the	Af1521	macrodomain	based	as	well	as	phosphoproteomic	or	 boronic	 acid	 based	 enrichment	methodologies,	 require	 large	 amounts	 of	 input	material	 and	 might	 have	 biases	 towards	 specific	 modification	 sites	 [109].	 To	reproducibly	detect	in	vivo	ADP-ribosylation	sites	independently	of	an	ADPr	specific	enrichment	method,	we	established	a	protein	 immunopurification	 (IP)	protocol	 in	combination	 with	 targeted	 proteomic	 measurements.	 For	 this	 we	 overexpressed	FLAG-tagged	proteins,	which	were	previously	identified	to	be	ADP-ribosylated	using	the	Af1521	enrichment.	In	particular,	we	choose	proteins,	which	were	modified	by	ARTD1	(result	chapter	2.1).	The	proteins	were	overexpressed	in	control	HeLa	cells	or	in	HeLa	cells	with	stable	knockdown	of	either	ARTD1	or	ARTD2.	Cell	lines	were	subsequently	 treated	 with	 H2O2	 and	 protein	 overexpression	 was	 verified	 by	Western	Blot	analysis	(Figure	15A).	We	also	probed	the	cell	lysates	with	an	anti	PAR		antibody	 (10H,	 in	 house),	 but	 failed	 to	 detect	 PARylation	 of	 the	 overexpressed	proteins,	 which	 could	 be	 due	 to	 the	 limited	 sensitivity	 of	 currently	 available	antibodies	[118]	(Figure	15A).	The	 overexpressed	 proteins	 were	 enriched	 using	 anti-FLAG	 beads,	 eluted	from	the	beads	using	FLAG	peptide	solution,	PARG	treated	and	digested	on	a	filter	(see	 PARG-FASP-Af1521	 in	 material	 and	 methods).	 Parallel	 reaction	 monitoring	(PRM)	 targeted	 MS	 measurements	 were	 performed	 to	 monitor	 known	 ADP-ribosylated	peptides	and	unmodified	peptides	of	the	overexpressed	protein.	
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Figure	 15	 The	 targeted	 proteomic	 approach	 allows	 the	measurement	 of	 ADP-ribosylated	 peptides	 of	
overexpressed	and	immunoprecipitated	proteins.	A)	Western	blot	analysis	confirmed	overexpression	of	the	proteins	 (upper	panel).	 PARylation	 of	 overexpressed	 constructs	 cannot	 be	detected	with	 a	 common	anti	 PAR	antibody.	B)	In	the	PRM	measurements	modified	as	well	as	unmodified	peptides	were	targeted	and	quantified.	Fractions	 of	 ADP-ribosylated	 peptides	 were	 calculated	 by	 dividing	 the	 measured	 levels	 of	 ADP-ribosylated	peptides	by	the	total	protein	levels	(as	measured	by	PRM).		The	 PRM	 measurements	 of	 ADP-ribosylated	 peptides	 were	 based	 on	 a	 method	previously	 established	 in	 our	 lab	 on	 Af1521	 enriched	 ADP-ribosylated	 peptides	[154].	 For	 four	 out	 of	 five	 overexpressed	 proteins	 we	 were	 able	 to	 target	 and	measure	 the	 previously	 identified	 ADP-ribosylated	 peptides	 in	 the	 PRM	measurement.	 ADP-ribosylation	 of	 all	 four	 peptides	 was	 dependent	 on	 ARTD1	(Figure	15B).	Unfortunately,	we	were	not	able	to	resolve	the	exact	modification	site	on	 to	 the	 identified	 peptide	 due	 to	 extensive	 fragmentation	 of	 the	 ADP-ribose	moiety	with	HCD,	which	let	to	the	detection	of	only	few	peptide	fragment	ions	still	carrying	parts	of	the	ADP-ribose.	To	overcome	this	fragmentation	issue	it	would	be	worth	testing	the	PRM	approach	using	EThcD	or	ETD	instead	of	HCD	fragmentation,	which	could	be	a	very	powerful	method	in	accurately	determining	ADP-ribose	site	localization.	
4.7 SIRT6	is	auto-ADP-ribosylated	on	Y12	SIRT6	 is	 a	 broadly	 expressed,	 nuclear	 protein	with	 functions	 in	 genomic	 stability,	inflammation,	 and	 glucose/lipid	 metabolism	 [155].	 It	 was	 published	 that	 SIRT6	mono-ADP-ribosylates	 itself	as	well	as	ARTD1	[31,	156].	However,	 the	ADP-ribose	acceptor	 site(s)	 and	 amino	 acid	 type	 has	 not	 been	 identified.	 We	 thus	 purified	recombinant	SIRT6	form	bacteria	and	performed	an	in	vitro	ADP-ribosylation	assay.	
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Samples	were	processed	with	a	 tryptic	FASP	digestion,	an	Af1521	enrichment	and	finally	 analyzed	 on	 a	Qexactive	HF	MS.	Under	 the	 tested	 conditions,	we	 identified	Y12	of	SIRT6	as	ADP-ribosylated	acceptor	site	with	a	high	probability	and	supported	by	two	good	ADP-ribosylated	peptide	spectra	(Figure	16),	suggesting	that	SIRT6	is	modifying	another	acceptor	sites	than	the	intracellular	and	extracellular	ARTs.	
	
	
Figure	16	SIRT6	is	auto-ADP-ribosylated	at	Y12.	Two	HCD	ADP-ribosylated	-	peptide	spectra	of	automodified	recombinant	SIRT6	protein	recorded	with	a	Qexactive	HF	MS.	Site	directed	mutagenesis	and	in	vitro	modification	with	32P-NAD+	will	reveal	whether	 Y12	 is	 the	 only	 auto	modification	 site	 and	whether	 auto-modification	 of	Y12	is	necessary	for	SIRT6	function.	It	remains	to	be	tested	if	SIRT6	is	modified	on	Y12	in	vivo	at	the	same	amino	acid	residue.		
4.8 ADPRibase-Mn	treatment	of	ADP-ribosylated	peptides	Rat	 Mn2+-dependent	 ADP-ribose/CDP-alcohol	 pyrophosphatase	 (ADPRibase-Mn)	belongs	to	a	metallophosphoesterase	superfamily,	which	efficiently	hydrolyzes	free	ADP-ribose	 and	 PAR	 comparable	 to	 NUDIX	 hydrolases	 [157].	 Our	 group	 reported	earlier	that	incubation	of	in vitro ADP-ribosylated	ARTD1,	ARTD10	or	histone	H3	tail	with	recombinant	ADPRibase-Mn	decreased	PARylation	or	MARylation,	respectively	(Florian	Rosenthal,	PhD	Thesis,	unpublished	results).	MS-analysis	revealed	that	the	ADP-ribose	 is	 cleaved	 at	 the	 pyrophosphate	 bond,	 which	 results	 in	 a	 defined	phospho-ribose	 moiety	 attached	 to	 the	 protein	 (Florian	 Rosenthal,	 PhD	 Thesis,	unpublished	 results).	 Conversion	 of	 ADP-ribosylated	 peptides	 into	 phosphor-ribosylated	 peptides	 by	 NUDIX	 hydrolases	 or	 snake	 venom	 dieseterases	 can	 be	useful	 for	MS	analysis,	due	 to	 the	 reduced	size	and	charge	of	 the	phosphor-ribose	compared	 to	 the	 ADP-ribose	 [109,	 122].	 We	 thus	 aimed	 to	 analyze	 whether	
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replacing	PARG	with	ADPRibase-Mn	 in	 our	Af1521	proteomic	workflow	would	be	beneficial	 for	 the	 identification	 of	 ADP-ribosylation	 sites	 (Figure	 17A).	 We	 used	lysates	of	hydrogen-peroxide	stressed	HeLa	cells	to	generate	a	large	number	of	ADP-ribosylated	proteins.	Proteins	were	digested	with	trypsin,	but	unlike	in	the	original	protocol	 [57]	 PARG	 treatment	was	 omitted	 at	 this	 step	 and	 PARylated	 as	well	 as	MARylated	 peptides	 directly	 enriched	 using	 the	 Af1521	 macrodomain.	 These	peptides	 were	 subsequently	 subjected	 to	 demodification	 by	 either	 recombinant	PARG	 or	 ADPRibase-Mn.	 Measurements	 were	 done	 in	 triplicates	 to	 label-free	quantify	and	to	monitor	the	relative	abundance	of	modified	peptides	(Figure	17A).		
	
Figure	17		ADPRibase-Mn	treatment	can	be	used	instead	of	PARG	treatment	in	the	Af1521	approach.	A)	Adjusted	 enrichment	 strategy	 for	 ADP-ribosylation	 sites	 (orange).	 Hydrolase	 treatment	 is	 performed	 after	Af1521	 enrichment	 (indicated	 in	 red).	 B)	 Venn	 diagram	 of	 modified	 peptides	 after	 PARG	 or	 ADPRibse-Mn	treatment.	C)	Relative	abundance	or	ADP-ribosylated	and	phposhoribosylated	peptides	in	the	different	samples.	D)	 Overlap	 of	 identified	 ADP-ribosyalted	 peptides	 if	 the	 PARG	 treatment	 is	 done	 before	 or	 after	 the	 Af1521	enrichment.	ADPRibase-Mn	 led	 to	 a	 46%	 increase	 in	 identified	 unique	 modified	 (ADPr	 and	phospho-ribose)	peptides	compared	to	the	same	sample	treated	with	PARG	(Figure	17b).	After	the	ADPRibase-Mn	treatment,	only	70%	of	ADP-ribosylation	sites	were	converted	into	phospho-ribose	sites,	the	remaining	30%	were	still	ADP-ribosylated,	indicating	that	the	ADPRibase-Mn	treatment	was	not	very	efficient.	The	abundance	of	 ADP-ribosylated	 peptides	 after	 PARG	 treatment	 compared	 to	 the	 phospho-
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ribosylated	 and	 ADP-ribosylated	 peptides	 after	 ADPRibase-Mn	 treatment	 was	comparable,	 however	with	 a	 slightly	 increased	 variability	 in	 the	modified	 peptide	abundance	 after	 the	 ADPRibase-Mn	 treatment,	 which	 can	 be	 explained	 by	 the	simultaneous	appearance	of	a	phospho-ribosylated	and	an	ADP-ribosylated	version	of	the	peptide	in	some	cases	(Figure	17	C).	The	performed	ADPRibase-Mn	treatment	was	 not	 fully	 efficient	 and	 requires	 additional	 optimization	 or	 the	 substitution	 by	NUDIX	 hydrolases,	 which	 cleave	 the	 pyrophosphate	 bond	 even	 more	 efficiently	[123].	 Together,	 the	 conversion	 of	 PARylation	 and	 MARylation	 sites	 into	phophoribosylation	sites	was	beneficial	to	increase	the	coverage	of	ADP-ribosylated	peptides	and	the	number	of	identified	proteins.			 In	 order	 to	 test	 if	 the	 reduction	 of	 PAR	 after	 enrichment	 is	 beneficial	 in	contrast	 to	 the	 original	 protocol	where	PAR	 is	 reduced	before	 the	 enrichment	we	compared	 the	 two	 methods	 in	 terms	 of	 their	 ability	 to	 identify	 unique	 ADP-ribosylated	 peptides	 (Figure	 17d).	 When	 starting	 with	 a	 similar	 input	 peptide	amount,	we	observed	that	performing	the	PARG	treatment	after	the	enrichment	led	to	a	significant	loss	of	64%	of	unique	ADP-ribosylated	peptide	compared	to	the	ones	identified	with	the	PARG	pretreatment.	This	could	be	explained	by	a	loss	of	material	due	 to	 the	 additional	 steps	 after	 the	 enrichment	 (see	methods	 section).	 Thus,	 the	original	 enrichment	 protocol	 seemed	 overall	 to	 be	 the	most	 efficient	 version	 and	outperformed	the	benefits	gained	by	the	ADP-ribose	to	phospho-ribose	conversion,	due	to	the	additional	steps.	The	conversion	of	ADP-ribose	to	phospho-ribose	seems	only	useful	 for	enrichment	approaches	 that	directly	recognize	 the	phospho-ribose,	such	 as	 the	 conventional	 phospho	 enrichment	 or	 potentially	 antibodies	 raised	against	phospho-ribose	sites.	Furthermore,	it	could	be	useful	for	approaches	such	as	protein	immunopurification	(described	in	result	chapter	4.6)	or	for	in	vitro	analyses.	Shifting	 the	 hydrolase	 treatment	 after	 the	 enrichment	 can	 be	 beneficial	 in	 very	specific	 cases,	 for	 example	 in	 order	 to	 characterize	 the	 specificity	 of	 ADP-ribosylhydrolases	 as	 exemplified	 by	 the	 MAR	 degrading	 function	 of	 the	 ADP-ribosylhydrolases	3	(ARH3)	(result	chapter	2.2).		
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4.9 Methods	to	unpublished	results		
Filter	 aided	 sample	 preparation	 (FASP)	 in	 combination	 with	 PARG	 treatment	 and	
Af1521	enrichment	(PARG-FASP-Af1521).		FASP	was	done	in	accordance	to	the	original	protocol	[158].	Depending	on	the	size	of	 the	 protein	 of	 interest	 a	 Microcon-30-kDa-cutoff	 or	 a	 Microcon-10-kDa-cutoff	centrifugal	 filter	unit	 (Millipore)	was	used.	Filter	units	were	always	centrifuged	at	14,000g	at	20	°C	for	20	min	or	longer	if	needed	for	all	indicated	washes	and	buffer	exchange	 steps.	 We	 processed	 samples	 with	 amounts	 ranging	 from	 5-250	 µg	proteins.	Samples	were	diluted	and	reduced	in	Urea	Buffer	(8	M	Urea,	0.1M	Tris-HCl	pH	8)	containing	1	mM	DTT	and	transferred	to	a	size	exclusion	centrifugal	filter	and	washed	with	 200	 µl	 urea	 buffer.	 Samples	were	 subsequently	 alcylated	 using	 urea	buffer	containing	20	mM	chloroacetamide	and	washed	twice	with	100	μl	urea	buffer	and	three	times	with	100	µl	50	mM	ammonium	bicarbonate.	If	 it	was	necessary	to	reduce	 PARylation	 of	 the	 corresponding	 protein	 to	 MARylation,	 proteins	 were	resolved	on	the	filter	with	PARG	buffer	(50	mM	Tris-HCL	pH	8,	10mM	MgCl2,	250	uM	DTT,	 50	 mM	 NaCl)	 and	 treated	 with	 PARG	 as	 described	 in	 [159].	 The	 filter	 was	subsequently	washed	again	with	100	µl	50	mM	ammonium	bicarbonate	and	the	“on	filter	 digestion”	 performed	 in	 50	 mM	 ammonium	 bicarbonate	 using	 the	recommended	ratio	of	a	sequencing	grade	modified	protease	(mainly	trypsin,	but	in	certain	 cases	 also	 chymotrypsin,	 Glu-C	 or	 Arg-C	 all	 from	 Promega)	 overnight	 at	room	temperature.	Peptides	were	eluted	from	the	filter	units	by	centrifugation	and	the	 filters	washed	once	more	with	50	µl	50	mM	ammonium	bicarbonate.	 Samples	were	 subsequently	 purified	 over	 a	 C18	 stage	 tip	 and	 prepared	 for	MS	 analysis	 as	describe	 in	 [159].	 In	 some	 indicated	 cases,	 the	 Af1521	 peptide	 enrichment	 was	performed	after	the	FASP	digest.	For	this	the	eluted	peptides	were	resolved	in	500	µl	PARG	buffer	(50	mM	Tris-HCL	pH	8,	10mM	MgCl2,	250	uM	DTT,	50	mM	NaCl)	and	enriched	as	well	as	analyzed	by	MS	as	described	in	[159].					
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PRM	measurement	of	ADP-ribosylation	sites	on	FLAG	purified	protein	FLAG-tagged	proteins	were	overexpressed	in	HeLa	cell	using	GenJet™	In	Vitro	DNA	Transfection	 Reagent	 (SignaGen).	 Two	 days	 after	 transfection	 cells	 were	 treated	with	1mM	H2O2	for	10min	and	subsequently	lysed	in	the	presence	of	PJ34	and	tannic	acid.	 Purification	 and	 FLAG	 peptide	 elution	 was	 performed	 using	 FLAG	Immunoprecipitation	Kit	(Sigma)	according	to	the	provided	protocol.	Proteins	were	eluted	using	a	FLAG	peptide	elution,	were	PARG	treated	and	digested	on	filter	and	prepared	for	MS	analysis.		The	 PRM	 assay	 was	 developed	 using	 the	 data	 from	 the	 previous	 shotgun	experiments	 (result	 chapter	2.1).	 The	MS	was	operated	 and	data	was	 analyzed	 as	described	in	[154].		
Thrombocyte	treatment	and	extract	preparation		Thrombocyte-rich	 plasma	 of	 5-pooled	 buffy	 coats	 (39%	 plasma	 out	 of	 5x	 450ml	blood	 donation)	 was	 incubated	 with	 1	 mM	 acetylsalicylic	 acid.	 After	 addition	 of	EDTA,	the	thrombocytes	were	collected	by	centrifugation	at	800g	for	15	min.	The	pellet	was	resuspended	in	a	Ca2+	free	Tyrode's	buffer	(140	mM	NaCl,	3	mM	KCl,	12	mM	NaHCO3,	0.4	mM	NaH2PO4,	2	mM	MgCl2,	5.6	mM	glucose;	pH	6.2)	in	the	presence	of	1	μM	prostaglandin	E1	and	again	centrifuged	at	600	×	g	at	37°C	for	10	min.	The	pellet	was	then	resuspended	using	a	Tyrode's	buffer	(140	mM	NaCl,	3	mM	KCl,	12	mM	NaHCO3,	0.4	mM	NaH2PO4,	1	mM	MgCl2,	2	mM	CaCl2,	5.6	mM	glucose;	pH	7.4)	to	a	final	concentration	of	5	×	108/mL	(standard	thrombocyte	suspension),	and	divided	into	 3	 aliquots.	 The	 aliquots	 were	 incubated	 for	 10	 min	 at	 37°C	 either	 without	treatment	or	stimulated	by	either	4	U/ml	Thrombin	or	1	mM	H2O2	for	10	min.	After	these	treatments,	cells	were	immediately	lysed	and	processed	as	described	in	[159].	Enriched	ADP-ribosylated	peptides	were	analyzed	on	a	Q	Exactive	MS.			 	
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 DISCUSSION	AND	PERSPECTIVES		
1 Summary	of	the	results	The	first	aim	of	this	thesis	was	to	establish	methodologies	to	study	ADP-ribosylation	at	 the	proteomic	 level.	 In	 collaboration	with	 the	Nielsen	 laboratory	 (University	 of	Copenhagen)	we	established	an	approach	to	enrich	ADP-ribosylated	peptides,	which	allows	us	now	to	map	ADP-ribosylation	sites	 in	cultured	cells	and	primary	 tissues	[57,	159].	Next,	we	systematically	optimized	the	MS	measurement	and	established	a	method,	 which	 is	 highly	 efficient	 in	 identifying	 and	 accurately	 localizing	 ADP-ribosylation	sites	by	using	a	dual	peptide	fragmentation	approach	[145].	Moreover,	we	revised	our	bioinformatics	pipeline	and	performed	systematic	manual	validation	of	 annotated	 MS	 spectra	 in	 order	 to	 check	 for	 unexpected	 ADP-ribose	 acceptor	amino	acids	(results	chapter	2.1).	These	technological	improvements	led	to	several	important	 findings.	 We	 identified	 more	 than	 900	 ADP-ribosylation	 sites	 in	 HeLa	cells	and	mouse	 liver	tissue.	ADP-ribosylation	in	HeLa	cells	under	genotoxic	stress	conditions	revealed	mainly	modification	of	nuclear	proteins,	which	were	involved	in	transcription,	chromosome	organization	as	well	as	DNA	and	RNA	metabolism.	In	 the	 second	 aim	we	 addressed	 the	 specificity	 and	 contribution	 of	ARTD1	and	ARTD2	to	the	H2O2-induced	ADP-ribosylome	in	HeLa	cells.	We	identified	ARTD1	as	 the	 main	 mediator	 of	 nuclear	 ADP-ribosylation	 during	 this	 condition,	 while	ARTD2	seemed	to	play	only	a	marginal	role.	ARTD1-mediated	ADP-ribosylation	was	selectively	modifying	S	and	Y	acceptor	sites,	but	not	R	sites.		In	 the	 third	 aim,	 we	 identified	 the	 ADP-ribosylomes	 of	 heart	 and	 skeletal	muscle	 tissue,	 which	 revealed	 a	 widespread	 role	 of	 ARTC1-mediated	 R-specific-ADP-ribosylation	 of	 extracellular	 and	 plasma	 membrane	 proteins,	 as	 well	 as	 an	ARTC1-independent	 ADP-ribosylome	 in	 mitochondria.	 We	 found	 that	 the	 heme-binder	HPX	is	a	target	of	ARTC1	and	confirmed	with	a	biochemical	assay	that	ARTC1	modifies	 HPX	 also	 in	 vitro	 and	 that	 this	 modification	 inhibits	 its	 heme	 binding	function.		
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2 Towards	 identifying	 the	 complete	 ADP-ribosylome	 and	 limitations	 of	
current	proteomic	approaches	to	do	so		For	 a	 complete	 characterization	 of	 a	 single	 ADP-ribosylation	 site,	 the	 following	points	need	 to	be	addressed	 [109]:	1)	determination	of	 the	exact	ADP-ribosylated	amino	acid	acceptor	 site;	2)	 identification	of	 the	enzymes	 responsible	 for	 transfer	and	 hydrolysis	 of	 the	 specific	 ADP-ribosylation	 site;	 3)	 assessment	 of	 the	 ADP-ribosylation	 state	 (MAR,	 PAR,	 branched)	 and	 4)	 definition	 of	 the	 site	occupancy/stoichiometry	 that	 is,	 the	 fraction	of	a	given	modification	site	occupied	by	ADP-ribosylation.	During	my	PhD	I	have	undertaken	efforts	to	approach	several	of	these	points	at	the	level	of	the	ADP-ribosylome.		To	 identify	 the	 exact	 ADP-ribose	 amino	 acid	 acceptor	 sites	 (point	 1),	 the	Af1521	enrichment	approach	was	developed.	The	approach	 is	very	well	suited	 for	this	and	currently	the	method	of	choice	that	allows	the	broadest	coverage	of	ADP-ribosylation	 sites	 in	 untreated,	 non-genetically	 modified	 samples	 [57,	 145].	 In	combination	with	ETD	based	peptide	fragmentations,	this	method	allows	the	highly	accurate	 identification	 of	 bona	 fide	 ADP-ribosylation	 sites.	 However,	 it	 is	 not	 yet	clear	whether	 the	 established	 approach	 is	 unbiased	 regarding	 certain	 amino	 acid	ADP-ribose	 acceptor	 site,	 as	 already	 discussed	 by	 another	 group	 [122].	 In	 theory	Af1521	should	bind	free	ADP-ribose	and	thus	binds	to	the	terminal	ADP-ribose	unit	of	 a	PAR	chain	or	 to	a	MARylated	 site	 [47].	However,	we	could	 so	 far	not	exclude	that	 the	 ADP-ribose	 acceptor	 amino	 acid	 or	 the	 surrounding	 peptide	 sequence	influence	 the	 binding	 affinity	 and	 efficiency	 of	 Af1521	 to	modified	 peptides.	 This	could	be	systematically	investigated	by	characterizing	the	binding	affinity	of	several	synthetically	 ADP-ribosylated	 peptides	 with	 defined	 sequences	 and	 ADP-ribose	acceptor	sites.		Another	 bias	 in	 identifying	 ADP-ribose	 acceptor	 sites	 could	 be	 introduced	during	MS	analysis.	Specific	ADP-ribosylation	sites	might	not	be	detected,	wrongly	assigned	 or	 underestimated,	 since	 different	 amino	 acid	 ADP-ribose	 linkages	 have	distinct	stabilities,	of	which	some	are	 labile	and	might	 fully	 fragment	not	allowing	any	acceptor	site	assignment	[132].		
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Furthermore,	 the	 number	 of	 charges	 on	 peptide	 ions	 is	 a	 very	 important	parameter	for	MS	analysis	and	defines	whether	a	specific	peptide	is	at	all	detectable.	Peptides	 are	 usually	 measured	 in	 a	 positive	 ion	 mode	 and	 the	 charge	 state	 of	 a	peptide	is	mainly	controlled	by	its	length,	number	of	basic	amino	acids	and	chemical	modifications	 [160].	 ADP-ribosylation	 contains	 two	 negative	 charges	 and	 has	therefore	 a	 significant	 influence	 on	 the	 charge	 state	 of	 the	 peptide,	 potentially	leading	 to	 ionization	 or	 detection	 problems	 for	 certain	 peptides.	 Potential	approaches	 to	 tackle	 these	 problems	 could	 be	 to	 increase	 the	 charges	 on	 the	peptides,	 for	 example	 by	 partially	 digesting	 proteins	 or	 digesting	 with	 another	protease	 and	 thus	 increasing	 the	 length	 of	 the	 peptide	 [125],	 or	 by	 reducing	 the	negative	 charges	of	ADP-ribose	 (by	 converting	ADP-ribose	 to	phospho-ribose	or	 a	hydroxamic	 acid	 derivative).	 Yet,	 other	 possibilities	 would	 include	 analyzing	 the	peptides	 in	 a	 negative	 ion	 MS	 mode,	 to	 include	 single	 charged	 species	 or	 to	 use	gentler	fragmentation	and	ionization	methods.		In	order	to	move	towards	a	more	complete	coverage	of	the	ADP-ribosylome	(e.g.	 also	 to	detect	 very	 low	abundant,	 but	 functionally	 important	 sites),	 it	will	 be	important	 to	 increase	 the	 coverage	of	 the	ADP-ribosylation	 sites.	Approaches	 that	might	 help	 to	 do	 so	 include	 proteome	 fractionation	 prior	 to	 the	 enrichment	 (e.g.	high	 pH	 fractionation	 [108]),	 tandem	 enrichments	 (e.g.	 enrichment	 on	 protein	 as	well	 as	 on	 peptide	 level,	 or	 a	 combination	 of	 different	 enrichments	 [161])	 or	introduction	of	ADP-ribose	binding	reagents	with	higher	affinity	(e.g.	antibodies	or	engineered	 proteins).	 Furthermore,	 altering	 the	 protease	 or	 digestion	 protocol	might	allow	the	identification	of	previously	undetected	ADP-ribosylation	sites.		We	have	started	addressing	 the	 relationship	between	ADP-ribosylation	site	and	 ADP-ribosyltransferase/hydrolase	 (point	 2),	 by	 using	 siRNA	 or	 knockout	approaches	 in	 cellular	 systems	 and	 animal	 models.	 These	 “subtractive	 ADP-ribosylome	 approaches”	 have	 been	 useful	 in	 identifying	 the	 ADP-ribosylome	targeted	 by	 ARTD1,	 ARTD2,	 ARTC1,	 ARTC2.2	 and	ARH3	 (Results	 chapter	 2.2,	 2.1,	4.2).	 However,	 this	 approach	 is	 only	 applicable	 for	 a	 subset	 of	 biological	 samples	and	 provides	 only	 indirect	 proof	 of	 the	 enzyme-substrate	 relationship.	 A	 genetic	chemical	proteomic	approach	has	been	established	 that	 identifies	direct	ARTD1,	2	
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and	 3	 targets	 by	 target	 labeling,	 but	 which	 is	 limited	 to	 cell	 lysates	 or	 extracted	nuclei	[59].	A	very	promising	new	direction	could	be	the	combination	of	labeled,	cell	permeable	 NAD+	 precursors	 analogs	 [127]	 with	 modified	 analog	 sensitive	endogenous	ARTDs	(e.g.	by	CRISPR/Cas9	genome	editing)	[59].		The	 structure	 of	 MARylation	 versus	 PARylation	 (point	 3)	 has	 been	 largely	neglected	 in	 current	 proteomic	 approaches,	 although	MARylation	 and	 PARylation	are	 two	 distinct	 PTMs,	 with	 different	 biological	 functions	 (see	 introduction).	Furthermore,	PARylation	is	very	heterogeneous	in	terms	of	its	length	and	degree	of	branching,	which	 could	 serve	 as	 a	 distinct	mode	of	 signaling.	None	of	 the	 current	established	proteomic	techniques	can	discriminate	between	bona	fide	MAR	and	PAR	sites.	This	could	be	addressed	by	exchanging	the	Af1521	macrodomain	with	MAR	or	PAR	 specific	 binding	 modules	 or	 alternatively,	 by	 using	 selective	 MAR	 or	 PAR	hydrolases	to	erase	one	modification	type	or	label	the	demodified	ADP-ribosylated	acceptor	site	(e.g	by	providing	heavy	water	for	the	hydrolysis).		The	estimation	of	stoichiometry	(point	4)	is	an	inherent	challenge	for	all	PTM	analyses.	 For	protein	ADP-ribosylation	 first	 attempts	were	done	using	 the	Af1521	enrichment	approach	for	H2O2	treated	HeLa	cells	in	a	SILAC	setting,	combined	with	data	 characterizing	 general	 protein	 regulation	 during	 H2O2	treatment	 [57].	 This	analysis	provided	stoichiometric	 information	 for	55	ADP-ribosylation	sites.	Half	of	the	ADP-ribosylation	sites	had	less	than	11%	stoichiometry.	Interestingly	R	residue	had	the	highest	ADP-ribosylation	site	occupancy.	Alternatively,	 targeted	proteomic	approaches	(i.e.	PRM	as	demonstrated	in	[154]	and	results	chapter	4.6)	are	also	well	suited	 to	 define	 occupancy	 information	 for	 specific	 modified	 sites.	 It	 will	 be	interesting	 to	 monitor	 stoichiometric	 changes	 of	 defined	 ADP-ribosylation	 sites	during	 specific	 treatments,	 since	 this	 might	 help	 identifying	 the	 functional	 and	physiological	relevant	sites.	Modification	sites	that	are	important	for	a	response	to	specific	 stimuli	 are	 expected	 to	 be	 tightly	 regulated	 and	 to	 exhibit	 a	 defined	stoichiometric	 change,	 while	 the	 irrelevant	 sites	 should	 remain	 unchanged.	 By	combining	PRM	measurements	with	previous	immunopurification	of	single	proteins	or	 proteome	 fractionation	 it	 should	 be	 possible	 to	measure	 total	 protein	 level	 as	well	as	the	abundance	of	a	certain	modification	site.		
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3 Towards	an	atlas	of	tissue	specific	ADP-ribosylation.		The	 human	 protein	 atlas	 consists	 of	 a	 tissue-based	 and	 a	 subcellular	 map	 of	 the	human	proteome	as	well	as	a	pathology	atlas	and	is	a	core	resource	 in	the	field	of	human	biology	and	disease,	cited	by	thousands	of	research	paper	[162-164].	Other	efforts	 in	 this	direction	 include	 the	cell	 surface	protein	atlas,	 the	cancer	proteome	atlas	and	the	mouse	brain	protein	atlas	[165-167].	Various	similar	approaches	were	undertaken	to	systematically	map	and	categorize	PTMs	and	several	bioinformatics	efforts	exist	 in	 summarizing	and	 integrating	 this	 information	 in	databases	 such	as	PhosphoSitePlus,	 IPTMnet	 or	 SwissPalm	 [168-170].	 These	 resources	 are	 readily	integrated	 into	UniProt	and	 thus	easy	accessible	and	broadly	used	by	researchers.	Proteomic	 attempts	 to	 study	 ADP-ribosylation	 at	 the	 resolution	 of	 a	 single	 ADP-ribose	 acceptor	 site	 with	 high	 accuracy	 is	 now	 coming	 of	 age	 and	 a	 wealth	 of	literature	 already	 exists	 where	 ADP-ribosylation	 sites	 have	 been	 identified	biochemically	or	by	Edman	sequencing	[134].	It	is	clear	that	some	kind	of	database	or	central	repository	is	needed	to	summarize,	annotate	and	curate	measured	ADP-ribosylation	sites	 in	a	protein	centric	way,	 in	order	 to	make	the	existing	data	easy	accessible	for	the	broader	scientific	community.	Leung	et	al	have	undertaken	a	first	approach	 to	 summarize	 the	 findings	 from	 the	 last	 40	 years	 in	 a	 protein	 ADP-ribosylation	 database,	 called	 ADPriboDB	 [171].	 Each	 entry	 into	 the	 database	was	annotated	manually	by	at	least	two	independent	curators	and	the	database	contains	12’428	entries,	comprising	2’389	proteins	 form	459	papers	by	September	2017.	 If	the	 ADP-riboslation	 field	 is	 embarking	 now	 on	 creating	 a	 true	 cellular	 or	 tissue	specific	 ADP-ribosylation	 atlas,	 the	 following	 highly	 critical	 points	 need	 to	 be	considered:	 1)	 origin	 of	 sample,	 2)	 sample	 preparation	 and	 3)	 method	 for	 ADP-ribosylation	 site	 identification.	 Information	 about	 the	 sample	 origin	 (point	 1)	includes	whether	the	sample	was	derived	from	an	 in	vitro	or	 in	vivo	system.	For	 in	
vitro	modified	samples,	the	reaction	conditions	need	to	be	reviewed	and	for	in	vivo	systems	 the	 genetic	 background	 is	 key.	 Caution	 should	 be	 taken	 with	 in	 vitro	samples.	It	is	known	that	in	vitro	PTM	reactions	might	result	in	the	catalysis	of	non-physiological	 modification	 sites	 [172].	 Some	 of	 the	 main	 reasons	 are	 non-
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physiological	protein	concentration,	missing	(co)factors,	altered	PTM	pattern	of	the	recombinant	 protein	 or	 differential	 folding	 of	 the	 proteins	 as	 well	 as	 the	 overall	absent	of	 the	cellular	context	 [172].	 In	 the	case	of	ARTD1,	 it	was	reported	 that	 its	activity	 and	 selectivity	 is	 strongly	 dependent	 on	 the	 presence	 of	 HPF1	 [61].	Moreover,	depending	on	 the	used	NAD+	concentration,	different	modification	sites	have	 been	 observed	 [94].	 It	 is	 therefore	 important	 to	 accurately	 describe	 under	which	 conditions	 in	vitro	 reactions	were	performed	 (i.e.	 buffer	 composition,	NAD+	concentration	 and	 origin	 of	 proteins)	 and	 the	ADP-ribosylation	 field	 should	make	additional	efforts	to	systematically	test	different	reaction	conditions	and	to	agree	on	standard	procedures.	For	investigations	in	cells	or	in	vivo	the	genetic	background	is	crucial.	One	type	of	proteomic	method	requires	the	knock	down	of	PARG	in	order	to	“stabilize”	 or	 “amplify”	 the	 ADP-ribosylation	 signal	 [58],	 however	 the	 excessive	accumulation	of	PAR	chains	 that	are	not	 rapidly	degraded	under	 these	conditions,	might	induce	additional	perturbation	of	the	physiological	settings	[173].	For	in	vivo	experiments	 it	 is	 important	 to	 first	 quantify	 the	 ADP-ribosyltransferases	 and	hydrolases	 in	 a	 respective	 biological	 sample	 and	 to	 second	 compare	 the	 ADP-ribosylome	of	tissues	or	cells	lacking	a	specific	ADP-ribosyltransferase	or	hydrolase	against	an	unperturbed	counterpart.		In	terms	of	sample	preparation	(point	2),	cell	and	tissue	harvesting	as	well	as	cell	lysis	are	critical.	It	was	shown	that	shearing	of	DNA	or	release	of	NAD+	can	lead	to	 unphysiological	 ADP-ribosylation,	 if	 buffers	 are	 not	 supplemented	 with	 PARPi	and	 ARTC	 inhibitor	 or	 ideally	 by	 harvesting	 the	 lysates	 with	 a	 denaturing	 lysis	buffer	 [50].	 For	 tissue	 harvesting	 the	 release	 of	 NAD+	 and	 unphysiological	 ADP-ribosylation	is	the	biggest	challenge,	which	can	however	be	overcome	by	immediate	snap	freezing	the	tissue,	or	by	the	injection	of	ARTC	inhibitor	or	ARTC	inactivating	antibody	before	extracting	the	tissues	[174].	Furthermore,	non-inhibited	activity	of	PARG	and	ARH3	can	lead	to	an	underestimation	of	ADP-ribosylation	sites.	It	is	thus	important	 that	 the	 field	 is	 sensitized	 to	 these	 aspects	 and	only	procedures,	which	take	all	measures	to	preserve	the	endogenous	ADP-ribosylome,	should	be	accepted	for	publication.	
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Considering	 which	 method	 to	 apply	 for	 the	 identification	 of	 the	 ADP-ribosylation	site	(point	3)	is	very	important	in	order	to	appreciate	the	confidence	of	the	identified	modification	site.	As	discussed	above,	enrichment	techniques	and	the	applied	 MS	 methods	 significantly	 influence	 which	 sites	 are	 detectable	 and	determine	 the	 accuracy	 of	 the	 localization.	 To	make	 this	 aspect	 more	 visible,	 we	have	created	an	interactive	ADP-ribosylation	spectra	database,	where	good	quality	sample	 spectra	 of	 ADP-ribosylated	 peptides	 fragmented	 with	 HCD	 or	 EThcD	 are	deposited	 and	 described	 (Results	 Chapter	 2.1).	 This	 allows	 now	 colleagues	performing	 MS	 analyses	 or	 who	 analyze	 data	 created	 by	 MS	 to	 judge	 the	quality/accuracy	 of	 the	 ADP-ribosylation	 site	 localization	 and	 adjust	 their	measurements	accordingly.	
4 Nuclear	serine	ADP-ribosylation	Nuclear	 ADP-ribosylation	 has	 come	 a	 long	 way	 since	 the	 first	 detection	 of	 PAR	synthesis	in	isolated	nulcei	in	1963	[175].	While	for	a	long	time	the	main	focus	for	PARylation	 was	 on	 the	 DNA	 damage	 response,	 it	 is	 now	 clear	 that	 nuclear	PARylation	 has	 many	 different	 molecular	 functions	 ranging	 from	 DNA	 repair	 to	regulation	of	chromatin	structure,	gene	expression	and	RNA	processing,	as	well	as	various	 biological	 processes	 such	 as	 responses	 to	 genotoxic	 stress,	 development,	aging,	inflammation,	metabolism	or	cancer	[176].			 The	 first	 large	 scale	 ADP-ribosylation-site	 proteomic	 study	 by	 Zhang	 et	 al	claimed	 to	 have	 found	 hundreds	 of	 ADP-ribosylation	 sites	 on	 E	 and	D	 in	HCT116	cells	 in	 response	 to	 genotoxic	 stress	 which	 were	 mostly	 sensitive	 to	 PARPi	treatment	[58].	In	the	initial	Af1521	peptide	enrichment	proteomic	study	performed	by	us,	we	could	not	confirm	the	broad	E	and	D	ADP-ribosylation	observed	by	Zhang	
et	 al,	 however	 we	 found	 K	 to	 be	 the	 main	 ADP-ribose	 acceptor	 site	 [57,	 145].	Reanalysis	of	the	same	data	by	others	and	us,	as	well	as	the	 introduction	of	better	suited	 EThcD	 peptide	 fragmentation	 by	 us,	 revealed	 that	 a	 large	 number	 of	 the	previously	 annotated	 lysine	 ADP-ribose	 acceptor	 sites	 were	 rather	 serine	 ADP-ribose	 acceptor	 sites	 [62,	145]	 (Results	Chapter	2.1).	We	have	now	evidence,	 that	most	of	the	nuclear	ADP-ribosylation	measured	by	our	methods	consist	of	S-specific	
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and	to	a	much	less	extent	Y-specific	ADP-ribosylation,	although	we	cannot	rule	out	that	 also	 K,	 D	 and	 E	 are	 modified.	 The	 predominant	 nuclear	 S-specific	 ADP-ribosylation	 was	 also	 identified	 and	 confirmed	 by	 other	 groups	 with	 alternative	methods	[62,	125].	
Zhang	et	al	have	observed	a	“broad”	distribution	of	E	and	D	ADP-ribosylation	sites	along	different	proteins	(e.g	38	distinct	ADP-ribosylation	sites	in	ARTD1),	with	53%	of	the	identified	ADP-ribosylated	proteins	containing	more	than	one	site	[58].	In	 contrast	 to	 this	 analysis,	we	 found	only	30%	of	proteins	having	more	 than	one	ADP-ribosylation	 site	 and	often	 in	 relative	 close	proximity	 (e.g.	 11	K	or	 S	 sites	on	ARTD1,	 all	 within	 its	 auto	 modification	 domain).	 From	 SILAC	 and	 targeted	proteomic	 measurements	 we	 know	 that	 the	 ADP-ribosylation	 sites	 on	 ARTD1	detected	 by	 us	 belong	 to	 the	 highest	 abundant	 ADP-ribosylation	 sites	 in	 these	sample	 types	 [57,	 154].	 In	 fact	 we	 were	 even	 able	 to	 detect	 two	 of	 the	 S-ADP-ribosylation	sites	on	ARTD1	without	any	enrichment	in	whole	cell	lysates	from	H2O2	treated	 HeLa	 cells,	 strongly	 indicating	 that	 these	 are	 highly	 abundant	 ADPr-sites	[57,	154].	It	is	unlikely	that	the	discrepancy	in	ADP-ribosylation	site	distribution	of	our	datasets	compared	to	 the	ones	 from	Zhang	et	al.	 are	due	 to	different	used	cell	lines	 (HeLa	 versus	HCT116).	However,	 one	 possibility	 to	 explain	 this	 discrepancy	might	be	that	E	and	D	ADP-ribosylation	sites	have	a	much	lower	stoichiometry	than	S	sites.	The	boronic	acid	enrichment	applied	by	Zhang	et	al	presumably	has	a	higher	affinity	for	ADP-ribosylation	sites	than	the	Af1521	enrichment,	is	however	biased	in	detecting	only	E	and	D	sites,	hence	it	is	not	possible	to	directly	compare	this	E	and	D	ADP-ribosylation	sites	 to	the	S	ADP-ribosylation	sites.	To	address	this	discrepancy	the	boronic	acid	approach	needs	to	be	repeated	in	a	way	that	side	stoichiometry	can	be	 calculated	 and	 compared	 to	 the	 ones	 obtained	 for	 the	 S	ADP-ribosylation	 sites	identified	by	us	or	adjusted	in	a	way	that	the	method	would	allow	the	detection	of	other	 ADP-ribosylation	 sites.	 Furthermore,	 expanding	 the	 toolbox	 of	 ADP-ribose	binders	 for	 enrichment	 will	 answer	 if	 the	 Af1521	 enrichment	 is	 biased	 against	enriching	E	and	D	ADP-ribosylation	sites.	We	 and	 others	 have	 identified	 that	 nuclear	 S-ADP-ribosylation	 sites	 are	favorably	adjacent	 to	 a	K	or	R	amino	acid	 residue.	The	 reason	or	 requirement	 for	
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this	 amino	 acid	motif	 is	 so	 far	 unclear.	 One	 could	 speculate	 that	 these	 positively	charged	 amino	 acids	 interact	 with	 the	 negatively	 charged	 phospho	 groups	 of	 the	ADP-ribose	 or	 create	 a	 favorable	 environment	 for	 the	 catalysis	 of	 S-specific	 ADP-ribosylation.	It	is	currently	not	clear	if	this	simple	motif	contributes	to	the	selectivity	of	 ARTDs	 against	 certain	 sites,	 which	 is	 more	 likely	 mediated	 by	 protein-protein	interactions	and	tertiary	structural	properties.	The	relevance	of	the	identified	motif	on	 S-ADP-ribosylation	 by	 ARTD1	 could	 be	 further	 investigated	 by	 in	 vitro	 ADP-ribosylation	 assays	where	 the	motif	 in	 substrate	 proteins	 is	 altered,	 abolished	 or	newly	introduced.	One	 of	 the	 most	 striking	 findings	 in	 the	 field	 in	 the	 recent	 years	 was	 the	identification	 of	 histone	 parylation	 factor	 1	 (HPF1)	 and	 its	 influence	 on	 ARTD1’s	activity	and	specificity.	Association	of	HPF1	with	ARTD1	not	only	seems	to	shift	its	activity	 from	 auto-modification	 to	 PARylation	 of	 histones,	 but	 it	 also	 alters	 the	specificity	 of	 ARTD1	 towards	 S-ADP-ribosylation	 sites	 [61,	 62].	 In	 principle,	 the	concept	of	protein	factors	to	activate	or	modulate	ADP-ribosylation	is	not	new,	since	so-called	ADP-ribosylation	factors	(ARF)	in	eukaryotic	cells	were	found	to	stimulate	ADP-ribosylation	catalyzed	by	E.	Coli	enterotoxins	and	cholera	toxins,	however	the	finding	that	this	is	also	the	case	for	an	endogenous	ARTD	was	unexpected	[177].	The	obvious	remaining	question	now	is,	whether	other	ADP-ribosylation	factors	exist	to	modulate	different	ARTD1	activities	and	specificities	or	even	activities	of	ARTDs	in	general.	 A	 mechanism	 that	 shows	 some	 similarities	 to	 HPF1/ARTD1	 complex	formation	 was	 recently	 also	 identified	 for	 ARTD9.	 ARTD9	 was	 thought	 to	 be	 a	catalytically	 inactive	 enzyme,	 however	 in	 complex	 with	 ubiquitin	 ligase	 Dtx3L,	 it	ADP-ribosylates	 the	 carboxyl	 terminus	 of	 ubiquitin	 [22].	 When	 comparing	 the	 S-ADP-ribosylation	 mediated	 by	 the	 ARTD1/HPF1	 complex	 to	 the	 ubiquitination	system,	 it	 is	 attractive	 to	 hypothesize	 that	 the	 few	ARTDs	 that	 exist	 in	 eukaryotic	cells	have	a	similar	role	as	the	E1	ubiquitin-activating	enzymes	and	the	E2	ubiquitin-conjugating	enzymes,	whereas	ADP-ribosylation	factors	(such	as	HPF1)	would	act	in	a	 way	 comparable	 to	 the	 large	 group	 of	 E3-ligases	 (more	 than	 600	 in	 humans),	providing	a	degree	of	specificity	to	the	PTM	and	defining	which	targets	are	modified.		
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5 Extracellular	arginine	ADP-ribosylation	and	its	medical	relevance	In	this	PhD	thesis	we	have	shown	that	cell	surface	and	extracellular	R-specific	ADP-ribosylation	 is	mediated	 in	 a	 tissue	 specific	manner	 either	 by	ARTC1	or	ARTC2.2.	ARTC2.2	is	not	present	in	human,	however	ARTC1	is	conserved	and	shows	a	similar	tissue	 specific	 expression	 profile	 as	 in	mouse,	 therefore	 it	 is	 likely	 that	 R-specific	MARylation	 is	 also	 occurring	 in	 human	 tissues.	 We	 only	 started	 to	 estimate	 the	extent	 of	 ARTC1	 mediated	 R-specific	 MARylation,	 already	 under	 endogenous	conditions,	 since	 almost	 nothing	 is	 known	 about	 its	 biological	 functions.	 This	extracellular	modification	has	the	potential	to	be	biologically	and	medically	relevant	since	 it	 targets	 several	 key	 nodes	 in	 signal	 transduction.	 For	ARTC2.2	 it	 has	 been	shown	 that	 it	 sensitizes	 cells	 for	 extreme	 conditions,	 where	 an	 excess	 of	 danger	signals	(i.e.	NAD+)	are	present	in	the	extracellular	milieu,	as	observed	in	the	vicinity	of	dying	cells	and	during	 inflammation	 [35].	 It	 is	very	well	possible	 that	ARTC1	 is	also	 activated	 by	 high	 local	 NAD+	 concentrations,	 which	 potentially	 occur	 during	muscle	 overuse,	 stress	 or	 tissue	 damage	 as	 well	 as	 more	 severe	 conditions	 like	ischemia-reperfusion.	 The	 function	 of	 ARTC1	 mediated	 ADP-ribosylation	 for	 the	muscle	 tissue	 remains	 unclear.	 This	 could	 be	 studied	 in	 specific	mouse	models	 of	muscle	tissue	injury	or	myocardial	ischemia-reperfusion	injury	in	WT	versus	ARTC1	KO	mice.	 In	 a	 first	 step,	 it	 would	 be	 interesting	 to	 test	 if	 lack	 of	 ARTC1	 in	 these	pathological	 models	 has	 a	 sensitizing	 or	 protective	 effect.	 Comparing	 the	 ARTC1	mediated	ADP-ribosylome	from	untreated	controls	might	identify	modified	targets,	which	have	a	known	function	during	the	stress	response	and	which	can	be	followed	up	in	functional	studies.		We	 have	 already	 collected	 data	 for	 hundreds	 of	 ARTC1	 dependent	 ADP-ribosylation	 sites	 in	 the	 heart	 and	 skeletal	muscle.	 Now	 it	would	 be	 important	 to	determine,	which	sites	are	functionally	relevant	in	the	context	of	physiological	and	pathophysiological	responses.	Modified	signaling	receptors	are	promising	targets	to	follow	 up	 with	 functional	 studies	 in	 cultured	 cells	 or	 animal	 models	 [97,	 144].	Transmembrane	 signal	 receptors	 are	 often	 positioned	 at	 key	 nodes	 of	 signaling	pathways;	 therefore	 modulation	 of	 their	 ligand-binding	 properties	 or	 complex	
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assemblies	 have	 the	 potential	 to	 influence	 a	 broad	 spectrum	 of	 downstream	effectors	 [178].	 We	 identified	 R86	 of	 the	 IL-1α/β	 co-receptor,	 i.e.	 interleukin	 1	receptor	 accessory	 protein	 (IL1RAP),	 to	 be	 ADP-ribosylated	 in	 mouse	 heart	 and	skeletal	muscle	 tissue.	 It	will	 be	 interesting	 to	 test	 if	 ADP-ribosylation	 of	 the	 IL-1	receptor	 complex	 is	 promoting	 or	 inhibiting	 IL-1α	 or	 β	 binding	 and	 thereby	modulating	 its	 downstream	 signaling.	 Ligand	 binding	 or	 receptor	 complex	formation	of	the	IL-1	receptor	can	be	tested	by	in	vitro	ADP-ribosylation	of	IL1RAP	and	 subsequent	 affinity	 binding	measurements	with	 IL-1α	 for	 example	by	 surface	plasmon	resonance	[179].	Downstream	signaling	effects	of	IL1RAP	ADP-ribosylation	could	be	determined	by	monitoring	induced	gene	expression	changes	(e.g.	IL6	as	a	direct	 downstream	 target	 of	 IL-1α/β	 signaling),	 reporter	 gene	 assays	 or	phosphorylation	states	of	intracellular	signaling	components	(e.g.	IRAK)	[180].		Due	to	their	accessibility	by	antibodies	in	vivo,	extracellular	PTMs	provide	an	interesting	 avenue	 for	 diagnostic	 tools	 and	 medical	 interventions.	 Extracellular	ADP-ribosylation	 could	be	used	as	 a	marker	 for	 stressed	 cells	or	 to	 visualize	 cells	exposed	to	NAD+	in	proximity	of	dying	cells.	Blockade	of	ARTC2.2	activity	in	mice	by	an	inactivating	nanobody	protected	regulatory	T	cell	and	Natural	Killer	T	cells	from	NAD+	 induced	 cell	 death	 (i.e.	 NICD)	 and	 showed	 benefits	 in	 mouse	 model	 of	autoimmune	 diabetes	 [35,	 174,	 181].	 This	 observation	 strongly	 suggests	 that	blocking	 individual	 ARTC	 member	 by	 antibodies	 or	 specific	 inhibitors	 might	 be	beneficial	 for	 the	 treatment	of	pathological	 conditions.	Along	 this	 line,	 it	would	be	interesting	 to	 treat	mice	with	 ARTC1	 inactivating	 antibodies	 in	mouse	model	 (e.g	LPS	induced	sepsis	or	ischemia-reperfusion)	to	evaluate	possible	beneficial	effects.	Antibodies	against	mono-ADP-ribosylated	proteins	or	specific	ARTC1-induced	ADP-ribosylation	 sites	 could	 be	 tested	 by	 immunohistochemistry	 to	 visualize	 cells	 or	tissue	areas	that	are	stressed	ore	were	exposed	to	NAD+		
6 How	to	proceed	to	the	next	level	–	a	short	perspective		A	 series	 of	 proteome-wide	 analyses	 for	 ADP-ribosylated	 proteins	 across	 different	cell	lines	and	tissues	have	so	far	been	published	or	are	included	in	this	thesis	[57].	An	open	issue	remains	now,	how	these	lists	of	modified	proteins	can	be	used	in	the	
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most	 efficient	 way	 to	 foster	 further	 validation	 and	 to	 elucidate	 the	 functional	relevance	 of	 ADP-ribosylation.	 The	 most	 important	 part	 is	 to	 categorize	 and	summarize	 all	 identified	 ADP-ribosylation	 sites	 in	 an	 easy	 accessible	 database	 as	discussed	 above.	 However,	 researchers	 interested	 in	 the	 biological	 function	 and	clinical	 relevance	 of	 ADP-ribosylation	 sites	 need	 to	 be	 able	 to	 prioritize	 ADP-ribosylated	proteins	and	chose	promising	targets	for	follow	up	studies.	An	obvious	criterion	 would	 be	 ADP-ribosylation	 site(s)	 that	 have	 been	 identified	 with	independent	methods,	 on	 a	 protein	 that	 has	 previously	 been	 associated	with	 key	biological	 processes	 and	 whose	 structural	 analysis	 suggest	 that	 the	 ADP-ribosylation	 site	 could	 interfere	 or	 enhance	 protein	 function.	 However,	 with	 the	growing	list	and	increasing	numbers	of	modified	proteins	these	choices	can	become	very	difficult	 and	 cumbersome.	Alternatively	 and	 if	 enough	data	 is	 available,	 PTM	sites	 could	 also	 be	 systematically	 prioritized	 by	 sophisticated	 bioinformatics	approaches	that	identify	sites	which	likely	have	a	regulatory	role	in	protein	function	by	 considering	 their	 participation	 in	 cross-regulatory	 events,	 regulating	 domain	activity	or	mediating	protein-protein	 interactions	 [182].	This	 type	of	 selection	has	shown	before	 for	phosphorylation	 that	most	probably	only	 a	 small	 fraction	of	 the	identified	 modification	 sites	 are	 likely	 to	 have	 a	 significant	 biological	 role,	underlining	the	importance	of	choosing	targets	to	follow	up	by	mechanistic	studies	[182].	 Additionally,	 further	 proteomic	 experiments	 should	 aim	 at	 testing	 samples	under	pathological	conditions	or	sensitive	to	clinical	available	inhibitors	(i.e.	ARTC	or	ARTD	inhibitors)	and	could	reveal	which	ADP-ribosylation	sites	are	functionally	important.	 Modification	 sites	 that	 are	 evolutionary	 conserved	 between	 different	species	or	groups	of	sites	that	are	temporally	or	spatially	correlated	might	also	point	at	their	significance	[109,	113].		It	might	be	promising	to	collect	all	available	data	and	to	establish	a	spectral	library,	that	can	be	used	for	targeted	or	data-independent	proteomic	measurements	with	 the	 aim	 to	 quantify	 stress	 specific,	 functionally	 relevant	 and	 ARTD	 specific	ADP-ribosylation	sites.	This	could	be	extended	to	characterize	protein	levels	of	ADP-ribosyltransferases,	ADP-ribosylhydrolases,	NAD+	producing	or	consuming	enzymes	and	potential	 ADP-ribosylation	 factors.	 Ideally,	 this	 tool	would	 allow	 generating	 a	
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snapshot	of	all	 components	and	 their	activities	of	 the	expanded	 “ADP-ribosylation	machinery”	 in	 a	 certain	 condition.	 The	MS	 assay	 could	 be	 used	 to	 screen	 a	 large	cohort	 of	 medically	 relevant	 samples	 and	 might	 allow	 identifying	 samples	 or	conditions	during	which	 the	ADP-ribosylation	machinery	 is	altered	or	deregulated	and	might	 thus	allow	an	assessment	 if	 it	 is	worthwhile	 to	 study	a	particular	ADP-ribosylation	site	in	greater	detail	for	the	specific	condition.						 	
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ABBREVIATIONS	
 ABBREVIATIONS	ADP	 Adenosine	diphosphate	ADPr	 ADP-ribose	ADPRibase-Mn	 ADP-ribose/CDP-alcohol	pyrophosphatase	ARF	 ADP-ribosylation	factor	ARH	 ADP-ribosylhydrolase	ART	 ADP-ribosyltransferase	ARTC	 ADP-ribosyltransferase	C2/C3	cholera	toxin-like	ARTD	 ADP-ribosyltransferase	diphtheria	toxin	like	BRCA1/2	 Breast	Cancer	gene	1/2	BRCT	 BRCA1	C-terminal	(BRCT)	domains	CID	 Collision-induced	dissociation	DDA	 Data	dependent	acquisition		DIA	 Data	independent	acquisition			ETD	 Electron	transfer	dissociation	EThcD	 Electron-transfer/higher-energy	collision	dissociation	FASP	 Filter	aided	sample	preparation		FHA	 Forkhead-associated	GDH	 Glutamate	dehydrogenase	GPI	 Glycosylphophatidylinositol		HCD	 Higher-energy	collisional	dissociation		HNP1	 human	neutrophil	peptide	1	HPF1	 Histone	parylation	factor	1		IFNγ	 Interferone	gamma		IL17	 Interleukin	17	IMAC	 Immobilized	Metal	Affinity	Chromatography	IP	 Immunopurification	ITGA	 Integrin	alpha	7	ITGB1	 Integrin	beta	1	kDA	 Kilo	Daltion	LC	 Liquid	chromatography	column	m/z	 Ion	mass-to-charge	ratio		MAR	 Mono	ADP-ribosylation		MCD	 Methionine-	and	choline-deficient	diet	MEF	 Mouse	embryonic	fibroblast	MS	 Mass	spectrometry	NA	 Nicotinamide	NAD+	 Nicotinamide	adenine	dinucleotide		NAFLD	 Non-alcoholic	fatty	liver	disease	NAM	 Nicotinic	acid		NASH	 Non-alcoholic	steatohepatitis	NR	 Nicotinamide	riboside	
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ABBREVIATIONS	
OB-fold	 oligonucleotiode/oligosaccharide-binding	fold		PA	 Protective	antigen	PAR	 Poly-ADP-ribosylation	PARG	 poly-ADP-ribose	glycohydrolase	PARP	 Poly(ADP-ribose)polymerases	PARPi	 PARP	inhibitor	PBM	 PAR-binding	motif	PBZ	 PAR-binding	zinc	finge	PAR-binding	motif				PRM	 Parallel	reaction	monitoring			PTM	 Post-translational	modification	RRM	 RNA	recognition	motif	SP	 Signal	peptide	TNFα	 Tumor	necrosis	factor	alpha				 	
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